Improvements in survival and clinical benefit with gem
patients with advanced pancreas cancer: a randomized

Journal of Clinical Oncology

15, 2403-2413

DOI: 10.1200/jco.1997.15.6.2403

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2012, 6, 280.	0.6	3
2	The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncology Reports, 1994, 20, 863.	1.2	8
3	Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphon acetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. Annals of Oncology, 1997, 8, 917-918.	0.6	4
5	Gemcitabine. Drugs, 1997, 54, 447-472.	4.9	224
6	Current and Emerging Treatments for Pancreatic Cancer. Drugs and Aging, 1997, 11, 285-295.	1.3	8
8	Chemotherapy. Lancet, The, 1997, 349, S7-S9.	6.3	15
9	Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.. Journal of Clinical Oncology, 1997, 15, 3394-3398.	0.8	324
10	Clinical Response Benefit in Patients with Advanced Pancreatic Cancer. Digestion, 1997, 58, 503-507.	1.2	39
12	Treatment of pancreatic cancer. International Journal of Gastrointestinal Cancer, 1997, 22, 81-93.	0.4	24
13	Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investigational New Drugs, 1998, 16, 93-96.	1.2	13
14	Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Investigational New Drugs, 1998, 16, 275-278.	1.2	27
15	Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs, 1998, 16, 333-335.	1.2	8
16	A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Investigational New Drugs, 1998, 16, 325-330.	1.2	29
17	PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Investigational New Drugs, 1998, 16, 315-318.	1.2	2
19	New antimetabolites in cancer chemotherapy and their clinical impact. British Journal of Cancer, 1998, 78, 1-7.	2.9	114
20	Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. British Journal of Cancer, 1998, 78, 9-13.	2.9	22
21	The role of gemcitabine in the treatment of other tumours. British Journal of Cancer, 1998, 78, 21-25.	2.9	129
22	A Phase II pilot trial of 13-cis retinoic acid and interferon-? in patients with advanced pancreatic carcinoma. Cancer, 1998, 83, 2317-2323.	2.0	39

#	Article	IF	Citations
23	Evolving trends in combined modality therapy for pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 227-234.	2.0	5
24	Chemotherapy in the treatment of cancer of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 235-241.	2.0	27
25	Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 242-250.	2.0	37
26	Chemotherapy and chemoradiotherapy for esophageal cancer. Critical Reviews in Oncology/Hematology, 1998, 28, 173-180.	2.0	10
27	Adjuvant therapy for pancreatic cancer: back to the future. International Journal of Radiation Oncology Biology Physics, 1998, 42, 59-63.	0.4	38
28	Gemcitabine-associated autonomic neuropathy. Lancet, The, 1998, 351, 644.	6.3	22
29	Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treatment Reviews, 1998, 24, 133-156.	3.4	24
31	Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 1998, 34, 1358-1362.	1.3	26
32	Limited options for patients with pancreatic cancer. Drugs and Therapy Perspectives, 1998, 12, 8-10.	0.3	0
33	Evaluation of Clinical Benefit of Chemotherapy in Patients with Upper Gastrointestinal Cancer. Acta OncolÃ³gica, 1998, 37, 651-659.	0.8	25
34	Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.. International Journal of Oncology, 1998, 12, 825-32.	1.4	21
35	Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.. International Journal of Oncology, 1998, 13, 839-48.	1.4	24
36	Palliative chemotherapy. American Journal of Hospice and Palliative Medicine, 1998, 15, 93-103.	0.8	12
37	Phase II Study with Gemcitabine in Gallbladder and Biliary Tract Carcinomas_a. Oncology Research and Treatment, 1998, 21, 232-234.	0.8	26
39	Single-dose etoposide in advanced pancreatic and biliary cancer, a phase II study.. Oncology Reports, 1998, 5, 931-4.	1.2	20
40	Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Annals of Oncology, 1998, 9, 1003-1008.	0.6	82
41	Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study. Annals of Oncology, 1998, 9, 1035-1037.	0.6	14
42	Gemcitabine â€“ a major advance?. Annals of Oncology, 1998, 9, 1265-1267.	0.6	10

#	Article	IF	Citations
43	A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Annals of Oncology, 1998, 9, 1343-1345.	0.6	121
44	Second bone marrow transplantation in non-Hodgkin's lymphoma.. Journal of Clinical Oncology, 1998, 16, 804-806.	0.8	4
45	Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Frontiers in Bioscience - Landmark, 1998, 3, e193-203.	3.0	20
46	Clinical benefit as a primary efficacy endpoint.. Journal of Clinical Oncology, 1998, 16, 803-804.	0.8	12
47	Is concomitant radiotherapy and chemotherapy superior to optimal radiotherapy alone in anal cancer?. Journal of Clinical Oncology, 1998, 16, 802-803.	0.8	3
48	Chemotherapy for Advanced Pancreatic Cancer: The History is Changing. Tumori, 1998, 84, 308-311.	0.6	5
49	Adjuvant therapy for pancreatic cancer current status. Frontiers in Bioscience - Landmark, 1998, 3, e186-192.	3.0	13
50	Paclitaxel and concurrent radiation for locally advanced pancreatic carcinoma. Frontiers in Bioscience - Landmark, 1998, 3, e204-206.	3.0	6
51	Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg. Tumori, 1998, 84, 335-347.	0.6	14
52	Trends in Cancer Pain Management. Cancer Control, 1999, 6, 136-145.	0.7	41
53	Chemotherapy for advanced pancreatic cancer: It may no longer be ignored. Annals of Oncology, 1999, 10, 105-110.	0.6	24
54	A phase Iâ€“II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology, 1999, 10, 1377-1379.	0.6	43
55	Phase I-II Study of Gemcitabine and Fluorouracil as a Continuous Infusion in Patients With Pancreatic Cancer. Journal of Clinical Oncology, 1999, 17, 585-585.	0.8	171
56	Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study. Journal of Clinical Oncology, 1999, 17, 1779-1779.	0.8	79
57	Phase II/Pharmacodynamic Trial of Dose-Intensive, Weekly Parenteral Hydroxyurea and Fluorouracil Administered With Interferon Alfa-2a in Patients With Refractory Malignancies of the Gastrointestinal Tract. Journal of Clinical Oncology, 1999, 17, 1771-1771.	0.8	9
58	Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development. Journal of Clinical Oncology, 1999, 17, 3631-3652.	0.8	511
59	Phase I Trial of Twice-Weekly Gemcitabine and Concurrent Radiation in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 1999, 17, 2208-2208.	0.8	226
60	Pancreatic Disease in the Elderly. Clinics in Geriatric Medicine, 1999, 15, 579-605.	1.0	26

#	Article	IF	Citations
61	Chemoprotection against Cytosine Nucleoside Analogs Using the Human Cytidine Deaminase Gene. , 1999, 36, 124-142.		3
62	Gastrointestinal Cancer in the Elderly. Clinics in Geriatric Medicine, 1999, 15, 627-640.	1.0	7
63	Evaluation of Palliative Endpoints in Oncology Clinical Trials. Cancer Control, 1999, 6, 1-4.	0.7	13
64	La Chemioterapia Adiuvante Concomitante Del Carcinoma Pancreatico. Tumori, 1999, 85, 36-42.	0.6	0
65	PossibilitÃ Di Palliazione Nel Carcinoma Pancreatico. Tumori, 1999, 85, 47-53.	0.6	3
66	Two Consecutive Phase II Studies of 5-Fluorouracil/Leucovorin/Mitomycin C and of Gemcitabine in Patients with Advanced Biliary Cancer. Oncology, 1999, 56, 177-180.	0.9	132
67	VirulizinÂ® - a review of its antineoplastic activity. Expert Opinion on Investigational Drugs, 1999, 8, 1721-1735.	1.9	10
68	Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. Annals of Oncology, 1999, 10, S305-S307.	0.6	9
69	Gemcitabine: A real major advance?. Annals of Oncology, 1999, 10, 609-610.	0.6	1
70	Palliation of pain and jaundice: An overview. Annals of Oncology, 1999, 10, S165-S169.	0.6	14
71	Anaphylaxis after oxaliplatin. Annals of Oncology, 1999, 10, 610.	0.6	26
72	Pancreaticobiliary cancer: The future aspects of medical oncology. Annals of Oncology, 1999, 10, S296-S299.	0.6	11
73	Current chemotherapeutic possibilities in pancreaticobiliary cancer. Annals of Oncology, 1999, 10, S157-S161.	0.6	23
74	Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?. Journal of the National Cancer Institute, 1999, 91, 1281-1287.	3.0	187
75	Measure Once or TwiceÂDoes It Really Matter?. Journal of the National Cancer Institute, 1999, 91, 494-495.	3.0	12
76	Evaluation of Pancreatic Proteolytic Enzyme Treatment of Adenocarcinoma of the Pancreas, With Nutrition and Detoxification Support. Nutrition and Cancer, 1999, 33, 117-124.	0.9	61
77	Pancreatic Disease. , 1999, , .		0
78	Irradiation for unresectable pancreatic cancer. Journal of Gastrointestinal Surgery, 1999, 3, 351-353.	0.9	0

#	Article	IF	Citations
79	Chemotherapy for pancreatic adenocarcinoma. Journal of Gastrointestinal Surgery, 1999, 3, 354-356.	0.9	0
80	Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 1999, 45, 291-295.	0.4	35
81	Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. British Journal of Haematology, 1999, 106, 78-85.	1.2	125
82	The Matrix Metalloproteinases and Their Inhibitors in the Treatment of Pancreatic Cancer. Annals of the New York Academy of Sciences, 1999, 880, 288-307.	1.8	86
83	Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer, 1999, 79, 491-494.	2.9	7
84	A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer, 1999, 80, 1595-1598.	2.9	81
85	Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. British Journal of Cancer, 1999, 80, 1797-1802.	2.9	41
86	Adjuvant Therapy for Pancreatic Cancer. World Journal of Surgery, 1999, 23, 937-945.	0.8	39
87	Palliative Chemotherapy and Radiotherapy for Pancreatic Cancer: Is It Worthwhile?. World Journal of Surgery, 1999, 23, 950-953.	0.8	7
88	Role of chemotherapy against micrometastatic cancer. Cancer and Metastasis Reviews, 1999, 18, 151-172.	2.7	1
89	Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Investigational New Drugs, 1999, 17, 57-61.	1.2	25
90	Supraadditive effect of 2 â€² ,2 â€² -difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemotherapy and Pharmacology, 1999, 44, 117-123.	1.1	148
93	Fortschritte in der zytostatischen und supportiven Therapie des Pankreaskarzinoms. Onkologe, 1999, 5, 221-226.	0.7	1
94	Assessment of the quality of life of patients with advanced and end-stage cancer or serious infections with a symptom-based or an impact-based instrument. Supportive Care in Cancer, 1999, 7, 64-70.	1.0	10
95	Chemoradiation for Localized Pancreatic Cancer: Another Perspective. Annals of Surgical Oncology, 1999, 6, 4-7.	0.7	5
96	Chemoradiotherapy in the Management of Localized Tumors of the Pancreas. Annals of Surgical Oncology, 1999, 6, 117-122.	0.7	22
97	Non-surgical treatments of pancreatic cancer. International Journal of Clinical Oncology, 1999, 4, 257-266.	1.0	14
98	Invited Commentary. Current Gastroenterology Reports, 1999, 1, 87-88.	1.1	2

#	Article	IF	Citations
99	Carcinoma of the Pancreas. Current Treatment Options in Gastroenterology, 1999, 2, 227-237.	0.3	1
100	An investigational new drug treatment program for patients with gemcitabine. Cancer, 1999, 85, 1261-1268.	2.0	237
101	Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. , 1999, 85, 1269-1276.		34
102	New Chemoimmunotherapy: Courtesy of a More Flexible Food and Drug Administration. Cancer Investigation, 1999, 17, 371-373.	0.6	0
103	A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. European Journal of Cancer, 1999, 35, 1805-1808.	1.3	13
105	Management of cancer pain. Lancet, The, 1999, 353, 1695-1700.	6.3	719
106	Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology, 1999, 53, 243-250.	0.5	16
107	AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 1999, 117, 1464-1484.	0.6	354
108	Recent advances in cancer chemotherapy. Academic Radiology, 1999, 6, 696-705.	1.3	0
109	Practical Recommendations for the Management of Adenocarcinoma of the Pancreas. Drugs, 1999, 57, 69-79.	4.9	13
110	Treatment of cancer of the exocrine pancreas. American Journal of Surgery, 1999, 177, 257-265.	0.9	34
111	Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology, 1999, 17, 485-485.	0.8	757
112	Gemcitabine for the Treatment of Advanced Biliary Tract Carcinomas: Evaluation of Two Different Dose Regimens. Oncology Research and Treatment, 1999, 22, 498-501.	0.8	18
113	Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial. Annals of Oncology, 1999, 10, 1307-1310.	0.6	48
114	Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565. Journal of Clinical Oncology, 2000, 18, 2780-2787.	0.8	177
115	Phase II study of the multitargeted antifolate LY231514 (ALIMTAâ„¢, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Annals of Oncology, 2000, 11, 101-104.	0.6	84
116	A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296). Oncology, 2000, 58, 215-218.	0.9	77
117	Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anti-Cancer Drugs, 2000, 11, 623-628.	0.7	32

#	Article	IF	Citations
118	Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anti-Cancer Drugs, 2000, 11, 635-638.	0.7	80
119	The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anti-Cancer Drugs, 2000, 11, 771-786.	0.7	25
120	A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: Correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Annals of Oncology, 2000, 11, 1165-1170.	0.6	16
121	Intra-arterial chemotherapy for unresectable pancreatic cancer. Annals of Oncology, 2000, 11, 569-574.	0.6	20
122	Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Annals of Oncology, 2000, 11, 1399-1403.	0.6	138
123	A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology, 2000, 11, 1309-1312.	0.6	32
124	Unresectable Adenocarcinoma of the Pancreas: Patterns of Failure and Treatment Results. Cancer Investigation, 2000, 18, 309-313.	0.6	12
125	Phase I clinical trial of allogeneic mixed lymphocyte culture (cytoimplant) delivered by endoscopic ultrasound?guided fine-needle injection in patients with advanced pancreatic carcinoma. , 2000, 88, 1325-1335.		255
126	Gangliosides as targets for immunotherapy for pancreatic adenocarcinoma. Cancer, 2000, 88, 1828-1836.	2.0	29
127	A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer, 2000, 88, 2505-2511.	2.0	43
128	Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer, 2000, 89, 74-82.	2.0	149
129	Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. Cancer, 2000, 89, 314-327.	2.0	194
130	Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. Cancer, 2000, 89, 1706-1713.	2.0	34
131	Cost analysis of pancreatic carcinoma treatment. Cancer, 2000, 89, 1917-1924.	2.0	39
135	Management of the frail person with advanced cancer. Critical Reviews in Oncology/Hematology, 2000, 33, 143-148.	2.0	90
136	Gene therapy for pancreatic cancerâ€"current and prospective strategies. Surgical Oncology, 2000, 9, 181-191.	0.8	23
137	Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast, 2000, 9, 338-342.	0.9	83
138	Pharmacokinetics of Gemcitabine and 2',2'-Difluorodeoxyuridine in a Patient with Ascites. Pharmacotherapy, 2000, 20, 1204-1207.	1.2	7

#	Article	IF	Citations
139	Current approaches and future strategies for pancreatic carcinoma. Investigational New Drugs, 2000, 18, 43-56.	1.2	33
140	A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413). Investigational New Drugs, 2000, 18, 269-273.	1.2	13
141	Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. Clinical and Experimental Metastasis, 2000, 18, 379-384.	1.7	21
142	Evaluation of Gemcitabine in Patients with Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group. Gynecologic Oncology, 2000, 76, 204-207.	0.6	82
143	Decrease of CA 19â€“9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. British Journal of Cancer, 2000, 82, 1013-1016.	2.9	183
144	Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. British Journal of Cancer, 2000, 82, 1772-1775.	2.9	44
145	FDGâ€“PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. British Journal of Cancer, 2000, 83, 287-293.	2.9	111
146	Intra-Arterial Continuous Infusion for Treatment of Pancreatic and Biliary Tract Cancer: A Dose-Escalation Study of Fluorouracil Combined with Gemcitabine. International Journal of Gastrointestinal Cancer, 2000, 27, 225-234.	0.4	10
147	Pancreatic cancer. Current Treatment Options in Oncology, 2000, 1, 375-386.	1.3	28
148	New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production. Cancer Chemotherapy and Pharmacology, 2000, 45, 502-508.	1.1	15
149	Combined chemotherapy, radiotherapy, and immunotherapy for pancreatic carcinomaâ€”A case report. Advances in Therapy, 2000, 17, 133-139.	1.3	3
150	Outcomes Research in Surgical Oncology. Annals of Surgical Oncology, 2000, 7, 367-375.	0.7	32
151	The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery, 2000, 7, 53-57.	2.0	5
152	Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Annals of Oncology, 2000, 11, 183-188.	0.6	39
153	Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer.. Oncology Reports, 2000, 7, 875-7.	1.2	13
154	A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Annals of Oncology, 2000, 11, 421-426.	0.6	27
155	New Directions in Systemic Therapy of Pancreatic Cancer. Cancer Control, 2000, 7, 437-444.	0.7	18
156	A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Annals of Oncology, 2000, 11, 1267-1272.	0.6	48

#	Article	IF	Citations
157	Eastern Cooperative Oncology Group Phase I Trial of Protracted Venous Infusion Fluorouracil Plus Weekly Gemcitabine With Concurrent Radiation Therapy in Patients With Locally Advanced Pancreas Cancer: A Regimen With Unexpected Early Toxicity. Journal of Clinical Oncology, 2000, 18, 3384-3389.	0.8	115
158	SPECIAL DEPARTMENTS. Journal of Clinical Oncology, 2000, 18, 445-445.	0.8	3
159	Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Annals of Oncology, 2000, 11, 1161-1164.	0.6	26
160	A multispecialty approach to the diagnosis and management of pancreatic cancer. American Journal of Gastroenterology, 2000, 95, 17-31.	0.2	148
161	Impact of endoscopic ultrasound on the management and outcome of pancreatic carcinoma. American Journal of Gastroenterology, 2000, 95, 2248-2254.	0.2	68
162	Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.. International Journal of Oncology, 2000, 16, 1015-20.	1.4	5
163	Novel non-operative treatment and treatment strategies in pancreatic cancer. Expert Opinion on Investigational Drugs, 2000, 9, 1179-1195.	1.9	7
164	Pancreatic and hepatobiliary cancers: New treatment possibilities for pancreatic and biliary tumours. Annals of Oncology, 2000, 11, 165-172.	0.6	5
165	Chemotherapy for upper gastrointestinal tumours. Postgraduate Medical Journal, 2000, 76, 321-321.	0.9	8
166	A phase II study. European Journal of Cancer, 2000, 36, 1016-1025.	1.3	195
167	Regional chemotherapy in the treatment of advanced pancreatic cancerÂâ€" is it relevant?. European Journal of Cancer, 2000, 36, 957-965.	1.3	29
168	CANCER AND AGING. Hematology/Oncology Clinics of North America, 2000, 14, 1-16.	0.9	159
169	The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents. Drugs, 2000, 60, 1-14.	4.9	54
170	THE IMPORTANCE OF QUALITY-OF-LIFE ENDPOINTS IN CLINICAL TRIALS TO THE PRACTICING ONCOLOGIST. Hematology/Oncology Clinics of North America, 2000, 14, 877-886.	0.9	18
172	Gemcitabine in the treatment of bladder cancer. Expert Opinion on Pharmacotherapy, 2000, 1, 547-553.	0.9	2
173	CANCER IN THE FRAIL PATIENT. Hematology/Oncology Clinics of North America, 2000, 14, 235-250.	0.9	119
174	Acute enlargement and subsequent rupture of an abdominal aortic aneurysm in a patient receiving chemotherapy for pancreatic carcinoma. Journal of Vascular Surgery, 2000, 32, 197-200.	0.6	38
175	Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Gastroenterology, 2000, 118, A647.	0.6	0

#	Article	IF	Citations
176	SURGICAL MANAGEMENT OF HEREDITARY PANCREATIC CANCER. Medical Clinics of North America, 2000, 84, 749-759.	1.1	15
177	Pancreatic Cancer. Drugs, 2000, 59, 1071-1089.	4.9	71
178	Gemcitabine-Associated Pneumocystis carinii Pneumonia. Clinical Drug Investigation, 2000, 20, 65-66.	1.1	2
179	Assessment of Quality of Life During Chemotherapy. Acta OncolÃ³gica, 2001, 40, 175-184.	0.8	53
180	Personal experience in advanced pancreatic cancer: retrospective analysis on the use of 5-fluorouracil or gemcitabine. Digestive and Liver Disease, 2001, 33, 503.	0.4	0
181	Gemcitabine: Progress in the Treatment of Pancreatic Cancer. Oncology, 2001, 60, 8-18.	0.9	142
182	CÃ¡ncer de pÃ¡ncreas. Medicine, 2001, 8, 3165-3171.	0.0	0
183	Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma. International Journal of Clinical Oncology, 2001, 6, 59-65.	1.0	11
184	Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. European Journal of Surgical Oncology, 2001, 27, 477-481.	0.5	8
185	Novel clinical strategies for the treatment of pancreatic carcinoma. Trends in Molecular Medicine, 2001, 7, 30-37.	3.5	36
186	Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. European Journal of Cancer, 2001, 37, 1381-1384.	1.3	10
187	Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, The, 2001, 358, 1576-1585.	6.3	1,019
188	Gastrointestinal malignancies. Primary Care - Clinics in Office Practice, 2001, 28, 647-660.	0.7	4
189	ADJUVANT THERAPY FOR PANCREATIC CANCER. Surgical Clinics of North America, 2001, 81, 667-681.	0.5	14
190	TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA. Surgical Clinics of North America, 2001, 81, 683-690.	0.5	8
191	Activity of Gemcitabine and Continuous Infusion Fluorouracil in Advanced Pancreatic Cancer. Oncology, 2001, 60, 43-48.	0.9	32
192	Concomitant Radiotherapy with Protracted 5-fluorouracil Infusion in Locally Advanced Carcinoma of the Pancreas: A Phase Ii Study. Tumori, 2001, 87, 398-401.	0.6	9
193	Pancreatic Cancer: Does Octreotide Offer Any Promise?. Chemotherapy, 2001, 47, 134-149.	0.8	9

#	Article	IF	Citations
194	Matrix Metalloproteinase Inhibition of Pancreatic Cancer: Matching Mechanism of Action to Clinical Trial Design. Journal of Clinical Oncology, 2001, 19, 3445-3446.	0.8	23
195	Palliative systemic antineoplastic therapy. , 2001, , 399-420.		0
196	Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factorâ€"Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. Journal of Clinical Oncology, 2001, 19, 145-156.	0.8	542
197	Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2001, 19, 4202-4208.	0.8	300
199	Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer. Annals of Oncology, 2001, 12, 101-103.	0.6	54
200	Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial. Journal of Clinical Oncology, 2001, 19, 3447-3455.	0.8	410
201	Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?. Journal of Clinical Oncology, 2001, 19, 265-272.	0.8	324
202	Gemcitabine in Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 296-298.	0.6	16
203	Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 496-499.	0.6	142
204	Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Annals of Oncology, 2001, 12, 675-679.	0.6	41
205	A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma. Annals of Oncology, 2001, 12, 1399-1402.	0.6	51
206	Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatinâ€"vindesine. Annals of Oncology, 2001, 12, 1221-1230.	0.6	94
207	Is there quality in clinical benefit?. Annals of Oncology, 2001, 12, 1191-1193.	0.6	9
208	Definitive Results of a Phase II Trial of Cisplatin, Epirubicin, Continuous-Infusion Fluorouracil, and Gemcitabine in Stage IV Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2001, 19, 2679-2686.	0.8	85
209	Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Annals of Oncology, 2001, 12, 183-186.	0.6	160
210	Retinoic Acid Enhances the Cytotoxic Effects of Gemcitabine and Cisplatin in Pancreatic Adenocarcinoma Cells. Pancreas, 2001, 23, 273-279.	0.5	43
211	Evaluation of pancreatic carcinoma with FDG PET. Abdominal Imaging, 2001, 26, 254-259.	2.0	54
212	Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer. Current Gastroenterology Reports, 2001, 3, 129-135.	1.1	7

#	Article	IF	Citations
213	Quâ€™apporte lâ€™Ã©choendoscopie dans le cancer du pancrÃ©as?. Acta Endoscopica, 2001, 31, 43-55.	0.0	4
214	Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. International Journal of Radiation Oncology Biology Physics, 2001, 49, 665-671.	0.4	32
215	Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1275-1279.	0.4	57
216	Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. International Journal of Radiation Oncology Biology Physics, 2001, 50, 1317-1322.	0.4	85
217	Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer 1 1Preliminary abstract submitted to the 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May 20â€“23, 2000.. International Journal of Radiation Oncology Biology Physics, 2001, 51, 974-981.	0.4	24
219	Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Critical Reviews in Oncology/Hematology, 2001, 39, 147-154.	2.0	33
220	Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas. Journal of Gastrointestinal Surgery, 2001, 5, 2-5.	0.9	20
221	A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer, 2001, 92, 414-419.	2.0	23
222	Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer, 2001, 92, 569-577.	2.0	126
223	Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. International Journal of Cancer, 2001, 96, 132-139.	2.3	38
224	Phase II Study of Concurrent Gemcitabine and Radiotherapy in Locally Advanced Stage IIIB Cervical Carcinoma. Gynecologic Oncology, 2001, 81, 404-407.	0.6	33
225	Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine. Investigational New Drugs, 2001, 19, 101-104.	1.2	19
226	Toxicity and Efficacy of Concurrent Gemcitabine and Radiotherapy for Locally Advanced Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2001, 29, 09-18.	0.4	82
227	Phase I Study of Concomitant Gemcitabine and IMRT for Patients with Unresectable Adenocarcinoma of the Pancreatic Head. International Journal of Gastrointestinal Cancer, 2001, 30, 123-132.	0.4	57
228	A phase II trial of marimastat in advanced pancreatic cancer. British Journal of Cancer, 2001, 85, 1865-1870.	2.9	91
229	Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy, 2001, 8, 308-315.	2.3	274
230	Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia, 2001, 15, 875-890.	3.3	423
231	Gemcitabine/Carboplatin Versus Cisplatin/Etoposide for Patients With Poor-Prognosis Small Cell Lung Cancer: A Phase III Randomized Trial With Quality-of-Life Evaluation. Seminars in Oncology, 2001, 28, 15-18.	0.8	12

#	Article	IF	Citations
232	Combining Gemcitabine With Radiation in Pancreatic Cancer: Understanding Important Variables Influencing the Therapeutic Index. Seminars in Oncology, 2001, 28, 25-33.	0.8	29
233	Phase II Study of Gemcitabine, 5-Fluorouracil, and Leucovorin in Patients With Pancreatic Cancer. Seminars in Oncology, 2001, 28, 44-49.	0.8	10
234	Recent advances in the use of radiosensitizing nucleosides. Seminars in Radiation Oncology, 2001, 11, 270-280.	1.0	50
235	Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications. Surgical Oncology, 2001, 10, 1-23.	0.8	26
236	Combination Gemcitabine and Docetaxel Therapy in Advanced Adenocarcinoma of the Pancreas. Oncology, 2001, 60, 316-321.	0.9	54
237	Irinotecan Combined with Gemcitabine, 5â€Fluorouracil, Leucovorin, and Cisplatin (Gâ€FLIP) is an Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer. Oncologist, 2001, 6, 488-495.	1.9	81
238	Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2001, 31, 7-12.	0.6	61
239	Gemcitabine in the Second-Line Therapy of Patients with Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research Network. Cancer Investigation, 2001, 19, 335-339.	0.6	53
240	Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors. Expert Review of Anticancer Therapy, 2001, 1, 258-268.	1.1	3
241	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. British Journal of Cancer, 2001, 85, 1850-1852.	2.9	36
242	Assessment of Quality of Life During Chemotherapy. Acta OncolÃ³gica, 2001, 40, 175-184.	0.8	65
243	Survival and quality of life in gastrointestinal tumors: Two different end points?. Annals of Oncology, 2001, 12, S31-S36.	0.6	5
244	Quality of life as a primary end point in oncology. Annals of Oncology, 2001, 12, S3-S6.	0.6	61
245	Pancreatic Cancer: Cost-Effectiveness of Imaging Technologies for Assessing Resectability. Radiology, 2001, 221, 93-106.	3.6	51
246	Long term survival after pancreatic resection for pancreatic adenocarcinoma. American Journal of Gastroenterology, 2001, 96, 2609-2615.	0.2	91
247	Current Options for Palliative Treatment in Patients with Pancreatic Cancer. Digestive Diseases, 2001, 19, 63-75.	0.8	9
249	Aktueller Stand multimodaler Therapiekonzepte beim Pankreaskarzinom. Viszeralchirurgie, 2001, 36, 20-28.	0.0	3
251	Inhibition of Growth and Metastasis of Human Pancreatic Cancer Growing in Nude Mice by PTK 787/ZK222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases. Cancer Biotherapy and Radiopharmaceuticals, 2001, 16, 359-370.	0.7	105

#	Article	IF	Citations
252	Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 1182-1191.	0.8	85
253	Phase II Study of Antiâ€"Gastrin-17 Antibodies, Raised to G17DT, in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 4225-4231.	0.8	105
254	Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Annals of Oncology, 2002, 13, 1756-1762.	0.6	31
255	Phase I study of rubitecan and gemcitabine in patients with advanced malignancies. Annals of Oncology, 2002, 13, 1819-1825.	0.6	9
256	Assessing outcomes in palliative chemotherapy. Expert Opinion on Pharmacotherapy, 2002, 3, 693-700.	0.9	5
257	Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297. Journal of Clinical Oncology, 2002, 20, 3270-3275.	0.8	679
258	Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. British Journal of Cancer, 2002, 86, 1270-1275.	2.9	109
259	A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. British Journal of Cancer, 2002, 86, 1551-1554.	2.9	57
260	A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. British Journal of Cancer, 2002, 86, 680-685.	2.9	125
261	Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients. British Journal of Cancer, 2002, 87, 716-719.	2.9	15
262	Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. British Journal of Cancer, 2002, 87, 497-501.	2.9	22
263	A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. British Journal of Cancer, 2002, 87, 161-167.	2.9	514
264	Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study. Journal of Clinical Oncology, 2002, 20, 1512-1518.	0.8	144
265	Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Annals of Oncology, 2002, 13, 553-557.	0.6	23
266	Novel endpoints and design of early clinical trials. Annals of Oncology, 2002, 13, 139-143.	0.6	46
267	Phase Iâ€"II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Annals of Oncology, 2002, 13, 1479-1489.	0.6	70
268	Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils. International Journal of Oncology, 2002, 21, 649.	1.4	4
269	Localized Adenocarcinoma of the Pancreas: The Rationale for Preoperative Chemoradiation. Oncologist, 2002, 7, 34-45.	1.9	75

#	Article	IF	Citations
270	Photodynamic Therapy and Endoscopic Ultrasound-Guided Therapy for Pancreatic Cancer. , 2002, , 343-346.		0
272	Novel treatments and therapies in development for pancreatic cancer. Expert Opinion on Investigational Drugs, 2002, 11, 769-786.	1.9	21
274	An Introduction to Pancreatic Adenocarcinoma Genetics, Pathology and Therapy. Cancer Biology and Therapy, 2002, 1, 607-613.	1.5	44
275	Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2002, 20, 674-679.	0.8	23
276	Low-dose trimetrexate glucuronate and protracted5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer. Annals of Oncology, 2002, 13, 582-588.	0.6	3
277	Advanced pancreatic cancerâ€"5 years on. Annals of Oncology, 2002, 13, 1165-1168.	0.6	8
278	Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 160-164.	0.8	127
279	New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer. Acta OncolÃ³gica, 2002, 41, 582-595.	0.8	37
280	Phase I Evaluation of Prolonged-Infusion Gemcitabine With Irinotecan for Relapsed or Refractory Leukemia or Lymphoma. Journal of Clinical Oncology, 2002, 20, 2995-3000.	0.8	28
281	Phase II Study of Gemcitabine, UFT and Leucovorin in Patients with Advanced Pancreatic Cancer. Acta OncolÃ³gica, 2002, 41, 689-694.	0.8	10
282	Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Annals of Oncology, 2002, 13, 1576-1582.	0.6	15
283	A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Annals of Oncology, 2002, 13, 1185-1191.	0.6	113
284	Photodynamic therapy for cancer of the pancreas. Gut, 2002, 50, 549-557.	6.1	264
285	Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 3130-3136.	0.8	132
286	Raltitrexed: current clinical status and future directions. Annals of Oncology, 2002, 13, 513-522.	0.6	62
287	Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-GuÃ©rinâ€"Refractory Transitional-Cell Carcinoma of the Bladder. Journal of Clinical Oncology, 2002, 20, 3193-3198.	0.8	189
288	A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study. Oncology, 2002, 62, 299-304.	0.9	16
289	Translational Research: Stop, Look, Listenâ€"If You Expect to Grow Up Tall. Cancer Biology and Therapy, 2002, 1, 718-720.	1.5	0

#	Article	IF	Citations
290	Pancreatic Cancer: Evidence-Based Diagnosis and Treatment. Clinical Obstetrics and Gynecology, 2002, 45, 855-865.	0.6	2
291	Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin. Pancreas, 2002, 25, 360-365.	0.5	28
292	New drugs for patients with pancreatic cancer. Current Opinion in Oncology, 2002, 14, 621-627.	1.1	12
293	Palliative MEFLEP Therapy in Advanced Pancreatic Cancer: Excellent Response in a Patient with Her-2/neu Amplification. Pancreas, 2002, 25, e10-e14.	0.5	2
294	Update on pancreatic cancer. Current Opinion in Oncology, 2002, 14, 424-430.	1.1	30
295	Intraoperative hyperthermia in conjunction with multi-schedule chemotherapy (pre-, intra- and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 pancreatic adenocarcinoma. International Journal of Hyperthermia, 2002, 18, 233-252.	1.1	16
296	EUS-guided fine needle aspiration of the liver: Indications, yield, and safety based on an international survey of 167 cases. Gastrointestinal Endoscopy, 2002, 55, 859-862.	0.5	190
297	Overview: Gemcitabine as Single-Agent Therapy for Advanced Breast Cancers. Clinical Breast Cancer, 2002, 3, S8-S11.	1.1	22
298	The Palliative Benefit of Irinotecan in 5-Fluorouracilâ€"Refractory Colorectal Cancer: Its Prospective Evaluation by a Multicenter Canadian Trial. Clinical Colorectal Cancer, 2002, 2, 93-101.	1.0	17
299	Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma. Clinical Lymphoma and Myeloma, 2002, 3, 97-104.	2.1	18
300	NMR Structure of a Gemcitabine-Substituted Model Okazaki Fragmentâ€. Biochemistry, 2002, 41, 839-846.	1.2	23
301	Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial. Oncology, 2002, 62, 2-8.	0.9	138
302	Regional chemotherapy. Hematology/Oncology Clinics of North America, 2002, 16, 199-215.	0.9	2
303	Advanced Pancreatic Cancer. American Journal of Cancer, 2002, 1, 323-340.	0.4	5
304	Strategies for Improving Quality of Life in Older Patients with Metastatic Breast Cancer. Drugs and Aging, 2002, 19, 605-622.	1.3	15
305	Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 2002, 51, vi1-vi9.	6.1	441
306	Phase II Study of Docetaxel in Patients with Pancreatic Cancer Previously Untreated with Cytotoxic Chemotherapy. Cancer Investigation, 2002, 20, 464-472.	0.6	39
307	Toxicity of a 24-Hour Infusion of Gemcitabine in Biliary Tract and Pancreatic Cancer: A Pilot Study. Cancer Investigation, 2002, 20, 180-185.	0.6	10

#	Article	IF	Citations
308	Emerging biological therapies for pancreatic carcinoma. European Journal of Surgical Oncology, 2002, 28, 370-378.	0.5	16
309	Gemcitabineâ€“radiotherapy in patients with locally advanced pancreatic cancer. European Journal of Cancer, 2002, 38, 1212-1217.	1.3	75
310	Baseline quality of life predicts survival in patients with advanced colorectal cancer. European Journal of Cancer, 2002, 38, 1351-1357.	1.3	210
311	Vinorelbine in androgen-independent metastatic prostatic carcinomaâ€”a phase II study. European Journal of Cancer, 2002, 38, 1626-1632.	1.3	31
312	Pemetrexed: a multitargeted antifolate (ALIMTAâ„¢, LY-231514). Expert Review of Anticancer Therapy, 2002, 2, 13-22.	1.1	14
313	A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. Hematology/Oncology Clinics of North America, 2002, 16, 123-138.	0.9	7
314	Randomized Clinical Trials in Pancreatic Cancer. Surgical Oncology Clinics of North America, 2002, 11, 207-229.	0.6	34
315	Exploiting molecular targets in pancreatic cancer. Hematology/Oncology Clinics of North America, 2002, 16, 139-157.	0.9	10
316	Interventional endoscopy, and neoadjuvant therapy and the gastroenterologist. Hematology/Oncology Clinics of North America, 2002, 16, 53-79.	0.9	8
317	The Clinical Significance of Quality-of-Life Results: Practical Considerations for Specific Audiences. Mayo Clinic Proceedings, 2002, 77, 572-583.	1.4	83
318	Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 1182-1191.	0.8	125
319	Cytotoxic Chemotherapy for Pancreatic Cancer: Past, Present, and Future. , 2002, , 311-320.		0
321	Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study. Journal of Clinical Oncology, 2002, 20, 1512-1518.	0.8	191
322	Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia. Journal of Clinical Oncology, 2002, 20, 674-679.	0.8	36
323	Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 160-164.	0.8	155
324	Pyrimidine Antimetabolites. , 2002, , 527-534.		0
325	Pancreatic Cancer: What the Oncologist Can Offer for Palliation. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 121-124.	1.8	7
326	Antiangiogenic Strategies in Pancreatic Cancer. , 2002, , 357-367.		2

#	Article	IF	Citations
327	Postoperative Adjuvant Therapy: Past, Present, and Future Trial Development. , 2002, , 235-242.		3
328	Gemcitabine-based combination treatment of pancreatic cancer. Seminars in Oncology, 2002, 29, 25-35.	0.8	62
329	Present and future treatment of pancreatic cancer. Seminars in Oncology, 2002, 29, 23-31.	0.8	45
330	Complementary and alternative medicine: Opportunities and challenges for cancer management and research. Seminars in Oncology, 2002, 29, 531-545.	0.8	63
331	High-dose intravenous gamolenate reduces survival time in people with inoperable pancreatic cancer. Evidence-based Oncology, 2002, 3, 87-89.	0.1	0
332	Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality. Seminars in Oncology, 2002, 29, 2-8.	0.8	8
333	Gemcitabine in the treatment of advanced pancreatic cancer: A comparative analysis of randomized trials. Seminars in Oncology, 2002, 29, 9-16.	0.8	16
334	Future directions in the treatment of pancreatic cancer. Seminars in Oncology, 2002, 29, 31-39.	0.8	7
335	Review of gemcitabine in biliary tract carcinoma. Seminars in Oncology, 2002, 29, 40-45.	0.8	27
336	Pemetrexed in pancreatic cancer. Seminars in Oncology, 2002, 29, 49-53.	0.8	4
337	Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Seminars in Oncology, 2002, 29, 31-37.	0.8	35
338	Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Seminars in Oncology, 2002, 29, 55-60.	0.8	19
339	Pemetrexed in patients with gastrointestinal carcinoma. Seminars in Oncology, 2002, 29, 42-49.	0.8	5
340	Improving the information content of categorical clinical trial endpoints. Contemporary Clinical Trials, 2002, 23, 502-514.	2.0	49
341	The Importance of Quality-of-Life Measurements in Oncology. Clinical Lung Cancer, 2002, 4, 110.	1.1	0
342	Assessment of Patient-Reported Clinical Outcome in Pancreatic and Other Hepatobiliary Cancers. Journal of Pain and Symptom Management, 2002, 24, 32-44.	0.6	80
343	Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis. Journal of Surgical Oncology, 2002, 79, 10-16.	0.8	24
344	Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. Journal of Surgical Oncology, 2002, 81, 138-143.	0.8	83

#	Article	IF	Citations
345	Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. International Journal of Cancer, 2002, 102, 101-108.	2.3	141
346	Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. International Journal of Cancer, 2002, 97, 386-392.	2.3	47
347	A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer, 2002, 94, 97-103.	2.0	89
348	Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. Cancer, 2002, 94, 902-910.	2.0	347
349	New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer, 2002, 95, 941-945.	2.0	75
350	On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer, 2002, 95, 933-940.	2.0	38
351	The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer, 2002, 95, 928-932.	2.0	27
352	Gemcitabine-based therapy in pancreas cancer. Cancer, 2002, 95, 923-927.	2.0	42
353	Gemcitabine and platinum combinations in pancreatic cancer. Cancer, 2002, 95, 908-911.	2.0	17
354	Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer, 2002, 95, 912-922.	2.0	38
355	Metastatic pancreatic cancer. Current Treatment Options in Oncology, 2002, 3, 449-457.	1.3	23
356	Current and future strategies for combined-modality therapy in pancreatic cancer. Current Oncology Reports, 2002, 4, 202-212.	1.8	8
357	NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Langenbeck's Archives of Surgery, 2002, 386, 570-574.	0.8	35
358	Efficacy of Ukrain in the treatment of pancreatic cancer. Langenbeck's Archives of Surgery, 2002, 387, 84-89.	0.8	13
359	What's new in pancreatic cancer treatment?. Journal of Hepato-Biliary-Pancreatic Surgery, 2002, 9, 61-75.	2.0	10
360	Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. British Journal of Surgery, 2002, 88, 662-668.	0.1	38
361	Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Critical Reviews in Oncology/Hematology, 2002, 43, 57-62.	2.0	15
362	Multimodality Treatment Approaches in Pancreatic Cancer: Current Status and Future Perspectives. European Surgery - Acta Chirurgica Austriaca, 2002, 34, 42-57.	0.3	3

#	Article	IF	Citations
363	Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. European Journal of Cancer Care, 2002, 11, 100-107.	0.7	11
364	Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1293-1302.	0.4	190
365	Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. International Journal of Radiation Oncology Biology Physics, 2002, 53, 140-145.	0.4	41
366	Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 146-150.	0.4	149
367	Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1180-1193.	0.4	107
368	Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers â€“ a new active regimen. British Journal of Cancer, 2002, 87, 850-853.	2.9	15
369	Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 670-676.	0.4	42
370	The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study. Investigational New Drugs, 2002, 20, 117-121.	1.2	15
371	Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Investigational New Drugs, 2002, 20, 351-356.	1.2	74
372	Surgical and medical therapy for pancreatic carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2002, 16, 435-455.	1.0	36
373	Locally Advanced Pancreatic Cancer Treated with Radiation and 5-Fluorouracil. Clinical Oncology, 2002, 14, 308-312.	0.6	12
374	Unresolved Issues in the Management of Locally Advanced Non-Metastatic Pancreas Cancer. Clinical Oncology, 2002, 14, 303-307.	0.6	0
375	Pretreatment CA 19-9 Level as a Prognostic Factor in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine. International Journal of Gastrointestinal Cancer, 2002, 32, 35-42.	0.4	91
376	Drug Development in Pancreatic Cancer: Finally, Biology Begets Therapy. International Journal of Gastrointestinal Cancer, 2003, 32, 91-106.	0.4	0
377	Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer. Journal of Neuro-Oncology, 2003, 63, 201-205.	1.4	25
378	Mitomycin C, Carboplatin and Protracted Venous Infusion 5-Fluorouracil in Advanced Oesophagoâ€“gastric and Pancreatic Cancer: Results of Two Phase II Studies. Clinical Oncology, 2003, 15, 92-97.	0.6	1
379	Current approaches to novel therapeutics in pancreatic cancer. Investigational New Drugs, 2003, 21, 113-129.	1.2	6
380	Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma. Chinese-German Journal of Clinical Oncology, 2003, 2, 213-215.	0.1	0

#	Article	IF	Citations
381	Chemotherapeutic advances in pancreatic cancer. Current Oncology Reports, 2003, 5, 219-226.	1.8	23
382	Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts. Cancer Chemotherapy and Pharmacology, 2003, 51, 247-255.	1.1	12
386	Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. European Journal of Health Economics, 2003, 4, 216-221.	1.4	12
387	Phase-II Trial Using Gemcitabine as Monochemotherapy in Patients with Metastasized Pancreatic Carcinoma. European Surgery - Acta Chirurgica Austriaca, 2003, 35, 337-341.	0.3	1
388	Phase-II Trial Using Gemcitabine as Monochemotherapy in Patients with Metastasized Pancreatic Carcinoma. European Surgery - Acta Chirurgica Austriaca, 2003, 35, 342-343.	0.3	0
389	Palliation of pancreatic cancer using electrolytic ablation. Surgical Endoscopy and Other Interventional Techniques, 2003, 17, 207-211.	1.3	6
390	Quality of life in oncology trials: a clinical guide. Seminars in Radiation Oncology, 2003, 13, 235-247.	1.0	68
391	The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. Colorectal Disease, 2003, 5, 36-44.	0.7	3
392	Design of Phase II cancer trials evaluating survival probabilities. BMC Medical Research Methodology, 2003, 3, 6.	1.4	46
393	Gemcitabine combination chemotherapy of ovarian cancer. Gynecologic Oncology, 2003, 90, S16-S20.	0.6	19
394	Combined modality therapy for pancreatic cancer. Seminars in Oncology, 2003, 30, 71-79.	0.8	27
395	The emerging role of pemetrexed (alimta) and gemcitabine in non-small cell lung cancer. Seminars in Oncology, 2003, 30, 37-44.	0.8	8
396	New perspectives in the management of pancreas cancer. Seminars in Oncology, 2003, 30, 3-10.	0.8	44
397	The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas. Seminars in Oncology, 2003, 30, 54-61.	0.8	43
398	Erlotinib (Tarceva): An update on the clinical trial program. Seminars in Oncology, 2003, 30, 34-46.	0.8	80
399	Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer, 2003, 97, 170-178.	2.0	10
400	Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer, 2003, 97, 1346-1352.	2.0	29
401	Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer, 2003, 98, 1627-1634.	2.0	70

#	Article	IF	Citations
402	A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2003, 55, 1305-1310.	0.4	30
403	Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. International Journal of Radiation Oncology Biology Physics, 2003, 56, 974-980.	0.4	46
404	Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 98-104.	0.4	197
405	Clinical research in pancreatic cancer: The Radiation Therapy Oncology Group trials. International Journal of Radiation Oncology Biology Physics, 2003, 56, 31-37.	0.4	37
406	Chemotherapy for advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2003, 56, 16-23.	0.4	47
407	Radiation therapy with once-weekly gemcitabine in pancreatic cancer: Current status of clinical trials. International Journal of Radiation Oncology Biology Physics, 2003, 56, 10-15.	0.4	35
409	Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?. International Journal of Radiation Oncology Biology Physics, 2003, 56, 3-9.	0.4	24
410	Inhibition of the Phosphatidylinositol 3â€²â€“Kinase Signaling Pathway Increases the Responsiveness of Pancreatic Carcinoma Cells to Sulindac,. Journal of Gastrointestinal Surgery, 2003, 7, 354-363.	0.9	22
411	Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. Journal of Gastrointestinal Surgery, 2003, 7, 766-772.	0.9	91
412	Chemotherapy for pancreatic cancer. Alimentary Pharmacology and Therapeutics, 2003, 18, 1049-1069.	1.9	57
413	Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. British Journal of Cancer, 2003, 88, 1180-1184.	2.9	113
414	A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. British Journal of Cancer, 2003, 89, 239-242.	2.9	20
415	Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. British Journal of Cancer, 2003, 89, 1413-1417.	2.9	151
416	A phase II irinotecanâ€“cisplatin combination in advanced pancreatic cancer. British Journal of Cancer, 2003, 89, 1860-1864.	2.9	10
417	Role of NF-Î¹B and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene, 2003, 22, 3243-3251.	2.6	467
418	Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene, 2003, 22, 7524-7536.	2.6	267
419	Improving the evaluation of new cancer treatments: challenges and opportunities. Nature Reviews Cancer, 2003, 3, 303-309.	12.8	136
420	Rethinking clinical trials for cytostatic drugs. Nature Reviews Cancer, 2003, 3, 540-545.	12.8	68

#	Article	IF	Citations
421	Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines. Pancreatology, 2003, 3, 367-374.	0.5	8
422	Should patients with locally advanced, non-metastatic carcinoma of the pancreas be irradiated?. Pancreatology, 2003, 3, 359-366.	0.5	14
423	The role of intraoperative radiotherapy in pancreatic cancer. Surgical Oncology Clinics of North America, 2003, 12, 965-977.	0.6	27
424	Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. Gastroenterology, 2003, 124, A787.	0.6	0
425	Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology, 2003, 125, 1203-1218.	0.6	111
426	Surrogate end points of quality of life assessment: have we really found what we are looking for?. Health and Quality of Life Outcomes, 2003, 1, 71.	1.0	21
427	Quality of Life and the Treatment of Advanced Lung Cancer. Clinical Lung Cancer, 2003, 5, 28-32.	1.1	24
428	Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade?. Digestive and Liver Disease, 2003, 35, 421-427.	0.4	12
429	RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochemical and Biophysical Research Communications, 2003, 311, 786-792.	1.0	126
430	A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. Journal of Surgical Research, 2003, 113, 151-160.	0.8	132
431	Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Letters, 2003, 201, 107-116.	3.2	106
432	New chemotherapy agents in veterinary medicine. Veterinary Clinics of North America - Small Animal Practice, 2003, 33, 629-649.	0.5	18
433	A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. European Journal of Cancer, 2003, 39, 1377-1383.	1.3	20
434	Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. European Journal of Cancer, 2003, 39, 1547-1551.	1.3	22
435	Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. European Journal of Cancer, 2003, 39, 2334-2340.	1.3	45
436	The â€˜two-weekâ€™ target for the diagnosis of pancreatic carcinoma: an achievable aim?. European Journal of Surgical Oncology, 2003, 29, 575-579.	0.5	7
438	Paclitaxel and Concurrent Radiation in Upper Gastrointestinal Cancers. Cancer Investigation, 2003, 21, 887-896.	0.6	22
439	Developments in the Systemic Therapy of Pancreatic Cancer. Cancer Investigation, 2003, 21, 73-86.	0.6	30

#	Article	IF	Citations
440	Biweekly Low-dose Sequential Gemcitabine, 5-Fluorouracil, Leucovorin, And Cisplatin (Gfp): A Highly Active Novel Therapy For Metastatic Adenocarcinoma Of The Exocrine Pancreas. Cancer Investigation, 2003, 21, 489-496.	0.6	11
441	Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study. Expert Opinion on Pharmacotherapy, 2003, 4, 581-586.	0.9	9
442	Symptom Control. Cancer Investigation, 2003, 21, 564-578.	0.6	13
443	Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Annals of Oncology, 2003, 14, 1291-1298.	0.6	29
444	What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation, 2003, 21, 526-535.	0.6	94
445	Intra-Arterial Infusion Chemotherapy With Angiotensin-II for Locally Advanced and Nonresectable Pancreatic Adenocarcinoma: Further Evaluation and Prognostic Implications. Annals of Surgical Oncology, 2003, 10, 927-934.	0.7	12
446	Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2003, 21, 3402-3408.	0.8	480
447	Treatment of Locally Advanced Pancreatic Cancer in the Real World: Population-Based Practices and Effectiveness. Journal of Clinical Oncology, 2003, 21, 3409-3414.	0.8	93
448	Phase II Trial of a 24-Hour Infusion of Gemcitabine in Previously Untreated Patients with Advanced Pancreatic Adenocarcinoma. Cancer Investigation, 2003, 21, 690-694.	0.6	23
449	Intravesical Gemcitabine Therapy for Superficial Transitional Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study. Journal of Clinical Oncology, 2003, 21, 697-703.	0.8	97
450	Combining Capecitabine and Gemcitabine in Patients With Advanced Pancreatic Carcinoma: A Phase I/II Trial. Journal of Clinical Oncology, 2003, 21, 66-68.	0.8	88
451	Oxaliplatin for Colorectal Cancer in the United States: Better Late Than Never. Journal of Clinical Oncology, 2003, 21, 2049-2051.	0.8	14
452	Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Annals of Oncology, 2003, 14, 97-104.	0.6	160
453	Adjuvant therapy in pancreatic cancer: historical and current perspectives. Annals of Oncology, 2003, 14, 675-692.	0.6	115
454	A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Annals of Oncology, 2003, 14, 1100-1105.	0.6	12
455	Ethics of Phase 1 Oncology Studies. JAMA - Journal of the American Medical Association, 2003, 290, 1075.	3.8	173
456	Phase II and Pharmacodynamic Study of the Farnesyltransferase Inhibitor R115777 as Initial Therapy in Patients With Metastatic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2003, 21, 1301-1306.	0.8	164
457	Surrogate Outcomes in Quality-of-Life Research: Where Will We End Up?. Journal of Clinical Oncology, 2003, 21, 1894-1895.	0.8	15

#	Article	IF	Citations
458	Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Annals of Oncology, 2003, 14, 388-394.	0.6	40
459	Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2003, 21, 3296-3302.	0.8	358
460	The Medical Management of Pancreatic Cancer: A Review. Oncologist, 2003, 8, 149-160.	1.9	43
461	Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care. Oncologist, 2003, 8, 18-34.	1.9	114
462	Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II study. Annals of Oncology, 2003, 14, 580-585.	0.6	65
463	Challenges of Developing Therapeutics That Target Signal Transduction in Patients With Gynecologic and Other Malignancies. Journal of Clinical Oncology, 2003, 21, 175s-186.	0.8	12
464	Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology, 2003, 14, 205-208.	0.6	27
465	Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Annals of Oncology, 2003, 14, 574-579.	0.6	23
466	Phase II Study of Gemcitabine plus Docetaxel in Advanced Pancreatic Cancer: A Hoosier Oncology Group Study. Oncology, 2003, 65, 218-223.	0.9	42
467	Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy. Integrative Cancer Therapies, 2003, 2, 345-352.	0.8	13
469	A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Annals of Oncology, 2003, 14, 1425-1429.	0.6	23
472	Advanced pancreatic cancer: is there a role for combination therapy?. Expert Review of Anticancer Therapy, 2003, 3, 729-739.	1.1	11
473	Initial Experience Combining Cyclooxygenase-2 Inhibition with Chemoradiation for Locally Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, S81-S84.	0.6	37
475	Establishment of Gemcitabine-Resistant Human Pancreatic Cancer Cells and Effect of Brefeldin-A on the Resistant Cell Line. Pancreas, 2003, 27, 220-224.	0.5	9
476	MEK Inhibition of Pancreatic Carcinoma Cells by U0126 and Its Effect in Combination with Sulindac. Pancreas, 2003, 27, 337-344.	0.5	31
477	Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas. Anti-Cancer Drugs, 2003, 14, 87-90.	0.7	10
478	Phase I Study of Oral CI-994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer. Cancer Journal (Sudbury, Mass), 2003, 9, 58-66.	1.0	50
479	Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 151-154.	0.6	26

#	Article	IF	Citations
480	Diagnosis, Staging, and Surveillance of Pancreatic Cancer. American Journal of Roentgenology, 2003, 180, 1311-1323.	1.0	100
481	Chemoradiotherapy in the Treatment of Regional Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 543-549.	0.6	23
482	Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?. Oncology Research and Treatment, 2003, 26, 462-467.	0.8	48
483	Forced Expression of Cytidine Deaminase Confers Sensitivity to Capecitabine. Oncology, 2003, 65, 267-274.	0.9	25
484	Chemotherapy Use among Medicare Beneficiaries at the End of Life. Annals of Internal Medicine, 2003, 138, 639.	2.0	262
485	Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2003, 21, 2920-2925.	0.8	49
486	Serum Tumor Markers may Precede Instrumental Response to Chemotherapy in Patients with Metastatic Cancer. International Journal of Biological Markers, 2003, 18, 295-300.	0.7	9
487	Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 151-154.	0.6	29
489	The Treatment of Locally Advanced Pancreatic Cancer: A Practice Guideline. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 161-167.	1.8	13
490	Weekly Gemcitabine and 24-Hour Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Phase Iâ€“II Study. Oncology, 2003, 64, 139-145.	0.9	10
491	Concomitant Gemcitabine (Gemzar^{Â®}) and Extended Nodes Irradiation in the Treatment of Pancreatic and Biliary Carcinoma: A Phase I Study. Oncology Research and Treatment, 2003, 26, 325-329.	0.8	9
492	Principles of palliative chemotherapy. , 2003, , 12-21.		0
493	Colon Cancer and Other Gastrointestinal Malignancies. , 2003, , 417-440.		1
494	Pain Relief with Short Term Irradiation in Locally Advanced Carcinoma of the Pancreas. Journal of Palliative Care, 2003, 19, 258-262.	0.4	52
495	Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control, 2004, 11, 32-38.	0.7	24
496	Gastrointestinal Cancers. , 0, , 117-139.		0
498	The Role of Growth Factor Signaling in Malignancy. , 2003, 115, 19-72.		13
499	Radiochemotherapy in Unresectable Pancreatic Cancer. , 2004, 38, 87-93.		1

#	Article	IF	Citations
500	The science of quality-of-life measurement in lung cancer. , 2004, , 160-177.		2
501	Statistical issues in the application of cancer outcome measures. , 2004, , 362-385.		3
502	Treatment of Metastatic Pancreatic Cancer with a Combination of Gemcitabine and 5-Fluorouracil: A Single Center Phase II Study. Tumori, 2004, 90, 192-195.	0.6	6
503	Clinical Trial Designs for Approval of New Anticancer Agents. , 2004, , 579-592.		1
504	Risk factors for coronary calcification in older subjects The Rotterdam Coronary Calcification Study. European Heart Journal, 2004, 25, 48-55.	1.0	75
506	Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients. Annals of Oncology, 2004, 15, 1576-1577.	0.6	0
507	Gemcitabine Combined with Docetaxel for the Treatment of Unresectable Pancreatic Carcinoma. Cancer Investigation, 2004, 22, 505-514.	0.6	26
512	Assessing Tumor-Related Signs and Symptoms to Support Cancer Drug Approval. Journal of Biopharmaceutical Statistics, 2004, 14, 5-21.	0.4	46
513	Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials. Journal of Biopharmaceutical Statistics, 2004, 14, 73-96.	0.4	133
514	Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics. Clinical Cancer Research, 2004, 10, 7692-7702.	3.2	18
515	A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenocarcinoma Cells. Cancer Research, 2004, 64, 3987-3993.	0.4	92
516	Management of Cancer Pain. JAMA - Journal of the American Medical Association, 2004, 291, 1067.	3.8	19
517	Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Annals of Oncology, 2004, 15, 224-229.	0.6	54
518	Gemcitabine: a Systematic Review. , 2004, , 70-78.		0
519	Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer?. Journal of Clinical Oncology, 2004, 22, 1966-1974.	0.8	68
520	Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis. Clinical Cancer Research, 2004, 10, 7775-7784.	3.2	77
521	The Biological and Therapeutic Importance of Gastrin Gene Expression in Pancreatic Adenocarcinomas. Cancer Research, 2004, 64, 5624-5631.	0.4	31
522	Gemcitabine Combined with Infusional 5-Fluorouracil and High-Dose Leucovorin for the Treatment of Advanced Carcinoma of the Pancreas. Chemotherapy, 2004, 50, 127-132.	0.8	11

#	Article	IF	Citations
523	Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate. Journal of Clinical Oncology, 2004, 22, 3776-3783.	0.8	537
524	Survival Efficacy of Adjuvant Cytosine-Analogue CS-682 in a Fluorescent Orthotopic Model of Human Pancreatic Cancer. Cancer Research, 2004, 64, 1828-1833.	0.4	31
525	Phase I Trial Using Weekly Administration of Gemcitabine and Docetaxel in Patients with Advanced Pancreatic Carcinoma. Chemotherapy, 2004, 50, 289-296.	0.8	13
526	Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Annals of Oncology, 2004, 15, 1613-1621.	0.6	77
527	A Modified Low-dose Regimen of Mitoxantrone and Prednisolone in Patients with Androgen-independent Prostate Cancer. Japanese Journal of Clinical Oncology, 2004, 34, 337-341.	0.6	1
528	Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen?. Laboratoriums Medizin, 2004, 28, 103-108.	0.1	0
529	Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Annals of Oncology, 2004, 15, 467-473.	0.6	84
530	Functional and Genetic Diversity in the Concentrative Nucleoside Transporter, CNT1, in Human Populations. Molecular Pharmacology, 2004, 65, 512-519.	1.0	76
531	Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice. Clinical Cancer Research, 2004, 10, 8028-8036.	3.2	128
532	Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Annals of Oncology, 2004, 15, 478-483.	0.6	129
533	Phase II Study of Gemcitabine Combined with Uracil-Tegafur in Metastatic Pancreatic Cancer. Oncology, 2004, 66, 32-37.	0.9	20
534	Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298). Oncology, 2004, 66, 303-309.	0.9	36
535	Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer. Oncology, 2004, 67, 93-97.	0.9	70
536	Raltitrexed plus Gemcitabine (TOMGEM) in Advanced Pancreatic Cancer. Oncology, 2004, 67, 338-343.	0.9	10
537	Ceravolo. Journal of Chemotherapy, 2004, 16, 589-594.	0.7	23
538	Gemcitabine and ISIS-2503 for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial. Journal of Clinical Oncology, 2004, 22, 4944-4950.	0.8	91
539	New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers. Oncologist, 2004, 9, 282-294.	1.9	77
540	Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. British Journal of Cancer, 2004, 91, 673-677.	2.9	102

#	Article	IF	Citations
541	Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. British Journal of Cancer, 2004, 90, 1715-1719.	2.9	39
543	Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2004, 22, 1430-1438.	0.8	740
544	Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Annals of Oncology, 2004, 15, 474-477.	0.6	22
545	Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2004, 22, 2610-2616.	0.8	466
547	Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu. Cancer Investigation, 2004, 22, 706-712.	0.6	176
548	Response to the letter â€œRandomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patientsâ€, by C. Allior (Ann. Oncol 2004; 15: 1576â€“1577). Annals of Oncology, 2004, 15, 1577-1578.	0.6	1
549	Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2004, 22, 238-243.	0.8	95
550	Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU International, 2004, 93, 491-494.	1.3	34
551	Modern management of pancreatic carcinoma. Internal Medicine Journal, 2004, 34, 475-481.	0.5	38
552	RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene, 2004, 23, 1539-1548.	2.6	227
553	Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer. Surgery, 2004, 136, 261-269.	1.0	58
554	Cancer in the elderly: pancreatic cancer. Surgical Oncology, 2004, 13, 201-210.	0.8	41
555	Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2). Gastroenterologie Clinique Et Biologique, 2004, 28, 645-650.	0.9	12
556	Endoscopic insertion of biliary stents in 18 patients with metallic duodenal stents who developed secondary malignant obstructive jaundice. Gastroenterologie Clinique Et Biologique, 2004, 28, 1209-1213.	0.9	36
557	Gastrointestinal cancer in older patients. Seminars in Oncology, 2004, 31, 206-219.	0.8	30
558	Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Seminars in Oncology, 2004, 31, 10-16.	0.8	14
559	Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors1 1No competing interests declared.. Journal of the American College of Surgeons, 2004, 198, 722-731.	0.2	300
560	siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity1 1No competing interests declared.This work was funded by the National Pancreas Foundation and departmental funding, Brigham and Womenâ€™s Hospital.. Journal of the American College of Surgeons, 2004, 198, 953-959.	0.2	73

#	Article	IF	Citations
561	Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer. European Urology, 2004, 46, 712-716.	0.9	16
562	Phase II Clinical Trial of 5-Fluorouracil, Trimetrexate, and Leucovorin (NFL) in Patients With Advanced Pancreatic Cancer. International Journal of Gastrointestinal Cancer, 2004, 34, 079-086.	0.4	6
563	Cancer and Leukemia Group B (CALGB) 89805: Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas. International Journal of Gastrointestinal Cancer, 2004, 34, 107-116.	0.4	88
564	Is Reporting of Recurrence Data Important in Pancreatic Cancer?. Annals of Surgical Oncology, 2004, 11, 304-309.	0.7	22
565	Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model. Clinical and Experimental Metastasis, 2004, 21, 347-352.	1.7	32
566	Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer. Investigational New Drugs, 2004, 22, 193-198.	1.2	89
567	Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Investigational New Drugs, 2004, 22, 315-322.	1.2	81
568	A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study. Investigational New Drugs, 2004, 22, 335-341.	1.2	3
569	Randomized controlled trials on hepato-biliary-pancreatic surgery. Journal of Hepato-Biliary-Pancreatic Surgery, 2004, 11, 381-389.	2.0	4
570	A phase II trial of FUdR in patients with advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2004, 130, 561-6.	1.2	3
572	Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer. International Journal of Clinical Oncology, 2004, 9, 174-8.	1.0	10
573	Chemoradiotherapy for pancreatic cancer: current status and perspectives. International Journal of Clinical Oncology, 2004, 9, 451-457.	1.0	13
574	Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. Journal of Gastrointestinal Surgery, 2004, 8, 1072-1078.	0.9	41
575	Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1461-1467.	0.4	54
576	5-fluorouracilâ€“based chemoradiation in unresectable pancreatic carcinoma: phase I-II dose-escalation study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1454-1460.	0.4	27
578	Effect of Chemoradiotherapy with Gemcitabine and Cisplatin on Locoregional Control in Patients with Primary Inoperable Pancreatic Cancer. World Journal of Surgery, 2004, 28, 1011-1018.	0.8	57
579	Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. Cancer Chemotherapy and Pharmacology, 2004, 53, 337-340.	1.1	13
580	A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2004, 54, 331-42.	1.1	76

#	Article	IF	Citations
581	A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemotherapy and Pharmacology, 2004, 54, 553-561.	1.1	5
582	New approaches for pancreatic cancer in Japan. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S78-82.	1.1	3
584	Novel therapies for pancreatic adenocarcinoma. Current Gastroenterology Reports, 2004, 6, 119-125.	1.1	14
585	Novel therapies for pancreatic adenocarcinoma. Current Oncology Reports, 2004, 6, 199-206.	1.8	20
586	Advances in the genetic screening, work-up, and treatment of pancreatic cancer. Current Treatment Options in Gastroenterology, 2004, 7, 343-354.	0.3	9
587	Cancer of pancreas. Critical Reviews in Oncology/Hematology, 2004, 50, 147-155.	2.0	19
588	Old and new drugs in systemic therapy of pancreatic cancer. Critical Reviews in Oncology/Hematology, 2004, 49, 135-151.	2.0	17
589	Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer, 2004, 100, 1793-1799.	2.0	92
590	Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer, 2004, 101, 133-138.	2.0	94
591	A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer, 2004, 101, 934-939.	2.0	78
592	Nuclear factor-?B and I?B kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer, 2004, 101, 2351-2362.	2.0	284
593	Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. International Journal of Cancer, 2004, 112, 184-189.	2.3	47
594	5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. Journal of Gene Medicine, 2004, 6, 514-525.	1.4	34
595	Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. International Journal of Radiation Oncology Biology Physics, 2004, 58, 768-772.	0.4	43
596	Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 444-452.	0.4	68
597	A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1494-1501.	0.4	46
598	Specific gene expression and therapy for pancreatic cancer using the cytosine deaminase gene directed by the rat insulin promoter. Journal of Gastrointestinal Surgery, 2004, 8, 98-108.	0.9	23
599	An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines. Cancer Research, 2004, 64, 3761-3766.	0.4	261

#	Article	IF	Citations
600	The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surgical Oncology Clinics of North America, 2004, 13, 711-735.	0.6	16
601	Adjuvant therapy for pancreatic cancer: current status and future directions. Surgical Oncology Clinics of North America, 2004, 13, 737-749.	0.6	2
602	The evolving role of postoperative adjuvant radiation therapy for pancreatic cancer. Surgical Oncology Clinics of North America, 2004, 13, 589-604.	0.6	2
603	Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986â€“2003. Surgical Oncology Clinics of North America, 2004, 13, 685-696.	0.6	18
604	Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal intergroup pancreatic cancer task force. Surgical Oncology Clinics of North America, 2004, 13, 751-760.	0.6	10
605	PHASE I PHARMACOKINETIC STUDY OF A SINGLE INTRAVESICAL INSTILLATION OF GEMCITABINE ADMINISTERED IMMEDIATELY AFTER TRANSURETHRAL RESECTION PLUS MULTIPLE RANDOM BIOPSIES IN PATIENTS WITH SUPERFICIAL BLADDER CANCER. Journal of Urology, 2004, 172, 485-488.	0.2	34
606	Photodynamic therapy for pancreatic carcinoma: experimental and clinical studies. Photodiagnosis and Photodynamic Therapy, 2004, 1, 145-155.	1.3	10
607	Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with???Advanced Pancreatic Cancer. Clinical Drug Investigation, 2004, 24, 661-670.	1.1	7
608	The Role of Pemetrexed in the Treatment of Gastrointestinal Malignancy. Clinical Colorectal Cancer, 2004, 4, 190-195.	1.0	6
609	Treatment of Patients with Advanced Non-Small Cell Lung Cancer. American Journal of Cancer, 2004, 3, 281-290.	0.4	5
610	Rapamycin-Induced Endothelial Cell Death and Tumor Vessel Thrombosis Potentiate Cytotoxic Therapy against Pancreatic Cancer. Clinical Cancer Research, 2004, 10, 2109-2119.	3.2	105
611	The quality of medical care at the end-of-life in the USA: existing barriers and examples of process and outcome measures. Palliative Medicine, 2004, 18, 202-216.	1.3	80
612	Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies. Surgical Oncology Clinics of North America, 2004, 13, 697-709.	0.6	3
613	Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for locally advanced pancreatic cancer: a phase Iâ€“II trial. European Journal of Surgical Oncology, 2004, 30, 671-680.	0.5	15
614	Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2004, 316, 71-77.	1.0	78
615	Molecular therapy in pancreatic adenocarcinoma. Lancet Oncology, The, 2004, 5, 541-549.	5.1	69
616	Pancreatic cancer and thromboembolic disease. Lancet Oncology, The, 2004, 5, 655-663.	5.1	229
617	Pancreatic cancer. Lancet, The, 2004, 363, 1049-1057.	6.3	1,761

#	Article	IF	Citations
619	Systemic siRNA-Mediated Gene Silencing. Annals of Surgery, 2004, 240, 667-676.	2.1	100
620	Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience. Anti-Cancer Drugs, 2004, 15, 575-579.	0.7	11
621	Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination. Anti-Cancer Drugs, 2004, 15, 725-728.	0.7	2
622	Clinical Significance of Dihydropyrimidine Dehydrogenase in Adjuvant 5-Fluorouracil Liver Perfusion Chemotherapy for Pancreatic Cancer. Annals of Surgery, 2004, 240, 840-844.	2.1	27
623	Systemic treatment of pancreatic cancer. European Journal of Gastroenterology and Hepatology, 2004, 16, 265-274.	0.8	40
624	Pancreatic Enzyme Extract Improves Survival in Murine Pancreatic Cancer. Pancreas, 2004, 28, 401-412.	0.5	12
625	Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anti-Cancer Drugs, 2004, 15, 203-209.	0.7	53
626	Treatment of Locally Advanced Pancreatic Cancer. Pancreas, 2004, 28, 293-295.	0.5	16
627	Systemic Chemotherapy for Pancreatic Cancer. Pancreas, 2004, 28, 301-304.	0.5	19
628	Recent Advances in Antimetabolite Cancer Chemotherapies. Annual Reports in Medicinal Chemistry, 2004, 39, 159-172.	0.5	2
629	Emerging drugs in pancreatic cancer. Expert Opinion on Emerging Drugs, 2004, 9, 73-89.	1.0	2
630	Development of a Cytokine-Modified Allogeneic Whole Cell Pancreatic Cancer Vaccine. , 2005, 103, 299-328.		6
632	Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. Oncology Reports, 2005, 14, 401.	1.2	1
633	Radiation Dose Considerations in the Palliative Treatment of Locally Advanced Adenocarcinoma of the Pancreas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 227-233.	0.6	11
634	5-Fluorouracil Intra-arterial Infusion Combined With Systemic Gemcitabine for Unresectable Pancreatic Cancer. Pancreas, 2005, 30, 223-226.	0.5	19
635	Graft-versus-Tumor Effect Against Advanced Pancreatic Cancer after Allogeneic Reduced-Intensity Stem Cell Transplantation. Transplantation, 2005, 79, 821-827.	0.5	28
636	A Phase II Study of Alternating Cycles of Split Course Radiation Therapy and Gemcitabine Chemotherapy for Inoperable Pancreatic or Biliary Tract Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 234-241.	0.6	24
637	A Pilot Study of Individualized Maximum Repeatable Dose (iMRD), a New Dose Finding System, of Weekly Gemcitabine for Patients With Metastatic Pancreas Cancer. Pancreas, 2005, 30, 206-210.	0.5	32

#	Article	IF	Citations
638	Chemosensitization of Pancreatic Carcinoma Cells to Enhance T Cell-Mediated Cytotoxicity Induced by Tumor Lysate-Pulsed Dendritic Cells. Journal of Immunotherapy, 2005, 28, 332-342.	1.2	33
639	Recent Advances on the Molecular Mechanisms Involved in Pancreatic Cancer Progression and Therapies. Pancreas, 2005, 31, 301-316.	0.5	91
640	CEACAM6 Is a Novel Biomarker in Pancreatic Adenocarcinoma and PanIN Lesions. Annals of Surgery, 2005, 241, 491-496.	2.1	78
641	Treatment of non-small cell lung cancer with gefitinib (???Iressa???, ZD1839): the Greek experience with a compassionate-use program. Anti-Cancer Drugs, 2005, 16, 191-198.	0.7	9
642	Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 62, 97-103.	0.4	8
643	Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1357-1362.	0.4	10
644	A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1345-1350.	0.4	138
645	Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: A multicenter Belgian phase II study. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1351-1356.	0.4	26
646	Mismatch repair proficiency is not required for radioenhancement by gemcitabine. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1504-1509.	0.4	9
647	Clinical trial design in hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 119-127.	1.0	4
648	Significance of Histological Response to Preoperative Chemoradiotherapy for Pancreatic Cancer. Annals of Surgical Oncology, 2005, 12, 214-221.	0.7	148
649	Photodynamic Therapy for Pancreatic and Biliary Tract Carcinoma. International Journal of Gastrointestinal Cancer, 2005, 35, 001-014.	0.4	29
650	Induction of Apoptosis and Cell Cycle Arrest by Imexon in Human Pancreatic Cancer Cell Lines. International Journal of Gastrointestinal Cancer, 2005, 36, 015-028.	0.4	22
651	The role of chemoradiation therapy in locally advanced pancreatic cancer. Hpb, 2005, 7, 109-113.	0.1	3
652	Impact of gemcitabine on the treatment of metastatic pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 62-66.	1.4	19
653	A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. British Journal of Cancer, 2005, 92, 445-448.	2.9	24
654	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. British Journal of Cancer, 2005, 92, 1352-1357.	2.9	56
655	Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. British Journal of Cancer, 2005, 92, 1650-1654.	2.9	137

#	Article	IF	Citations
656	Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). British Journal of Cancer, 2005, 93, 185-189.	2.9	92
657	Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. British Journal of Cancer, 2005, 92, 2134-2139.	2.9	62
658	CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. British Journal of Cancer, 2005, 93, 740-743.	2.9	139
659	Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene, 2005, 24, 4421-4432.	2.6	187
660	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005, 7, 469-483.	7.7	2,137
661	Viral oncolysis: Tumor-tailored therapy. Journal of Surgical Education, 2005, 62, 25-30.	0.7	1
662	K-ras as a target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2005, 1756, 127-144.	3.3	137
663	Docetaxel in the Management of Advanced Pancreatic Cancer. Seminars in Oncology, 2005, 32, 10-23.	0.8	11
664	Front-Line Therapy of Advanced Pancreatic Cancer. Seminars in Oncology, 2005, 32, 33-36.	0.8	23
665	Recent Updates on the Role of Chemotherapy in Pancreatic Cancer. Seminars in Oncology, 2005, 32, 1-3.	0.8	35
666	Chemotherapeutic Gemcitabine Doublets in Pancreatic Carcinoma. Seminars in Oncology, 2005, 32, 9-13.	0.8	9
667	Brief Communication: A New Combination in the Treatment of Advanced Pancreatic Cancer. Seminars in Oncology, 2005, 32, 5-6.	0.8	64
669	Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma. Gastroenterologie Clinique Et Biologique, 2005, 29, 1006-1009.	0.9	7
670	Cancer Pain Assessment in Clinical Trials. A Review of the Literature (1999â€“2002). Journal of Pain and Symptom Management, 2005, 29, 507-519.	0.6	57
671	Radiochemotherapy in the Management of Pancreatic Cancerâ€”Part I: Neoadjuvant Treatment. Seminars in Radiation Oncology, 2005, 15, 226-234.	1.0	44
672	Systemic Therapy for Pancreatic Cancer. Seminars in Radiation Oncology, 2005, 15, 245-253.	1.0	8
673	Multimodality Approaches for Pancreatic Cancer. Ca-A Cancer Journal for Clinicians, 2005, 55, 352-367.	157.7	28
674	Randomized phase II â€“ study evaluating EGFR targeting therapy with Cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer â€“ PARC: study protocol [ISRCTN56652283]. BMC Cancer, 2005, 5, 131.	1.1	61

#	Article	IF	Citations
675	Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer, 2005, 5, 61.	1.1	27
676	Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecologic Oncology, 2005, 96, 103-107.	0.6	52
677	New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: Potential use for suppression of local recurrence of pancreatic cancer. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2005, 73B, 203-207.	1.6	14
678	Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl) cytosine (4?-thio-FAC) in human pancreatic and ovarian tumor xenograft models. International Journal of Cancer, 2005, 114, 1002-1009.	2.3	9
679	Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. Cancer, 2005, 103, 1026-1035.	2.0	53
680	Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer, 2005, 104, 1237-1245.	2.0	33
681	Liposome-encapsulated curcumin. Cancer, 2005, 104, 1322-1331.	2.0	589
682	No evidence of gemcitabine accumulation during weekly administration. European Journal of Clinical Pharmacology, 2005, 61, 843-849.	0.8	14
683	Molecular Targeting of Pancreatic Disorders. World Journal of Surgery, 2005, 29, 325-333.	0.8	15
684	A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2005, 55, 559-564.	1.1	14
685	Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous Vasopressin in non-resectable pancreas cancer. Cancer Chemotherapy and Pharmacology, 2005, 56, 603-609.	1.1	9
686	Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2005, 56, 510-520.	1.1	38
687	A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD). Clinical and Translational Oncology, 2005, 7, 493-498.	1.2	5
688	Treatment of familial pancreatic cancer and its precursors. Current Treatment Options in Gastroenterology, 2005, 8, 365-375.	0.3	14
689	Trials of gene therapy for pancreatic carcinoma. Current Gastroenterology Reports, 2005, 7, 165-169.	1.1	2
690	Chemotherapy for advanced pancreatic cancer: Past, present, and future. Current Oncology Reports, 2005, 7, 186-195.	1.8	17
691	The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin. Molecular Imaging and Biology, 2005, 7, 236-243.	1.3	23
692	Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Investigational New Drugs, 2005, 23, 369-375.	1.2	99

#	Article	IF	Citations
693	A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study. Investigational New Drugs, 2005, 23, 485-487.	1.2	132
694	Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Investigational New Drugs, 2005, 23, 489-493.	1.2	62
695	Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis. Oncology Reports, 2005, 14, 1263.	1.2	2
697	The Current Status of Combined Radiotherapy and Chemotherapy for Locally Advanced or Resected Pancreas Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 637-642.	2.3	21
700	Postoperative Chemoradiotherapy of Pancreatic Cancer: What is the Appropriate Target Volume of Radiation Therapy?. Tumori, 2005, 91, 493-497.	0.6	3
701	Treatment of Metastatic Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 627-636.	2.3	16
702	Single-agent Gemcitabine in the Treatment of Advanced Biliary Tract Cancers: a Phase II Study. Japanese Journal of Clinical Oncology, 2005, 35, 68-73.	0.6	64
703	How to deal with difficult pain problems. Annals of Oncology, 2005, 16, ii79-ii87.	0.6	7
704	Therapeutic Synergism of Gemcitabine and CpG-Oligodeoxynucleotides in an Orthotopic Human Pancreatic Carcinoma Xenograft. Cancer Research, 2005, 65, 6388-6393.	0.4	68
705	Locally Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 4538-4544.	0.8	196
706	Current management of locally advanced pancreatic cancer. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 356-364.	1.7	20
707	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of pancreatic cancer. Annals of Oncology, 2005, 16, i24-i25.	0.6	3
708	RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine Chemoresistance. Clinical Cancer Research, 2005, 11, 3433-3438.	3.2	78
709	PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Annals of Oncology, 2005, 16, 1654-1661.	0.6	93
710	Intrinsic Chemoresistance to Gemcitabine Is Associated with Decreased Expression of BNIP3 in Pancreatic Cancer. Clinical Cancer Research, 2005, 11, 3094-3101.	3.2	152
711	Treatment Cost of Pancreatic Cancer in Japan: Analysis of the Difference after the Introduction of Gemcitabine. Japanese Journal of Clinical Oncology, 2005, 35, 526-530.	0.6	13
712	In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor. Clinical Cancer Research, 2005, 11, 7508-7515.	3.2	152
713	Phase I Study of Fixed Dose Rate Infusion of Gemcitabine in Patients with Unresectable Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 733-738.	0.6	7

#	Article	IF	Citations
714	Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Molecular Cancer Therapeutics, 2005, 4, 1222-1230.	1.9	57
715	Feasibility of US-guided High-Intensity Focused Ultrasound Treatment in Patients with Advanced Pancreatic Cancer: Initial Experience. Radiology, 2005, 236, 1034-1040.	3.6	252
716	Inhibition of Integrin-Linked Kinase by a Selective Small Molecule Inhibitor, QLT0254, Inhibits the PI3K/PKB/mTOR, Stat3, and FKHR Pathways and Tumor Growth, and Enhances Gemcitabine-Induced Apoptosis in Human Orthotopic Primary Pancreatic Cancer Xenografts. Cancer Research, 2005, 65, 1497-1504.	0.4	127
717	Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Journal of Clinical Oncology, 2005, 23, 9250-9256.	0.8	48
718	Phase II study of troxacitabine in chemotherapy-naÃ¯ve patients with advanced cancer of the pancreas. Annals of Oncology, 2005, 16, 289-293.	0.6	20
719	Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancerâ€"A Groupe Tumeurs Digestives of the FÃ©dÃ©ration Nationale des Centres de Lutte Contre le Cancer Study. Journal of Clinical Oncology, 2005, 23, 1228-1236.	0.8	203
721	Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. Cancer Biology and Therapy, 2005, 4, 102-109.	1.5	153
722	Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scandinavian Journal of Gastroenterology, 2005, 40, 1486-1492.	0.6	28
723	Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. British Journal of Cancer, 2005, 93, 35-40.	2.9	63
724	Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. British Journal of Cancer, 2005, 93, 1112-1116.	2.9	22
725	Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model. Cancer Research, 2005, 65, 10371-10380.	0.4	96
726	Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 8033-8040.	0.8	439
727	An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. Cancer Research, 2005, 65, 4031-4040.	0.4	206
728	Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut, 2005, 54, v1-v16.	6.1	207
729	Adjuvant Treatment for Resectable Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 4532-4537.	0.8	67
730	An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer. Oncology, 2005, 68, 171-178.	0.9	110
731	Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. Journal of Clinical Oncology, 2005, 23, 3509-3516.	0.8	878
733	Phase II Trial of Oral Rubitecan in Previously Treated Pancreatic Cancer Patients. Oncologist, 2005, 10, 183-190.	1.9	67

#	Article	IF	Citations
734	Antiangiogenic Treatment with Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model. Clinical Cancer Research, 2005, 11, 5622-5630.	3.2	35
735	Combined Modality Therapy of Gemcitabine and Radiation. Oncologist, 2005, 10, 34-51.	1.9	134
736	Adjuvant Systemic Chemotherapy with Gemcitabine for Stage IV Pancreatic Cancer: A Preliminary Report of Initial Experience. Chemotherapy, 2005, 51, 305-310.	0.8	5
737	Recent Advances in Combined Modality Treatment for Locally Advanced Pancreatic Cancer. Current Cancer Therapy Reviews, 2005, 1, 227-237.	0.2	3
738	Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Annals of Oncology, 2005, 16, 773-779.	0.6	14
739	A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology, 2005, 16, 1639-1645.	0.6	286
740	Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. International Journal of Oncology, 2005, 27, 1361.	1.4	18
741	Phase II Trial of Primary Radiation Therapy and Concurrent Chemotherapy for Patients with Locally Advanced Pancreatic Cancer. Oncology, 2005, 68, 493-499.	0.9	44
742	Final Results of a Prospective Trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen Followed by Radiotherapy after Curative Surgery for Pancreatic Adenocarcinoma. Oncology, 2005, 68, 239-245.	0.9	21
743	A Phase II Trial of Raltitrexed (Tomudex^{Â®}) in Advanced Pancreatic and Biliary Carcinoma. Oncology, 2005, 68, 299-305.	0.9	9
744	A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer. Oncology, 2005, 69, 421-427.	0.9	49
745	Pharmacokinetics of the Antineoplastic Drug Mitomycin C in Regional Chemotherapy Using the Aortic Stop Flow Technique in Advanced Pancreatic Carcinoma. Chemotherapy, 2005, 51, 1-8.	0.8	102
746	Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-Î°B inhibitor. International Journal of Oncology, 2005, 27, 1247.	1.4	2
747	Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomedicine and Pharmacotherapy, 2005, 59, S276-S280.	2.5	68
748	Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncology, The, 2005, 6, 369-376.	5.1	261
749	Combination chemotherapy for advanced pancreatic cancerâ€"has its time finally come?. Lancet Oncology, The, 2005, 6, 352-353.	5.1	2
750	Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiotherapy and Oncology, 2005, 76, 48-53.	0.3	323
751	Opioids and the management of cancer pain. European Journal of Cancer, Supplement, 2005, 3, 61-75.	2.2	3

#	Article	IF	Citations
752	Predictive value of heparanase expression in the palliative therapy of pancreatic cancer. Pancreatology, 2005, 5, 570-575.	0.5	9
753	Inhibition of different intracellular signal cascades in human pancreatic cancer cells. Pancreatology, 2005, 5, 251-258.	0.5	3
754	Anti-Angiogenic Treatment of Gastrointestinal Malignancies. Cancer Investigation, 2005, 23, 712-726.	0.6	19
755	Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study. Cancer Investigation, 2005, 23, 9-12.	0.6	45
756	Proteomic Analysis of Pancreatic Ductal Carcinoma Cells after Combined Treatment with Gemcitabine and Trichostatin A. Journal of Proteome Research, 2005, 4, 1909-1916.	1.8	23
757	Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Annals of Oncology, 2005, 16, 279-281.	0.6	128
758	Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 2005, 97, 173-177.	1.2	18
759	Pemetrexed: A multitargeted antifolate. Clinical Therapeutics, 2005, 27, 1343-1382.	1.1	114
760	Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer. Cancer Treatment Reviews, 2005, 31, 236-241.	3.4	2
761	A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. European Journal of Cancer, 2005, 41, 398-403.	1.3	125
762	Gastrointestinal cancer: recent developments in medical oncology. European Journal of Surgical Oncology, 2005, 31, 453-460.	0.5	25
763	Biochemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques. European Journal of Surgical Oncology, 2005, 31, 807-816.	0.5	6
764	Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain, 2005, 119, 233-246.	2.0	94
765	Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a Phase II prospective multicenter study. Urology, 2005, 66, 726-731.	0.5	92
766	Comparative Pharmacokinetics and Metabolic Pathway of Gemcitabine During Intravenous and Intra-arterial Delivery in Unresectable Pancreatic Cancer Patients. Clinical Pharmacokinetics, 2005, 44, 957-967.	1.6	24
767	Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. Gastroenterology, 2005, 128, 1642-1654.	0.6	142
768	Pancreatic Cancer: Basic and Clinical Aspects. Gastroenterology, 2005, 128, 1606-1625.	0.6	279
769	Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo. Pharmacological Research, 2005, 52, 271-282.	3.1	25

#	Article	IF	Citations
770	Enhancement of Gemcitabine-Induced Apoptosis by Restoration of p53 Function in Human Pancreatic Tumors. Oncology, 2005, 68, 179-189.	0.9	18
771	Induction of Apoptosis in Tumor-Associated Endothelial Cells and Therapy of Orthotopic Human Pancreatic Carcinoma in Nude Mice. Neoplasia, 2005, 7, 696-704.	2.3	29
773	Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer. American Journal of Cancer, 2005, 4, 185-191.	0.4	1
774	Current Advancements in Hard-To-Treat Cancers. American Journal of Cancer, 2005, 4, 105-113.	0.4	1
775	Role of gemcitabine in cancer therapy. Future Oncology, 2005, 1, 7-17.	1.1	288
776	Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer. Cancer Research, 2005, 65, 9064-9072.	0.4	224
777	Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer. American Journal of Cancer, 2006, 5, 213-221.	0.4	1
778	Current Treatment Strategies for Pancreatic Cancer in the Elderly. Drugs and Aging, 2006, 23, 403-410.	1.3	11
779	Phase II Study of Cisplatin Combined with Weekly Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Carcinoma. Pancreatology, 2006, 6, 635-641.	0.5	7
780	Evaluating Surgical Outcomes. Surgical Clinics of North America, 2006, 86, 129-149.	0.5	44
781	The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Review of Anticancer Therapy, 2006, 6, 531-544.	1.1	15
784	Treatment update for metastatic pancreatic cancer. Community Oncology, 2006, 3, 428-430.	0.2	0
785	Cellular pharmacology of gemcitabine. Annals of Oncology, 2006, 17, v7-v12.	0.6	588
786	Chemoradiotherapy in Patients with Pancreatic Carcinoma: Phase-I Study with a Fixed Radiation Dose and Escalating Doses of Weekly Gemcitabine. Pancreatology, 2006, 6, 109-116.	0.5	9
787	Quality-of-Life Outcomes in Oncology. Hematology/Oncology Clinics of North America, 2006, 20, 165-185.	0.9	25
788	Therapeutic Options for Gastrointestinal Carcinoids. Clinical Gastroenterology and Hepatology, 2006, 4, 526-547.	2.4	136
789	Cytotoxic Chemotherapy for Pancreatic Cancer. Drugs, 2006, 66, 1059-1072.	4.9	37
790	Applications of microarray technology to pancreatic cancer research and drug development. Expert Opinion on Drug Discovery, 2006, 1, 447-458.	2.5	0

#	Article	IF	Citations
791	A review of erlotinib and its clinical use. Expert Opinion on Pharmacotherapy, 2006, 7, 177-193.	0.9	74
792	Pancreatic cancer: a review of recent advances. Expert Opinion on Investigational Drugs, 2006, 15, 1395-1410.	1.9	74
793	Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. , 2006, , CD002093.		102
794	Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): A phase II study in elderly or poor performance status patients. Lung Cancer, 2006, 53, 355-360.	0.9	5
795	Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III randomized trial. Pancreatology, 2006, 6, 454-463.	0.5	29
796	Extended pancreatectomy with resection of the celiac axis: the modified Appleby operation. American Journal of Surgery, 2006, 192, 330-335.	0.9	80
797	Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics, 2006, 28, 1779-1802.	1.1	473
798	Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?. Drug Resistance Updates, 2006, 9, 1-18.	6.5	46
799	Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. European Journal of Cancer, 2006, 42, 864-870.	1.3	24
800	Strategies to eliminate cancer stem cells: Clinical implications. European Journal of Cancer, 2006, 42, 1293-1297.	1.3	52
801	The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. European Journal of Surgical Oncology, 2006, 32, 197-200.	0.5	6
802	Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma. European Journal of Surgical Oncology, 2006, 32, 297-302.	0.5	15
803	Cancers of the bowel and hepatobiliary tract. Update on Cancer Therapeutics, 2006, 1, 353-365.	0.9	1
804	Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone. World Journal of Gastroenterology, 2006, 12, 6973.	1.4	38
805	Anticancer effects of phenoxazine derivatives combined with tumor necrosis factor-related apoptosis-inducing ligand on pancreatic cancer cell lines, KLM-1 and MIA-PaCa-2. Oncology Reports, 2006, 15, 843.	1.2	8
806	New Strategies in the Treatment of Ta-T1 Transitional Cell Carcinoma (TCC) of the Bladder. Scientific World Journal, The, 2006, 6, 2632-2637.	0.8	1
807	Phase II Study of Fixed Dose Rate Gemcitabine With Cisplatin for Metastatic Adenocarcinoma of the Pancreas. Journal of Clinical Oncology, 2006, 24, 379-385.	0.8	68
808	Phase II Study of Induction Chemotherapy with Gemcitabine plus 5-Fluorouracil Followed by Gemcitabine-Based Concurrent Chemoradiotherapy for Unresectable Locally Advanced Pancreatic Cancer. Tumori, 2006, 92, 481-486.	0.6	14

#	Article	IF	Citations
809	Pancreatic cancer: an overview for allied healthcare practitioners. Gastrointestinal Nursing, 2006, 4, 12-21.	0.0	0
811	The paradox of response and survival in cancer therapeutics. Blood, 2006, 107, 431-434.	0.6	146
812	Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. American Journal of Clinical Nutrition, 2006, 83, 1345-1350.	2.2	633
814	Schedule-dependent Therapeutic Effects of Gemcitabine Combined with Uracil-Tegafur in a Human Pancreatic Cancer Xenograft Model. Pancreas, 2006, 33, 142-147.	0.5	11
815	A Phase II Study of Weekly Cisplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer: Is This a Strategy Still Worth Pursuing?. Pancreas, 2006, 32, 51-57.	0.5	12
816	Gemcitabine and Oxaliplatin in Patients With Pancreatic Adenocarcinoma. Pancreas, 2006, 32, 44-50.	0.5	11
817	In-vitro and in-vivo anti-cancer activity of a novel gemcitabineâ€“cardiolipin conjugate. Anti-Cancer Drugs, 2006, 17, 53-61.	0.7	38
818	The Clinical Usefulness of 18-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis, Staging, and Response Evaluation After Concurrent Chemoradiotherapy for Pancreatic Cancer. Journal of Clinical Gastroenterology, 2006, 40, 923-929.	1.1	158
819	High-level Skp2 Expression in Pancreatic Ductal Adenocarcinoma. Pancreas, 2006, 32, 376-381.	0.5	38
820	Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group Report. Pediatric Blood and Cancer, 2006, 46, 193-197.	0.8	20
821	Comparison of non-coplanar and coplanar irradiation techniques to treat cancer of the pancreas. Journal of Medical Imaging and Radiation Oncology, 2006, 50, 463-467.	0.6	7
822	Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 531-536.	1.4	7
823	Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 874-879.	1.4	9
824	Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 999-1003.	1.4	36
825	Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. Journal of Gastroenterology and Hepatology (Australia), 2006, 22, 060705083413015-???.	1.4	41
826	Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Chinese Journal of Digestive Diseases, 2006, 7, 49-54.	1.1	16
827	Raltitrexedâ€“eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. British Journal of Cancer, 2006, 94, 785-791.	2.9	73
828	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 2006, 94, 1107-1115.	2.9	71

#	Article	IF	Citations
829	Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British Journal of Cancer, 2006, 94, 1293-1299.	2.9	99
830	Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. British Journal of Cancer, 2006, 94, 1575-1579.	2.9	116
831	A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma. British Journal of Cancer, 2006, 94, 1572-1574.	2.9	11
832	Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. British Journal of Cancer, 2006, 95, 260-265.	2.9	33
833	A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer, 2006, 95, 587-592.	2.9	188
834	Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Therapy, 2006, 13, 520-529.	2.2	28
835	Current therapies and advances in the treatment of pancreatic cancer. Critical Reviews in Oncology/Hematology, 2006, 58, 231-241.	2.0	85
836	Chemotherapy for advanced pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 327-348.	1.0	20
837	The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 365-382.	1.0	45
838	Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1391-1398.	0.4	31
839	Adjuvant Treatment Strategies for Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2006, 10, 916-926.	0.9	13
840	Lentivirus-Mediated RNA Interference of HMGA1 Promotes Chemosensitivity to Gemcitabine in Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 2006, 10, 1254-1263.	0.9	29
841	Treatment With Gemcitabine and TRA-8 Anti-Death Receptor-5 mAb Reduces Pancreatic Adenocarcinoma Cell Viability In Vitro and Growth In Vivo. Journal of Gastrointestinal Surgery, 2006, 10, 1291-1300.	0.9	16
842	Successful Resection of Advanced Pancreatic Tail Cancer After Neoadjuvant Gemcitabine Chemotherapy: Report of a Case. Surgery Today, 2006, 36, 754-757.	0.7	7
843	Surgical treatment of liver metastases from pancreatic cancer. Hpb, 2006, 8, 85-88.	0.1	47
844	A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma. Annals of Surgical Oncology, 2006, 13, 150-158.	0.7	225
845	Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2006, 14, 118-127.	0.7	201
846	A Phase I Trial of Gemcitabine Administered as a 96-h Continuous Intravenous Infusion in Patients with Advanced Carcinoma and Lymphoma. Medical Oncology, 2006, 23, 369-376.	1.2	6

#	Article	IF	Citations
847	Combined Gemcitabine and Î±-Interferon Therapy for Pancreatic Cancer: Report of a Case. Digestive Diseases and Sciences, 2006, 51, 1285-1289.	1.1	2
848	A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study. Investigational New Drugs, 2006, 24, 515-520.	1.2	67
849	Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial. Journal of Gastroenterology, 2006, 41, 70-76.	2.3	26
850	Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 797-804.	1.4	69
851	Assessment and data analysis of health-related quality of life in clinical trials for gastric cancer treatments. Gastric Cancer, 2006, 9, 254-261.	2.7	4
852	Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568-574.	2.0	68
853	Evaluation of the Efficacy of Combined Continuous Arterial Infusion and Systemic Chemotherapy for the Treatment of Advanced Pancreatic Carcinoma. CardioVascular and Interventional Radiology, 2006, 29, 362-370.	0.9	14
854	Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemotherapy and Pharmacology, 2006, 57, 185-190.	1.1	82
855	Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2006, 57, 647-653.	1.1	138
856	Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. Cancer Chemotherapy and Pharmacology, 2006, 58, 419-426.	1.1	5
857	Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemotherapy and Pharmacology, 2006, 58, 771-775.	1.1	22
858	Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2006, 59, 361-367.	1.1	21
859	Maintenance Chemotherapy after Chemoradiation Improves Survival of Patients with Locally Advanced Pancreatic Carcinoma. Strahlentherapie Und Onkologie, 2006, 182, 210-215.	1.0	14
860	Gene therapy developments for pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 285-298.	1.0	31
861	What's new in pancreatic cancer treatment pipeline?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 315-326.	1.0	11
862	New target-based agents involve new clinical trial designs. Clinical and Translational Oncology, 2006, 8, 581-587.	1.2	0
863	Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Current Gastroenterology Reports, 2006, 8, 111-120.	1.1	4
865	Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy. Gastroenterologie Clinique Et Biologique, 2006, 30, 224-230.	0.9	23

#	Article	IF	Citations
866	Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Gastroenterologie Clinique Et Biologique, 2006, 30, 357-363.	0.9	35
869	Cancer of the pancreas. Gastroenterologie Clinique Et Biologique, 2006, 30, 75-80.	0.9	1
870	Adjuvant Therapy for Pancreatic Cancer: Current Status, Future Directions. Seminars in Oncology, 2006, 33, 10-13.	0.8	16
871	Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model. Surgery, 2006, 140, 66-71.	1.0	10
872	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285.	1.1	103
873	Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer, 2006, 106, 693-702.	2.0	30
874	A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer, 2006, 106, 1339-1346.	2.0	100
875	Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer, 2006, 107, 676-685.	2.0	76
876	In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. International Journal of Cancer, 2006, 118, 2337-2343.	2.3	108
877	Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. International Journal of Cancer, 2006, 118, 2639-2643.	2.3	70
878	Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study. Oncology Reports, 2006, 15, 1201.	1.2	18
879	Pathotropic nanoparticles for cancer gene therapy Rexin-Gâ„¢ IV: Three-year clinical experience. International Journal of Oncology, 2006, 29, 1053.	1.4	13
880	Single-Agent Gemcitabine for Biliary Tract Cancers. Oncology, 2006, 70, 358-365.	0.9	23
881	Epidermal Growth Factor Receptor (EGFR) Inhibitors in Gastrointestinal Cancer. Oncology Research and Treatment, 2006, 29, 99-105.	0.8	4
882	Capecitabine in carcinoma of the pancreas. Expert Opinion on Pharmacotherapy, 2006, 7, 1633-1639.	0.9	8
883	Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line capan-2. Cancer Biology and Therapy, 2006, 5, 1294-1303.	1.5	9
884	Pancreatic and periampullary cancers: treatment and outcome. British Journal of Hospital Medicine (London, England: 2005), 2006, 67, 14-20.	0.2	4
885	Chemotherapy and Other Systemic Therapies for Hepatocellular Carcinoma and Liver Metastases. Seminars in Interventional Radiology, 2006, 23, 099-108.	0.3	16

#	Article	IF	Citations
886	Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma?. Nature Clinical Practice Oncology, 2006, 3, 424-425.	4.3	1
889	Erlotinib or capecitabine with gemcitabine in pancreatic cancer?. Future Oncology, 2006, 2, 161-163.	1.1	1
890	Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. Oncology, 2006, 70, 255-264.	0.9	154
891	Current state of adjuvant therapy in resected pancreatic adenocarcinoma. Acta OncolÃ³gica, 2006, 45, 124-135.	0.8	17
892	Rethinking Risk-Benefit Assessment for Phase I Cancer Trials. Journal of Clinical Oncology, 2006, 24, 2987-2990.	0.8	75
893	Efficacy of systemic therapy in advanced pancreatic carcinoma. Acta OncolÃ³gica, 2006, 45, 136-143.	0.8	9
894	Endoscopic Oncology. , 2006, , .		0
895	A Phase I/II Study of Combination Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 557-563.	0.6	14
896	Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. Cancer Research, 2006, 66, 3928-3935.	0.4	307
897	Inhibition of cell growth and nuclear factor-ÎºB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Molecular Cancer Therapeutics, 2006, 5, 2484-2493.	1.9	55
898	Cancer du pancrÃ©as exocrine. , 2006, , 159-178.		0
899	Gemcitabine Doublets in Advanced Pancreatic Cancer: Should We Move On?. Journal of Clinical Oncology, 2006, 24, 327-329.	0.8	12
900	Single Nucleotide Polymorphisms of RecQ1, RAD54L, and ATM Genes Are Associated With Reduced Survival of Pancreatic Cancer. Journal of Clinical Oncology, 2006, 24, 1720-1728.	0.8	133
901	Gemcitabine: monochemotherapy of breast cancer. Annals of Oncology, 2006, 17, v169-v172.	0.6	15
902	New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis. Journal of Clinical Oncology, 2006, 24, 252-258.	0.8	126
903	Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma. Cancer Research, 2006, 66, 981-988.	0.4	71
904	Phase I Study of Bryostatin 1 and Gemcitabine. Clinical Cancer Research, 2006, 12, 7059-7062.	3.2	22
905	Locally Advanced Pancreatic Cancer: Current Therapeutic Approach. Oncologist, 2006, 11, 612-623.	1.9	89

#	Article	IF	Citations
906	Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2006, 24, 4441-4447.	0.8	254
907	Transforming Growth Factor Î± Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines. Cancer Research, 2006, 66, 3802-3812.	0.4	53
908	Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine. Clinical Cancer Research, 2006, 12, 4925-4932.	3.2	90
909	Intravesical Gemcitabine in BCG-Refractory T1G3 Transitional Cell Carcinoma of the Bladder: A Pilot Study. Urologia Internationalis, 2006, 76, 106-111.	0.6	28
910	A Phase I Study of Oral Uracil-Tegafur Prior to Weekly Intravenous Gemcitabine in Patients with Advanced Pancreatic Cancer. Chemotherapy, 2006, 52, 98-102.	0.8	5
911	Phase I/II Trial of Hyperfractionated Accelerated Chemoradiotherapy for Unresectable Advanced Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 504-510.	0.6	8
912	Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Annals of Oncology, 2006, 17, 1096-1102.	0.6	84
913	Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Molecular Cancer Therapeutics, 2006, 5, 1387-1395.	1.9	83
914	Quality and Quantity of Life with Pancreatic Cancer. Digestion, 2006, 74, 116-117.	1.2	2
915	Update in Cancer Pain Syndromes. Journal of Palliative Medicine, 2006, 9, 1414-1434.	0.6	31
916	Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Molecular Cancer Therapeutics, 2006, 5, 2013-2022.	1.9	21
918	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. British Journal of Cancer, 2006, 95, 1474-1482.	2.9	260
919	Gene Therapy Based on Gemcitabine Chemosensitization Suppresses Pancreatic Tumor Growth. Molecular Therapy, 2006, 14, 758-767.	3.7	40
920	Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. British Journal of Cancer, 2006, 94, 481-485.	2.9	123
921	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2006, 24, 3946-3952.	0.8	619
922	Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB Journal, 2006, 20, 1982-1991.	0.2	88
923	Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer. Clinical Cancer Research, 2006, 12, 7099-7107.	3.2	52
924	Combination Treatment with TRA-8 Antiâ€"Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer. Clinical Cancer Research, 2007, 13, 5535s-5543s.	3.2	37

#	Article	IF	Citations
925	Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Cancer Research, 2007, 67, 9903-9912.	0.4	35
926	Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3460-3465.	3.3	404
927	Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2007, 18, ii19-ii20.	0.6	2
928	Emerging drugs for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2007, 12, 301-311.	1.0	3
929	A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. British Journal of Cancer, 2007, 96, 1358-1367.	2.9	10
930	Phase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer. British Journal of Cancer, 2007, 96, 1353-1357.	2.9	16
931	A New Method of Biliary Sampling for Cytopathological Examination During Endoscopic Retrograde Cholangiography. American Journal of Gastroenterology, 2007, 102, 550-557.	0.2	18
932	HER family inhibitors in pancreatic cancer: current status and future directions. Expert Opinion on Therapeutic Targets, 2007, 11, 337-347.	1.5	6
933	Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. British Journal of Cancer, 2007, 97, 464-471.	2.9	35
934	Is gemcitabine cost effective in cancer treatment?. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 239-249.	0.7	1
935	Role of platinum agents in the management of advanced pancreatic cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2719-2727.	0.9	17
937	Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer. Oncology, 2007, 73, 221-227.	0.9	46
938	Enhanced Antitumor Effect of Combined Triptolide and Ionizing Radiation. Clinical Cancer Research, 2007, 13, 4891-4899.	3.2	45
939	Neoadjuvant Therapy in Pancreatic Cancer. Cancer Investigation, 2007, 25, 267-273.	0.6	48
940	Complications of Urologic Surgery and Practice. , 0, , .		4
942	Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Annals of Oncology, 2007, 18, 1935-1942.	0.6	95
943	A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. Annals of Oncology, 2007, 18, 576-580.	0.6	9
944	Cholangiocarcinoma and its management. Gut, 2007, 56, 1755-1756.	6.1	38

#	Article	IF	Citations
945	Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease. Clinical Cancer Research, 2007, 13, 1926-1935.	3.2	65
946	Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Journal of Clinical Oncology, 2007, 25, 2313-2321.	0.8	25
947	Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy?. Oncology Research and Treatment, 2007, 30, 39-42.	0.8	11
948	Gemcitabine versus Gemcitabineâ€“Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group. Journal of Thoracic Oncology, 2007, 2, 135-140.	0.5	44
949	Irinotecan plus Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer: A Phase II Study. Oncology, 2007, 72, 279-284.	0.9	6
950	Prognostic Factors and Prognostic Index for ChemonaÃ¯ve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer. Oncology, 2007, 73, 41-51.	0.9	58
951	Short Time to Progression under First-Line Chemotherapy Is a Negative Prognostic Factor for Time to Progression and Residual Survival under Second-Line Chemotherapy in Advanced Pancreatic Cancer. Oncology, 2007, 73, 335-339.	0.9	18
952	GEMCITABINE COMBINED WITH S-1 CHEMOTHERAPY IS EFFECTIVE FOR PANCREATIC AND GASTRIC DOUBLE CANCERS. Pancreas, 2007, 35, 85.	0.5	1
953	Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Annals of Oncology, 2007, 18, 745-751.	0.6	61
955	Arterial Infusion of 5-Fluorouracil Combined with Concurrent Radiotherapy for Unresectable Pancreatic Cancer: Results from a Pilot Study. American Journal of Roentgenology, 2007, 189, 421-428.	1.0	14
957	Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Annals of Oncology, 2007, 18, 1652-1659.	0.6	105
960	Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biology and Therapy, 2007, 6, 1569-1575.	1.5	63
961	Targeting signal transduction in pancreatic cancer treatment. Expert Opinion on Therapeutic Targets, 2007, 11, 673-694.	1.5	45
962	Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 2607-2615.	0.8	387
963	Curcumin Potentiates Antitumor Activity of Gemcitabine in an Orthotopic Model of Pancreatic Cancer through Suppression of Proliferation, Angiogenesis, and Inhibition of Nuclear Factor-ÎºBâ€“Regulated Gene Products. Cancer Research, 2007, 67, 3853-3861.	0.4	561
964	Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification. Cancer Research, 2007, 67, 4425-4433.	0.4	51
965	Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 267.	3.8	2,144
966	Gemcitabine, Cisplatin, and Radiotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. Journal of Clinical Oncology, 2007, 25, 2567-2572.	0.8	66

#	Article	IF	Citations
967	Potential clinical applications of epothilones: a review of phase II studies. Annals of Oncology, 2007, 18, v28-v34.	0.6	22
968	TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Molecular Cancer Therapeutics, 2007, 6, 3198-3207.	1.9	42
969	Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncology, 2007, 3, 247-254.	1.1	19
970	Combination Chemotherapy in Advanced Pancreatic Cancer: Time to Raise the White Flag?. Journal of Clinical Oncology, 2007, 25, 2159-2161.	0.8	30
971	FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-EntÃ©rologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Annals of Oncology, 2007, 18, 498-503.	0.6	49
972	Phase II Study of Combination Chemotherapy with Gemcitabine and Cisplatin for Patients with Metastatic Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 515-520.	0.6	11
973	Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 4587-4592.	0.8	51
974	Mechanisms of Disease: chronic inflammation and cancer in the pancreasâ€"a potential role for pancreatic stellate cells?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 454-462.	1.7	94
975	Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research, 2007, 13, 5876-5882.	3.2	30
976	Pharmacokinetics of Gemcitabine in Japanese Cancer Patients: The Impact of a Cytidine Deaminase Polymorphism. Journal of Clinical Oncology, 2007, 26, 32-42.	0.8	168
977	Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 114-120.	0.6	52
978	Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut, 2007, 56, 1275-1282.	6.1	70
979	G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opinion on Biological Therapy, 2007, 7, 397-404.	1.4	32
980	Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies. Journal of Clinical Oncology, 2007, 25, 326-331.	0.8	485
981	Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of Clinical Oncology, 2007, 25, 2212-2217.	0.8	543
982	Lessons Learned in the Management of Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 1949-1952.	0.8	33
983	Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2007, 25, 4787-4792.	0.8	161
984	Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Annals of Oncology, 2007, 18, 82-87.	0.6	13

#	Article	IF	Citations
987	Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. International Journal of Oncology, 2007, 31, 1345.	1.4	36
988	siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway. Oncology Reports, 2007, 18, 673.	1.2	14
989	Targets, Trials, and Travails in Pancreas Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 1042-1053.	2.3	10
990	Down-regulation of the nuclear factor-Î¹B by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncology Reports, 2007, 17, 1445.	1.2	2
991	Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncology Reports, 0, , .	1.2	27
992	Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy. Cancer Journal (Sudbury, Mass), 2007, 13, 175-184.	1.0	24
993	A Phase II Trial of Perifosine in Locally Advanced, Unresectable, or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 26-31.	0.6	56
994	Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 257-262.	1.0	21
995	A Phase I Study of Gemcitabine and Uracil-Ftorfar (UFT)/Leucovorin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 101-105.	0.6	1
996	Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anti-Cancer Drugs, 2007, 18, 569-579.	0.7	28
997	Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anti-Cancer Drugs, 2007, 18, 1109-1111.	0.7	18
998	Targeted agents in the treatment of pancreatic cancer: history and lessons learned. Current Opinion in Oncology, 2007, 19, 390-395.	1.1	9
999	COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 526-530.	0.6	34
1000	Impact of Gemcitabine on the Survival of Patients With Stage IV Pancreatic Cancer. Pancreas, 2007, 34, 335-339.	0.5	4
1001	The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. International Journal of Oncology, 2007, , .	1.4	11
1002	FOLFOX-6 Combination as the First-Line Treatment of Locally Advanced and/or Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 15-20.	0.6	56
1003	Pooled efficacy analysis from a phase Iâ€“II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anti-Cancer Drugs, 2007, 18, 263-271.	0.7	20
1004	A Pure Invasive Micropapillary Carcinoma of the Pancreatic Head. Pancreas, 2007, 35, 190-192.	0.5	18

#	Article	IF	Citations
1005	PATHOLOGICAL EVALUATION OF ADVANCED PANCREATIC CANCER AFTER GEMCITABINE TREATMENT. Pancreas, 2007, 35, 85.	0.5	1
1006	Update in colorectal, hepatobiliary and pancreatic cancers. Update on Cancer Therapeutics, 2007, 2, 141-156.	0.9	0
1007	Phase II Trial of Gemcitabine, Prednisone, and Zoledronic Acid in Pretreated Patients with Hormone Refractory Prostate Cancer. Urology, 2007, 69, 347-351.	0.5	14
1008	Long-term survival after pancreatic cancer treatment. American Journal of Surgery, 2007, 194, S127-S130.	0.9	8
1009	Adjuvant chemotherapyâ€"the standard after resection for pancreatic cancer. American Journal of Surgery, 2007, 194, S131-S137.	0.9	3
1010	Contrast-enhanced ultrasonography depicts small tumor vessels for the evaluation of pancreatic tumors. European Journal of Radiology, 2007, 61, 163-169.	1.2	16
1011	Hypoxic abdominal stop-flow perfusion in the treatment of advanced pancreatic cancer: A phase II evaluation/trial. European Journal of Surgical Oncology, 2007, 33, 72-78.	0.5	18
1012	NRAGE suppresses metastasis of melanoma and pancreatic cancer in vitro and in vivo. Cancer Letters, 2007, 250, 268-275.	3.2	29
1013	PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: The ghost regimen. Cancer Letters, 2007, 256, 25-28.	3.2	17
1014	Androgen Receptor Blockade in Experimental Combination Therapy of Pancreatic Cancer. Journal of Surgical Research, 2007, 142, 378-386.	0.8	30
1015	Estrogen Receptor Î²/Î± Ratio Predicts Response of Pancreatic Cancer Cells to Estrogens and Phytoestrogens. Journal of Surgical Research, 2007, 140, 55-66.	0.8	52
1016	Antiâ€"Mesothelin Immunotoxin SS1P in Combination with Gemcitabine Results in Increased Activity against Mesothelin-Expressing Tumor Xenografts. Clinical Cancer Research, 2007, 13, 7166-7171.	3.2	60
1017	Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines. Cancer Investigation, 2007, 25, 411-418.	0.6	118
1018	Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer. Drugs and Aging, 2007, 24, 865-879.	1.3	31
1019	Adjuvant Therapy in Pancreatic Cancer. Drugs, 2007, 67, 2293-2310.	4.9	55
1020	Alpha-v Integrins as Therapeutic Targets in Oncology. Cancer Investigation, 2007, 25, 632-646.	0.6	94
1021	Medical treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2007, 7, 533-544.	1.1	16
1022	Adjuvant therapy for pancreatic cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2533-2541.	0.9	4

#	Article	IF	Citations
1023	Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma. Cancer Investigation, 2007, 25, 366-371.	0.6	11
1024	Epidermal Growth Factor Receptor-Targeted Therapy for Pancreatic Cancer. Cancer Investigation, 2007, 25, 647-657.	0.6	26
1025	Management of cancer from an unknown primary. Expert Opinion on Pharmacotherapy, 2007, 8, 445-455.	0.9	9
1026	Her signaling in pancreatic cancer. Expert Opinion on Biological Therapy, 2007, 7, 823-829.	1.4	17
1027	Dose-Intense PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) in Advanced Pancreatic Adenocarcinoma: A Dose-Finding Study. Cancer Investigation, 2007, 25, 594-598.	0.6	12
1028	Emerging drugs for biliary cancer. Expert Opinion on Emerging Drugs, 2007, 12, 571-589.	1.0	11
1029	Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature. Oncologist, 2007, 12, 1332-1335.	1.9	62
1030	Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2007, 25, 1960-1966.	0.8	3,396
1031	Synthesis of Second-Generation Sansalvamide A Derivatives: Novel Templates as Potential Antitumor Agents. Journal of Organic Chemistry, 2007, 72, 1980-2002.	1.7	41
1032	Treatment Options for Hepatobiliary and Pancreatic Cancer. Mayo Clinic Proceedings, 2007, 82, 628-637.	1.4	58
1034	A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo. Neoplasia, 2007, 9, 625-633.	2.3	19
1035	Trial of Adjuvant Gemcitabine for Pancreatic Cancer: The Jury Is Still Out. Pancreatology, 2007, 7, 548.	0.5	1
1036	Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. British Journal of Cancer, 2007, 96, 457-463.	2.9	266
1037	Multimodality Therapy for Pancreatic Cancer. Gastroenterology Clinics of North America, 2007, 36, 391-411.	1.0	1
1038	Antimetabolites. , 2007, , 55-79.		4
1039	Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evidence, 2007, .	4.7	0
1040	Preoperative Chemoradiation and Intra-Operative Radiotherapy for Pancreatic Carcinoma. Tumori, 2007, 93, 53-60.	0.6	11
1041	Apoptosis-related gene expression profile is changed by gemcitabine in pancreatic cancer cell line (PANC-1). Suizo, 2007, 22, 14-20.	0.1	3

#	Article	IF	Citations
1042	Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study. Clinical Medicine Oncology, 2007, 1, CMO.S285.	0.2	12
1045	Trends in stomach and pancreatic cancer incidence and mortality in England and Wales, 1951â€“2000. British Journal of Surgery, 2007, 94, 1162-1171.	0.1	28
1046	Effects of base excision repair gene polymorphisms on pancreatic cancer survival. International Journal of Cancer, 2007, 120, 1748-1754.	2.3	48
1047	Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancerin vitro and in nude mice. International Journal of Cancer, 2007, 120, 2704-2709.	2.3	37
1048	Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. International Journal of Cancer, 2007, 120, 1355-1363.	2.3	183
1049	The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer, 2007, 109, 292-299.	2.0	136
1050	Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress?. Cancer, 2007, 110, 525-533.	2.0	87
1051	PKC 412 smallâ€molecule tyrosine kinase inhibitor. Cancer, 2007, 110, 1457-1468.	2.0	26
1052	A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer, 2007, 110, 2768-2774.	2.0	8
1053	Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. Journal of Surgical Oncology, 2007, 95, 507-512.	0.8	79
1054	Pancreatic cancer: From pathogenesis to cure. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 997-1014.	1.0	11
1055	Gemcitabine in advanced biliary tract cancers. Critical Reviews in Oncology/Hematology, 2007, 61, 230-242.	2.0	17
1056	13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer â€" Report of a Pilot Phase II Study. Clinical Oncology, 2007, 19, 150-153.	0.6	29
1057	Identification of Sansalvamide a analog potent against pancreatic cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5072-5077.	1.0	32
1058	Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 211-218.	0.4	22
1059	Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1027-1036.	0.4	41
1060	Full-Dose Gemcitabine and Concurrent Radiotherapy for Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 801-808.	0.4	203
1061	A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 809-816.	0.4	104

#	Article	IF	Citations
1062	Overâ€expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. Journal of Pathology, 2007, 213, 275-282.	2.1	58
1063	The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis. Psycho-Oncology, 2007, 16, 863-868.	1.0	100
1064	Intratumoural injection of the toll-like receptor-2/6 agonist â€˜macrophage-activating lipopeptide-2â€™ in patients with pancreatic carcinoma: a phase I/II trial. British Journal of Cancer, 2007, 97, 598-604.	2.9	84
1066	Cutaneous metastasis as the first clinical manifestation of pancreatic adenocarcinoma: A case treated with gemcitabine. Journal of Dermatology, 2007, 34, 662-664.	0.6	14
1067	Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Science, 2007, 98, 605-611.	1.7	55
1068	Different professionals? knowledge and perceptions of the management of people with pancreatic cancer. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 44-51.	0.7	6
1069	Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 187-198.	0.7	3
1070	Synergistic activity of troxacitabine (Troxatylâ„¢) and gemcitabine in pancreatic cancer. BMC Cancer, 2007, 7, 121.	1.1	25
1071	Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1095-1106.	1.9	133
1072	bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells. Journal of Cellular and Molecular Medicine, 2007, 11, 349-361.	1.6	30
1074	Objective Physical Activity and Self-Reported Quality of Life in Patients Receiving Palliative Chemotherapy. Journal of Pain and Symptom Management, 2007, 33, 676-685.	0.6	74
1075	Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation. Journal of Pain and Symptom Management, 2007, 34, 244-252.	0.6	48
1076	Treatment of Advanced Pancreatic Cancer. Seminars in Oncology, 2007, 34, S25-S30.	0.8	57
1077	Future Chemoradiation Strategies in Pancreatic Cancer. Seminars in Oncology, 2007, 34, 335-346.	0.8	33
1078	Future Strategies for Targeted Therapies and Tailored Patient Management in Pancreatic Cancer. Seminars in Oncology, 2007, 34, 354-364.	0.8	9
1079	Locally Advanced Pancreatic Cancer: A Review. Seminars in Oncology, 2007, 34, 327-334.	0.8	31
1080	Cytotoxic Therapy for Advanced Pancreatic Adenocarcinoma. Seminars in Oncology, 2007, 34, 347-353.	0.8	63
1082	Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option?. Gastroenterologie Clinique Et Biologique, 2007, 31, 151-156.	0.9	6

#	Article	IF	Citations
1083	Present Status of Management of Cancer Pancreas: A Brief Review. Apollo Medicine, 2007, 4, 310-315.	0.0	0
1084	Antitumor Effect of Gemcitabine on Orthotopically Inoculated Human Gallbladder Cancer Cells in Nude Mice. Annals of Surgical Oncology, 2007, 14, 1374-1380.	0.7	13
1085	A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin. Annals of Surgical Oncology, 2007, 14, 2088-2096.	0.7	204
1086	A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study. Annals of Surgical Oncology, 2007, 14, 3202-3209.	0.7	68
1087	Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells. Annals of Surgical Oncology, 2007, 14, 3629-3637.	0.7	396
1088	Concurrent Chemoradiotherapy for Advanced Pancreatic Cancer. Strahlentherapie Und Onkologie, 2007, 183, 301-306.	1.0	30
1089	Prognostic Implication of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer. World Journal of Surgery, 2007, 31, 147-154.	0.8	77
1090	Comparison of Intrahepatic and Pancreatic Perfusion on Fusion Images Using a Combined SPECT/CT System and Assessment of Efficacy of Combined Continuous Arterial Infusion and Systemic Chemotherapy in Advanced Pancreatic Carcinoma. CardioVascular and Interventional Radiology, 2007, 30, 912-921.	0.9	9
1091	A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2007, 59, 447-454.	1.1	47
1092	The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2007, 60, 211-218.	1.1	8
1093	Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemotherapy and Pharmacology, 2007, 60, 295-303.	1.1	45
1094	A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2007, 60, 489-494.	1.1	18
1095	A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2007, 60, 871-882.	1.1	2
1096	The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2007, 61, 167-175.	1.1	82
1097	A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium. Investigational New Drugs, 2007, 25, 553-558.	1.2	75
1098	Gene expression profiling of breast cancer cells in response to gemcitabine: NF-Î°B pathway activation as a potential mechanism of resistance. Breast Cancer Research and Treatment, 2007, 102, 157-172.	1.1	63
1099	Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. International Journal of Clinical Oncology, 2007, 12, 268-273.	1.0	15
1100	Pancreatic cancer â€" Palliative therapy: chemotherapy. Chinese-German Journal of Clinical Oncology, 2007, 6, 142-148.	0.1	0

#	Article	IF	Citations
1102	Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. Journal of Gastroenterology, 2007, 42, 389-394.	2.3	67
1103	Progress in the Development of Prognostic and Predictive Markers for Gastrointestinal Malignancies. Current Treatment Options in Oncology, 2007, 8, 339-351.	1.3	16
1104	Pancreatic cancer: An update. Current Oncology Reports, 2007, 9, 170-176.	1.8	29
1105	Transitions to palliation: Two solitudes or inevitable integration?. Current Oncology Reports, 2007, 9, 285-289.	1.8	11
1107	Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells. Journal of Inorganic Biochemistry, 2007, 101, 1517-1524.	1.5	61
1108	Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: An observational study. Critical Reviews in Oncology/Hematology, 2008, 68, 178-182.	2.0	26
1109	Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer and Metastasis Reviews, 2008, 27, 495-522.	2.7	75
1110	Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer. Digestive Diseases and Sciences, 2008, 53, 564-570.	1.1	56
1111	A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs, 2008, 26, 241-247.	1.2	33
1112	A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Investigational New Drugs, 2008, 26, 369-379.	1.2	74
1113	A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 615-621.	1.1	156
1114	A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2008, 61, 1019-1026.	1.1	13
1115	Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 875-882.	1.1	39
1116	Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemotherapy and Pharmacology, 2008, 61, 883-892.	1.1	31
1117	Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemotherapy and Pharmacology, 2008, 62, 355-361.	1.1	29
1118	Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemotherapy and Pharmacology, 2008, 62, 647-653.	1.1	20
1119	A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2008, 62, 673-678.	1.1	18
1120	A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2008, 62, 763-768.	1.1	13

#	Article	IF	Citations
1121	Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemotherapy and Pharmacology, 2008, 62, 1055-1064.	1.1	135
1122	High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. Cancer Chemotherapy and Pharmacology, 2008, 63, 85-89.	1.1	22
1123	Pancreatic Cancer Cell Genetics and Signaling Response to Treatment Correlate with Efficacy of Gemcitabine-Based Molecular Targeting Strategies. Journal of Gastrointestinal Surgery, 2008, 12, 288-296.	0.9	24
1124	Postoperative Adjuvant Chemotherapy Improves Survival after Surgical Resection for Pancreatic Carcinoma. Journal of Gastrointestinal Surgery, 2008, 12, 534-541.	0.9	17
1125	Innovative TherapieansÃtze fÃ¼r das Pankreasadenokarzinom. Onkopipeline, 2008, 1, 8-10.	0.0	0
1127	Cancer pain: Perspectives of a medical oncologist. Current Pain and Headache Reports, 2008, 12, 270-276.	1.3	3
1128	Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors. Medical Oncology, 2008, 25, 81-87.	1.2	7
1129	Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan. International Journal of Clinical Oncology, 2008, 13, 127-131.	1.0	6
1130	Chemoradiotherapy for unresectable pancreatic cancer. International Journal of Clinical Oncology, 2008, 13, 121-126.	1.0	28
1131	ChimiothÃ©rapie et qualitÃ© de vie dans le cancer du sein mÃ©tastatique: Ã©tat des lieux. Oncologie, 2008, 10, 580-590.	0.2	0
1132	The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. Supportive Care in Cancer, 2008, 16, 359-370.	1.0	46
1133	Use of chemotherapy at the end of life in a Portuguese oncology center. Supportive Care in Cancer, 2008, 16, 321-327.	1.0	33
1134	Lifting symptom burdenâ€"how far off the ground are we?. Supportive Care in Cancer, 2008, 16, 757-761.	1.0	8
1135	Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer. Journal of Gastroenterology, 2008, 43, 233-238.	2.3	2
1136	Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer. Journal of Gastroenterology, 2008, 43, 875-880.	2.3	1
1137	A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma. Radiation Oncology, 2008, 3, 30.	1.2	6
1138	Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines. Phytotherapy Research, 2008, 22, 477-486.	2.8	56
1139	Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. Cancer, 2008, 112, 1037-1042.	2.0	58

#	Article	IF	Citations
1140	Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as secondâ€line therapy for patients with advanced pancreatic cancer. Cancer, 2008, 113, 2046-2052.	2.0	130
1141	A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer, 2008, 113, 2448-2456.	2.0	37
1142	Neoadjuvant treatment for pancreatic cancerâ€"A review. Critical Reviews in Oncology/Hematology, 2008, 65, 263-274.	2.0	24
1143	Pancreatic cancer: Progress in cancer therapy. Critical Reviews in Oncology/Hematology, 2008, 67, 27-38.	2.0	32
1144	Pancreatic cancer: From molecular signature to target therapy. Critical Reviews in Oncology/Hematology, 2008, 68, 197-211.	2.0	40
1145	Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: A cyclic tetrapeptide scaffold. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2549-2554.	1.0	21
1146	Chemoradiotherapy for Locally Advanced Pancreatic Cancer: a Radiotherapy Dose Escalation and Organ Motion Study. Clinical Oncology, 2008, 20, 541-547.	0.6	13
1147	Locally Advanced Non-Metastatic Pancreatic Cancer â€" Can We Do More?. Clinical Oncology, 2008, 20, 532-534.	0.6	2
1148	Annexin II Overexpression Predicts Rapid Recurrence after Surgery in Pancreatic Cancer Patients Undergoing Gemcitabine-Adjuvant Chemotherapy. Annals of Surgical Oncology, 2008, 15, 3157-3168.	0.7	60
1149	Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2008, 15, 3521-3531.	0.7	43
1150	Cancer Pain and Analgesia. Annals of the New York Academy of Sciences, 2008, 1138, 278-298.	1.8	118
1151	Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience. Radiation Medicine, 2008, 26, 587-596.	0.8	20
1152	Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. European Radiology, 2008, 18, 468-476.	2.3	24
1153	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Laboratory Investigation, 2008, 88, 773-784.	1.7	34
1154	Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey. Bone Marrow Transplantation, 2008, 42, 99-103.	1.3	7
1155	Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene, 2008, 27, 2810-2822.	2.6	70
1156	Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British Journal of Cancer, 2008, 98, 1425-1430.	2.9	96
1157	Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. British Journal of Cancer, 2008, 99, 6-13.	2.9	98

#	Article	IF	Citations
1158	Survival from cancer of the pancreas in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S24-S25.	2.9	7
1159	Palliative treatment of pancreatic cancer. Journal of Digestive Diseases, 2008, 9, 1-7.	0.7	21
1160	Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 1292-1297.	1.4	21
1161	Endoscopic ultrasound-guided ethanol injection in the pancreas in a porcine model: A preliminary study. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e1-e6.	1.4	15
1162	Enhanced distribution of NK012, a polymeric micelleâ€encapsulated SNâ€38, and sustained release of SNâ€38 within tumors can beat a hypovascular tumor. Cancer Science, 2008, 99, 1258-1264.	1.7	42
1163	Establishment and molecular profiling of a novel human pancreatic cancer panel for 5â€FU. Cancer Science, 2008, 99, 1859-1864.	1.7	12
1164	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer, 2008, 8, 82.	1.1	377
1165	Pancreatic Cancer. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 157-188.	9.6	634
1166	Biological Approaches to Therapy of Pancreatic Cancer. Pancreatology, 2008, 8, 431-461.	0.5	24
1167	Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 1595-1607.	0.9	9
1168	Radiosensitization By Gemcitabine Fixed-Dose-Rate Infusion Versus Bolus Injection in a Pancreatic Cancer Model. Translational Oncology, 2008, 1, 44-49.	1.7	12
1170	Targeted Cancer Therapy. , 2008, , .		11
1171	Drug Insight: antiangiogenic therapies for gastrointestinal cancersâ€"focus on monoclonal antibodies. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 250-267.	1.7	32
1172	Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. American Journal of Surgery, 2008, 195, 757-762.	0.9	49
1173	Enhancement of somatostatin-receptor-targeted 177Lu-[DOTA0-Tyr3]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nuclear Medicine and Biology, 2008, 35, 673-678.	0.3	23
1174	Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Letters, 2008, 259, 39-49.	3.2	95
1175	Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines. Cancer Letters, 2008, 259, 231-239.	3.2	16
1176	MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Letters, 2008, 264, 241-249.	3.2	23

#	Article	IF	Citations
1177	Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. European Journal of Cancer, 2008, 44, 1895-1903.	1.3	41
1178	Neoadjuvant and adjuvant strategies for pancreatic cancer. European Journal of Surgical Oncology, 2008, 34, 297-305.	0.5	29
1179	Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. European Journal of Surgical Oncology, 2008, 34, 756-764.	0.5	52
1180	Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 4491-4499.	3.2	1,158
1181	Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet, The, 2008, 371, 2101-2108.	6.3	241
1182	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncology, The, 2008, 9, 39-44.	5.1	130
1183	Trials in palliative treatmentâ€"have the goal posts been moved?. Lancet Oncology, The, 2008, 9, 186-187.	5.1	33
1184	Treatment of Pancreatic Adenocarcinoma: A European Perspective. Surgical Oncology Clinics of North America, 2008, 17, 569-586.	0.6	6
1185	Caffeic Acid Phenethyl Ester Induces Apoptosis of Human Pancreatic Cancer Cells Involving Caspase and Mitochondrial Dysfunction. Pancreatology, 2008, 8, 558-565.	0.5	52
1186	Multidetector Computed Tomography During Combined Therapy for Pancreatic Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2008, 6, 842-848.e3.	2.4	4
1187	Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America, 2008, 17, 279-301.	0.6	12
1188	International Registries of Families at High Risk of Pancreatic Cancer. Pancreatology, 2008, 8, 566-576.	0.5	64
1189	Translation of Recent Advances and Discoveries in Molecular Biology and Immunology in the Diagnosis and Treatment of Pancreatic Cancer. Surgical Oncology Clinics of North America, 2008, 17, 357-376.	0.6	1
1190	Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study. Cancer Investigation, 2008, 26, 47-52.	0.6	23
1191	Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 192 T advanced unresectable pancreatic cancer. Definitive results of the 2000â€"01 FFCD/SFRO study. Annals of Oncology, 2008, 19, 1592-1599.	0.6	601
1192	Activated Epidermal Growth Factor Receptor as a Novel Target in Pancreatic Cancer Therapy. Journal of Proteome Research, 2008, 7, 4651-4658.	1.8	42
1193	Synthesis and Cytotoxicity of a New Class of Potent Decapeptide Macrocycles. Organic Letters, 2008, 10, 177-180.	2.4	17
1194	Biology and management of pancreatic cancer. Postgraduate Medical Journal, 2008, 84, 478-497.	0.9	254

#	Article	IF	Citations
1195	Kinetic Investigation of the Inhibitory Effect of Gemcitabine on DNA Polymerization Catalyzed by Human Mitochondrial DNA Polymerase. Journal of Biological Chemistry, 2008, 283, 15339-15348.	1.6	25
1196	Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Annals of Oncology, 2008, 19, 1624-1628.	0.6	55
1197	Targeted therapies for pancreatic cancer. British Medical Bulletin, 2008, 87, 97-130.	2.7	26
1198	S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2008, 39, 49-53.	0.6	20
1199	Adjuvant Therapy for Surgically Resected Pancreatic Adenocarcinoma. JAMA - Journal of the American Medical Association, 2008, 299, 1066.	3.8	18
1200	Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas. Japanese Journal of Clinical Oncology, 2008, 39, 2-15.	0.6	126
1202	Efficacy of Gemcitabine for Locally Advanced Pancreatic Cancer: Comparison with 5-Fluorouracil-Based Chemoradiotherapy. Chemotherapy, 2008, 54, 302-308.	0.8	18
1203	New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. Oncologist, 2008, 13, 289-298.	1.9	81
1204	Polymorphisms in DNA Repair Genes, Smoking, and Pancreatic Adenocarcinoma Risk. Cancer Research, 2008, 68, 4928-4935.	0.4	102
1205	Early Therapy Evaluation of Combined Antiâ€"Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging. Cancer Research, 2008, 68, 8369-8376.	0.4	45
1206	Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Molecular Cancer Therapeutics, 2008, 7, 638-647.	1.9	61
1207	Fixed Dose Rate Infusion of Gemcitabine with Oral Doxifluridine and Leucovorin for Advanced Unresectable Pancreatic Cancer: A Phase II Study. Chemotherapy, 2008, 54, 54-62.	0.8	7
1208	RETROSPECTIVE ANALYSIS OF CHEMORADIOTHERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER. Pancreas, 2008, 37, 112.	0.5	0
1209	Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biology and Therapy, 2008, 7, 596-601.	1.5	9
1210	APOPTOSIS-RELATED GENE EXPRESSION PROFILE IS CHANGED BY GEMCITABINE IN PANCREATIC CANCER CELL LINE (PANC-1). Pancreas, 2008, 37, 111.	0.5	0
1211	USEFULNESS OF CHEMOTHERAPY WITH GEMCITABINE FOR UNRESECTABLE ADVANCED PANCREATIC CARCINOMA. Pancreas, 2008, 37, 113.	0.5	0
1212	Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy. Japanese Journal of Clinical Oncology, 2008, 38, 755-761.	0.6	46
1213	COMBINED CHEMOTHERAPY WITH S-1 AND GEMCITABINE INDUCED DUODENAL PENETRATION OF PANCREATIC HEAD CANCER. Pancreas, 2008, 37, 116.	0.5	1

#	Article	IF	Citations
1214	Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opinion on Therapeutic Targets, 2008, 12, 1389-1401.	1.5	16
1215	Oral Vinorelbine as First Line Chemotherapy in Unfit Elderly Patients with Hormone-Refractory Prostate Cancer. Journal of Chemotherapy, 2008, 20, 368-373.	0.7	3
1217	Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biology and Therapy, 2008, 7, 523-531.	1.5	33
1218	Venous Thromboembolism and Pancreatic Cancer: Incidence, Pathogenesis and Clinical Implications. Onkologie, 2008, 31, 129-135.	1.1	3
1219	Prolongation of Survival and Improvement in Performance Status following Palliative Chemotherapy in Gastrointestinal Cancer Patients with a Poor Performance Status. Oncology, 2008, 74, 135-142.	0.9	5
1220	Biologic therapies for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2008, 8, 1331-1338.	1.1	6
1221	Novel advances in pancreatic cancer treatment. Expert Review of Anticancer Therapy, 2008, 8, 993-1002.	1.1	47
1222	Novel Approaches to Deliver Gemcitabine to Cancers. Current Pharmaceutical Design, 2008, 14, 1124-1137.	0.9	101
1223	Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial. Journal of Clinical Oncology, 2008, 26, 942-947.	0.8	140
1224	Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. Expert Review of Anticancer Therapy, 2008, 8, 1611-1621.	1.1	1
1225	Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells. British Journal of Cancer, 2008, 98, 1226-1233.	2.9	4
1226	Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Review of Anticancer Therapy, 2008, 8, 511-523.	1.1	37
1227	Patient-Reported Outcomes of Patients With Advanced Biliary Tract Cancers Receiving Gemcitabine Plus Capecitabine: A Multicenter, Phase II Trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology, 2008, 26, 3702-3708.	0.8	72
1228	Past and Future of Pancreas Cancer: Are We Ready to Move Forward Together?. Journal of Clinical Oncology, 2008, 26, 3478-3480.	0.8	12
1229	Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Molecular Cancer Therapeutics, 2008, 7, 2845-2854.	1.9	27
1230	Allogeneic Granulocyte Macrophage Colony-Stimulating Factorâ€“Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation. Clinical Cancer Research, 2008, 14, 1455-1463.	3.2	309
1231	Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. Clinical Cancer Research, 2008, 14, 4943-4950.	3.2	63
1232	Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trialâ€”SAKK 44/00â€“CECOG/PAN.1.3.001. Journal of Clinical Oncology, 2008, 26, 3695-3701.	0.8	93

#	Article	IF	Citations
1233	Single-Nucleotide Polymorphisms of DNA Damage Response Genes Are Associated with Overall Survival in Patients with Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 2042-2048.	3.2	53
1234	Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer. Molecular Cancer Therapeutics, 2008, 7, 2464-2475.	1.9	28
1235	Systemic Therapy for Biliary Tract Cancers. Oncologist, 2008, 13, 415-423.	1.9	195
1236	Pilot Study of Combination Chemotherapy Using Irinotecan plus S-1 for Metastatic Pancreatic Cancer. Oncology, 2008, 75, 67-70.	0.9	5
1237	CA 19-9 Response as an Early Indicator of the Effectiveness of Gemcitabine in Patients with Advanced Pancreatic Cancer. Oncology, 2008, 75, 120-126.	0.9	28
1238	Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Annals of Oncology, 2008, 19, 1742-1748.	0.6	6
1239	Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology, 2008, 26, 3496-3502.	0.8	684
1240	Pancreatic Cancer: A Review and Update. Clinical Journal of Oncology Nursing, 2008, 12, 735-741.	0.3	24
1241	Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii25-ii26.	0.6	8
1242	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Annals of Oncology, 2008, 19, 86-91.	0.6	72
1243	Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta OncolÃ³gica, 2008, 47, 337-346.	0.8	30
1244	Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players. Clinical Cancer Research, 2008, 14, 1284-1285.	3.2	141
1245	Neuropilin-2â€“Mediated Tumor Growth and Angiogenesis in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2008, 14, 8052-8060.	3.2	84
1246	Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. Molecular Cancer Therapeutics, 2008, 7, 3624-3631.	1.9	30
1247	Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Annals of Oncology, 2008, 19, 340-347.	0.6	70
1248	Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer. Molecular Therapy, 2008, 16, 979-984.	3.7	46
1249	The treatment of advanced pancreatic cancer: current evidence and future challenges. Annals of Oncology, 2008, 19, vii304-vii308.	0.6	3
1250	Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?. Oncologist, 2008, 13, 562-576.	1.9	103

#	Article	IF	Citations
1251	Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Molecular Cancer Therapeutics, 2008, 7, 2884-2893.	1.9	37
1252	Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma. Journal of Clinical Oncology, 2008, 26, 4544-4550.	0.8	55
1253	Reflections on Medical Oncology: 25 Years of Clinical Trialsâ€"Where Have We Come and Where Are We Going?. Journal of Clinical Oncology, 2008, 26, 6-8.	0.8	62
1254	Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology, 2008, 26, 3487-3495.	0.8	441
1255	Small Molecules: Big Changes in the Cancer Treatment Paradigm. Journal of Pharmacy Practice, 2008, 21, 17-35.	0.5	2
1256	Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma. JAMA - Journal of the American Medical Association, 2008, 299, 1019.	3.8	684
1257	Phase II Stopping Rules That Employ Response Rates and Early Progression. Journal of Clinical Oncology, 2008, 26, 3715-3720.	0.8	14
1258	Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head. Journal of Clinical Oncology, 2008, 26, 2526-2531.	0.8	174
1259	Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Japanese Journal of Clinical Oncology, 2008, 38, 227-229.	0.6	95
1260	The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer. Clinical Cancer Research, 2008, 14, 5142-5149.	3.2	113
1262	Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy, 2008, 8, 975-991.	1.1	6
1263	Current Adjuvant and Targeted Therapies for Pancreatic Adenocarcinoma. Current Medicinal Chemistry, 2008, 15, 1674-1683.	1.2	15
1264	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology, 2008, 5, 256-267.	4.3	78
1265	ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology. Current Medicinal Chemistry, 2008, 15, 978-990.	1.2	95
1266	Telomerase Transcriptional Targeting of Inducible Bax/TRAIL Gene Therapy Improves Gemcitabine Treatment of Pancreatic Cancer. Molecular Therapy, 2008, 16, 252-260.	3.7	18
1268	Pancreatic cancerâ€"is the wall crumbling?. Annals of Oncology, 2008, 19, 1224-1230.	0.6	31
1269	The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncology, 2008, 4, 41-50.	1.1	18
1270	Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?. Future Oncology, 2008, 4, 241-255.	1.1	0

#	Article	IF	Citations
1271	RECENT ADVANCES IN CHEMOTHERAPY FOR PANCREATIC CARCINOMA. Pancreas, 2008, 37, 111.	0.5	0
1272	PRESENT STATUS OF ADJUVANT CHEMOTHERAPY FOR PANCREATIC CANCER. Pancreas, 2008, 37, 112.	0.5	0
1273	Weekly Docetaxel as Salvage Therapy in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer. Journal of Chemotherapy, 2008, 20, 509-512.	0.7	25
1274	ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. International Journal of Oncology, 0, , .	1.4	8
1275	Development and validation of eleven symptom indexes to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Research in Human Capital and Development, 2007, , 53-66.	0.1	2
1276	Cancer of the Pancreas: Are we Making Progress? A Review of Studies in the US Oncology Research Network. Cancer Control, 2008, 15, 308-313.	0.7	56
1277	Survival and Prognostic Factors of Unresectable Pancreatic Cancer. Journal of Clinical Gastroenterology, 2008, 42, 86-91.	1.1	62
1278	The Role of Nuclear Factor Î²B in Pancreatic Cancer and the Clinical Applications of Targeted Therapy. Pancreas, 2008, 36, 225-235.	0.5	84
1279	Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 221-224.	0.6	2
1280	Chemotherapy with Gemcitabine in Advanced Biliary Tract Carcinoma. Reviews on Recent Clinical Trials, 2008, 3, 70-78.	0.4	6
1281	OUTCOMES OF GEMCITABINE TREATMENT FOR INVASIVE DUCTAL PANCREATIC CANCER. Pancreas, 2008, 37, 112.	0.5	0
1282	Borderline Resectable Pancreatic Cancer: On the Edge of Survival. Cancer Control, 2008, 15, 295-307.	0.7	44
1283	New directions in the management of advanced pancreatic cancer: a review. Anti-Cancer Drugs, 2008, 19, 435-446.	0.7	36
1284	PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 145-150.	0.6	21
1285	Gemcitabine Plus Celecoxib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 157-162.	0.6	69
1286	Efficacy and Safety of Metallic Stents in Patients With Unresectable Pancreatic Cancer Receiving Gemcitabine. Pancreas, 2008, 37, 405-410.	0.5	23
1287	Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies. Cancer Journal (Sudbury, Mass), 2008, 14, 170-177.	1.0	65
1288	Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 140-144.	0.6	41

#	Article	IF	Citations
1289	Hemolytic-Uremic Syndrome Associated With Gemcitabine Treatment for Metastatic Pancreatic Cancer. Journal of Clinical Gastroenterology, 2008, 42, 551-552.	1.1	11
1291	Arsenic Trioxide in Patients With Adenocarcinoma of the Pancreas Refractory to Gemcitabine. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 553-556.	0.6	41
1292	Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma. Pancreas, 2008, 37, 154-158.	0.5	184
1293	EFFORTS TO IMPROVE THE ANTI-TUMOR EFFECT OF GEMCITABINE IN HUMAN PANCREATIC CANCER. Pancreas, 2008, 37, 111-112.	0.5	0
1294	From the podium to the patient: bringing the 2008 ASCO meeting to the clinic. Anti-Cancer Drugs, 2008, 19, 941-956.	0.7	0
1295	Antitumor Efficacy of Trastuzumab in Nude Mice Orthotopically Xenografted With Human Pancreatic Tumor Cells Expressing Low Levels of HER-2/neu. Journal of Immunotherapy, 2008, 31, 537-544.	1.2	16
1296	Prognostic Factors in Patients With Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Chemotherapy. Pancreas, 2008, 36, 56-60.	0.5	16
1297	Neoadjuvant Chemoradiation in Patients With Potentially Resectable Pancreatic Cancer. Pancreas, 2008, 36, 26-32.	0.5	40
1298	A Phase II Trial of Imatinib Mesylate in Patients With Metastatic Pancreatic Cancer. Pancreas, 2008, 36, 341-345.	0.5	19
1299	Inhibition of Human Pancreatic Cell Line MIA PaCa2 Proliferation by HA-But, a Hyaluronic Butyric Ester. Pancreas, 2008, 36, e15-e23.	0.5	19
1300	Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy. Pancreas, 2008, 37, 269-274.	0.5	83
1301	Treatment of locally advanced and metastatic pancreatic cancer. , 0, , 166-174.		0
1302	Exocrine pancreas. , 0, , 151-158.		0
1303	Erlotinib in the treatment of advanced pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 83.	3.0	52
1304	EGFR Expression in Gallbladder Carcinoma in North America. International Journal of Medical Sciences, 2008, 5, 285-291.	1.1	31
1305	Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics: Targets and Therapy, 2008, 2, 707.	3.0	17
1306	Clinical trial designs for more rapid proof-of-principle and approval. , 2008, , 53-87.		1
1307	Endoscopic Ultrasound-Guided Intratumoural Therapy for Pancreatic Cancer. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 405-410.	1.8	31

#	Article	IF	Citations
1308	Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas. Clinical Medicine Oncology, 2008, 2, CMO.S919.	0.2	1
1309	Pancreas Cancer Survival in the Gemcitabine Era. Clinical Medicine Oncology, 2008, 2, CMO.S334.	0.2	5
1310	Effects of a Sequential Combination of Hyperthermia and Gemcitabine in the Treatment of Advanced Unresectable Pancreatic Cancer: A Retrospective Study. Thermal Medicine, 2008, 24, 131-139.	0.0	9
1313	Cyclopentenyl cytosine has biological and anti-tumour activity, but does not enhance the efficacy of gemcitabine and radiation in two animal tumour models. International Journal of Oncology, 2009, 34, 813-9.	1.4	3
1314	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics: Targets and Therapy, 2009, , 419.	3.0	19
1315	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics: Targets and Therapy, 2009, , 429.	3.0	2
1316	First-line simplified GEMOX (S-GemOx) versus classical GEMOX inÂmetastatic pancreatic cancer (MPA): results ofÂaÂGERCOR randomized phase II study. Bulletin Du Cancer, 2009, 96, e18-e22.	0.6	11
1317	Pancreatectomy for Pancreatic Cancer with Reference to Combined Resection of the Vessels, Twenty Nine Year Experience by a Single Surgeon. Keio Journal of Medicine, 2009, 58, 103-109.	0.5	12
1318	Polyethylene Glycosylated Curcumin Conjugate Inhibits Pancreatic Cancer Cell Growth through Inactivation of Jab1. Molecular Pharmacology, 2009, 76, 81-90.	1.0	103
1319	Emerging drugs in the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2009, 14, 311-328.	1.0	13
1320	Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer. Oncology, 2009, 76, 270-274.	0.9	35
1321	Management of advanced pancreatic cancer. Expert Review of Clinical Pharmacology, 2009, 2, 527-541.	1.3	4
1322	Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 2009, 324, 1457-1461.	6.0	2,730
1323	Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 2231-2237.	0.8	611
1324	Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy, 2009, 1, 223-239.	1.0	35
1325	Pancreatic cancer: advances in medical therapy. Expert Review of Clinical Pharmacology, 2009, 2, 173-180.	1.3	0
1326	Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1 E6201: A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2009, 27, 3778-3785.	0.8	382
1327	Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review. Journal of Clinical Oncology, 2009, 27, 2269-2277.	0.8	221

#	Article	IF	Citations
1328	Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British Journal of Cancer, 2009, 100, 1842-1845.	2.9	35
1329	A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. British Journal of Cancer, 2009, 101, 1658-1663.	2.9	149
1330	Clinical importance of B7-H3 expression in human pancreatic cancer. British Journal of Cancer, 2009, 101, 1709-1716.	2.9	148
1331	A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. British Journal of Cancer, 2009, 101, 908-915.	2.9	385
1332	Cancer: The Road to Amiens. Journal of Clinical Oncology, 2009, 27, 328-333.	0.8	97
1333	Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development. Journal of Clinical Oncology, 2009, 27, 5487-5491.	0.8	26
1334	A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Annals of Oncology, 2009, 20, 1397-1401.	0.6	21
1335	Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 193-198.	0.8	275
1336	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Molecular Cancer Therapeutics, 2009, 8, 1484-1493.	1.9	39
1337	UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Molecular Cancer Therapeutics, 2009, 8, 36-44.	1.9	48
1338	AMG 479, a fully human antiâ€“insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics, 2009, 8, 1095-1105.	1.9	124
1339	Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904. Journal of Clinical Oncology, 2009, 27, 5506-5512.	0.8	84
1340	Gemcitabine and vinorelbine therapy for patients with Hodgkin lymphoma. Pediatric Health, 2009, 3, 525-532.	0.3	0
1341	Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers. Oncology, 2009, 76, 254-261.	0.9	41
1342	Thymidylate Synthase and Dihydropyrimidine Dehydrogenase Are Upregulated in Pancreatic and Biliary Tract Cancers. Pathobiology, 2009, 76, 193-198.	1.9	16
1343	Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Oncology, 2009, 77, 40-48.	0.9	20
1344	Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?. Oncology, 2009, 77, 217-223.	0.9	28
1345	A Pilot Study for Combination Chemotherapy Using Gemcitabine and S-1 for Advanced Pancreatic Cancer. Oncology, 2009, 77, 300-303.	0.9	28

#	Article	IF	Citations
1346	A Case of Long Survival in Advanced Pancreatic Cancer With Multiple Liver Metastases Successfully Treated by Combined Chemotherapy of S-1 and Gemcitabine. Pancreas, 2009, 38, 489.	0.5	0
1347	Gemcitabine Combined With Uracil-Tegafur in Patients With Advanced Pancreatic Cancer. Journal of the National Medical Association, 2009, 101, 761-764.	0.6	0
1348	A Digest of the Pancreatic Cancer Registry Report 2007. Pancreas, 2009, 38, 487.	0.5	5
1349	A Novel Strategy for Advanced Pancreatic Cancer-Progression of Molecular Targeting Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 877-881.	0.9	8
1350	Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer. Current Clinical Pharmacology, 2009, 4, 102-112.	0.2	45
1351	Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 162-184.	0.9	38
1352	Changing the clinical picture of challenging tumors: tales becoming reality?. Future Oncology, 2009, 5, 785-802.	1.1	1
1353	Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor. Molecular Cancer Research, 2009, 7, 1572-1581.	1.5	96
1354	Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study. Oncology Research and Treatment, 2009, 32, 99-102.	0.8	21
1355	Natural Products and their Analogues as Efficient Anticancer Drugs. Mini-Reviews in Medicinal Chemistry, 2009, 9, 560-571.	1.1	68
1356	A Novel Interventional Radiology Technique for Arterial Infusion Chemotherapy Against Advanced Pancreatic Cancer. American Journal of Roentgenology, 2009, 192, W168-W177.	1.0	16
1357	The Potential use of Dendritic Cell-based Immunotherapy for Treatment of Pancreatic Cancer. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2009, 9, 191-202.	0.5	0
1358	Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 38-46.	1.7	11
1359	Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine. Journal of Clinical Oncology, 2009, 27, 2261-2268.	0.8	40
1361	CLUSTERING CONTEXT-SPECIFIC GENE REGULATORY NETWORKS. , 2009, , 444-455.		7
1362	Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 797-806.	0.6	55
1363	A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Annals of Oncology, 2009, 20, 239-243.	0.6	41
1364	Chemoradiotherapy in pancreatic carcinoma. Indian Journal of Medical and Paediatric Oncology, 2009, 30, 55-60.	0.1	2

#	Article	IF	Citations
1365	Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv37-iv40.	0.6	27
1366	Pancreatic Disease. InnovAiT, 2009, 2, 662-673.	0.0	1
1367	Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV. Clinical Cancer Research, 2009, 15, 511-519.	3.2	84
1368	Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase Iâ€“II study. Annals of Oncology, 2009, 20, 1369-1374.	0.6	13
1369	Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines. Molecular Cancer Research, 2009, 7, 890-896.	1.5	54
1370	Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity. Clinical Cancer Research, 2009, 15, 6367-6377.	3.2	39
1371	Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opinion on Investigational Drugs, 2009, 18, 469-479.	1.9	28
1372	Alternate Endpoints for Screening Phase II Studies. Clinical Cancer Research, 2009, 15, 1873-1882.	3.2	78
1373	Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies. Journal of Clinical Oncology, 2009, 27, e213-e214.	0.8	12
1374	The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase. Cancer Research, 2009, 69, 4567-4572.	0.4	155
1375	Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?. Expert Reviews in Molecular Medicine, 2009, 11, e34.	1.6	6
1376	MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Molecular Cancer Therapeutics, 2009, 8, 1067-1074.	1.9	308
1377	Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World Journal of Gastroenterology, 2009, 15, 737.	1.4	31
1378	Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma. Clinical Cancer Research, 2009, 15, 2913-2919.	3.2	188
1379	Patient-Reported Outcomes as a Component of the Primary Endpoint in a Double-Blind, Placebo-Controlled Trial in Advanced Pancreatic Cancer. Journal of Pain and Symptom Management, 2009, 37, 135-143.	0.6	22
1380	An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery, 2009, 146, 241-249.	1.0	15
1381	Enhanced magnetic resonance imaging of experimental pancreatic tumor in vivo by block copolymer-coated magnetite nanoparticles with TGF-Î² inhibitor. Journal of Controlled Release, 2009, 140, 306-311.	4.8	60
1382	Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer, 2009, 9, 132.	1.1	51

#	Article	IF	Citations
1383	Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer, 2009, 9, 66.	1.1	36
1384	Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochemical Pharmacology, 2009, 77, 1674-1683.	2.0	52
1385	Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochemical Pharmacology, 2009, 78, 273-283.	2.0	85
1387	CD44â€positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. International Journal of Cancer, 2009, 125, 2323-2331.	2.3	266
1388	Gemcitabine and oxaliplatin combination chemotherapy for metastatic wellâ€differentiated neuroendocrine carcinomas. Cancer, 2009, 115, 3392-3399.	2.0	60
1389	Surgical management for a malignant bowel obstruction with recurrent gastrointestinal carcinoma. Journal of Surgical Oncology, 2010, 101, 228-232.	0.8	12
1390	La recherche clinique en cancÃ©rologie digestive: de la cible Ã la vÃ©ritable personnalisation du traitement?. Oncologie, 2009, 11, 325-330.	0.2	0
1392	The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Surgery, 2009, 16, 485-492.	2.0	24
1393	Clinical impact of radiotherapy for locally advanced pancreatic cancer. Journal of Gastroenterology, 2009, 44, 1209-1214.	2.3	10
1394	A comprehensive study of Sansalvamide A derivatives: The structureâ€“activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorganic and Medicinal Chemistry, 2009, 17, 5806-5825.	1.4	43
1395	Cumulative Morbidity and Late Mortality in Long-Term Survivors of Exocrine Pancreas Cancer. Journal of Gastrointestinal Cancer, 2009, 40, 46-50.	0.6	11
1396	Consensus on the treatment of pancreatic cancer in Spain. Clinical and Translational Oncology, 2009, 11, 290-301.	1.2	4
1397	Axitinibâ€”a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Targeted Oncology, 2009, 4, 297-305.	1.7	80
1398	Pancreatic cancer â€“ ASCO 2009. Memo - Magazine of European Medical Oncology, 2009, 2, 211-213.	0.3	0
1399	Quality of life in palliative care. Journal of Medicine and the Person, 2009, 7, 11-18.	0.1	2
1401	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 313-319.	1.1	89
1402	A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. Cancer Chemotherapy and Pharmacology, 2009, 63, 331-341.	1.1	5
1403	Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 529-533.	1.1	31

#	Article	IF	Citations
1404	Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 535-541.	1.1	27
1405	Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 63, 1141-1145.	1.1	58
1406	Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2009, 64, 317-325.	1.1	18
1407	Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemotherapy and Pharmacology, 2009, 64, 177-181.	1.1	48
1408	Phase II trial of S-1 in combination with gemcitabine for chemo-naÃ¯ve patients with locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 707-713.	1.1	28
1409	Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 1173-1179.	1.1	20
1410	Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2009, 64, 1211-1219.	1.1	15
1411	A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer. BMC Surgery, 2009, 9, 1.	0.6	19
1412	Tumor biology and cancer therapy â€“ an evolving relationship. Cell Communication and Signaling, 2009, 7, 19.	2.7	11
1413	Dkkâ€3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas. Cancer Science, 2009, 100, 1414-1420.	1.7	47
1414	Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. Acta Pharmacologica Sinica, 2009, 30, 1337-1343.	2.8	57
1415	Combined inhibition of PAK7, MAP3K7 and CK2Î± kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts. Cancer Gene Therapy, 2009, 16, 731-740.	2.2	22
1416	Combination of human tumor necrosis factor-alpha (hTNF-Î±) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Therapy, 2009, 16, 841-847.	2.2	47
1417	Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene, 2009, 28, 2903-2909.	2.6	113
1418	Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. British Journal of Cancer, 2009, 100, 1032-1036.	2.9	86
1419	High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. British Journal of Cancer, 2009, 100, 1444-1451.	2.9	152
1420	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study â€“ The UK ABC-01 Study. British Journal of Cancer, 2009, 101, 621-627.	2.9	243
1421	Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer â€“ a multi-centre randomised phase II study. British Journal of Cancer, 2009, 101, 1853-1859.	2.9	58

#	Article	IF	Citations
1422	Gemcitabineâ€induced radiation recall in the treatment of pancreatic cancer. Asia-Pacific Journal of Clinical Oncology, 2009, 5, 17-23.	0.7	2
1423	Modelling Population-Based Cancer Survival Trends by using Join Point Models for Grouped Survival Data. Journal of the Royal Statistical Society Series A: Statistics in Society, 2009, 172, 405-425.	0.6	21
1424	Dendritic Cellâ€Based Vaccines for Pancreatic Cancer and Melanoma. Annals of the New York Academy of Sciences, 2009, 1174, 33-40.	1.8	26
1425	Radiotherapy in England in 2007: Modelled Demand and Audited Activity. Clinical Oncology, 2009, 21, 575-590.	0.6	29
1426	Gemcitabine-Based Combination Chemotherapy Followed by Radiation With Capecitabine as Adjuvant Therapy for Resected Pancreas Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1450-1455.	0.4	12
1427	Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies. Surgery Today, 2009, 39, 466-475.	0.7	43
1428	Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial. Journal of Clinical Oncology, 2009, 27, 6243-6250.	0.8	79
1429	Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer. Cancer Investigation, 2009, 28, 186-194.	0.6	72
1430	Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. Cutaneous and Ocular Toxicology, 2009, 28, 181-184.	0.5	4
1431	Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treatment Reviews, 2009, 35, 167-174.	3.4	50
1432	Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treatment Reviews, 2009, 35, 221-227.	3.4	80
1433	Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treatment Reviews, 2009, 35, 335-339.	3.4	94
1434	Pancreatic cancer: Current and future treatment strategies. Cancer Treatment Reviews, 2009, 35, 431-436.	3.4	86
1435	Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions. Cancer Treatment Reviews, 2009, 35, 676-684.	3.4	30
1436	Cachexia in pancreatic cancer â€“ Mechanisms and potential intervention. European E-journal of Clinical Nutrition and Metabolism, 2009, 4, e337-e343.	0.4	1
1437	A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. European Journal of Cancer, 2009, 45, 1589-1596.	1.3	66
1438	A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. European Journal of Cancer, 2009, 45, 2519-2527.	1.3	18
1439	Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?. European Journal of Cancer, 2009, 45, 2249-2252.	1.3	37

#	Article	IF	Citations
1440	Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Letters, 2009, 273, 250-256.	3.2	22
1441	Brucein D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase. Cancer Letters, 2009, 281, 42-52.	3.2	73
1442	The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2009, 13, 123-143.	0.6	14
1444	Cancers of the Pancreas and Hepatobiliary System. Seminars in Oncology Nursing, 2009, 25, 76-92.	0.7	12
1445	Compound MMH01 possesses toxicity against human leukemia and pancreatic cancer cells. Toxicology in Vitro, 2009, 23, 418-424.	1.1	13
1446	Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Review of Anticancer Therapy, 2009, 9, 1473-1485.	1.1	25
1447	Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer. Gastroenterology, 2009, 136, 187-195.	0.6	392
1448	Personalized Medicine for Pancreatic Cancer: A Step in the Right Direction. Gastroenterology, 2009, 136, 43-45.	0.6	20
1449	Inhibition of Î³-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2009, 136, 1741-1749.e6.	0.6	155
1450	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 185-189.	1.0	1
1451	Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. Journal of Translational Medicine, 2009, 7, 43.	1.8	91
1452	Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. Journal of Hematology and Oncology, 2009, 2, 13.	6.9	21
1453	Plumbagin, Isolated from Plumbago zeylanica, Induces Cell Death through Apoptosis in Human Pancreatic Cancer Cells. Pancreatology, 2009, 9, 797-809.	0.5	56
1454	The Molecular Basis of Cancer and the Development of Targeted Therapy. Surgical Clinics of North America, 2009, 89, 1-15.	0.5	13
1455	Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 412-422.	8.2	194
1456	Pancreatology. , 2009, , .		0
1457	Surgical Treatment of Pancreatic Diseases. , 2009, , .		5
1458	Surgery in Multimodal Management of Solid Tumors. , 2009, , .		1

#	Article	IF	Citations
1459	Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2009, 28, 83.	3.5	59
1460	HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment. Expert Review of Anticancer Therapy, 2009, 9, 1439-1441.	1.1	9
1461	Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells. Cancer Research, 2009, 69, 5876-5884.	0.4	226
1462	Recurrent cutaneous toxic erythema induced by gemcitabine in a patient with pancreatic cancer. Cutaneous and Ocular Toxicology, 2009, 28, 144-148.	0.5	7
1463	Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. Journal of Clinical Oncology, 2009, 27, 5660-5669.	0.8	211
1464	Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiotherapy and Oncology, 2009, 92, 238-243.	0.3	55
1465	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews Clinical Oncology, 2009, 6, 507-518.	12.5	332
1466	Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 4138-4146.	3.2	79
1467	A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology, 2009, 9, 404-409.	0.5	37
1468	Multidetector CT Evaluation of the Course of Nonresectable Pancreatic Carcinomas with Neoadjuvant Therapy. Pancreatology, 2009, 9, 621-630.	0.5	9
1469	Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117Âpatients. Gastroenterologie Clinique Et Biologique, 2009, 33, 1036-1044.	0.9	16
1470	Medical Management of Pancreatic Adenocarcinoma. Pancreatology, 2009, 9, 223-232.	0.5	13
1471	Gemcitabine-Based Chemogene Therapy for Pancreatic Cancer Using Ad-dCK::UMK GDEPT and TS/RR siRNA Strategies. Neoplasia, 2009, 11, 637-650.	2.3	65
1472	Pancreatic cancer: Incidence, treatment and survival trends â€“ 1175 cases in Calvados (France) from 1978 to 2002. Gastroenterologie Clinique Et Biologique, 2009, 33, 1045-1051.	0.9	23
1474	Multidisciplinary Approach to Tumors of the Pancreas and Biliary Tree. Surgical Clinics of North America, 2009, 89, 115-131.	0.5	11
1475	Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scandinavian Journal of Gastroenterology, 2009, 44, 782-786.	0.6	113
1476	Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anti-Cancer Drugs, 2009, 20, 634-638.	0.7	41
1477	Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 44-48.	0.6	33

#	Article	IF	Citations
1478	Second-Line Treatment With a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 348-352.	0.6	54
1479	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy for Pancreatic Cancer. Pancreas, 2009, 38, 815-819.	0.5	7
1480	Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas. Cancer Journal (Sudbury, Mass), 2009, 15, 339-343.	1.0	47
1481	A Combination Therapy of Gemcitabine With Immunotherapy for Patients With Inoperable Locally Advanced Pancreatic Cancer. Pancreas, 2009, 38, e69-e74.	0.5	100
1482	Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer. Annals of Surgery, 2009, 250, 88-95.	2.1	104
1483	Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 115-121.	0.6	23
1484	Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients With Advanced Solid Malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 607-611.	0.6	2
1485	The Usefulness of Perfusion-Weighted Magnetic Resonance Imaging in Advanced Pancreatic Cancer. Pancreas, 2009, 38, 644-648.	0.5	9
1486	Changes in Tumor Vascularity Depicted by Contrast-Enhanced Ultrasonography as a Predictor of Chemotherapeutic Effect in Patients With Unresectable Pancreatic Cancer. Pancreas, 2009, 38, 30-35.	0.5	34
1487	The Flavonoid Apigenin Potentiates the Growth Inhibitory Effects of Gemcitabine and Abrogates Gemcitabine Resistance in Human Pancreatic Cancer Cells. Pancreas, 2009, 38, 409-415.	0.5	42
1488	Photodynamic therapy for pancreatic and biliary tract carcinoma. , 2009, , .		0
1489	Liver Perfusion Chemotherapy With 5-Fluorouracil Followed by Systemic Gemcitabine Administration for Resected Pancreatic Cancer. Pancreas, 2009, 38, 161-167.	0.5	22
1490	Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncology Reports, 2009, , .	1.2	18
1491	Pancreatic cancer therapy with a novel pump for controlled drug release. Oncology Reports, 2009, 23, .	1.2	2
1492	Modalities for Evaluating Chemotherapeutic Efficacy and Survival Time in Patients with Advanced Pancreatic Cancer: Comparison between FDG-PET, CT, and Serum Tumor Markers. Internal Medicine, 2009, 48, 867-875.	0.3	48
1493	Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. The Cochrane Library, 2009, , CD002093.	1.5	24
1494	A Case Report. Pancreas, 2009, 38, 489.	0.5	0
1495	A fiber modified adenovirus vector that targets to the EphrinA2 receptor reveals enhanced gene transfer to ex vivo pancreatic cancer. International Journal of Oncology, 2009, 36, .	1.4	3

#	Article	IF	Citations
1496	Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancers. Journal of Chemotherapy, 2009, 21, 698-700.	0.7	2
1497	Granulocyte-Colony Stimulating Factor-Producing Pancreatic Adenosquamous Carcinoma Showing Aggressive Clinical Course. Internal Medicine, 2009, 48, 687-691.	0.3	51
1498	Cancer of Unknown Primary Site in which Tumor Marker-Oriented Chemotherapy was Effective and Pancreatic Cancer was Finally Confirmed at Autopsy. Internal Medicine, 2009, 48, 1651-1656.	0.3	1
1499	Peritoneal Metastases. , 2009, , 1104-1124.		0
1500	Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. International Journal of Oncology, 2009, 36, .	1.4	7
1501	Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncology Reports, 2009, 22, 105-13.	1.2	21
1502	Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 174-179.	0.8	11
1503	Enhanced Antitumor Effect of Combined Gemcitabine and Proton Radiation in the Treatment of Pancreatic Cancer. Pancreas, 2009, 38, 782-790.	0.5	15
1504	Magnetic resonance image-guided photodynamic therapy of xenograft pancreas tumors with verteporfin. Proceedings of SPIE, 2009, , .	0.8	6
1505	Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions. American Journal of Therapeutics, 2010, 17, 79-85.	0.5	1
1506	What Else in Gemcitabine-Pretreated Advanced Pancreatic Cancer? An Update of Second Line Therapies. Reviews on Recent Clinical Trials, 2010, 5, 43-56.	0.4	11
1507	Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy. Current Cancer Drug Targets, 2010, 10, 319-331.	0.8	37
1509	Gemox: A Widely Useful Therapy Against Solid Tumors-Review and Personal Experience. Journal of Chemotherapy, 2010, 22, 298-303.	0.7	7
1510	Update on Pancreatic Cancer Treatment. Nurse Practitioner, 2010, 35, 16-22.	0.2	3
1511	Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma. Journal of Immunotherapy, 2010, 33, 828-833.	1.2	950
1512	Blockade of Delta-Like Ligand 4 Signaling Inhibits Both Growth and Angiogenesis of Pancreatic Cancer. Pancreas, 2010, 39, 897-903.	0.5	36
1513	Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anti-Cancer Drugs, 2010, 21, 447-452.	0.7	90
1514	Evaluation of the Clinical Significance of Focal Adhesion Kinase and Src Expression in Human Pancreatic Ductal Adenocarcinoma. Pancreas, 2010, 39, 930-936.	0.5	23

#	Article	IF	Citations
1515	HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients. Annals of Surgery, 2010, 252, 499-506.	2.1	84
1516	Erlotinib 150â€‰mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the â€˜Arbeitsgemeinschaft Internistische Onkologieâ€™. Anti-Cancer Drugs, 2010, 21, 94-100.	0.7	28
1517	Identifying Molecular Markers for Chemosensitivity to Gemcitabine in Pancreatic Cancer. Pancreas, 2010, 39, 473-485.	0.5	30
1518	Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer. Pancreas, 2010, 39, 1284-1292.	0.5	26
1519	Review and Commentary on the Role of Radiation Therapy in the Adjuvant Management of Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 101-106.	0.6	11
1520	Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagulation and Fibrinolysis, 2010, 21, 452-458.	0.5	22
1521	Impact of S-1 on the Survival of Patients With Advanced Pancreatic Cancer. Pancreas, 2010, 39, 989-993.	0.5	27
1522	One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin. Oncology Reports, 2010, 24, 767-9.	1.2	7
1524	Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 972-1017.	2.3	152
1525	Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncology Reports, 2010, 23, 1183-92.	1.2	116
1526	A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncology Reports, 2010, 24, 795-801.	1.2	64
1527	Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncology Reports, 2010, 23, 1375-82.	1.2	41
1528	Anti-tumor effect by inhibition of NF-ÎºB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncology Reports, 2010, , .	1.2	1
1530	Pancreatic Cancer: Pathobiology, Treatment Options, and Drug Delivery. AAPS Journal, 2010, 12, 223-232.	2.2	95
1531	Chitosan and Glyceryl Monooleate Nanostructures Containing Gemcitabine: Potential Delivery System for Pancreatic Cancer Treatment. AAPS PharmSciTech, 2010, 11, 392-401.	1.5	42
1532	EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer. Annals of Surgical Oncology, 2010, 17, 1442-1452.	0.7	24
1533	Society of Surgical Oncology Presidential Address: The War on Cancerâ€”Shifting from Disappointment to New Hope. Annals of Surgical Oncology, 2010, 17, 1971-1978.	0.7	4
1534	Adjuvant Radiation Therapy for Distal Pancreatic Cancer: Is There a Role?. Annals of Surgical Oncology, 2010, 17, 3082-3084.	0.7	3

#	Article	IF	Citations
1535	Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. European Radiology, 2010, 20, 1786-1791.	2.3	78
1536	Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews, 2010, 62, 346-361.	6.6	376
1537	Ukrain Affects Pancreas Cancer Cell Phenotype in vitro by Targeting MMP-9 and Intra-/Extracellular SPARC Expression. Pancreatology, 2010, 10, 545-552.	0.5	19
1538	Vascular Reconstruction During Pancreatoduodenectomy for Ductal Adenocarcinoma of the Pancreas Improves Resectability but does not Achieve Cure. World Journal of Surgery, 2010, 34, 2648-2661.	0.8	63
1539	A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 527-536.	1.1	33
1540	A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 287-294.	1.1	19
1541	Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 395-403.	1.1	53
1542	External Beam Radiotherapy Plus 24-Hour Continuous Infusion of Gemcitabine in Unresectable Pancreatic Carcinoma: Long-Term Results of a Phase II Study. International Journal of Radiation Oncology Biology Physics, 2010, 76, 831-838.	0.4	18
1543	Patterns of Radiotherapy Practice for Pancreatic Cancer in Japan: Results of the Japanese Radiation Oncology Study Group (JROSG) Survey. International Journal of Radiation Oncology Biology Physics, 2010, 77, 743-750.	0.4	7
1544	Estimating Optimal Dose of Twice-Weekly Gemcitabine for Concurrent Chemoradiotherapy in Unresectable Pancreatic Carcinoma: Mature Results of GEMRT-01 Phase I Trial. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1426-1432.	0.4	21
1545	Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials, 2010, 31, 9340-9356.	5.7	121
1548	Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. Journal of Gastroenterology, 2010, 45, 1146-1154.	2.3	33
1549	Three cases of locally advanced pancreatic cancer successfully treated with chemoradiation and chemotherapy. Clinical Journal of Gastroenterology, 2010, 3, 186-190.	0.4	0
1550	Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical Journal of Gastroenterology, 2010, 3, 307-317.	0.4	4
1551	Prior splenic irradiation reduces hematologic adverse events during chemotherapy in pancreatic tail cancer: a report of a patient with liver cirrhosis. Clinical Journal of Gastroenterology, 2010, 3, 337-342.	0.4	0
1552	Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumor Biology, 2010, 31, 351-357.	0.8	46
1553	The Global Impact of Endoscopic Ultrasound (EUS) Regarding the Survival of a Pancreatic Adenocarcinoma in a Tertiary Hospital. Journal of Gastrointestinal Cancer, 2010, 41, 165-172.	0.6	2
1554	ABC Transporters as Molecular Effectors of Pancreatic Oncogenic Pathways: The Hedgehog-GLI Model. Journal of Gastrointestinal Cancer, 2010, 41, 153-158.	0.6	19

#	Article	IF	Citations
1555	Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Medical Oncology, 2010, 27, 430-433.	1.2	6
1556	Pharmacogenetics and pharmacoepigenetics of gemcitabine. Medical Oncology, 2010, 27, 1133-1143.	1.2	23
1557	Pterostilbene Inhibits Pancreatic Cancer In Vitro. Journal of Gastrointestinal Surgery, 2010, 14, 873-879.	0.9	43
1558	A Single Institution Review of Adjuvant Therapy Outcomes for Resectable Pancreatic Adenocarcinoma: Outcome and Prognostic Indicators. Journal of Gastrointestinal Surgery, 2010, 14, 1159-1169.	0.9	20
1559	Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients. Journal of Gastrointestinal Surgery, 2010, 14, 1547-1559.	0.9	103
1560	Could we use clinical benefit to evaluate the effects of chinese medicine on the treatment of cancer?. Chinese Journal of Integrative Medicine, 2010, 16, 9-10.	0.7	10
1561	In Vitro and In Vivo Anticancer Activity of a Novel Nano-sized Formulation Based on Self-assembling Polymers Against Pancreatic Cancer. Pharmaceutical Research, 2010, 27, 2694-2703.	1.7	30
1562	Pilot study of irinotecan/oxaliplatin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Investigational New Drugs, 2010, 28, 343-349.	1.2	15
1563	Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: An original drug delivery pathway. Journal of Controlled Release, 2010, 147, 163-170.	4.8	85
1564	Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine, 2010, 17, 161-169.	2.3	93
1565	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer, 2010, 10, 368.	1.1	152
1566	Cytotoxicity screening of Bangladeshi medicinal plant extracts on pancreatic cancer cells. BMC Complementary and Alternative Medicine, 2010, 10, 52.	3.7	52
1567	Targeted drug delivery in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 97-104.	3.3	46
1568	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer, 2010, 116, 5325-5335.	2.0	77
1569	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	2.0	143
1570	Drug therapy: Sorafenib. Hepatology, 2010, 51, 1843-1849.	3.6	23
1571	Chemoradiotherapy with or without Induction Chemotherapy for Locally Advanced Pancreatic Cancer: a UK Multi-institutional Experience. Clinical Oncology, 2010, 22, 564-569.	0.6	15
1572	Synthesis of 4â€²-ester analogs of resveratrol and their evaluation in malignant melanoma and pancreatic cell lines. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1198-1201.	1.0	21

#	Article	IF	Citations
1573	18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1420-1425.	0.4	119
1574	Intraoperative Radiotherapy for Resected Pancreatic Cancer: AÂMulti-Institutional Retrospective Analysis of 210 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 77, 734-742.	0.4	53
1575	Adjuvant Pancreatic Cancer Therapy: No One Should Go It Alone or Be Left Behind. International Journal of Radiation Oncology Biology Physics, 2010, 77, 645-647.	0.4	2
1576	Proposing the Lymphatic Target Volume for Elective Radiation Therapy for Nasopharyngeal Cancer: A Pooled Analyses of Clinical Evidence. International Journal of Radiation Oncology Biology Physics, 2010, 78, S449.	0.4	0
1577	Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiation Oncology, 2010, 5, 28.	1.2	33
1578	Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer. Radiation Oncology, 2010, 5, 60.	1.2	4
1579	TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. Journal of Molecular Signaling, 2010, 5, 18.	0.5	18
1580	Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. British Journal of Pharmacology, 2010, 160, 998-1007.	2.7	68
1581	Unresectable pancreatic adenocarcinoma: do we know who survives?. Hpb, 2010, 12, 561-566.	0.1	13
1582	CA19â€9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia-Pacific Journal of Clinical Oncology, 2010, 6, 98-105.	0.7	35
1583	XAF1 as a prognostic biomarker and therapeutic target in pancreatic cancer. Cancer Science, 2010, 101, 559-567.	1.7	48
1584	In vitro and in vivo evidence that a combination of lapatinib plus Sâ€1 is a promising treatment for pancreatic cancer. Cancer Science, 2010, 101, 468-473.	1.7	20
1585	Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Science, 2010, 101, 433-439.	1.7	101
1586	Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. Cancer Science, 2010, 101, 2351-2360.	1.7	46
1587	Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. British Journal of Cancer, 2010, 103, 52-60.	2.9	74
1588	Inhibition of reninâ€“angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. British Journal of Cancer, 2010, 103, 1644-1648.	2.9	150
1589	Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacologica Sinica, 2010, 31, 741-745.	2.8	16
1590	KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nature Reviews Cancer, 2010, 10, 683-695.	12.8	502

#	Article	IF	Citations
1591	Small interfering RNA against the apurinic or apyrimidinic endonuclease enhances the sensitivity of human pancreatic cancer cells to gemcitabine in vitro. Journal of Digestive Diseases, 2010, 11, 224-230.	0.7	13
1592	Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma. Gut and Liver, 2010, 4, 384-388.	1.4	13
1593	Management of mucinous cystic neoplasms of the pancreas. World Journal of Gastroenterology, 2010, 16, 5682.	1.4	77
1594	Metastatic Pancreatic Cancer: Systemic Therapy. Medical Radiology, 2010, , 137-146.	0.0	0
1596	Use of chemotherapy and radiotherapy in patients with pancreatic cancer in Victoria (2002â€“2003): a retrospective cohort study. Medical Journal of Australia, 2010, 192, 323-327.	0.8	9
1597	Current and emerging therapies for the treatment of pancreatic cancer. OncoTargets and Therapy, 2010, 3, 111.	1.0	32
1598	Therapeutic Antibodies for the Treatment of Pancreatic Cancer. Scientific World Journal, The, 2010, 10, 1107-1120.	0.8	15
1599	Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model. PLoS ONE, 2010, 5, e9430.	1.1	62
1600	The Locally Advanced Nonmetastatic Cancer. Medical Radiology, 2010, , 123-136.	0.0	0
1601	Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers. Oncology Letters, 2010, 1, 231-235.	0.8	10
1602	Fixed-Dose-Rate Gemcitabine Infusion in Patients with Advanced Pancreatic or Biliary Tree Adenocarcinoma. Tumori, 2010, 96, 405-410.	0.6	5
1603	Tumors of the Pancreatic Body and Tail. World Journal of Oncology, 2010, 1, 52-65.	0.6	15
1604	Metastatic Pancreatic Cancer Response to Treatment with Cetuximab and Gemcitabine plus Capecitabine: A Case Report and Review of the Literature. Tumori, 2010, 96, 764-767.	0.6	2
1605	Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access Journal of Clinical Trials, 2010, 2010, 37.	1.5	26
1606	Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World Journal of Gastroenterology, 2010, 16, 673.	1.4	49
1607	Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2010, 56, 22-26.	0.3	3
1608	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. Journal of Clinical Oncology, 2010, 28, 1645-1651.	0.8	279
1609	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. JAMA - Journal of the American Medical Association, 2010, 304, 1073.	3.8	1,206

#	Article	IF	Citations
1610	Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2423-2429.	1.9	14
1611	Current Management of Gallbladder Carcinoma. Oncologist, 2010, 15, 168-181.	1.9	279
1612	Gemcitabine-based Cytotoxic Doublets Chemotherapy for Advanced Pancreatic Cancer: Updated Subgroup Meta-analyses of Overall Survival. Japanese Journal of Clinical Oncology, 2010, 40, 432-441.	0.6	33
1613	Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2010, 16, 986-994.	3.2	41
1614	Weekly Paclitaxel After Failure of Gemcitabine in Pancreatic Cancer Patients with Malignant Ascites: A Retrospective Study. Japanese Journal of Clinical Oncology, 2010, 40, 1135-1138.	0.6	22
1615	Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment. Molecular and Cellular Proteomics, 2010, 9, 695-704.	2.5	33
1616	Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer. Oncologist, 2010, 15, e1-e4.	1.9	7
1617	Transplanting Normal Vascular Proangiogenic Cells to Tumor-Bearing Mice Triggers Vascular Remodeling and Reduces Hypoxia in Tumors. Cancer Research, 2010, 70, 6283-6292.	0.4	24
1618	Translating Clinical Trials into Meaningful Outcomes. Clinical Cancer Research, 2010, 16, 5951-5955.	3.2	19
1619	Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506. Japanese Journal of Clinical Oncology, 2010, 40, 573-579.	0.6	63
1620	A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603). Oncologist, 2010, 15, 1310-1319.	1.9	58
1621	Improved Survival of Left-sided Pancreas Cancer after Surgery. Japanese Journal of Clinical Oncology, 2010, 40, 530-536.	0.6	35
1622	Salirasib in the treatment of pancreatic cancer. Future Oncology, 2010, 6, 885-891.	1.1	40
1623	Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past. Clinical Cancer Research, 2010, 16, 5963-5971.	3.2	23
1624	The Glasgow Prognostic Score Is a Good Predictor of Treatment Outcome in Patients with Unresectable Pancreatic Cancer. Chemotherapy, 2010, 56, 501-506.	0.8	48
1625	Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan. Japanese Journal of Clinical Oncology, 2010, 40, 183-187.	0.6	2
1626	Pancreatic Resections for Advanced M1-Pancreatic Carcinoma: The Value of Synchronous Metastasectomy. HPB Surgery, 2010, 2010, 1-6.	2.2	44
1627	Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. Cancers, 2010, 2, 1565-1575.	1.7	6

#	Article	IF	Citations
1628	S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure. Japanese Journal of Clinical Oncology, 2010, 40, 567-572.	0.6	24
1630	Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. Journal of Clinical Oncology, 2010, 28, 4450-4456.	0.8	254
1631	Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert Review of Anticancer Therapy, 2010, 10, 1545-1557.	1.1	13
1632	Intratumoral Injection of32P-Chromic Phosphate in the Treatment of Implanted Pancreatic Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 215-224.	0.7	9
1633	Proton-Pump Inhibitor as Palliative Care for Chemotherapy-Induced Gastroesophageal Reflux Disease in Pancreatic Cancer Patients. Journal of Palliative Medicine, 2010, 13, 815-818.	0.6	12
1634	Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Groupâ€“Directed Intergroup Trial S0205. Journal of Clinical Oncology, 2010, 28, 3605-3610.	0.8	570
1635	Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Clinical Oncology, 2010, 28, 3617-3622.	0.8	758
1636	Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 529-540.	1.1	37
1637	Explaining Marginal Benefits to Patients, When â€œMarginalâ€•Means Additional but Not Necessarily Small. Clinical Cancer Research, 2010, 16, 5981-5986.	3.2	22
1638	Phase II clinical trials in oncology: are we hitting the target?. Expert Review of Anticancer Therapy, 2010, 10, 427-438.	1.1	7
1639	Chemoradiation in Pancreatic Adenocarcinoma: A Literature Review. Oncologist, 2010, 15, 259-269.	1.9	25
1640	Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer. Journal of Clinical Oncology, 2010, 28, 2058-2063.	0.8	36
1641	Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions. Cancers, 2010, 2, 2044-2054.	1.7	28
1642	A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model. Molecular Cancer Therapeutics, 2010, 9, 2582-2592.	1.9	83
1643	Study of Apoptosis Induction and Deoxycytidine Kinase/Cytidine Deaminase Modulation in the Synergistic Interaction of a Novel Ceramide Analog and Gemcitabine in Pancreatic Cancer Cells. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 419-426.	0.4	13
1644	Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan. Japanese Journal of Clinical Oncology, 2010, 40, 774-780.	0.6	34
1645	Systemic therapy for metastatic pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2010, 2, 85-106.	1.4	5
1646	Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy. Annals of Oncology, 2010, 21, 189-190.	0.6	15

#	Article	IF	Citations
1647	A Step Forward in the Treatment of Advanced Biliary Tract Cancer. New England Journal of Medicine, 2010, 362, 1335-1337.	13.9	40
1648	Berberine Inhibits Cell Growth and Mediates Caspase-Independent Cell Death in Human Pancreatic Cancer Cells. Planta Medica, 2010, 76, 1155-1161.	0.7	41
1649	MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. Cancer Research, 2010, 70, 4528-4538.	0.4	409
1650	Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer. Cancer Biology and Therapy, 2010, 10, 99-107.	1.5	19
1651	Retrospective Analysis of the Efficacy of Gemcitabine for Previously Treated AIDS-Associated Kaposiâ€™s Sarcoma in Western Kenya. Oncology, 2010, 78, 5-11.	0.9	15
1652	Recent Advances in Combined Modality Therapy. Oncologist, 2010, 15, 372-381.	1.9	37
1653	Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut, 2010, 59, 1527-1534.	6.1	70
1654	Optimal treatment of metastatic pancreatic cancer. Gut, 2010, 59, 1454-1455.	6.1	4
1655	The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model. Cancer Prevention Research, 2010, 3, 1417-1426.	0.7	49
1656	Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biology and Therapy, 2010, 9, 632-639.	1.5	32
1657	Adjuvant Therapy in Pancreatic Cancer. Digestive Diseases, 2010, 28, 684-692.	0.8	24
1658	Challenges of drug resistance in the management of pancreatic cancer. Expert Review of Anticancer Therapy, 2010, 10, 1647-1661.	1.1	47
1659	Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer. Cancer Biology and Therapy, 2010, 10, 108-109.	1.5	0
1661	Cancer Stem Cells: A Novel Paradigm for Cancer Prevention and Treatment. Mini-Reviews in Medicinal Chemistry, 2010, 10, 359-371.	1.1	82
1662	Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. American Journal of Veterinary Research, 2010, 71, 799-808.	0.3	17
1663	Kinase signaling pathways as targets for intervention in pancreatic cancer. Cancer Biology and Therapy, 2010, 9, 754-763.	1.5	26
1664	Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Expert Opinion on Drug Safety, 2010, 9, 207-213.	1.0	12
1665	The role of radiotherapy in locally advanced pancreatic carcinoma. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 437-447.	8.2	36

#	Article	IF	Citations
1666	Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer. Molecular Cancer Therapeutics, 2010, 9, 2068-2078.	1.9	46
1668	Novel Targets for Pancreatic Cancer Therapy. Surgical Oncology Clinics of North America, 2010, 19, 419-429.	0.6	10
1669	DNA Mutational Differences in Cytological Specimens from Pancreatic Cancer and Cholangiocarcinoma. Pancreatology, 2010, 10, 429-433.	0.5	9
1670	Randomized Clinical Trials in Pancreatic Adenocarcinoma. Surgical Oncology Clinics of North America, 2010, 19, 115-150.	0.6	5
1671	Pharmacokinetic Evaluation of Pancreatic Arterial Infusion Chemotherapy after Unification of the Blood Supply in an Animal Model. Journal of Vascular and Interventional Radiology, 2010, 21, 116-121.	0.2	12
1672	Curative Radiation Therapy for Pancreatic Malignancies. Surgical Clinics of North America, 2010, 90, 341-354.	0.5	6
1673	Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells. Neoplasia, 2010, 12, 740-747.	2.3	100
1674	Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. International Journal of Oncology, 2010, 37, .	1.4	4
1675	EUS-guided in vivo microdialysis of the pancreas: a novel technique with potential diagnostic and therapeutic application. Gastrointestinal Endoscopy, 2010, 71, 176-179.	0.5	6
1676	Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointestinal Endoscopy, 2010, 71, 260-265.	0.5	46
1677	Survival in pancreatic cancer: the best is yet to come. Gastrointestinal Endoscopy, 2010, 72, 84-85.	0.5	4
1678	Pancreatic cancer stem cells â€“ update and future perspectives. Molecular Oncology, 2010, 4, 431-442.	2.1	74
1679	Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. Journal of the Royal College of Surgeons of Edinburgh, 2010, 8, 239-246.	0.8	65
1680	The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Molecular Cancer, 2010, 9, 298.	7.9	70
1681	Quantification of Gemcitabine Incorporation into Human DNA by LC/MS/MS as a Surrogate Measure for Target Engagement. Analytical Chemistry, 2010, 82, 6576-6583.	3.2	18
1682	Ultrasonic Nanotherapy of Pancreatic Cancer: Lessons from Ultrasound Imaging. Molecular Pharmaceutics, 2010, 7, 22-31.	2.3	78
1685	Dihydroartemisinin inactivates NF-Î¹B and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Letters, 2010, 293, 99-108.	3.2	149
1686	A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. European Journal of Cancer, 2010, 46, 526-533.	1.3	30

#	Article	IF	Citations
1687	Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. European Journal of Cancer, 2010, 46, 2753-2762.	1.3	91
1688	Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology, 2010, 7, 163-172.	12.5	704
1689	Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer. Nutrition and Cancer, 2010, 62, 1137-1141.	0.9	230
1690	Pancreatic Cancer. New England Journal of Medicine, 2010, 362, 1605-1617.	13.9	2,474
1691	Palliative Chemotherapy for Pancreatic Malignancies. Surgical Clinics of North America, 2010, 90, 365-375.	0.5	4
1692	Beneficial Effects of 5-Fluorouracil and Heparin-Based Portal Infusion Chemotherapy Combined with Mitomycin C and Cisplatin after Curative Resection of Pancreatic Cancer. Pancreatology, 2010, 10, 250-258.	0.5	13
1693	Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy. Neoplasia, 2010, 12, 807-IN8.	2.3	130
1694	Advanced Phase I/II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Gemcitabine-resistant Metastatic Pancreatic Cancer. Molecular Therapy, 2010, 18, 435-441.	3.7	64
1695	Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2010, 29, 15.	3.5	6
1696	Incorporation of Gemcitabine and Cytarabine into DNA by DNA Polymerase Î² and Ligase III/XRCC1. Biochemistry, 2010, 49, 4833-4840.	1.2	38
1697	Pancreatic cancer: Progress made. Acta OncolÃ³gica, 2010, 49, 407-417.	0.8	29
1698	Extracellular-protein-enhanced cellular uptake of squalenoyl gemcitabine from nanoassemblies. Soft Matter, 2010, 6, 5570.	1.2	24
1699	Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta OncolÃ³gica, 2010, 49, 423-430.	0.8	15
1700	Rexin-G, a targeted genetic medicine for cancer. Expert Opinion on Biological Therapy, 2010, 10, 819-832.	1.4	57
1701	Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. Annals of Oncology, 2010, 21, 2390-2395.	0.6	21
1702	Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data. Applied Health Economics and Health Policy, 2010, 8, 37-51.	1.0	3
1703	Chemoprevention strategies for pancreatic cancer. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 347-356.	8.2	106
1704	Any progress in pancreatic cancer? Well, but progress for Acta Oncologica. Acta OncolÃ³gica, 2010, 49, 404-406.	0.8	1

#	Article	IF	Citations
1705	Noninvasive Monitoring of Therapy-Induced Microvascular Changes in a Pancreatic Cancer Model Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with P846, a New Low-Diffusible Gadolinium-Based Contrast Agent. Radiation Research, 2011, 175, 10-20.	0.7	14
1706	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. Expert Review of Anticancer Therapy, 2011, 11, 1713-1717.	1.1	3
1707	Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect. Molecular Cancer Therapeutics, 2011, 10, 505-517.	1.9	33
1708	The Past, Present, and Future of Biomarkers: A Need for Molecular Beacons for the Clinical Management of Pancreatic Cancer. Advances in Surgery, 2011, 45, 301-321.	0.6	22
1709	Acycloguanosyl 5â€²-thymidyltriphosphate, a Thymidine Analogue Prodrug Activated by Telomerase, Reduces Pancreatic Tumor Growth in Mice. Gastroenterology, 2011, 140, 709-720.e9.	0.6	10
1710	Yet Another Nucleoside Analog for Pancreatic Cancer. Gastroenterology, 2011, 140, 400-404.	0.6	2
1711	Medical treatment of pancreatic cancer: New hopes after 10years of gemcitabine. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 364-374.	0.7	13
1712	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. Digestive and Liver Disease, 2011, 43, 225-230.	0.4	8
1713	Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Gastrointestinal Endoscopy, 2011, 74, 548-555.	0.5	75
1714	Cucurmosin induces apoptosis of BxPC-3 human pancreatic cancer cells via inactivation of the EGFR signaling pathway. Oncology Reports, 2011, 27, 891-7.	1.2	23
1715	Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms. PLoS ONE, 2011, 6, e27306.	1.1	173
1716	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experience. Lung Cancer, 2011, 73, 351-355.	0.9	12
1717	A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer. Drug Safety, 2011, 34, 175-186.	1.4	9
1718	Panzem. , 2011, , 2781-2781.		0
1719	New standards and a predictive biomarker for adjuvant therapy. Nature Reviews Clinical Oncology, 2011, 8, 70-72.	12.5	17
1720	CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. Science, 2011, 331, 1612-1616.	6.0	1,407
1721	Efficacy and Safety of Standardized Allergen-Removed <i>Rhus verniciflua</i> Stokes Extract in Patients with Advanced or Metastatic Pancreatic Cancer: A Korean Single-Center Experience. Oncology, 2011, 81, 312-318.	0.9	20
1722	Induction Chemotherapy. , 2011, , .		5

#	Article	IF	Citations
1723	The MASCC Textbook of Cancer Supportive Care and Survivorship. , 2011, , .		11
1724	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death and Disease, 2011, 2, e152-e152.	2.7	191
1725	Gastrointestinal Oncology. , 2011, , .		2
1726	Phage Display. , 2011, , 2836-2839.		0
1727	Platelet-Derived Growth Factor. , 2011, , 2908-2910.		0
1728	Myelosuppression of Thrombocytes and Monocytes Is Associated with a Lack of Synergy between Chemotherapy and Anti-VEGF Treatment. Neoplasia, 2011, 13, 419-427.	2.3	17
1729	In vivo real-time imaging of gemcitabine-leaded growth inhibition in the orthotopic transplantation model of human pancreatic tumor. Acta Pharmaceutica Sinica B, 2011, 1, 220-225.	5.7	6
1730	Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Cancer Letters, 2011, 305, 32-39.	3.2	27
1731	Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-ÎºB inhibitor for pancreatic cancer in mice. Cancer Letters, 2011, 306, 92-98.	3.2	11
1732	Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Letters, 2011, 307, 18-25.	3.2	27
1733	An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. Cancer Letters, 2011, 313, 76-83.	3.2	38
1734	Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer Letters, 2011, 313, 218-225.	3.2	54
1737	A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. European Journal of Cancer, 2011, 47, 199-205.	1.3	24
1738	Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. European Journal of Cancer, 2011, 47, 1676-1681.	1.3	318
1739	Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 612-620.	2.0	21
1740	Pancreatic Cancer Stem Cells as New Targets for Diagnostics and Therapy. Else-KrÃ¶ner-Fresenius-Symposia, 2011, , 116-134.	0.1	1
1741	Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets. OncoTargets and Therapy, 2011, 4, 27.	1.0	23
1742	Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer â€" A Veterans Affairs Cancer Registry analysis. Journal of Geriatric Oncology, 2011, 2, 209-214.	0.5	22

#	Article	IF	Citations
1743	Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer. Trends in Pharmacological Sciences, 2011, 32, 201-205.	4.0	15
1744	FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncology, The, 2011, 12, 8-9.	5.1	42
1745	The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncology, The, 2011, 12, 693-702.	5.1	147
1746	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncology, The, 2011, 12, 256-262.	5.1	356
1747	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 364, 1817-1825.	13.9	6,140
1748	Stromal biology and therapy in pancreatic cancer. Gut, 2011, 60, 861-868.	6.1	652
1749	Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: A meta-analysis. Radiotherapy and Oncology, 2011, 99, 108-113.	0.3	76
1750	Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiotherapy and Oncology, 2011, 99, 114-119.	0.3	45
1751	Adjuvant chemoradiotherapy in pancreatic adenocarcinomaâ€“Are we forcing a milestone?. International Journal of Surgery, 2011, 9, 329-331.	1.1	1
1752	Pancreatic cancer. Lancet, The, 2011, 378, 607-620.	6.3	2,155
1753	Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World Journal of Gastroenterology, 2011, 17, 867.	1.4	189
1755	Clinical Application of Image-Guided Iodine-125 Seed Implantation Therapy in Patients with Advanced Pancreatic Cancer. , 2011, , .		0
1756	Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar, 2011, S3, 16-22.	0.8	7
1757	Metastatic Pancreatic Cancer. , 0, , 333-343.		0
1758	Quality of Life Outcomes in Radiotherapy of Lung Cancer. Medical Radiology, 2011, , 661-673.	0.0	0
1759	Recent Patents Concerning Targeted Therapy of Apoptosis Resistance in Pancreatic Cancer. Recent Patents on DNA & Gene Sequences, 2011, 5, 28-34.	0.7	4
1760	Gemcitabine in elderly patients with advanced pancreatic cancer. World Journal of Gastroenterology, 2011, 17, 3497.	1.4	49
1761	Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer. Critical Reviews in Therapeutic Drug Carrier Systems, 2011, 28, 293-356.	1.2	5

#	Article	IF	Citations
1762	Randomized trials in exocrine pancreatic cancer. Przeglad Gastroenterologiczny, 2011, 2, 85-96.	0.3	1
1763	Cytotoxic T Lymphocytes and Vaccine Development 2011. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-1.	3.0	1
1764	Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer: Rationale and Report of Early Data. International Journal of Surgical Oncology, 2011, 2011, 1-7.	0.3	23
1765	Exploiting the Nucleotide Substrate Specificity of Repair DNA Polymerases To Develop Novel Anticancer Agents. Molecules, 2011, 16, 7994-8019.	1.7	13
1766	Phase II Study of Radiation Therapy Combined With Weekly Low-Dose Gemcitabine for Locally Advanced, Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 115-119.	0.6	32
1767	RNA Binding Protein CUGBP2/CELF2 Mediates Curcumin-Induced Mitotic Catastrophe of Pancreatic Cancer Cells. PLoS ONE, 2011, 6, e16958.	1.1	65
1768	Early Therapy Evaluation of Combined Cetuximab and Irinotecan in Orthotopic Pancreatic Tumor Xenografts by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Molecular Imaging, 2011, 10, 7290.2010.00040.	0.7	23
1769	Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer. Oncology Reports, 2011, 27, 423-32.	1.2	2
1770	Combination Paclitaxel and Inhibitor of Nuclear Factor ÎºB Activation Improves Therapeutic Outcome for Model Mice With Peritoneal Dissemination of Pancreatic Cancer. Pancreas, 2011, 40, 600-607.	0.5	11
1771	Systemic Gemcitabine and Capecitabine Plus Intra-Arterial Epirubicin and Cisplatin as Second-Line Chemotherapy in Gemcitabine-Failure Pancreatic Cancer. Pancreas, 2011, 40, 983-984.	0.5	1
1772	Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer. Journal of Immunotherapy, 2011, 34, 92-99.	1.2	91
1773	Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anti-Cancer Drugs, 2011, 22, 864-874.	0.7	17
1774	Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 321-325.	0.6	97
1775	Advances in pancreatic cancer. Current Opinion in Gastroenterology, 2011, 27, 460-466.	1.0	29
1776	Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anti-Cancer Drugs, 2011, 22, 719-731.	0.7	8
1777	Phase I/II Study of Hepatic Arterial Infusion Chemotherapy With Gemcitabine in Patients With Unresectable Intrahepatic Cholangiocarcinoma (JIVROSG-0301). American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 58-62.	0.6	40
1778	Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 70-75.	0.6	33
1779	Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas, 2011, 40, 415-421.	0.5	35

#	Article	IF	Citations
1780	Metastatic pancreatic cancer: old drugs, new paradigms. Current Opinion in Oncology, 2011, 23, 390-395.	1.1	32
1781	A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 460-465.	0.6	60
1782	Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation. International Journal of Oncology, 2011, 39, 1381-90.	1.4	26
1783	Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer. Current Cancer Drug Targets, 2011, 11, 734-751.	0.8	97
1784	Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. Pancreas, 2011, 40, 657-663.	0.5	20
1785	A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells. Oncology Reports, 2011, 27, 867-72.	1.2	13
1786	Potentially resectable pancreatic cancer in elderly patients: is surgery a reasonable choice?. Aging Health, 2011, 7, 463-467.	0.3	0
1787	Pancreatic cancer: a whistle-stop tour. Gastrointestinal Nursing, 2011, 9, 41-45.	0.0	0
1788	PPARÎ³ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. International Journal of Oncology, 2011, 40, 679-85.	1.4	18
1789	Synergistic antitumor effect of interferon-ÃŸ with gemcitabine in interferon-Î±-non-responsive pancreatic cancer cells. International Journal of Oncology, 2011, 38, 1237-43.	1.4	5
1790	Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncology Reports, 2011, 25, 1253-61.	1.2	18
1791	Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells. Experimental and Therapeutic Medicine, 2011, 2, 969-975.	0.8	7
1792	ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine. Oncology Reports, 2012, 27, 182-8.	1.2	17
1793	Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-Î¹B. Molecular Medicine Reports, 2011, 4, 221-7.	1.1	36
1794	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Science, 2011, 102, 425-431.	1.7	51
1795	Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). Cancer Science, 2011, 102, 622-629.	1.7	15
1796	Transforming growth factorâ€beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Science, 2011, 102, 1193-1200.	1.7	108
1797	Insig2 is overexpressed in pancreatic cancer and its expression is induced by hypoxia. Cancer Science, 2011, 102, 1137-1143.	1.7	13

#	Article	IF	Citations
1798	Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. Hpb, 2011, 13, 153-157.	0.1	20
1799	Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer. Hpb, 2011, 13, 597-604.	0.1	19
1801	Reviewing the standard of care in pancreatic adenocarcinoma: A critical appraisal. Surgical Practice, 2011, 15, 87-97.	0.1	0
1802	Perineural invasion and associated pain in pancreatic cancer. Nature Reviews Cancer, 2011, 11, 695-707.	12.8	348
1803	MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene, 2011, 30, 1449-1459.	2.6	232
1804	Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene, 2011, 30, 3468-3476.	2.6	33
1805	NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery, 2011, 149, 311-320.	1.0	101
1807	Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 841-849.	1.7	88
1808	Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 859-870.	1.7	148
1809	PP046-SUN SERUM TRIGLYCERIDE LEVELS, SAFETY AND TOLERABILITY OF HIGH-DOSE-RATE INFUSION OF OMEGA-3-RICH LIPID EMULSION IN PATIENTS WITH ADVANCED PANCREATIC CANCER. Clinical Nutrition Supplements, 2011, 6, 40-41.	0.0	0
1810	Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Free Radical Biology and Medicine, 2011, 50, 926-933.	1.3	27
1811	Overcoming drug resistance in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 817-828.	1.5	194
1812	Epidermal growth factor receptor-targeted treatment strategies in advanced pancreatic cancer: Is K-RAS mutational testing ready for prime time?. Memo - Magazine of European Medical Oncology, 2011, 4, 257-259.	0.3	0
1813	Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells. Cellular and Molecular Biology Letters, 2011, 16, 101-13.	2.7	31
1814	Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines. Annals of Surgical Oncology, 2011, 18, 371-379.	0.7	36
1815	MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer. Annals of Surgical Oncology, 2011, 18, 2381-2387.	0.7	81
1816	Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after Resection. Annals of Surgical Oncology, 2011, 18, 2699-2705.	0.7	39
1817	HuR's role in gemcitabine efficacy: an exception or opportunity?. Wiley Interdisciplinary Reviews RNA, 2011, 2, 435-444.	3.2	15

#	Article	IF	Citations
1818	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Investigational New Drugs, 2011, 29, 1057-1065.	1.2	11
1819	A phase I study of topotecan and gemcitabine in advanced solid tumors. Investigational New Drugs, 2011, 29, 1390-1394.	1.2	0
1820	Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells. Clinical and Experimental Metastasis, 2011, 28, 367-376.	1.7	36
1821	Potential of Amino Acid/Dipeptide Monoester Prodrugs of Floxuridine in Facilitating Enhanced Delivery of Active Drug to Interior Sites of Tumors: A Two-Tier Monolayer In Vitro Study. Pharmaceutical Research, 2011, 28, 2575-2588.	1.7	16
1822	Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 235-240.	1.4	31
1823	The current potential of highâ€intensity focused ultrasound for pancreatic carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 295-303.	1.4	39
1824	Adjuvant surgical therapy for patients with initiallyâ€unresectable pancreatic cancer with longâ€term favorable responses to chemotherapy. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 712-716.	1.4	35
1825	Pancreatic cancer stem cells: new insights and perspectives. Journal of Gastroenterology, 2011, 46, 966-973.	2.3	35
1826	Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1469-1475.	1.2	27
1827	Somatic variation and cancer: therapies lost in the mix. Human Genetics, 2011, 130, 79-91.	1.8	40
1828	Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer, 2011, 14, 81-90.	2.7	32
1829	ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. International Journal of Clinical Oncology, 2011, 16, 387-394.	1.0	17
1830	Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. International Journal of Clinical Oncology, 2011, 16, 539-545.	1.0	26
1831	A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity. International Journal of Clinical Oncology, 2011, 16, 637-645.	1.0	7
1832	Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-Î± on pancreatic cancer cells. International Journal of Clinical Oncology, 2011, 16, 671-678.	1.0	26
1833	Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunology, Immunotherapy, 2011, 60, 99-109.	2.0	38
1834	Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study. Cancer Immunology, Immunotherapy, 2011, 60, 1097-1107.	2.0	48
1835	Gemcitabine enhances Wilmsâ€™ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunology, Immunotherapy, 2011, 60, 1289-1297.	2.0	46

#	Article	IF	Citations
1836	The Promise of a Personalized Genomic Approach to Pancreatic Cancer and Why Targeted Therapies Have Missed the Mark. World Journal of Surgery, 2011, 35, 1766-1769.	0.8	8
1837	NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer. World Journal of Surgery, 2011, 35, 1580-1589.	0.8	50
1838	Pancreatic Cancer, Healthcare Cost, and Loss of Productivity: A Registerâ€based Approach. World Journal of Surgery, 2011, 35, 2298-2305.	0.8	32
1839	Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology, 2011, 67, 183-192.	1.1	7
1840	Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 249-254.	1.1	53
1841	A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemotherapy and Pharmacology, 2011, 67, 511-517.	1.1	8
1842	A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 891-897.	1.1	30
1843	Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 475-479.	1.1	10
1844	A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 157-164.	1.1	350
1845	Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 215-221.	1.1	27
1846	Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy. Cancer Chemotherapy and Pharmacology, 2011, 68, 571-582.	1.1	14
1847	Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 677-683.	1.1	6
1848	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. Cancer Chemotherapy and Pharmacology, 2011, 68, 1017-1026.	1.1	6
1849	Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 1431-1438.	1.1	20
1850	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemotherapy and Pharmacology, 2011, 68, 1173-1178.	1.1	6
1851	Chemoradiation for Unresectable Gall Bladder Cancer: Time to Review Historic Nihilism?. Journal of Gastrointestinal Cancer, 2011, 42, 222-227.	0.6	15
1852	Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. Clinical and Translational Oncology, 2011, 13, 61-66.	1.2	2
1853	Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clinical and Translational Oncology, 2011, 13, 426-429.	1.2	24

#	Article	IF	Citations
1854	SEOM clinical guidelines for the treatment of pancreatic cancer. Clinical and Translational Oncology, 2011, 13, 528-535.	1.2	5
1855	Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas. Memo - Magazine of European Medical Oncology, 2011, 4, 94-97.	0.3	1
1856	Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer. Clinical Journal of Gastroenterology, 2011, 4, 391-395.	0.4	5
1857	Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 35, 109-113.	0.6	27
1858	Improvement in Treatment and Outcome of Pancreatic Ductal Adenocarcinoma in North China. Journal of Gastrointestinal Surgery, 2011, 15, 1026-1034.	0.9	10
1859	Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine. Chinese Journal of Integrative Medicine, 2011, 17, 228-231.	0.7	2
1860	Combination of recombinant adenovirus-p53 with radiochemotherapy in unresectable pancreatic carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 194-200.	0.7	5
1861	Defining New Paradigms for the Treatment of Pancreatic Cancer. Current Treatment Options in Oncology, 2011, 12, 111-125.	1.3	36
1862	Current Treatment Options for Pancreatic Carcinoma. Current Oncology Reports, 2011, 13, 195-205.	1.8	33
1863	Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer. BMC Cancer, 2011, 11, 15.	1.1	26
1864	The impact of surgical outcome after pancreaticoduodenectomy in elderly patients. World Journal of Surgical Oncology, 2011, 9, 102.	0.8	41
1865	Clinical application of CT-guided 125I seed interstitial implantation for local recurrent rectal carcinoma. Radiation Oncology, 2011, 6, 138.	1.2	21
1866	Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients. Radiation Oncology, 2011, 6, 88.	1.2	10
1867	A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. Journal of Hematology and Oncology, 2011, 4, 11.	6.9	61
1868	Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers in Surgery and Medicine, 2011, 43, 565-574.	1.1	96
1869	Phase 1 clinical trials in 83 patients with pancreatic cancer. Cancer, 2011, 117, 77-85.	2.0	8
1870	A phase 2 trial of gemcitabine, 5â€fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma. Cancer, 2011, 117, 2620-2628.	2.0	24
1871	Targeting ILâ€13RÎ±2 in human pancreatic ductal adenocarcinoma with combination therapy of ILâ€13â€PE and gemcitabine. International Journal of Cancer, 2011, 128, 1221-1231.	2.3	25

#	Article	IF	Citations
1872	Transient gene silencing of galectinâ€3 suppresses pancreatic cancer cell migration and invasion through degradation of Î²â€catenin. International Journal of Cancer, 2011, 129, 2775-2786.	2.3	81
1873	Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancerâ€”A review. International Journal of Cancer, 2011, 129, 1031-1041.	2.3	28
1874	Intraoperative Radiotherapy for Unresectable Pancreatic Cancer: A Multi-Institutional Retrospective Analysis of 144 Patients. International Journal of Radiation Oncology Biology Physics, 2011, 80, 111-118.	0.4	14
1875	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 181-188.	0.4	230
1876	Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Critical Reviews in Oncology/Hematology, 2011, 78, 252-259.	2.0	29
1877	In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles. International Journal of Pharmaceutics, 2011, 409, 278-288.	2.6	90
1878	MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts. Clinical Cancer Research, 2011, 17, 2799-2806.	3.2	237
1879	Role of the RAS in Pancreatic Cancer. Current Cancer Drug Targets, 2011, 11, 412-420.	0.8	27
1880	Metastatic pancreatic cancerâ€”is FOLFIRINOX the new standard?. Nature Reviews Clinical Oncology, 2011, 8, 452-453.	12.5	23
1881	Endoscopic management of malignant biliary obstruction by means of covered metallic stents: primary stent placement vs. re-intervention. Endoscopy, 2011, 43, 1039-1044.	1.0	30
1882	Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Expert Review of Anticancer Therapy, 2011, 11, 1555-1565.	1.1	13
1883	Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. International Journal of Hyperthermia, 2011, 27, 101-107.	1.1	73
1884	Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment. Molecular Cancer Therapeutics, 2011, 10, 2135-2145.	1.9	185
1885	Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2011, 29, 4105-4112.	0.8	721
1886	Development of an integrated pancreatic disease service. Frontline Gastroenterology, 2011, 2, 71-76.	0.9	2
1887	Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biology and Therapy, 2011, 12, 165-168.	1.5	63
1888	Vitamin E Î´-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-ÎºB Activation in Pancreatic Cancer. Molecular Cancer Therapeutics, 2011, 10, 2363-2372.	1.9	92
1889	Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 953-958.	0.6	44

#	Article	IF	Citations
1890	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics, 2011, 12, 1641-1652.	0.6	45
1891	Notch Signaling Activated by Replication Stressâ€“Induced Expression of Midkine Drives Epithelialâ€“Mesenchymal Transition and Chemoresistance in Pancreatic Cancer. Cancer Research, 2011, 71, 5009-5019.	0.4	121
1892	Molecular Endoscopic Ultrasound for Diagnosis of Pancreatic Cancer. Cancers, 2011, 3, 872-882.	1.7	6
1893	The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. Cancers, 2011, 3, 267-284.	1.7	4
1894	Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial. Chemotherapy, 2011, 57, 156-161.	0.8	16
1895	Induction of Apoptosis and Autophagy in Human Pancreatic Cancer Cells by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin. American Journal of Biomedical Sciences, 0, , 278-291.	0.2	7
1896	Oncolytic virotherapy for pancreatic cancer. Expert Reviews in Molecular Medicine, 2011, 13, e18.	1.6	23
1897	Phytochemicals in Cancer Prevention. , 2011, , 2882-2885.		0
1898	Pancreatic cancer treatment and research: an international expert panel discussion. Annals of Oncology, 2011, 22, 1500-1506.	0.6	51
1899	Integrating Pain Metrics into Oncology Clinical Trials. Clinical Cancer Research, 2011, 17, 6646-6650.	3.2	15
1900	Systemic Therapy for Elderly Patients with Gastrointestinal Cancer. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S6983.	0.6	2
1901	Current Immunotherapeutic Approaches in Pancreatic Cancer. Clinical and Developmental Immunology, 2011, 2011, 1-15.	3.3	66
1902	Gemcitabine Monotherapy Associated with Posterior Reversible Encephalopathy Syndrome. Case Reports in Oncology, 2011, 4, 82-87.	0.3	21
1903	Gemcitabine and Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer. Oncology, 2011, 80, 97-101.	0.9	16
1904	5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma. Oncology, 2011, 80, 301-306.	0.9	88
1905	Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials. Oncology, 2011, 81, 143-150.	0.9	15
1906	Long-Term Relapse-Free Survival by Interdisciplinary Collaboration in a Patient with Metastatic Pancreatic Cancer (UICC IV). Case Reports in Oncology, 2011, 4, 413-419.	0.3	2
1907	Paclitaxel-Based Chemotherapy for Advanced Pancreatic Cancer after Gemcitabine-Based Therapy Failure: A Case Series of 5 Patients. Case Reports in Oncology, 2011, 4, 534-541.	0.3	5

#	Article	IF	Citations
1908	Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. International Journal of Oncology, 2011, 39, 473-82.	1.4	23
1909	KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy. Oncology, 2011, 81, 3-8.	0.9	41
1910	A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer. Oncology, 2011, 80, 175-180.	0.9	30
1911	Phase I Dose-Finding Study of Vandetanib in Combination with Gemcitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma. Oncology, 2011, 81, 50-54.	0.9	41
1914	Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial. Clinical Cancer Research, 2011, 17, 4091-4100.	3.2	60
1915	3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis. Molecular Cancer Therapeutics, 2011, 10, 2146-2156.	1.9	19
1916	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of Î²-Lapachone for Pancreatic Cancer Therapy. Clinical Cancer Research, 2011, 17, 275-285.	3.2	96
1917	Reduced Plasma Level of CXC Chemokine Ligand 7 in Patients with Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 160-171.	1.1	45
1918	Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1275-E1284.	3.3	65
1919	In Vitro Synergistic Cytotoxic Effect of Triptolide Combined with Hydroxycamptothecin on Pancreatic Cancer Cells. The American Journal of Chinese Medicine, 2011, 39, 121-134.	1.5	24
1920	Shaped Beam Radiosurgery. , 2011, , .		0
1921	Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. Journal of Clinical Oncology, 2011, 29, 4548-4554.	0.8	957
1922	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biology and Therapy, 2011, 12, 598-609.	1.5	103
1923	Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. Molecular Cancer Therapeutics, 2011, 10, 3-8.	1.9	238
1924	Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. Journal of Experimental Medicine, 2011, 208, 469-478.	4.2	590
1925	Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Bioscience Reports, 2011, 31, 45-55.	1.1	65
1926	Metastatic Pancreatic Cancer: What Can Nurses Do?. Clinical Journal of Oncology Nursing, 2011, 15, 424-428.	0.3	2
1927	Management strategies in pancreatic cancer. American Journal of Health-System Pharmacy, 2011, 68, 573-584.	0.5	23

#	Article	IF	Citations
1928	Rationale for Possible Targeting of Histone Deacetylase Signaling in Cancer Diseases with a Special Reference to Pancreatic Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-8.	3.0	15
1929	Treatment of Pancreatic Cancer: What Can We Really Predict Today?. Cancers, 2011, 3, 675-699.	1.7	8
1930	Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma. International Journal of Molecular Sciences, 2011, 12, 5895-5907.	1.8	12
1931	Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer. ISRN Oncology, 2011, 2011, 1-5.	2.1	7
1932	The Anti-tumor Effects of Vitamin D in Other Cancers. , 2011, , 1763-1773.		1
1933	Eastern Canadian Colorectal Cancer Consensus Conference: Application of New Modalities of Staging and Treatment of Gastrointestinal Cancers. Current Oncology, 2012, 19, 169-174.	0.9	3
1934	nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer. Cancer Discovery, 2012, 2, 260-269.	7.7	359
1935	Quality of Life and Toxicity of Stereotactic Radiotherapy in Pancreatic Tumors: A Case Series. Cancer Investigation, 2012, 30, 149-155.	0.6	23
1936	Peroxisome Proliferator-Activated Receptor Gamma and Regulations by the Ubiquitin-Proteasome System in Pancreatic Cancer. PPAR Research, 2012, 2012, 1-13.	1.1	9
1937	Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?. Gastroenterology Research and Practice, 2012, 2012, 1-6.	0.7	7
1938	Efficacy of the New Double-Layer Stent for Unresectable Distal Malignant Biliary Obstruction: A Single-Center Retrospective Study. Diagnostic and Therapeutic Endoscopy, 2012, 2012, 1-8.	1.5	4
1939	An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. Frontiers in Oncology, 2012, 2, 175.	1.3	2
1940	A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303. Clinical Cancer Research, 2012, 18, 577-584.	3.2	91
1941	CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis. Molecular Cancer Therapeutics, 2012, 11, 1598-1608.	1.9	19
1942	BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of Oncology, 2012, 23, 2799-2805.	0.6	184
1943	Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 3414-3427.	3.2	30
1944	Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. Journal of Experimental Medicine, 2012, 209, 437-444.	4.2	92
1945	Enhanced Antitumor Effect of Combination Therapy With Gemcitabine and Guggulsterone in Pancreatic Cancer. Pancreas, 2012, 41, 1048-1057.	0.5	26

#	Article	IF	Citations
1946	Biomarkers in Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 530-538.	1.0	101
1947	Pancreatic adenocarcinoma: ESMOâ€“ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii33-vii40.	0.6	307
1948	Interventional Radiology and the Pancreatic Cancer Patient. Cancer Journal (Sudbury, Mass), 2012, 18, 591-601.	1.0	10
1949	Human Correlates of Provocative Questions in Pancreatic Pathology. Advances in Anatomic Pathology, 2012, 19, 351-362.	2.4	29
1950	A Neoadjuvant Strategy for the Management of Nonmetastatic Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 602-608.	1.0	6
1951	The Pancreas Cancer Microenvironment. Clinical Cancer Research, 2012, 18, 4266-4276.	3.2	1,087
1952	Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	1.6	41
1953	Unresectable Pancreatic Cancer: Arterial Embolization to Achieve a Single Blood Supply for Intraarterial Infusion of 5-Fluorouracil and Full-Dose IV Gemcitabine. American Journal of Roentgenology, 2012, 198, 1445-1452.	1.0	16
1954	The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance. Current Molecular Medicine, 2012, 12, 288-303.	0.6	71
1955	Pancreatic Cancer Surgery: The State of the Art. Current Drug Targets, 2012, 13, 764-771.	1.0	13
1956	An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors. Current Cancer Drug Targets, 2012, 12, 439-452.	0.8	29
1957	Synthetic Lethality to Overcome Cancer Drug Resistance. Current Medicinal Chemistry, 2012, 19, 3858-3873.	1.2	18
1958	Progress in pancreatic cancer: moving beyond gemcitabine?. Expert Review of Anticancer Therapy, 2012, 12, 997-1000.	1.1	1
1959	Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 341-346.	1.4	30
1960	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Annals of Oncology, 2012, 23, 942-947.	0.6	12
1961	HuRâ€™s post-transcriptional regulation of death receptor 5 in pancreatic cancer cells. Cancer Biology and Therapy, 2012, 13, 946-955.	1.5	36
1964	Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?. Pharmacogenomics, 2012, 13, 977-979.	0.6	3
1965	Safety and Optimal Management of Hepatic Arterial Infusion Chemotherapy After Pancreatectomy for Pancreatobiliary Cancer. American Journal of Roentgenology, 2012, 198, 923-930.	1.0	7

#	Article	IF	Citations
1966	Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 1352-1363.	3.2	212
1967	MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene, 2012, 31, 4935-4945.	2.6	75
1968	A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naÃ¯ve patients with unresectable exocrine adenocarcinoma of the pancreas â€“ a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. British Journal of Cancer, 2012, 107, 280-286.	2.9	67
1969	A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. British Journal of Cancer, 2012, 106, 1934-1939.	2.9	89
1970	Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics Journal, 2012, 12, 395-403.	0.9	32
1971	Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. British Journal of Cancer, 2012, 106, 1033-1038.	2.9	160
1972	Qingyihuaji Formula Inhibits Progress of Liver Metastases From Advanced Pancreatic Cancer Xenograft by Targeting to Decrease Expression of Cyr61 and VEGF. Integrative Cancer Therapies, 2012, 11, 37-47.	0.8	21
1973	VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Annals of Oncology, 2012, 23, 2812-2820.	0.6	31
1974	Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. International Journal of Oncology, 2012, 41, 949-958.	1.4	34
1975	KRASG12D- and BRAFV600E-Induced Transformation of Murine Pancreatic Epithelial Cells Requires MEK/ERK-Stimulated IGF1R Signaling. Molecular Cancer Research, 2012, 10, 1228-1239.	1.5	21
1976	Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study. Chemotherapy, 2012, 58, 371-380.	0.8	2
1977	Nanomedicine: pharmacological perspectives. Nanotechnology Reviews, 2012, 1, .	2.6	14
1978	Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers, 2012, 4, 989-1035.	1.7	29
1979	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Annals of Oncology, 2012, 23, 1214-1222.	0.6	91
1980	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Annals of Oncology, 2012, 23, 2834-2842.	0.6	167
1981	Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 446-450.	0.6	16
1982	Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer. Pancreas, 2012, 41, 1029-1038.	0.5	35
1983	Dual Combination Therapy Targeting DR5 and EMMPRIN in Pancreatic Adenocarcinoma. Molecular Cancer Therapeutics, 2012, 11, 405-415.	1.9	21

#	Article	IF	Citations
1984	The value of progression-free survival to patients with advanced-stage cancer. Nature Reviews Clinical Oncology, 2012, 9, 41-47.	12.5	58
1985	A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. Oncology, 2012, 82, 75-82.	0.9	7
1986	Acute Generalized Exanthematous Pustulosis Induced by Erlotinib (Tarceva) with Superimposed Staphylococcus aureus Skin Infection in a Pancreatic Cancer Patient: A Case Report. Case Reports in Oncology, 2012, 5, 253-259.	0.3	8
1987	Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients. Oncology Letters, 2012, 3, 1314-1318.	0.8	10
1988	BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer. Molecular Cancer Therapeutics, 2012, 11, 2644-2653.	1.9	63
1989	Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab. Journal of Immunotherapy, 2012, 35, 367-373.	1.2	28
1990	Editorial [Hot Topic: Pancreatic Cancer: Between Bench and Bedside (Guest Editors: Davide Melisi and) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	10
1991	Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer. Current Drug Targets, 2012, 13, 789-794.	1.0	2
1992	Safety and Effectiveness of Cryosurgery on Advanced Pancreatic Cancer. Pancreas, 2012, 41, 809-811.	0.5	6
1993	Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas. Journal of Immunotherapy, 2012, 35, 629-640.	1.2	59
1994	Clinical and Immunologic Evaluation of Dendritic Cellâ€"Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma. Pancreas, 2012, 41, 195-205.	0.5	122
1995	Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics. Current Drug Targets, 2012, 13, 811-828.	1.0	15
1996	Expanding Surgical Treatment of Pancreatic Cancer. Pancreas, 2012, 41, 678-684.	0.5	15
1997	Monoclonal Antibodies and Other Targeted Therapies for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 653-664.	1.0	19
1998	Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Pancreatic Cancer. Annals of Surgery, 2012, 255, 95-102.	2.1	107
1999	Human Equilibrative Nucleoside Transporter 1 Expression Predicts Survival of Advanced Cholangiocarcinoma Patients Treated With Gemcitabine-Based Adjuvant Chemotherapy After Surgical Resection. Annals of Surgery, 2012, 256, 288-296.	2.1	39
2000	Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines. Anti-Cancer Drugs, 2012, 23, 505-514.	0.7	5
2001	Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: Comparative proteomic analyses. Molecular Medicine Reports, 2012, 6, 767-773.	1.1	17

#	Article	IF	Citations
2002	Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas Responsive to Combination Therapy with Gemcitabine and S-1. Internal Medicine, 2012, 51, 727-732.	0.3	8
2004	Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. International Journal of Oncology, 2012, 41, 2093-2102.	1.4	73
2005	Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-Î²B pathways. Oncology Reports, 2012, 28, 501-510.	1.2	83
2006	An International Multicenter Randomized Controlled Trial of G17DT in Patients With Pancreatic Cancer. Pancreas, 2012, 41, 374-379.	0.5	69
2007	Chemotherapy and Other Supportive Modalities in the Palliative Setting for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 633-641.	1.0	5
2008	Why is pancreatic cancer difficult to treat in the elderly?. Aging Health, 2012, 8, 301-307.	0.3	2
2010	Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. International Journal of Oncology, 2012, 41, 855-861.	1.4	66
2011	Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro. International Journal of Oncology, 2012, 40, 1049-1057.	1.4	49
2012	Prognostic factors in patients with pancreatic cancer. Experimental and Therapeutic Medicine, 2012, 3, 423-432.	0.8	42
2013	Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1Î± and P-gp in the human pancreatic carcinoma cell line PANC-1. Oncology Reports, 2012, 27, 1567-72.	1.2	18
2014	Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Oncology Letters, 2012, 4, 792-798.	0.8	17
2015	Surgical outcome of pancreatic cancer using radical antegrade modular pancreatosplenectomy procedure. World Journal of Gastroenterology, 2012, 18, 5595.	1.4	21
2016	Treatment options for advanced pancreatic cancer: a review. Expert Review of Anticancer Therapy, 2012, 12, 1327-1336.	1.1	36
2017	What We Have Learned About Pancreatic Cancer From Mouse Models. Gastroenterology, 2012, 142, 1079-1092.	0.6	151
2018	Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 1531-1539.	1.2	17
2019	A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 2371-2376.	1.2	12
2020	Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102	1.2	92
2021	Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunology, Immunotherapy, 2012, 61, 1373-1385.	2.0	242

#	Article	IF	Citations
2022	DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1463-1474.	1.2	52
2023	Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1625-1630.	1.2	7
2024	Anticancer therapies in specialized palliative careâ€"a multicenter survey. Supportive Care in Cancer, 2012, 20, 2385-2389.	1.0	6
2025	Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 717-722.	1.4	31
2026	Electrochemical investigations of an anticancer drug in the presence of sodium dodecyl sulfate as an enhancing agent at carbon paste electrode. Journal of Applied Electrochemistry, 2012, 42, 917-923.	1.5	21
2027	Dextran-Catechin Conjugate: A Potential Treatment Against the Pancreatic Ductal Adenocarcinoma. Pharmaceutical Research, 2012, 29, 2601-2614.	1.7	78
2028	EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2012, 22, 318-330.	7.7	339
2029	Phase I Study of Conformal Radiotherapy and Concurrent Full-Dose Gemcitabine With Erlotinib for Unresected Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, e187-e192.	0.4	6
2030	Interfractional Dose Variations in Intensity-Modulated Radiotherapy With Breath-Hold for Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1619-1626.	0.4	12
2031	Concurrent Radiotherapy and Gemcitabine for Unresectable Pancreatic Adenocarcinoma: Impact of Adjuvant Chemotherapy on Survival. International Journal of Radiation Oncology Biology Physics, 2012, 83, 559-565.	0.4	8
2032	Treatment of Locally Advanced Pancreatic Cancer: The Role of Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 508-518.	0.4	36
2033	Radiation Therapy With Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 921-926.	0.4	4
2034	Novel Immunocompetent Murine Models Representing Advanced Local and Metastatic Pancreatic Cancer. Journal of Surgical Research, 2012, 176, 359-366.	0.8	20
2035	Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. Journal of Surgical Research, 2012, 178, 758-767.	0.8	66
2036	Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224Radium-loaded wires releasing alpha-emitting atoms. Translational Research, 2012, 159, 32-41.	2.2	22
2037	High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 655-660.	0.6	58
2038	Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. Pancreatology, 2012, 12, 475-479.	0.5	12
2039	Hedgehog signaling: From the cuirass to the heart of pancreatic cancer. Pancreatology, 2012, 12, 388-393.	0.5	9

#	Article	IF	Citations
2040	The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery. European Journal of Surgical Oncology, 2012, 38, 1051-1057.	0.5	19
2041	Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Practical Radiation Oncology, 2012, 2, 77-85.	1.1	28
2042	Management of Cancer in the Older Adult. Clinics in Geriatric Medicine, 2012, 28, 33-49.	1.0	12
2043	Radiofrequency Ablation of Liver Metastasis in Patients with Locally Controlled Pancreatic Ductal Adenocarcinoma. Journal of Vascular and Interventional Radiology, 2012, 23, 635-641.	0.2	41
2044	Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Pancreatology, 2012, 12, 409-416.	0.5	19
2045	Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). Gastroenterology Clinics of North America, 2012, 41, 189-209.	1.0	31
2046	Locally Advanced Pancreatic Cancer. Seminars in Oncology, 2012, 39, e9-e22.	0.8	5
2047	Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. Pancreatology, 2012, 12, 219-226.	0.5	10
2048	HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology, 2012, 12, 146-155.	0.5	20
2049	Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Therapy, 2012, 19, 374-381.	2.2	133
2050	Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. International Journal of Hyperthermia, 2012, 28, 597-604.	1.1	40
2051	A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiotherapy and Oncology, 2012, 103, 25-31.	0.3	108
2052	Clinical Calculator of Conditional Survival Estimates for Resected and Unresected Survivors of Pancreatic Cancer. Archives of Surgery, 2012, 147, 513-9.	2.3	48
2053	Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. Hpb, 2012, 14, 260-268.	0.1	19
2054	Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. Hpb, 2012, 14, 365-372.	0.1	77
2055	Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. Hpb, 2012, 14, 539-547.	0.1	123
2056	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer, 2012, 106, 508-516.	2.9	233
2057	Why RECIST Works and Why It Should Stayâ€"Counterpoint. Cancer Research, 2012, 72, 5151-5157.	0.4	28

#	Article	IF	Citations
2058	Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy. Journal of Ethnopharmacology, 2012, 140, 614-623.	2.0	131
2059	Achyranthes aspera (Apamarg) leaf extract inhibits human pancreatic tumor growth in athymic mice by apoptosis. Journal of Ethnopharmacology, 2012, 142, 523-530.	2.0	18
2060	Circulating Myeloid Dendritic Cells as Prognostic Factors in Patients with Pancreatic Cancer Who Have Undergone Surgical Resection. Journal of Surgical Research, 2012, 173, 299-308.	0.8	54
2061	Molecular Profiling of Synchronous and Metachronous Cancers of the Pancreas Reveal Molecular Mimicry Between Samples from the Same Patient. Journal of Surgical Research, 2012, 176, 154-158.	0.8	5
2062	Engineering fibrotic tissue in pancreatic cancer: A novel three-dimensional model to investigate nanoparticle delivery. Biochemical and Biophysical Research Communications, 2012, 419, 32-37.	1.0	40
2063	DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochemical and Biophysical Research Communications, 2012, 421, 98-104.	1.0	88
2064	Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. Cancer Letters, 2012, 314, 119-125.	3.2	15
2065	Combinational therapy: New hope for pancreatic cancer?. Cancer Letters, 2012, 317, 127-135.	3.2	85
2066	Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids. Cancer Letters, 2012, 319, 23-30.	3.2	31
2067	Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge. Cancer Letters, 2012, 320, 138-149.	3.2	70
2068	Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Letters, 2012, 323, 29-40.	3.2	139
2069	Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. European Journal of Cancer, 2012, 48, 1283-1292.	1.3	273
2070	Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?. European Journal of Cancer, 2012, 48, 385-388.	1.3	84
2071	Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines. Gene, 2012, 498, 300-307.	1.0	15
2072	The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 77-87.	8.2	91
2073	Reversal of Multidrug Resistance by Gefitinib Via RAF1/ERK Pathway in Pancreatic Cancer Cell Line. Anatomical Record, 2012, 295, 2122-2128.	0.8	19
2074	Biomarkerâ€driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral S rc inhibitor, in previously treated pancreatic cancer. Cancer Medicine, 2012, 1, 207-217.	1.3	14
2075	Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. Lasers in Surgery and Medicine, 2012, 44, 755-761.	1.1	11

#	Article	IF	Citations
2076	Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?. BMC Cancer, 2012, 12, 104.	1.1	28
2077	Quality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tract. BMC Cancer, 2012, 12, 390.	1.1	31
2078	L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial. Nutrition Journal, 2012, 11, 52.	1.5	93
2079	Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. Journal of Translational Medicine, 2012, 10, 161.	1.8	32
2080	New biomarkers and targets in pancreatic cancer and their application to treatment. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 435-444.	8.2	194
2081	Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice. International Journal of Oncology, 2012, 41, 2269-2275.	1.4	5
2083	Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma. Gastroenterology, 2012, 143, 664-674.e6.	0.6	218
2084	Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway. Acta Histochemica, 2012, 114, 641-646.	0.9	24
2085	Systemic treatment of advanced pancreatic cancer. Cancer Treatment Reviews, 2012, 38, 843-853.	3.4	108
2086	Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: Molecular basis for therapeutic implications. Cytokine and Growth Factor Reviews, 2012, 23, 343-356.	3.2	37
2087	Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 401-409.	2.0	56
2088	EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointestinal Endoscopy, 2012, 75, 332-338.	0.5	138
2089	EUS-guided celiac ganglion irradiation with iodine-125 seeds for pain control in pancreatic carcinoma: a prospective pilot study. Gastrointestinal Endoscopy, 2012, 76, 945-952.	0.5	66
2090	Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointestinal Endoscopy, 2012, 76, 962-971.	0.5	95
2091	Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery, 2012, 152, 851-862.	1.0	97
2092	Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Surgery, 2012, 152, S152-S156.	1.0	28
2093	Clinical trial design in older adults with cancerâ€"The need for new paradigms. Journal of Geriatric Oncology, 2012, 3, 368-375.	0.5	30
2094	Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics Journal, 2012, 12, 1-9.	0.9	10

#	Article	IF	Citations
2095	Emerging cell-cycle inhibitors for pancreatic cancer therapy. Expert Opinion on Emerging Drugs, 2012, 17, 571-582.	1.0	10
2096	Myxoma Virus Sensitizes Cancer Cells to Gemcitabine and Is an Effective Oncolytic Virotherapeutic in Models of Disseminated Pancreatic Cancer. Molecular Therapy, 2012, 20, 759-768.	3.7	52
2097	Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology. Chinese Journal of Integrative Medicine, 2012, 18, 730-736.	0.7	15
2098	Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time. Journal of Gastrointestinal Cancer, 2012, 43, 396-404.	0.6	24
2099	PDGFRÎ² expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker. Medical Oncology, 2012, 29, 2824-2830.	1.2	59
2100	Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. Medical Oncology, 2012, 29, 2831-2837.	1.2	7
2101	Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Medical Oncology, 2012, 29, 3092-3100.	1.2	187
2102	Stromal Cell-Derived Factor 1Î± Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer. Neoplasia, 2012, 14, 690-IN6.	2.3	44
2103	Different effects of carbon ion beams and X-rays on clonogenic survival and DNA repair in human pancreatic cancer stem-like cells. Radiotherapy and Oncology, 2012, 105, 258-265.	0.3	78
2104	Cystic Pancreatic Lesions. , 2012, , 173-191.		0
2105	Pancreatic Ductal Adenocarcinoma. , 2012, , 153-171.		1
2106	Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: An improved understanding of lung cancer therapeutic intervention. European Journal of Pharmaceutical Sciences, 2012, 47, 1006-1014.	1.9	65
2107	Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. Clinical Proteomics, 2012, 9, 8.	1.1	17
2108	Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin. Journal of Gastrointestinal Cancer, 2012, 43, 42-45.	0.6	1
2109	Aptamer-Mediated Delivery of Chemotherapy to Pancreatic Cancer Cells. Nucleic Acid Therapeutics, 2012, 22, 295-305.	2.0	67
2110	Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliative Care, 2012, 11, 19.	0.8	3
2111	The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer. Radiation Oncology, 2012, 7, 203.	1.2	10
2112	Targeting Anticancer Drug Delivery to Pancreatic Cancer Cells Using a Fucose-Bound Nanoparticle Approach. PLoS ONE, 2012, 7, e39545.	1.1	46

#	Article	IF	Citations
2113	Pristimerin Causes G1 Arrest, Induces Apoptosis, and Enhances the Chemosensitivity to Gemcitabine in Pancreatic Cancer Cells. PLoS ONE, 2012, 7, e43826.	1.1	50
2114	Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. PLoS ONE, 2012, 7, e29794.	1.1	213
2115	Hepatic Arterial Therapy with Drug-Eluting Beads in the Management of Metastatic Pancreatic Carcinoma to the Liver: A Multi-Institutional Registry. Journal of Oncology, 2012, 2012, 1-6.	0.6	8
2116	Role of Wnt/β-catenin Signaling in Drug Resistance of Pancreatic Cancer. Current Pharmaceutical Design, 2012, 18, 2464-2471.	0.9	130
2117	Current Knowledge on Pancreatic Cancer. Frontiers in Oncology, 2012, 2, 6.	1.3	62
2118	Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. Frontiers in Bioscience - Landmark, 2012, 17, 2698.	3.0	17
2119	Quitter enfin des mauvais rÃ©sultats de la chimiothÃ©rapie dans le cancer du pancrÃ©as mÃ©tastatique grÃ¢ce Ã un groupe coopÃ©ratif franÃ§ais. Bulletin Du Cancer, 2012, 99, 405.	0.6	0
2120	Role of Pharmacogenetics in Gastrointestinal Cancer. , 2012, , .		1
2121	Medical Therapy of Pancreatic Cancer: Current Status and Future Targets. , 2012, , .		0
2122	Failure of Pancreatic Cancer Chemotherapy: Consequences of Drug Resistance Mechanisms. , 0, , .		2
2123	Significant Association Between Vegf-A and ABCB1 Polymorphisms and Survival in Metastatic Pancreatic Adenocarcinoma (MPA) Patients (PTS) Treated with Maintenance Sunitinib (MS). Annals of Oncology, 2012, 23, ix240-ix241.	0.6	0
2124	Brain Metastases in Gastrointestinal Cancers. Annals of Oncology, 2012, 23, ix221-ix222.	0.6	1
2125	Hepatobiliary Pancreatic Cancer: Cutting-Edge Drug Therapy. Annals of Oncology, 2012, 23, xi67-xi68.	0.6	0
2126	A review of clinical trials of chemotherapy for pancreatic cancer. Journal of Cancer Research and Experimental Oncology, 2012, 4, 1-20.	0.1	1
2127	A New Direction for Pancreatic Cancer Treatment: FOLFIRINOX in Context. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 232-237.	1.8	6
2128	The Potential Role of Curcumin for Treatment of Pancreatic Cancer. , 0, , .		5
2129	Pancreatic cancer: surgical management and outcomes after 6 years of followâ€up. Medical Journal of Australia, 2012, 196, 511-515.	0.8	43
2130	Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; September 8â€“10, 2011. Current Oncology, 2012, 19, 468-477.	0.9	1

#	Article	IF	Citations
2131	Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Oncology Letters, 2012, 3, 1186-1190.	0.8	21
2132	Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. Experimental and Therapeutic Medicine, 2012, 3, 931-936.	0.8	16
2133	External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy. Pancreas, 2012, 41, 738-744.	0.5	1
2134	Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: Aâ€ Retrospective Analysis of multicenter study (Anatolian Society of Medical Oncology). Neoplasma, 2012, 59, 297-301.	0.7	12
2135	Efficacy and Safety of Gemcitabine Monotherapy for Patients with Advanced Biliary Tract Cancer. Journal of Nippon Medical School, 2012, 79, 204-212.	0.3	2
2136	Recent Advances of Biliary Stent Management. Korean Journal of Radiology, 2012, 13, S62.	1.5	10
2137	Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. OncoTargets and Therapy, 2012, 5, 161.	1.0	15
2138	Inhibition of Human Pancreatic Tumor Growth by Cytokine-Induced Killer Cells in Nude Mouse Xenograft Model. Immune Network, 2012, 12, 247.	1.6	8
2139	Realâ€time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging. Cancer, 2012, 118, 2813-2819.	2.0	102
2140	Fractionated radioimmunotherapy with ⁹⁰Yâ€clivatuzumab tetraxetan and lowâ€dose gemcitabine is active in advanced pancreatic cancer. Cancer, 2012, 118, 5497-5506.	2.0	79
2141	Targeting the hedgehog signaling pathway with interacting peptides to Patched-1. Journal of Gastroenterology, 2012, 47, 452-460.	2.3	10
2143	Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity. Clinical Cancer Research, 2012, 18, 6519-6530.	3.2	60
2144	Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Investigational New Drugs, 2012, 30, 1138-1143.	1.2	60
2145	A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational New Drugs, 2012, 30, 1164-1174.	1.2	19
2146	A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Investigational New Drugs, 2012, 30, 1175-1183.	1.2	38
2147	Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study) Tj ETQq1 1 0.784314 rgBT /Over	1.2	13
2148	A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 1203-1207.	1.2	22
2149	A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Investigational New Drugs, 2012, 30, 1597-1606.	1.2	52

#	Article	IF	Citations
2150	A phase 2 study of oral MKC-1, an inhibitor of importin-Î², tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Investigational New Drugs, 2012, 30, 1614-1620.	1.2	7
2151	18F-FDG PET/CT Imaging Detects Therapy Efficacy of Anti-EMMPRIN Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts. Molecular Imaging and Biology, 2012, 14, 237-244.	1.3	19
2153	Dimethylamino Parthenolide Enhances the Inhibitory Effects of Gemcitabine in Human Pancreatic Cancer Cells. Journal of Gastrointestinal Surgery, 2012, 16, 1333-1340.	0.9	26
2154	Prospective Phase I Study of Capecitabine and Oxaliplatin Concurrent with Radiation Therapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma, and Retrospective Comparison to Concurrent 5-Fluorouracil/Radiation and Gemcitabine/Radiation. Journal of Gastrointestinal Cancer, 2012, 43, 258-266.	0.6	0
2155	A Rare Case of Metastatic Pancreatic Hepatoid Carcinoma Treated with Sorafenib. Journal of Gastrointestinal Cancer, 2012, 43, 97-102.	0.6	39
2156	Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma. Medical Oncology, 2012, 29, 957-961.	1.2	9
2157	Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	75
2158	Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3â€"T4 pancreatic cancer patients treated with preoperative gemcitabineâ€based chemoradiotherapy. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 413-425.	1.4	50
2159	Phase I trial of preoperative intratumoral injection of immature dendritic cells and OKâ€432 for resectable pancreatic cancer patients. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 465-475.	1.4	42
2160	Glycogen synthase kinase 3Î² inhibition sensitizes pancreatic cancer cells to gemcitabine. Journal of Gastroenterology, 2012, 47, 321-333.	2.3	48
2161	Safety evaluation of selfâ€expanding metallic biliary stents eluting gemcitabine in a porcine model. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 261-267.	1.4	40
2162	Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer. Cancer Science, 2012, 103, 58-66.	1.7	24
2163	Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2012, 21, 418-429.	7.7	1,664
2164	A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who Could Benefit from Second-line Chemotherapy. Clinical Oncology, 2012, 24, 105-111.	0.6	16
2165	Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells. FEBS Journal, 2012, 279, 1261-1273.	2.2	14
2166	Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. Journal of Cellular and Molecular Medicine, 2012, 16, 988-994.	1.6	9
2167	Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	57
2168	Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways. Toxicology and Applied Pharmacology, 2012, 262, 80-90.	1.3	45

#	Article	IF	Citations
2169	In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. Journal of Controlled Release, 2012, 157, 190-195.	4.8	50
2170	Mutagen-mediated enhancement of HIV-1 replication in persistently infected cells. Virology, 2012, 424, 147-153.	1.1	8
2171	Stem cells as the root of pancreatic ductal adenocarcinoma. Experimental Cell Research, 2012, 318, 691-704.	1.2	42
2172	Interferonâ€alpha modulates the chemosensitivity of <scp>CD</scp>133â€expressing pancreatic cancer cells to gemcitabine. Cancer Science, 2012, 103, 889-896.	1.7	16
2173	Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: <scp>GECA</scp>1. Cancer Science, 2012, 103, 1489-1492.	1.7	36
2174	Bone marrowâ€derived proangiogenic cells in pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 23-26.	1.4	7
2175	Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial. Annals of Surgical Oncology, 2012, 19, 2256-2263.	0.7	30
2176	Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer, 2012, 118, 571-578.	2.0	18
2177	Costâ€effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer, 2012, 118, 1119-1129.	2.0	55
2178	A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2012, 69, 415-424.	1.1	39
2179	The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2012, 69, 425-430.	1.1	10
2180	Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemotherapy and Pharmacology, 2012, 69, 477-484.	1.1	15
2181	Xenon-Inhalation Computed Tomography for Noninvasive Quantitative Measurement of Tissue Blood Flow in Pancreatic Tumor. Digestive Diseases and Sciences, 2012, 57, 801-805.	1.1	5
2182	Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Investigational New Drugs, 2012, 30, 258-265.	1.2	2
2183	Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 2012, 30, 382-386.	1.2	91
2184	Phase I and pharmacokinetic study of 3â€²-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Investigational New Drugs, 2012, 30, 316-326.	1.2	8
2185	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 779-786.	1.2	49
2186	Weight loss in cancer patients: a plea for a better awareness of the issue. Supportive Care in Cancer, 2012, 20, 301-309.	1.0	51

#	Article	IF	Citations
2187	A phase II study of oral Sâ€1 with concurrent radiotherapy followed by chemotherapy with Sâ€1 alone for locally advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 152-158.	1.4	42
2188	An analysis of human equilibrative nucleoside transporterâ€1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair crossâ€complementing geneâ€1 expression in patients with resected pancreas adenocarcinoma. Cancer, 2013, 119, 445-453.	2.0	42
2189	Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Radiation Oncology, 2013, 8, 160.	1.2	11
2190	Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Journal of Experimental and Clinical Cancer Research, 2013, 32, 12.	3.5	27
2191	Considerations for the prediction of survival time in pancreatic cancer based on registry data. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 527-536.	0.8	2
2192	Nuclear Medicine Therapy. , 2013, , .		5
2193	Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1065-1072.	1.1	33
2194	Neoadjuvant therapy in resectable pancreatic cancer: A critical review. Cancer Treatment Reviews, 2013, 39, 518-524.	3.4	39
2195	Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer, 2013, 13, 194.	1.1	35
2196	Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. British Journal of Cancer, 2013, 108, 1-8.	2.9	265
2197	Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs. Journal of Cellular Physiology, 2013, 228, 1834-1843.	2.0	10
2198	Benefit and Harms of New Anti-Cancer Drugs. Current Oncology Reports, 2013, 15, 270-275.	1.8	30
2199	Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study. Journal of Gastrointestinal Cancer, 2013, 44, 313-317.	0.6	9
2200	Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study. Supportive Care in Cancer, 2013, 21, 3271-3278.	1.0	10
2201	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 918-926.	1.2	26
2202	Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunology, Immunotherapy, 2013, 62, 1083-1091.	2.0	64
2203	CD40 immunotherapy for pancreatic cancer. Cancer Immunology, Immunotherapy, 2013, 62, 949-954.	2.0	95
2204	Notch1 Contributes to Chemoresistance to Gemcitabine and Serves as an Unfavorable Prognostic Indicator in Pancreatic Cancer. World Journal of Surgery, 2013, 37, 1688-1694.	0.8	15

#	Article	IF	Citations
2205	A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 637-642.	1.1	31
2206	Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 2013, 71, 765-775.	1.1	239
2207	Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 85-92.	1.1	21
2208	A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 93-101.	1.1	30
2210	Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. British Journal of Cancer, 2013, 108, 1488-1494.	2.9	44
2211	Nuclear factor ÎºB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Surgery Today, 2013, 43, 171-177.	0.7	10
2212	Therapeutic Advances in Pancreatic Cancer. Gastroenterology, 2013, 144, 1316-1326.	0.6	257
2213	Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo. Nanoscale Research Letters, 2013, 8, 176.	3.1	24
2214	CÃ¡ncer de pÃ¡ncreas exocrino. Medicine, 2013, 11, 1526-1531.	0.0	0
2215	Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 2013, 7, 232-247.	2.1	140
2216	Increased Survival After Resection of Pancreatic Cancer Liver Metastases. CirugÃa EspaÃ±ola (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	1
2217	Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2013, 14, 317-326.	5.1	299
2218	Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. European Journal of Cancer, 2013, 49, 2633-2642.	1.3	160
2219	Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer. Clinical and Experimental Metastasis, 2013, 30, 381-392.	1.7	21
2220	The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012. Annals of Oncology, 2013, 24, iv5-iv10.	0.6	8
2221	A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Investigational New Drugs, 2013, 31, 707-713.	1.2	86
2222	Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Toxicology Letters, 2013, 222, 23-35.	0.4	38
2223	Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. Journal of Clinical Oncology, 2013, 31, 4453-4461.	0.8	147

#	Article	IF	Citations
2224	Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Cancer Letters, 2013, 341, 166-177.	3.2	77
2225	Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine, 2013, 369, 1691-1703.	13.9	5,097
2226	A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 985-990.	1.1	11
2227	Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Molecular Cancer, 2013, 12, 104.	7.9	38
2228	Targeting the Rasâ€"ERK pathway in pancreatic adenocarcinoma. Cancer and Metastasis Reviews, 2013, 32, 147-162.	2.7	83
2229	EGFR and HER2 inhibition in pancreatic cancer. Investigational New Drugs, 2013, 31, 558-566.	1.2	28
2230	A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 685-695.	1.2	26
2231	Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. Journal of Translational Medicine, 2013, 11, 291.	1.8	79
2232	Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. Journal of Gastrointestinal Cancer, 2014, 45, 190-201.	0.6	24
2233	PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic. Cellular Oncology (Dordrecht), 2013, 36, 449-457.	2.1	25
2234	Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer. Journal of Radiation Oncology, 2013, 2, 369-379.	0.7	3
2235	The role of adjuvant chemoradiation in the treatment of pancreatic cancer. Journal of Radiation Oncology, 2013, 2, 391-400.	0.7	0
2236	S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Medical Oncology, 2013, 30, 747.	1.2	27
2237	A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 1291-1297.	1.1	16
2238	Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncology, The, 2013, 14, 1095-1103.	5.1	198
2239	Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. Cancer Letters, 2013, 338, 271-281.	3.2	17
2240	Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas. Hpb, 2013, 15, 951-957.	0.1	46
2241	Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Medicine, 2013, 5, 26.	3.6	18

#	Article	IF	Citations
2242	Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 2013, 62, 112-120.	6.1	866
2243	A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Investigational New Drugs, 2013, 31, 85-91.	1.2	29
2244	Radioimmunotherapy of Pancreatic Adenocarcinoma. , 2013, , 239-255.		0
2245	Chemotherapy in patients with advanced pancreatic cancer: too close to death?. Supportive Care in Cancer, 2013, 21, 157-163.	1.0	19
2246	Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation. Materials Science and Engineering C, 2013, 33, 1183-1192.	3.8	33
2247	miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Letters, 2013, 334, 211-220.	3.2	83
2248	Assessment of the stromal contribution to Sonic Hedgehogâ€dependent pancreatic adenocarcinoma. Molecular Oncology, 2013, 7, 1031-1042.	2.1	38
2249	â€œChronicâ€•metastatic pancreatic acinar cell carcinoma. Pancreatology, 2013, 13, 549-552.	0.5	16
2250	918 Overexpressing TNF-Alpha in Pancreatic Ductal Adenocarcinoma Cells and Fibroblasts Modifies Cell Survival and Reduces Fatty Acid Synthesis via Downregulation of Sterol Regulatory Element Binding Protein-1 and Activation of Acetyl CoA Carboxylase. Gastroenterology, 2013, 144, S-1067.	0.6	0
2251	Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Letters, 2013, 331, 250-261.	3.2	29
2252	A small-molecule induces apoptosis and suppresses metastasis in pancreatic cancer cells. European Journal of Pharmaceutical Sciences, 2013, 48, 658-667.	1.9	12
2253	Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model. International Journal of Pharmaceutics, 2013, 441, 499-506.	2.6	21
2255	In vitro study on the binding of gemcitabine to bovine serum albumin. Journal of Pharmaceutical and Biomedical Analysis, 2013, 75, 86-93.	1.4	83
2256	Current concepts and novel targets in advanced pancreatic cancer. Gut, 2013, 62, 317-326.	6.1	134
2257	Aptamer conjugated theragnostic multifunctional magnetic nanoparticles as a nanoplatform for pancreatic cancer therapy. RSC Advances, 2013, 3, 20579.	1.7	32
2259	Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis of Pancreatic Cancer Xenograft with Gemcitabine. Ultrasound in Medicine and Biology, 2013, 39, 1991-2000.	0.7	17
2260	Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2517-2525.	1.1	23
2261	Su1575 Long-Term Effect of Gemcitabine-Combined Endoscopic Ultrasonography- Guided Brachytherapy in Pancreatic Cancer. Gastrointestinal Endoscopy, 2013, 77, AB373.	0.5	4

#	Article	IF	Citations
2262	Loss of runtâ€related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Molecular Oncology, 2013, 7, 840-849.	2.1	28
2263	Pancreatic cancer: A comprehensive review and update. Disease-a-Month, 2013, 59, 368-402.	0.4	101
2264	Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Letters, 2013, 335, 41-51.	3.2	125
2265	Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors. Journal of Molecular Diagnostics, 2013, 15, 263-269.	1.2	66
2266	In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells. Cancer Letters, 2013, 334, 109-117.	3.2	47
2267	Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis. Pancreatology, 2013, 13, 415-422.	0.5	19
2268	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. European Journal of Cancer, 2013, 49, 593-603.	1.3	106
2269	Measuring Clinical Benefit: Use of Patient-Reported Outcomes (PRO) in Primary Brain Tumor Clinical Trials. Current Oncology Reports, 2013, 15, 27-32.	1.8	9
2270	FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Medical Oncology, 2013, 30, 361.	1.2	121
2271	Stent patency using competing risk model in unresectable pancreatic cancers inserted with biliary selfâ€expandable metallic stent. Digestive Endoscopy, 2013, 25, 67-75.	1.3	14
2272	Feasibility of a new selfâ€expandable metallic stent for patients with malignant colorectal obstruction. Digestive Endoscopy, 2013, 25, 160-166.	1.3	33
2273	Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patientsâ€™ quality of life. World Journal of Surgical Oncology, 2013, 11, 3.	0.8	7
2274	SnapShot: Pancreatic Cancer. Cancer Cell, 2013, 23, 424-424.e1.	7.7	33
2275	Multidisciplinary management of locally advancedâ€“borderline resectable adenocarcinoma of the head of the pancreas. Clinical and Translational Oncology, 2013, 15, 173-181.	1.2	9
2276	The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer. Current Oncology Reports, 2013, 15, 182-189.	1.8	85
2277	CXCR2: a target for pancreatic cancer treatment?. Expert Opinion on Therapeutic Targets, 2013, 17, 667-680.	1.5	44
2278	The serum miRâ€21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miRâ€21 expression confers chemoresistance by targeting FasL. Molecular Oncology, 2013, 7, 334-345.	2.1	161
2279	Whole blood interferonâ€Î³ levels predict the therapeutic effects of adoptive Tâ€cell therapy in patients with advanced pancreatic cancer. International Journal of Cancer, 2013, 133, 1119-1125.	2.3	17

#	Article	IF	Citations
2280	Associations of GSTM1 and GSTT1 polymorphisms with pancreatic cancer risk. Tumor Biology, 2013, 34, 705-712.	0.8	8
2281	Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications. Molecular Pharmaceutics, 2013, 10, 430-444.	2.3	176
2282	In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation. Cancer Chemotherapy and Pharmacology, 2013, 71, 379-388.	1.1	15
2283	Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer and Metastasis Reviews, 2013, 32, 585-602.	2.7	104
2284	Advanced-stage pancreatic cancer: therapy options. Nature Reviews Clinical Oncology, 2013, 10, 323-333.	12.5	183
2285	Insulin-Like Growth Factor 1 Receptor Promotes the Growth and Chemoresistance of Pancreatic Cancer. Digestive Diseases and Sciences, 2013, 58, 2705-2712.	1.1	26
2286	A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (TheracurminÂ®) in cancer patients. Cancer Chemotherapy and Pharmacology, 2013, 71, 1521-1530.	1.1	160
2287	Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1396-1404.	1.4	65
2288	Oncolytic myxoma virus: The path to clinic. Vaccine, 2013, 31, 4252-4258.	1.7	76
2289	Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy afterÂoperative resection. Surgery, 2013, 153, 565-575.	1.0	46
2290	Serine, glycine and one-carbon units: cancer metabolism in full circle. Nature Reviews Cancer, 2013, 13, 572-583.	12.8	1,221
2291	Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-Î¹B activation for pancreatic cancer. Cancer Letters, 2013, 333, 89-95.	3.2	26
2292	Inhibition of Nuclear Factor Kappa-B Enhances the Antitumor Effect of Combination Treatment with Tumor Necrosis Factor-Alpha Gene Therapy and Gemcitabine for Pancreatic Cancer in Mice. Journal of the American College of Surgeons, 2013, 216, 320-332e3.	0.2	16
2293	Nutritional support of the oncology patient. Critical Reviews in Oncology/Hematology, 2013, 87, 172-200.	2.0	98
2294	Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Therapy, 2013, 20, 222-228.	2.2	99
2295	Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira. Oncology Reports, 2013, 30, 149-156.	1.2	13
2296	Novel Multimodality Treatment Sequencing for Extrahepatic (Mid and Distal) Cholangiocarcinoma. Annals of Surgical Oncology, 2013, 20, 1230-1239.	0.7	11
2297	Elevated Preoperative Neutrophil-to-lymphocyte Ratio as a Predictor of Survival After Gastroenterostomy in Patients with Advanced Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2013, 20, 4330-4337.	0.7	47

#	Article	IF	Citations
2298	Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma: Improvements Needed in Population-Based Registries. Annals of Surgical Oncology, 2013, 20, 4338-4347.	0.7	8
2299	Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis. Clinical Cancer Research, 2013, 19, 3404-3415.	3.2	473
2300	The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 5572-5579.	3.2	56
2301	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the â€˜Arbeitsgemeinschaft Internistische Onkologieâ€™ (AIO-PK0104). Gut, 2013, 62, 751-759.	6.1	105
2302	Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis, 2013, 34, 2361-2369.	1.3	107
2303	Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 845-852.	1.1	11
2304	Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbeck's Archives of Surgery, 2013, 398, 989-996.	0.8	13
2305	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Investigational New Drugs, 2013, 31, 1375-1383.	1.2	6
2306	A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Investigational New Drugs, 2013, 31, 1294-1299.	1.2	45
2307	Identification of Occult Liver Metastases. Frontiers of Gastrointestinal Research, 2013, , 25-32.	0.1	2
2308	Overcoming therapeutic resistance in pancreatic cancer is not a simple mix of PDT and chemotherapy: Evaluation of PDT-chemotherapy combinations in 3D tumor models. Proceedings of SPIE, 2013, , .	0.8	1
2309	Clinically Meaningful Responses to Sequential Gemcitabine-Based Chemotherapy Regimens in a Patient with Metastatic Pancreatic Cancer. Case Reports in Oncology, 2013, 6, 72-77.	0.3	5
2310	The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement. Clinical Cancer Research, 2013, 19, 2629-2636.	3.2	110
2311	Photodynamic therapy of locally advanced pancreatic cancer (VERTPAC study): final clinical results. Proceedings of SPIE, 2013, , .	0.8	6
2312	Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. Journal of Medical Economics, 2013, 16, 1379-1386.	1.0	17
2315	Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management. Gastrointestinal Tumors, 2014, 1, 41-52.	0.3	16
2317	Increased Expression of Survivin in Hepatoblastoma after Chemotherapy. European Journal of Pediatric Surgery, 2013, 23, 400-404.	0.7	9
2319	Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?. ISRN Oncology, 2013, 2013, 1-6.	2.1	6

#	Article	IF	Citations
2320	Curcumin Inhibits Tumor Growth and Angiogenesis in an Orthotopic Mouse Model of Human Pancreatic Cancer. BioMed Research International, 2013, 2013, 1-8.	0.9	77
2321	Predictive Modeling of In Vivo Response to Gemcitabine in Pancreatic Cancer. PLoS Computational Biology, 2013, 9, e1003231.	1.5	28
2322	What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International, 2013, 2013, 1-14.	0.9	19
2323	Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Frontiers in Physiology, 2013, 4, 331.	1.3	38
2324	Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic Cancer. Current Oncology, 2013, 20, 90-106.	0.9	53
2325	Gemcitabine-induced gouty arthritis attacks. Journal of Oncology Pharmacy Practice, 2013, 19, 284-288.	0.5	4
2326	Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of Oncology, 2013, 24, 1792-1801.	0.6	27
2327	LCL124, a Cationic Analog of Ceramide, Selectively Induces Pancreatic Cancer Cell Death by Accumulating in Mitochondria. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 167-178.	1.3	47
2328	Uptake and Patterns of Use of Gemcitabine for Metastatic Pancreatic Cancer: A Population-Based Study. Cancer Investigation, 2013, 31, 316-322.	0.6	18
2329	Pancreatic cancer: why is it so hard to treat?. Therapeutic Advances in Gastroenterology, 2013, 6, 321-337.	1.4	250
2330	Safety and Effectiveness of Gemcitabine in 855 Patients with Pancreatic Cancer under Japanese Clinical Practice Based on Post-marketing Surveillance in Japan. Japanese Journal of Clinical Oncology, 2013, 43, 139-145.	0.6	5
2331	The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): History and Future Direction. Japanese Journal of Clinical Oncology, 2013, 43, 2-7.	0.6	4
2332	Achieving the Best of Both Worlds. Journal of Clinical Oncology, 2013, 31, 3-4.	0.8	8
2333	Pooled Survival and Response Data From Phase III Randomized Controlled Trials for Gemcitabine-based Regimes in the Treatment of Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 411-414.	0.6	24
2334	Pancreatic cancer. JAAPA: Official Journal of the American Academy of Physician Assistants, 2013, 26, 27-32.	0.1	2
2335	Integrated Genomic, Transcriptomic, and RNA-Interference Analysis of Genes in Somatic Copy Number Gains in Pancreatic Ductal Adenocarcinoma. Pancreas, 2013, 42, 1016-1026.	0.5	3
2336	The Association of Rash Severity With Overall Survival. Pancreas, 2013, 42, 32-36.	0.5	16
2337	Clinical Outcomes of Chemotherapy for Diabetic and Nondiabetic Patients With Pancreatic Cancer. Pancreas, 2013, 42, 202-208.	0.5	54

#	Article	IF	Citations
2338	Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer. Pancreas, 2013, 42, 511-515.	0.5	9
2339	Phase II Study of Gemcitabine in Combination With Regional Arterial Infusion of Nafamostat Mesilate for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 44-48.	0.6	30
2340	Molecularly Targeted Therapies in Metastatic Pancreatic Cancer. Pancreas, 2013, 42, 760-773.	0.5	26
2341	Tumor Vessel Depiction With Contrast-Enhanced Endoscopic Ultrasonography Predicts Efficacy of Chemotherapy in Pancreatic Cancer. Pancreas, 2013, 42, 990-995.	0.5	31
2342	Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer. Pancreas, 2013, 42, 1157-1163.	0.5	64
2343	Cisplatin-Modified De Gramont in Second-Line Therapy for Pancreatic Adenocarcinoma. Pancreas, 2013, 42, 1138-1142.	0.5	1
2344	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. Anti-Cancer Drugs, 2013, 24, 980-985.	0.7	19
2345	Use of Gemcitabine With Multi-stage Surgical Resection as Successful Second-line Treatment of Metastatic Pancreatoblastoma. Journal of Pediatric Hematology/Oncology, 2013, 35, e7-e10.	0.3	9
2346	Combination Treatment With Comprehensive Cryoablation and Immunotherapy in Metastatic Pancreatic Cancer. Pancreas, 2013, 42, 1143-1149.	0.5	72
2347	Disrupting Cytokine Signaling in Pancreatic Cancer. Pancreas, 2013, 42, 813-818.	0.5	59
2348	Incidence, Prognosis, and Possible Treatment Strategies of Peritoneal Carcinomatosis of Pancreatic Origin. Pancreas, 2013, 42, 72-75.	0.5	87
2349	Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival. Molecular Cancer Research, 2013, 11, 901-911.	1.5	84
2350	The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model. Journal of Cancer, 2013, 4, 585-596.	1.2	95
2351	Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1857-1862.	3.3	50
2352	Pancreatic Cancer Clinical Trials and Accrual in the United States. Journal of Clinical Oncology, 2013, 31, 3432-3438.	0.8	56
2353	Successful Treatment with Nab-Paclitaxel and Gemcitabine after FOLFIRINOX Failure in a Patient with Metastasized Pancreatic Adenocarcinoma. Oncology Research and Treatment, 2013, 36, 763-765.	0.8	11
2354	Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 1473.	3.8	1,447
2355	Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 239-243.	0.6	39

#	Article	IF	Citations
2356	Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer. Pancreas, 2013, 42, 11-19.	0.5	101
2357	Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy. Frontiers in Oncology, 2013, 3, 155.	1.3	26
2358	Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis. Gut, 2013, 62, 310-316.	6.1	58
2359	Phase II Study of Dasatinib (BMSâ€354825) in Patients With Metastatic Adenocarcinoma of the Pancreas. Oncologist, 2013, 18, 1091-1092.	1.9	60
2360	Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway. Biochemistry Research International, 2013, 2013, 1-9.	1.5	37
2361	Tumor-Specific Expression of Organic Anion-Transporting Polypeptides: Transporters as Novel Targets for Cancer Therapy. Journal of Drug Delivery, 2013, 2013, 1-12.	2.5	91
2362	5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy. Chemotherapy, 2013, 59, 273-279.	0.8	49
2363	Diagnosis and management of pancreatic cancer. Cmaj, 2013, 185, 1219-1226.	0.9	68
2364	Lowâ€dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. International Journal of Cancer, 2013, 133, 98-107.	2.3	138
2365	Mucinous cystic neoplasms of the pancreas with ovarian stroma. ANZ Journal of Surgery, 2013, 83, 985-990.	0.3	34
2366	Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers. Clinical Pharmacology in Drug Development, 2013, 2, 367-378.	0.8	3
2367	Recent progress in pancreatic cancer. Ca-A Cancer Journal for Clinicians, 2013, 63, 318-348.	157.7	743
2368	Adenovirusâ€mediated Interferonâ€Î³ Gene Therapy Induced Human Pancreatic Carcinoma Capanâ€2 Cell Apoptosis In Vitro and In Vivo. Anatomical Record, 2013, 296, 604-610.	0.8	8
2369	Inhibition of checkpoint kinase 2 (CHK 2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. Journal of Cellular and Molecular Medicine, 2013, 17, 1261-1270.	1.6	28
2370	Phase 2, multicenter, openâ€label study of tigatuzumab (CSâ€1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapyâ€naive patients with unresectable or metastatic pancreatic cancer. Cancer Medicine, 2013, 2, 925-932.	1.3	80
2371	Value of peritoneal cytology in potentially resectable pancreatic cancer. British Journal of Surgery, 2013, 100, 1791-1796.	0.1	55
2372	Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer. Cancer Science, 2013, 104, 423-430.	1.7	29
2373	Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology, 2013, 63, 157-166.	1.6	41

#	Article	IF	Citations
2374	A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British Journal of Cancer, 2013, 109, 920-925.	2.9	146
2375	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. Cancer Biology and Therapy, 2013, 14, 340-346.	1.5	13
2376	Endoscopic self-expandable metallic stent placement in malignant pyloric or duodenal obstruction: Does chemotherapy affect stent patency?. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 162-168.	0.7	15
2377	Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. British Journal of Cancer, 2013, 109, 739-746.	2.9	65
2378	Lamin B1 Is a Novel Therapeutic Target of Betulinic Acid in Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 4651-4661.	3.2	89
2379	CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12325-12330.	3.3	207
2380	Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. Journal of Clinical Oncology, 2013, 31, 1640-1648.	0.8	548
2381	Inhibition of Amyloid Precursor Protein Processing Enhances Gemcitabine-mediated Cytotoxicity in Pancreatic Cancer Cells. Journal of Biological Chemistry, 2013, 288, 30114-30124.	1.6	38
2382	Pancreatic cancer: is combination treatment better?. Clinical Practice (London, England), 2013, 10, 695-700.	0.1	1
2383	Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-Î²B and its regulated targets. International Journal of Oncology, 2013, 42, 1189-1196.	1.4	33
2384	Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer. The Cochrane Library, 0, , .	1.5	0
2385	Screening for Pancreatic Cancer. Annals of Surgery, 2013, 257, 17-26.	2.1	217
2386	Gemcitabine : CDA, hENT1 et dCK. , 2013, , 119-126.		0
2387	MicroRNA-29a induces resistance to gemcitabine through the Wnt/Î²-catenin signaling pathway in pancreatic cancer cells. International Journal of Oncology, 2013, 43, 1066-1072.	1.4	79
2389	Efficacy of Dimethylaminoparthenolide and Sulindac in Combination With Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. Pancreas, 2013, 42, 160-167.	0.5	23
2390	Sann-Joong-Kuey-Jian-Tang decreases the protein expression of Mcl-1 and TCTP and increases that of TNF-Î± and Bax in BxPC-3 pancreatic carcinoma cells. International Journal of Molecular Medicine, 2013, 32, 85-92.	1.8	5
2391	A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Molecular and Clinical Oncology, 2013, 1, 768-772.	0.4	12
2394	Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. OncoTargets and Therapy, 2013, 7, 33.	1.0	66

#	Article	IF	Citations
2395	Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial. OncoTargets and Therapy, 2013, 6, 491.	1.0	12
2396	Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma. Clinical Interventions in Aging, 2013, 8, 889.	1.3	15
2398	Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. PLoS ONE, 2013, 8, e67330.	1.1	29
2399	Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics. PLoS ONE, 2013, 8, e57522.	1.1	27
2400	Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis. PLoS ONE, 2013, 8, e57528.	1.1	53
2401	Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma. PLoS ONE, 2013, 8, e70216.	1.1	32
2402	Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens. PLoS ONE, 2013, 8, e77065.	1.1	62
2403	Identification of a Novel Subpopulation of Tumor-Initiating Cells from Gemcitabine-Resistant Pancreatic Ductal Adenocarcinoma Patients. PLoS ONE, 2013, 8, e81283.	1.1	8
2404	Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure. Pharmaceutics, 2013, 5, 261-276.	2.0	27
2405	The role of the renin angiotensin system in the treatment of advanced pancreatic cancer. Suizo, 2013, 28, 49-55.	0.1	0
2408	Impact of Diabetes Mellitus on the Outcome of Pancreatic Cancer. PLoS ONE, 2014, 9, e98511.	1.1	11
2409	DUSP1 Is a Novel Target for Enhancing Pancreatic Cancer Cell Sensitivity to Gemcitabine. PLoS ONE, 2014, 9, e84982.	1.1	51
2410	An In Vivo Study of the Effects on Serum Glucose, Amylase and Histopathology of the Feline Pancreatic Tissue Treated by Focused Ultrasound. PLoS ONE, 2014, 9, e88815.	1.1	3
2411	Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2014, 9, e104346.	1.1	39
2412	Antiproliferative Effects and Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells. PLoS ONE, 2014, 9, e106289.	1.1	45
2413	Human Equilibrative Nucleoside Transporter-1 Knockdown Tunes Cellular Mechanics through Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells. PLoS ONE, 2014, 9, e107973.	1.1	14
2414	A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer. PLoS ONE, 2014, 9, e108749.	1.1	37
2415	STAT3 as an emerging molecular target in pancreatic cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 115.	5.5	4

#	Article	IF	Citations
2416	Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. OncoTargets and Therapy, 2014, 7, 187.	1.0	25
2417	Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncology Reviews, 2014, 8, 246.	0.8	42
2418	The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget, 2014, 5, 1869-1884.	0.8	116
2419	Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy, 2014, 03, .	0.0	18
2420	Brain Metastases in Gastrointestinal Cancers: Is there a Role for Surgery?. International Journal of Molecular Sciences, 2014, 15, 16816-16830.	1.8	25
2421	Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?. World Journal of Gastroenterology, 2014, 20, 17648.	1.4	4
2422	Optimum chemotherapy in the management of metastatic pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 2352.	1.4	19
2423	Profile and potential of ixabepilone in the treatment of pancreatic cancer. Drug Design, Development and Therapy, 2014, 8, 923.	2.0	9
2424	Intervention on toll-like receptors in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 5808.	1.4	44
2425	Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World Journal of Gastroenterology, 2014, 20, 15564.	1.4	39
2426	AFP-producing acinar cell carcinoma treated by pancreaticoduodenectomy in a patient with a previous radical subtotal gastrectomy by gastric cancer. Korean Journal of Hepato-biliary-pancreatic Surgery, 2014, 18, 33.	1.0	6
2428	Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer. Current Oncology, 2014, 21, 41.	0.9	40
2429	Management of borderline and locally advanced pancreatic cancer: Where do we stand?. World Journal of Gastroenterology, 2014, 20, 2255.	1.4	76
2430	Therapeutic options for the management of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 11142.	1.4	114
2431	A Near-Complete Response to Treatment with Gemcitabine plus nabÂ®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report. Case Reports in Oncology, 2014, 7, 711-717.	0.3	5
2432	Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel. Gastrointestinal Cancer: Targets and Therapy, 0, , 89.	5.5	0
2433	Druggable Targets in Pancreatic Adenocarcinoma. Forum on Immunopathological Diseases and Therapeutics, 2014, 5, 195-214.	0.1	0
2434	Nuclear receptors and pathogenesis of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 12062.	1.4	31

#	Article	IF	Citations
2435	Ten Weeks to Live: a Population-Based Study on Treatment and Survival of Patients with Metastatic Pancreatic Cancer in the South of the Netherlands. Annals of Oncology, 2014, 25, iv237.	0.6	0
2436	Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?. World Journal of Gastroenterology, 2014, 20, 2224.	1.4	51
2438	Chemotherapy, radiotherapy, chemoradiotherapy and combination therapy in localised and locally advanced pancreatic cancer. The Cochrane Library, 0, , .	1.5	2
2439	The Use of Anti-CD40 mAb in Cancer. Current Topics in Microbiology and Immunology, 2014, 405, 165-207.	0.7	21
2440	Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. OncoImmunology, 2014, 3, e27614.	2.1	70
2441	The Multifunctional Growth Factor Midkine Promotes Proliferation and Migration in Pancreatic Cancer. Molecular Cancer Research, 2014, 12, 670-680.	1.5	39
2442	Pancreatic Adenocarcinoma. New England Journal of Medicine, 2014, 371, 2139-2141.	13.9	324
2443	Riproximinâ€™s activity depends on gene expression and sensitizes PDAC cells to TRAIL. Cancer Biology and Therapy, 2014, 15, 1185-1197.	1.5	11
2444	A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells. Molecular Cancer, 2014, 13, 221.	7.9	95
2445	Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials. Diagnostic Pathology, 2014, 9, 214.	0.9	5
2446	Translational Therapeutics in Genetically Engineered Mouse Models of Cancer. Cold Spring Harbor Protocols, 2014, 2014, pdb.top069997.	0.2	10
2447	Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?. World Journal of Surgical Oncology, 2014, 12, 347.	0.8	21
2448	Patient Reported Endpoints for Measuring Clinical Benefit in (High Grade Glioma) Primary Brain Tumor Patients. Current Treatment Options in Oncology, 2014, 15, 519-528.	1.3	21
2449	Promising new therapies in advanced pancreatic adenocarcinomas. Future Oncology, 2014, 10, 2629-2641.	1.1	10
2450	Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clinical Cancer Research, 2014, 20, 5937-5945.	3.2	255
2451	Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2014, 8, 739-747.	1.4	32
2452	Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. British Journal of Cancer, 2014, 110, 1943-1949.	2.9	59
2453	Advanced stage pancreatic cancer: novel therapeutic options. Expert Review of Clinical Pharmacology, 2014, 7, 487-498.	1.3	14

#	Article	IF	Citations
2454	Highâ€intensity focused ultrasound for treatment of pancreatic cancer: a systematic review. Journal of Evidence-Based Medicine, 2014, 7, 270-281.	2.4	16
2455	Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies. Tumor Biology, 2014, 35, 11551-11558.	0.8	4
2456	Upgrading gemcitabine with recycled kinase inhibitors. Cell Cycle, 2014, 13, 2810-2811.	1.3	1
2457	Drug discovery in renal diseaseâ€"towards a more efficient framework. Nature Reviews Nephrology, 2014, 10, 290-296.	4.1	5
2458	Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy. Oncologist, 2014, 19, 937-950.	1.9	9
2459	Desmoplasia and Chemoresistance in Pancreatic Cancer. Cancers, 2014, 6, 2137-2154.	1.7	121
2460	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Annals of Oncology, 2014, 25, 1750-1755.	0.6	164
2461	Comparative Proteomic Profiling of Pancreatic Ductal Adenocarcinoma Cell Lines. Molecules and Cells, 2014, 37, 888-898.	1.0	42
2462	Patient preferences in advanced or recurrent ovarian cancer. Cancer, 2014, 120, 3651-3659.	2.0	68
2463	Stratified Medicine for Pancreatic Cancer. , 2014, , 807-814.		0
2464	FOLFIRINOX â€“ a new paradigm in the treatment of pancreatic cancer. Expert Review of Anticancer Therapy, 2014, 14, 1115-1125.	1.1	14
2465	Integrating Traditional Medicine into Modern Inflammatory Diseases Care: Multitargeting byRhus vernicifluaStokes. Mediators of Inflammation, 2014, 2014, 1-17.	1.4	37
2466	Perfusion in the Tissue Surrounding Pancreatic Cancer and the Patientâ€™s Prognosis. BioMed Research International, 2014, 2014, 1-6.	0.9	12
2467	Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. Oncology Letters, 2014, 7, 1594-1598.	0.8	5
2468	Diabetes, pancreatic cancer, and metformin therapy. Frontiers in Physiology, 2014, 5, 426.	1.3	50
2469	Docetaxel-Encapsulating Small-Sized Polymeric Micelles with Higher Permeability and Its Efficacy on the Orthotopic Transplantation Model of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2014, 15, 23571-23588.	1.8	9
2470	Reflecting on Inpatient Palliative Chemotherapyâ€"Is There Ever a â€œRight Placeâ€•at the â€œRight Timeâ€?. Current Oncology, 2014, 21, 158-160.	0.9	0
2471	Safety Study of Photodynamic Therapy Using Talaporfin Sodium in the Pancreas and Surrounding Tissues in the Syrian Golden Hamster. International Journal of Photoenergy, 2014, 2014, 1-7.	1.4	1

#	Article	IF	Citations
2472	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Future Oncology, 2014, 10, 1255-1275.	1.1	5
2473	Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside. Cancer Treatment Reviews, 2014, 40, 1039-1047.	3.4	86
2474	Ubiquitin-specific protease 22-induced autophagy is correlated with poor prognosis of pancreatic cancer. Oncology Reports, 2014, 32, 2726-2734.	1.2	41
2475	Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway. Molecular Medicine Reports, 2014, 10, 3027-3034.	1.1	23
2476	Full-Dose Gemcitabine Is a More Effective Chemotherapeutic Agent Than 5-Fluorouracil for Concurrent Chemoradiotherapy as First-Line Treatment in Locally Advanced Pancreatic Cancer. Chemotherapy, 2014, 60, 191-199.	0.8	5
2477	Phase <scp>II</scp> study of <scp>FOLFIRINOX</scp> for chemotherapyâ€naÃ¯ve Japanese patients with metastatic pancreatic cancer. Cancer Science, 2014, 105, 1321-1326.	1.7	156
2478	nab-Paclitaxel: Novel Clinical and Experimental Evidence in Pancreatic Cancer. Zeitschrift Fur Gastroenterologie, 2014, 52, 360-366.	0.2	28
2479	The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. Cell Cycle, 2014, 13, 884-889.	1.3	19
2480	SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm. Gynecologic Oncology, 2014, 135, 3-7.	0.6	17
2481	The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 1277-1283.	1.5	5
2482	Clinical diagnosis and management of perihilar cholangiocarcinoma. Clinical Liver Disease, 2014, 3, 60-64.	1.0	2
2483	DNA synthesis inhibitors for the treatment of gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 2361-2372.	0.9	4
2484	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. Expert Opinion on Pharmacotherapy, 2014, 15, 143-150.	0.9	7
2485	Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors. Oncology, 2014, 86, 24-32.	0.9	45
2486	Outpatient Advance Care Planning for Patients with Metastatic Cancer: A Pilot Quality Improvement Initiative. Journal of Palliative Medicine, 2014, 17, 1231-1237.	0.6	25
2487	Comparison of the Efficacy of Covered versus Uncovered Metallic Stents in Treating Inoperable Malignant Common Bile Duct Obstruction: A Randomized Trial. Journal of Vascular and Interventional Radiology, 2014, 25, 1912-1920.	0.2	37
2488	Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology, 2014, 113, 35-40.	0.3	13
2489	Improved survival with combined gemcitabine and <scp>S</scp>â€1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 761-766.	1.4	25

#	Article	IF	Citations
2490	SPARC independent drug delivery and antitumour effects ofnab-paclitaxel in genetically engineered mice. Gut, 2014, 63, 974-983.	6.1	125
2491	COUPâ€TFII in pancreatic adenocarcinoma: Clinical implication for patient survival and tumor progression. International Journal of Cancer, 2014, 134, 1648-1658.	2.3	31
2492	Neutrophilâ€toâ€lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Medicine, 2014, 3, 406-415.	1.3	100
2493	Neoadjuvant Gemcitabine-based Accelerated Hyperfractionation Chemoradiotherapy for Patients with Borderline Resectable Pancreatic Adenocarcinoma. Japanese Journal of Clinical Oncology, 2014, 44, 1172-1180.	0.6	26
2494	Proteaseâ€activated receptorâ€1 drives pancreatic cancer progression and chemoresistance. International Journal of Cancer, 2014, 135, 2294-2304.	2.3	58
2495	Pancreatic cancer: current standards, working towards a new therapeutic approach. Expert Review of Anticancer Therapy, 2014, 14, 495-497.	1.1	8
2496	Response to <scp>GEMOX</scp> plus erlotinib in pancreatic cancer is associated with <scp>ERCC</scp>1 overexpression. European Journal of Clinical Investigation, 2014, 44, 958-964.	1.7	9
2497	Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics, 2014, 13, 1032-1043.	1.9	19
2498	Nanomedicine: The Promise and Challenges in Cancer Chemotherapy. Advances in Experimental Medicine and Biology, 2014, 811, 207-233.	0.8	19
2500	Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-ÎºB signaling. BMC Cancer, 2014, 14, 686.	1.1	35
2501	Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 102.	3.5	32
2502	Targeting mTOR dependency in pancreatic cancer. Gut, 2014, 63, 1481-1489.	6.1	107
2503	Chemotherapeutic Strategies in Advanced or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 194-200.	0.6	8
2504	Antiprotease Strategy in Pancreatic Cancer Treatment. Pancreas, 2014, 43, 53-63.	0.5	3
2505	Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer. Pancreas, 2014, 43, 1022-1031.	0.5	10
2506	A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine For Patients With Advanced Pancreatic Cancer. Journal of Immunotherapy, 2014, 37, 36-42.	1.2	62
2507	Taxanes. Anti-Cancer Drugs, 2014, 25, 584-592.	0.7	18
2508	Wilms Tumor Gene (WT1) Peptideâ€"based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer. Journal of Immunotherapy, 2014, 37, 105-114.	1.2	77

#	Article	IF	Citations
2509	Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer. Anti-Cancer Drugs, 2014, 25, 958-963.	0.7	12
2510	Expression of Akt Kinase-Interacting Protein 1, a Scaffold Protein of the PI3K/PDK1/Akt Pathway, in Pancreatic Cancer. Pancreas, 2014, 43, 1093-1100.	0.5	9
2511	Should Combination Chemotherapy Serve as the Backbone in Clinical Trials of Advanced Pancreatic Cancer?. Pancreas, 2014, 43, 343-349.	0.5	8
2512	Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials. Clinical Cancer Research, 2014, 20, 4176-4185.	3.2	12
2513	Proteomic Differences and Linkages between Chemoresistance and Metastasis of Pancreatic Cancer Using Knowledge-Based Pathway Analysis. , 2014, , 221-244.		1
2514	Advances in Primary Cell Culture of Pancreatic Cancer. , 2014, , 11-38.		0
2515	Spatiotemporal Proteomic Analyses during Pancreas Cancer Progression Identifies Serine/Threonine Stress Kinase 4 (STK4) as a Novel Candidate Biomarker for Early Stage Disease. Molecular and Cellular Proteomics, 2014, 13, 3484-3496.	2.5	21
2516	Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3Kâ€“Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2014, 20, 4047-4058.	3.2	34
2517	Erlotinib. Recent Results in Cancer Research, 2014, 201, 109-123.	1.8	13
2518	Long term survival of a metastatic patient with pancreatic adenocarcinoma: a rare case report and review of the literature. Turk Onkoloji Dergisi, 2014, 29, 108-111.	0.0	1
2519	Oncolytic viral therapy for pancreatic cancer: current research and future directions. Oncolytic Virotherapy, 2014, 3, 35.	6.0	13
2520	The Roles of Interferon Regulatory Factors 1 and 2 in the Progression of Human Pancreatic Cancer. Pancreas, 2014, 43, 909-916.	0.5	33
2521	Epigenetic targeting in pancreatic cancer. Cancer Treatment Reviews, 2014, 40, 656-664.	3.4	36
2522	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer, 2014, 50, 1422-1429.	1.3	28
2523	Polychemotherapy or gemcitabine in advanced pancreatic cancer: A meta-analysis. Digestive and Liver Disease, 2014, 46, 452-459.	0.4	19
2524	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease, 2014, 46, 182-186.	0.4	40
2525	Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888. Translational Oncology, 2014, 7, 439-445.	1.7	36
2526	Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine. Targeted Oncology, 2014, 9, 123-134.	1.7	36

#	Article	IF	Citations
2527	Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. Clinical and Translational Oncology, 2014, 16, 330-335.	1.2	74
2528	Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. Journal of Gastroenterology, 2014, 49, 1074-1080.	2.3	46
2529	CT-Guided Radioactive 125I Seed Implantation Therapy of Symptomatic Retroperitoneal Lymph Node Metastases. CardioVascular and Interventional Radiology, 2014, 37, 125-131.	0.9	15
2530	Sonoporation-Enhanced Chemotherapy Significantly Reduces Primary Tumour Burden in an Orthotopic Pancreatic Cancer Xenograft. Molecular Imaging and Biology, 2014, 16, 53-62.	1.3	112
2531	Antagonistic Effects of Anti-EMMPRIN Antibody When Combined with Chemotherapy Against Hypovascular Pancreatic Cancers. Molecular Imaging and Biology, 2014, 16, 85-94.	1.3	9
2532	Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. Cancer Immunology, Immunotherapy, 2014, 63, 321-333.	2.0	32
2533	Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 97-102.	1.1	20
2534	Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemotherapy and Pharmacology, 2014, 73, 113-124.	1.1	10
2535	Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemotherapy and Pharmacology, 2014, 73, 125-130.	1.1	103
2536	Syntheses of 5â€²-amino-2â€²,5â€²-dideoxy-2â€²,2â€²-difluorocytidine derivatives as novel anticancer nucleoside analogs. Tetrahedron Letters, 2014, 55, 598-602.	0.7	6
2537	Altered miRNA expression profiles are involved in the protective effects of troxerutin against ultraviolet B radiation in normal human dermal fibroblasts. International Journal of Molecular Medicine, 2014, 33, 957-963.	1.8	11
2538	Modified GTX as Second-Line Therapy for Advanced Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2014, 45, 109-112.	0.6	0
2539	Overexpressing TNF-Alpha in Pancreatic Ductal Adenocarcinoma Cells and Fibroblasts Modifies Cell Survival and Reduces Fatty Acid Synthesis via Downregulation of Sterol Regulatory Element Binding Protein-1 and Activation of Acetyl CoA Carboxylase. Journal of Gastrointestinal Surgery, 2014, 18, 257-268.	0.9	7
2540	First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 373-380.	1.1	63
2542	Evaluation of the effect of comorbidity on survival in pancreatic cancer by using â€œCharlson Comorbidity Indexâ€•and â€œCumulative Illness Rating Scaleâ€• Wiener Klinische Wochenschrift, 2014, 126, 36-41.	1.0	15
2543	Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumor Biology, 2014, 35, 2313-2318.	0.8	27
2544	Temperature-Sensitive Magnetic Drug Carriers for Concurrent Gemcitabine Chemohyperthermia. Advanced Healthcare Materials, 2014, 3, 714-724.	3.9	54
2545	Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Letters, 2014, 347, 183-190.	3.2	45

#	Article	IF	Citations
2546	A mathematical model for pancreatic cancer growth and treatments. Journal of Theoretical Biology, 2014, 351, 74-82.	0.8	102
2547	Pancreatic cancer. British Journal of Pharmacology, 2014, 171, 849-858.	2.7	59
2548	Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. British Journal of Cancer, 2014, 110, 1481-1487.	2.9	71
2549	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. International Journal of Cancer, 2014, 134, 731-739.	2.3	67
2550	The identification of novel 5â€²-amino gemcitabine analogs as potent RRM1 inhibitors. Bioorganic and Medicinal Chemistry, 2014, 22, 2303-2310.	1.4	8
2551	Synthesis and Cytostatic Evaluation of 4-N-Alkanoyl and 4-N-Alkyl Gemcitabine Analogues. Journal of Medicinal Chemistry, 2014, 57, 191-203.	2.9	22
2552	Targeting cancer stem cells by curcumin and clinical applications. Cancer Letters, 2014, 346, 197-205.	3.2	160
2553	Opportunities for translation: Targeting DNA repair pathways in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 45-54.	3.3	8
2554	Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Advanced Drug Delivery Reviews, 2014, 69-70, 1-18.	6.6	156
2555	Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: A comparison with its self-assembled nanoparticles. International Journal of Pharmaceutics, 2014, 468, 142-151.	2.6	48
2556	The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 2014, 79, 34-74.	3.1	1,028
2557	Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. International Journal of Clinical Oncology, 2014, 19, 634-642.	1.0	2
2558	Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 389-396.	1.1	41
2559	Pancreaticoduodenetomy combined with hepatic artery resection following preoperative hepatic arterial embolization. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 850-855.	1.4	24
2560	A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. Biochemical and Biophysical Research Communications, 2014, 454, 144-150.	1.0	10
2561	Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T AGEO randomised phase II study (FIRGEM). European Journal of Cancer, 2014, 50, 3116-3124.	1.3	27
2562	FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer, 2014, 13, 232-238.	1.0	60
2563	Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Expert Opinion on Investigational Drugs, 2014, 23, 1499-1515.	1.9	18

#	Article	IF	Citations
2564	Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. Seminars in Oncology, 2014, 41, 559-575.	0.8	3
2565	Cytotoxicity of gemcitabine enhanced by polyphenolics from Aronia melanocarpa in pancreatic cancer cell line AsPC-1. Journal of Clinical Pathology, 2014, 67, 949-954.	1.0	15
2566	Response to Nab-Paclitaxel plus Gemcitabine in a Patient with Primary Resistance to FOLFIRINOX. Journal of Gastrointestinal Cancer, 2014, 45, 278-281.	0.6	2
2567	Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Cancer Letters, 2014, 353, 68-77.	3.2	11
2568	Stromal MicroRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer. Journal of Surgical Oncology, 2014, 110, 952-959.	0.8	39
2570	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530.	0.8	36
2571	Vascular resection during radical resection of pancreatic adenocarcinomas: evolution over the past 15 years. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 623-638.	1.4	19
2572	BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. European Journal of Cancer, 2014, 50, 2251-2262.	1.3	38
2573	Edelfosine Lipid Nanoparticles Overcome Multidrug Resistance in K-562 Leukemia Cells by a Caspase-Independent Mechanism. Molecular Pharmaceutics, 2014, 11, 2650-2658.	2.3	20
2574	Chronic Pancreatitis and Systemic Inflammatory Response Syndrome Prevent Impact of Chemotherapy with Gemcitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer. Neoplasia, 2014, 16, 463-470.	2.3	15
2575	Screening for Pancreatic Cancer. Advances in Surgery, 2014, 48, 115-136.	0.6	20
2576	Locally Advanced Pancreatic Cancer: The Role of Definitive Chemoradiotherapy. Clinical Oncology, 2014, 26, 560-568.	0.6	42
2577	¹²⁵I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer. British Journal of Radiology, 2014, 87, 20130641.	1.0	6
2578	FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer, 2014, 14, 441.	1.1	30
2579	Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer, 2014, 14, 471.	1.1	105
2580	Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Journal of Translational Medicine, 2014, 12, 175.	1.8	52
2581	Pancreatic Adenocarcinoma. New England Journal of Medicine, 2014, 371, 1039-1049.	13.9	1,821
2582	Pancreatic stellate cells and pancreas cancer: Current perspectives and future strategies. European Journal of Cancer, 2014, 50, 2570-2582.	1.3	88

#	Article	IF	Citations
2583	Dynamic contrastâ€“enhanced ultrasonographic (DCE-US) assessment of the early response after combined gemcitabine and HIFU with low-power treatment for the mouse xenograft model of human pancreatic cancer. European Radiology, 2014, 24, 2059-2068.	2.3	14
2584	A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology, 2014, 14, 398-402.	0.5	18
2585	Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. Cell, 2014, 159, 80-93.	13.5	871
2586	Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunology, Immunotherapy, 2014, 63, 797-806.	2.0	46
2587	A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 131-139.	1.1	0
2588	Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology, 2014, 74, 333-340.	1.1	12
2589	Increased Rates of Duodenal Obstruction in Pancreatic Cancer Patients Receiving Modern Medical Management. Digestive Diseases and Sciences, 2014, 59, 2294-2298.	1.1	34
2590	A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Investigational New Drugs, 2014, 32, 739-745.	1.2	96
2591	Formulation and preclinical evaluation of 99mTcâ€“gemcitabine as a novel radiopharmaceutical for solid tumor imaging. Journal of Radioanalytical and Nuclear Chemistry, 2014, 302, 179-186.	0.7	28
2592	Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma. Integrative Cancer Therapies, 2014, 13, 332-340.	0.8	26
2593	Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene, 2014, 33, 3812-3819.	2.6	226
2594	Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group. European Journal of Medical Research, 2014, 19, 24.	0.9	12
2595	MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression. Cancer Letters, 2014, 347, 54-64.	3.2	69
2596	Quality-adjusted survival with combination nab-paclitaxelâ€‰+â€‰gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. Journal of Medical Economics, 2014, 17, 338-346.	1.0	22
2597	Enhanced Tumor Delivery of Gemcitabine via PEG-DSPE/TPGS Mixed Micelles. Molecular Pharmaceutics, 2014, 11, 1140-1150.	2.3	53
2598	Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. Journal of Clinical Oncology, 2014, 32, 2423-2429.	0.8	397
2599	Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer. Clinical Therapeutics, 2014, 36, 1054-1063.	1.1	10
2600	Management Options in Locally Advanced Pancreatic Cancer. Current Oncology Reports, 2014, 16, 388.	1.8	29

#	Article	IF	Citations
2601	Intravenous and Intraperitoneal Paclitaxel with S-1 for Refractory Pancreatic Cancer with Malignant Ascites: an Interim Analysis. Journal of Gastrointestinal Cancer, 2014, 45, 307-311.	0.6	18
2602	TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clinical and Translational Oncology, 2014, 16, 865-878.	1.2	5
2603	Case report of nab-paclitaxel in metastatic pancreatic cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 39-42.	0.3	1
2604	Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells. Tumor Biology, 2014, 35, 2461-2471.	0.8	46
2605	Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer â€“ the CONKO 004 pilot trial. BMC Cancer, 2014, 14, 204.	1.1	14
2606	Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial. Digestive and Liver Disease, 2014, 46, 950-955.	0.4	5
2607	One-Electron Oxidation of Gemcitabine and Analogs: Mechanism of Formation of C3â€² and C2â€² Sugar Radicals. Journal of the American Chemical Society, 2014, 136, 15646-15653.	6.6	15
2608	Intravenous Vitamin C and Cancer. Integrative Cancer Therapies, 2014, 13, 280-300.	0.8	99
2609	Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials, 2014, 35, 7077-7087.	5.7	137
2610	Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Letters, 2014, 348, 20-28.	3.2	24
2611	Development of a Symptom Index for Patients with Primary Brain Tumors. Value in Health, 2014, 17, 62-69.	0.1	21
2612	Resection or cryosurgery relates with pancreatic tumor type: Primary pancreatic cancer with previous non-pancreatic cancer or secondary metastatic cancer within the pancreas. Pancreatology, 2014, 14, 64-70.	0.5	6
2613	Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (â‰¥70 years of age): A retrospective cohort study at the National Center for Tumor Diseases Heidelberg. Pancreatology, 2014, 14, 211-215.	0.5	25
2614	Tumourâ€“stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies. Cancer Treatment Reviews, 2014, 40, 118-128.	3.4	108
2615	Â¿Sigue representando la infiltraciÃ³n arterial un criterio de irresecabilidad en el carcinoma de pÃ¡ncreas?. CirugÃa EspaÃ±ola, 2014, 92, 305-315.	0.1	6
2616	Use of herbal medicines and natural products: An alternative approach to overcoming the apoptotic resistance of pancreatic cancer. International Journal of Biochemistry and Cell Biology, 2014, 53, 224-236.	1.2	58
2617	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 2014, 50, 2072-2081.	1.3	283
2618	Multifunctionalization of magnetic nanoparticles for controlled drug release: A general approach. European Journal of Medicinal Chemistry, 2014, 82, 355-362.	2.6	55

#	Article	IF	Citations
2619	Is Arterial Infiltration Still a Criterion for Unresectability in Pancreatic Adenocarcinoma?. CirugÃa EspaÃ±ola (English Edition), 2014, 92, 305-315.	0.1	2
2620	A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. European Journal of Cancer, 2014, 50, 1909-1915.	1.3	31
2621	Circulating tumor cells in pancreatic cancer patients: Methods of detection and clinical implications. International Journal of Cancer, 2014, 134, 1-8.	2.3	107
2622	Novel strategies for managing pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 14717.	1.4	15
2623	Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. World Journal of Gastroenterology, 2014, 20, 2237.	1.4	105
2624	Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. Oncology Letters, 2014, 8, 1302-1306.	0.8	6
2626	Clinical Benefit Response in Pancreatic Cancer Trials Revisited. Oncology Research and Treatment, 2014, 37, 1-1.	0.8	14
2627	Nab-Paclitaxel for Metastatic Pancreatic Cancer: Clinical Outcomes and Potential Mechanisms of Action. Oncology Research and Treatment, 2014, 37, 128-134.	0.8	26
2628	Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. International Journal of Oncology, 2014, 44, 959-969.	1.4	51
2629	HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. International Journal of Oncology, 2014, 45, 311-321.	1.4	10
2630	Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review. International Journal of Oncology, 2014, 44, 319-326.	1.4	36
2632	MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2. Oncology Reports, 2014, 32, 2824-2830.	1.2	59
2633	Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. Molecular and Clinical Oncology, 2014, 2, 586-590.	0.4	3
2634	Personalization of Chemotherapy for Metastatic Pancreatic Cancer. Clinical Medicine Insights: Case Reports, 2014, 7, CCRep.S14478.	0.3	1
2635	Metastasis-Related Processes Show Various Degrees of Activation in Different Stages of Pancreatic Cancer Rat Liver Metastasis. Oncology Research and Treatment, 2014, 37, 464-470.	0.8	10
2636	Safety and efficacy of image-guided enzyme-targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer. Oncology Letters, 2014, 8, 404-408.	0.8	11
2637	Prognostic Factors in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine Chemotherapy: Clinical Characteristics of Long-Term Survivors. Annals of Oncology, 2014, 25, ii46.	0.6	0
2638	Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo. Oncology Letters, 2015, 9, 2353-2360.	0.8	8

#	Article	IF	Citations
2639	Stents with specialized functions: drug-eluting stents and stents with antireflux devices. Gastrointestinal Intervention, 2015, 4, 50-54.	0.1	4
2640	English language version of the S3-consensus guidelines onÂchronic pancreatitis: Definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Zeitschrift Fur Gastroenterologie, 2015, 53, 1447-1495.	0.2	125
2641	Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer. Oncology Reports, 2015, 33, 304-310.	1.2	46
2642	Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncology Letters, 2015, 10, 1204-1210.	0.8	2
2643	Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Medicine, 2015, 4, 1171-1177.	1.3	94
2644	Antitumor effect of antitissue factor antibodyâ€MMAE conjugate in human pancreatic tumor xenografts. International Journal of Cancer, 2015, 137, 1457-1466.	2.3	62
2645	Claudinâ€4 binder Câ€CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a <scp>MAPK</scp> pathway. Pharmacology Research and Perspectives, 2015, 3, e00196.	1.1	9
2646	Catecholâ€O â€methyltransferase, a new target for pancreatic cancer therapy. Cancer Science, 2015, 106, 576-583.	1.7	15
2647	Randomized phase <scp>II</scp>/<scp>III</scp> clinical trial of elpamotide for patients with advanced pancreatic cancer: <scp>PEGASUS</scp>â€<scp>PC</scp> Study. Cancer Science, 2015, 106, 883-890.	1.7	78
2648	Is repeating <scp>FOLFIRINOX</scp> in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?. Cancer Science, 2015, 106, 1100-1100.	1.7	1
2649	TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. International Journal of Oncology, 2015, 47, 857-866.	1.4	69
2651	Polyphenol-rich extract of Salvia chinensis exhibits anticancer activity in different cancer cell lines, and induces cell cycle arrest at the G0/G1-phase, apoptosis and loss of mitochondrial membrane potential in pancreatic cancer cells. Molecular Medicine Reports, 2015, 12, 4843-4850.	1.1	20
2652	New Advances in the Treatment of Metastatic Pancreatic Cancer. Digestion, 2015, 92, 175-184.	1.2	18
2653	Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discovery, 2015, 1, 15010.	2.0	14
2654	Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling. Scientific Reports, 2015, 5, 14404.	1.6	58
2655	Treatment of Advanced Pancreatic Cancer. , 2015, , 451-470.		0
2656	Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case. International Surgery, 2015, 100, 287-291.	0.0	2
2657	Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study. Internal Medicine, 2015, 54, 2969-2973.	0.3	12

#	Article	IF	Citations
2658	Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review). International Journal of Oncology, 2015, 47, 1203-1210.	1.4	43
2659	Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. Oncology Research and Treatment, 2015, 38, 596-603.	0.8	20
2660	Pancreatic Cancer: Progress in Systemic Therapy. Gastrointestinal Tumors, 2014, 1, 167-179.	0.3	11
2661	Measuring body composition using the bioelectrical impedance method can predict the outcomes of gemcitabine-based chemotherapy in patients with pancreatobiliary tract cancer. Oncology Letters, 2015, 10, 3535-3541.	0.8	6
2662	Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, e29-e36.	2.3	15
2664	Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies. Journal of Visualized Experiments, 2015, , e52801.	0.2	17
2665	Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1309-1314.	1.1	44
2668	Evaluation of low-dose fractionated radiation therapy as a chemopotentiator of gemcitabine in advanced pancreatic cancer: results from an international multi-institutional phase II trial. Journal of Radiation Oncology, 2015, 4, 401-409.	0.7	0
2669	A Long Gastrojejunostomy Is Associated With Decreased Incidence and Severity of Delayed Gastric Emptying After Pancreaticoduodenectomy. Pancreas, 2015, 44, 1273-1279.	0.5	11
2670	A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer, 2015, 15, 653.	1.1	9
2671	Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer, 2015, 15, 726.	1.1	18
2672	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. BMC Cancer, 2015, 15, 783.	1.1	37
2673	Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer, 2015, 15, 802.	1.1	17
2674	Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomography. Journal of Nanobiotechnology, 2015, 13, 90.	4.2	23
2675	A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World Journal of Surgical Oncology, 2015, 14, 14.	0.8	47
2676	Identification of potential biomarkers to differentially diagnose solid pseudopapillary tumors and pancreatic malignancies via a gene regulatory network. Journal of Translational Medicine, 2015, 13, 361.	1.8	24
2677	Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Experimental Hematology and Oncology, 2015, 4, 29.	2.0	49
2678	Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. Journal of Surgical Oncology, 2015, 111, 1028-1034.	0.8	65

#	Article	IF	Citations
2679	Increased Dose Single-agent Gemcitabine in Platinum-taxane Resistant Metastatic Ovarian Cancer. Tumori, 2015, 101, 36-40.	0.6	0
2680	Clinical trial end points relevant to patients and society for rare cancers. Clinical Investigation, 2015, 5, 599-612.	0.0	1
2681	Inhibition of ILâ€6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer. International Journal of Cancer, 2015, 137, 1035-1046.	2.3	94
2682	Prognostic Value of Altered N-Glycosylation of Circulating Glycoproteins in Patients With Unresectable Pancreatic Cancer Treated With Gemcitabine. Pancreas, 2015, 44, 551-556.	0.5	7
2683	Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. Pancreas, 2015, 44, 1141-1147.	0.5	64
2684	Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Pancreas, 2015, 44, 930-936.	0.5	18
2685	Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 322-325.	0.6	15
2686	Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer. Medicine (United States), 2015, 94, e1345.	0.4	9
2687	Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer. Pancreas, 2015, 44, 977-982.	0.5	46
2688	Management of cancer of the exocrine pancreas. , 0, , 212-223.		0
2689	Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. Oncotarget, 2015, 6, 13072-13087.	0.8	33
2690	Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience, 2015, 2, 517-532.	0.9	403
2691	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 2015, 6, 35087-35094.	0.8	40
2692	Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis. OncoTargets and Therapy, 2015, 8, 3315.	1.0	6
2694	Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Einstein (Sao Paulo, Brazil), 2015, 13, 347-351.	0.3	8
2695	Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology). Wspolczesna Onkologia, 2015, 2, 125-129.	0.7	0
2696	Induction of Antigen-Specific Cytotoxic T Lymphocytes by Chemoradiotherapy in Patients Receiving Wilms? Tumor 1-Targetted Dendritic Cell Vaccinations for Pancreatic Cancer. OMICS Journal of Radiology, 2015, 04, .	0.0	7
2697	Radio sensitization of Colon Cancer Cells Mediated by Gemcitabine through Cell Cycle Synchronization. Journal of Carcinogenesis & Mutagenesis, 2015, 6, .	0.3	0

#	Article	IF	Citations
2698	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Current Oncology, 2015, 22, 305-315.	0.9	0
2699	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. The Cochrane Library, 2015, , .	1.5	1
2700	Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Design, Development and Therapy, 2015, 9, 3529.	2.0	135
2701	Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug Design, Development and Therapy, 2015, 9, 3677.	2.0	11
2702	Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Design, Development and Therapy, 2015, 9, 3767.	2.0	189
2703	A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2015, 10, e0121197.	1.1	8
2704	Slug-Dependent Upregulation of L1CAM Is Responsible for the Increased Invasion Potential of Pancreatic Cancer Cells following Long-Term 5-FU Treatment. PLoS ONE, 2015, 10, e0123684.	1.1	35
2705	Curcuminoids and Ãâ€°-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon ÃŽÂ³ production. Frontiers in Physiology, 2015, 6, 129.	1.3	42
2706	Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. BioMed Research International, 2015, 2015, 1-7.	0.9	3
2707	Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines. Brazilian Journal of Medical and Biological Research, 2015, 48, 111-119.	0.7	78
2708	Update on the management of pancreatic cancer: Surgery is not enough. World Journal of Gastroenterology, 2015, 21, 3157-3165.	1.4	147
2709	Nursing Implications of Chemotherapy Agents and Their Associated Side Effects in Patients With Pancreatic Cancer. Clinical Journal of Oncology Nursing, 2015, 19, 751-757.	0.3	1
2710	Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	0.5	6
2711	Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.2	4
2712	MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. Gastroenterology Research and Practice, 2015, 2015, 1-11.	0.7	30
2713	Making Sense of Current and Emerging Therapies in Pancreatic Cancer: Balancing Benefit and Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e222-e227.	1.8	1
2714	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget, 2015, 6, 18162-18173.	0.8	90
2715	An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget, 2015, 6, 24947-24968.	0.8	41

#	Article	IF	Citations
2716	Pancreatic cancer vaccine: a unique potential therapy. Gastrointestinal Cancer: Targets and Therapy, 2015, , 1.	5.5	0
2717	Current Concepts in Pancreatic Cancer. , 2015, , .		0
2718	Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biology and Therapy, 2015, 16, 438-449.	1.5	46
2719	Patient-reported outcomes as end points and outcome indicators in solid tumours. Nature Reviews Clinical Oncology, 2015, 12, 358-370.	12.5	55
2720	Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut, 2015, 64, 1476-1484.	6.1	444
2721	Pancreatic cancer stromal biology and therapy. Genes and Diseases, 2015, 2, 133-143.	1.5	110
2722	Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. Journal of Hematology and Oncology, 2015, 8, 44.	6.9	40
2723	The Quest for an Effective Treatment for an Intractable Cancer. Advances in Cancer Research, 2015, 127, 283-306.	1.9	10
2724	Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 717-726.	0.9	6
2725	Pancreatic Adenocarcinoma. , 2015, , 283-313.		3
2726	Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study. Investigational New Drugs, 2015, 33, 963-968.	1.2	45
2727	Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma. Biomedicine and Pharmacotherapy, 2015, 73, 123-128.	2.5	31
2728	Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opinion on Pharmacotherapy, 2015, 16, 851-861.	0.9	8
2729	Special Series: Advances in GI Cancer. Journal of Clinical Oncology, 2015, 33, 1717-1720.	0.8	13
2730	Efficacy of Prophylactic Lowâ€“Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. Journal of Clinical Oncology, 2015, 33, 2028-2034.	0.8	217
2731	Nanoformulations for therapy of pancreatic and liver cancers. Nanomedicine, 2015, 10, 1515-1534.	1.7	7
2732	Patient-Derived Xenograft Models for Pancreatic Adenocarcinoma Demonstrate Retention of Tumor Morphology through Incorporation of Murine Stromal Elements. American Journal of Pathology, 2015, 185, 1297-1303.	1.9	93
2733	PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 1174-1184.	1.5	17

#	Article	IF	Citations
2734	Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. Gastrointestinal Cancer: Targets and Therapy, 0, , 11.	5.5	5
2735	Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. Journal of Chemotherapy, 2015, 27, 227-234.	0.7	13
2736	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Medicine, 2015, 4, 1224-1239.	1.3	16
2737	The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. BMC Cancer, 2015, 15, 513.	1.1	18
2738	Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy, 2015, 7, 1249-1258.	1.0	48
2739	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). Clinical Cancer Research, 2015, 21, 5563-5577.	3.2	51
2740	Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resistance Updates, 2015, 23, 55-68.	6.5	282
2741	Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2. Journal of Pharmaceutical Sciences, 2015, 104, 3162-3169.	1.6	14
2742	Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. Medicine (United States), 2015, 94, e1012.	0.4	18
2743	A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling. Gastroenterology, 2015, 149, 1685-1688.	0.6	4
2747	Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: A Fox Chase Cancer Center experience. Journal of Geriatric Oncology, 2015, 6, 454-461.	0.5	15
2748	Surgical and oncological impact of main pancreatic duct spread in invasive ductal adenocarcinoma: A clinicopathological study of 184 resected cases. Pancreatology, 2015, 15, 681-687.	0.5	8
2749	Standardized uptake value on positron emission tomography/computed tomography predicts prognosis in patients with locally advanced pancreatic cancer. Abdominal Imaging, 2015, 40, 3117-3121.	2.0	12
2750	CT-guided high-dose-rate brachytherapy in the interdisciplinary treatment of patients with liver metastases of pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2015, 14, 530-538.	0.6	19
2751	MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using 64Cu-NOTA-panitumumab F(ab')2 fragments. Nuclear Medicine and Biology, 2015, 42, 71-77.	0.3	35
2752	Neoadjuvant therapy for Non-metastatic Pancreatic Ductal Adenocarcinoma. Seminars in Oncology, 2015, 42, 86-97.	0.8	20
2753	Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. Journal of Controlled Release, 2015, 201, 90-99.	4.8	120
2754	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Letters, 2015, 358, 59-66.	3.2	48

#	Article	IF	Citations
2755	nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Journal of the National Cancer Institute, 2015, 107, dju413-dju413.	3.0	487
2756	Pancreatic cancer: diagnosis and treatments. Tumor Biology, 2015, 36, 1375-1384.	0.8	39
2757	The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal. Cancer and Metastasis Reviews, 2015, 34, 97-114.	2.7	69
2758	Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: An analysis for the impact of radiation and gemcitabine doses. Radiotherapy and Oncology, 2015, 114, 122-127.	0.3	33
2759	Pancreatic cancer genomics: where can the science take us?. Clinical Genetics, 2015, 88, 213-219.	1.0	13
2760	First-in-man Phase 1 Clinical Trial of Gene Therapy for Advanced Pancreatic Cancer: Safety, Biodistribution, and Preliminary Clinical Findings. Molecular Therapy, 2015, 23, 779-789.	3.7	93
2761	Non-radical resection versus bypass procedure for pancreatic cancer â€“ A consecutive series and systematic review. European Journal of Surgical Oncology, 2015, 41, 220-227.	0.5	35
2762	FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort. Annals of Surgical Oncology, 2015, 22, 295-301.	0.7	145
2763	Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic Advances in Medical Oncology, 2015, 7, 68-84.	1.4	123
2764	Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection. Journal of Gastrointestinal Surgery, 2015, 19, 6-14.	0.9	51
2765	Current Adjuvant Therapeutic Approaches for Pancreatic Cancer. Advances in Therapy, 2015, 32, 42-56.	1.3	6
2766	Gene and cell therapy for pancreatic cancer. Expert Opinion on Biological Therapy, 2015, 15, 505-516.	1.4	18
2767	Advances in Chemotherapy for Pancreatic Cancer. Indian Journal of Surgical Oncology, 2015, 6, 47-56.	0.3	5
2768	Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene, 2015, 559, 31-37.	1.0	22
2769	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 2015, 21, 2325-2337.	3.2	170
2770	An â€˜all in oneâ€™ approach for simultaneous chemotherapeutic, photothermal and magnetic hyperthermia mediated by hybrid magnetic nanoparticles. RSC Advances, 2015, 5, 25066-25078.	1.7	13
2771	An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 148-158.	1.2	9
2773	PBI-05204, a supercritical CO2 extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Investigational New Drugs, 2015, 33, 271-279.	1.2	38

#	Article	IF	Citations
2774	Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Cancer Chemotherapy and Pharmacology, 2015, 75, 683-690.	1.1	19
2775	Effect of NF-Î²B inhibition on chemoresistance in biliaryâ€“pancreatic cancer. Surgery Today, 2015, 45, 1481-1488.	0.7	22
2776	Aptamers Selected by Cell-SELEX for Theranostics. , 2015, , .		10
2777	Phase I pilot study of Wilms tumor gene 1 peptideâ€pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Science, 2015, 106, 397-406.	1.7	65
2778	A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Annals of Oncology, 2015, 26, 1923-1929.	0.6	89
2780	Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. Cancer Research, 2015, 75, 3738-3746.	0.4	76
2781	Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology, 2015, 15, 525-530.	0.5	0
2782	Pancreatic cancer: current management and treatment strategies. Postgraduate Medical Journal, 2015, 91, 601-607.	0.9	22
2783	Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumorÂresponse induced by BCG-stimulated dendritic cells viaÂaÂFas-dependent pathway. Pancreatology, 2015, 15, 233-239.	0.5	10
2784	Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor. Biomaterials, 2015, 67, 1-10.	5.7	96
2785	Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?. Advances in Biological Regulation, 2015, 59, 19-35.	1.4	65
2786	Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Translational Oncology, 2015, 8, 196-203.	1.7	21
2787	Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. Therapeutic Advances in Medical Oncology, 2015, 7, 198-205.	1.4	28
2788	Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2015, 76, 489-498.	1.1	59
2789	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 761-776.	0.9	11
2791	A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2015, 46, 284-290.	0.6	14
2793	ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2â€²-Deoxyuridine to Pancreatic Cancer. Nucleic Acid Therapeutics, 2015, 25, 180-187.	2.0	26
2794	Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Letters, 2015, 363, 1-6.	3.2	21

#	Article	IF	Citations
2795	Minimizing Systemic Leakage of Cisplatin during Percutaneous Isolated Pancreas Perfusion Chemotherapy: A Pilot Study. Radiology, 2015, 276, 102-109.	3.6	2
2796	Cost-effectiveness of the evaluation of a suspicious biliary stricture. Journal of Surgical Research, 2015, 195, 52-60.	0.8	8
2797	Approach to Patients With Pancreatic Cancer Without Detectable Metastases. Journal of Clinical Oncology, 2015, 33, 1770-1778.	0.8	117
2799	Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta OncolÃ³gica, 2015, 54, 403-410.	0.8	30
2800	Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization. Biochemical and Biophysical Research Communications, 2015, 458, 341-346.	1.0	22
2801	Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opinion on Investigational Drugs, 2015, 24, 781-794.	1.9	4
2802	Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. British Journal of Cancer, 2015, 112, 1301-1305.	2.9	19
2803	Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 623-634.	1.4	21
2804	Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 1135-1141.	1.1	56
2805	The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Journal of Cancer Research and Clinical Oncology, 2015, 141, 933-939.	1.2	21
2806	A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1653-1660.	1.2	22
2807	Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study. Investigational New Drugs, 2015, 33, 109-118.	1.2	9
2808	Pancreatic Cancer in the USA: Persistence of Undertreatment and Poor Outcome. Journal of Gastrointestinal Cancer, 2015, 46, 9-20.	0.6	38
2809	Sustained Disease Control with TOMOXIRI Regimen in a Patient with Metastatic Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2015, 46, 327-331.	0.6	1
2810	Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study. Medical Oncology, 2015, 32, 121.	1.2	10
2811	Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Tumor Biology, 2015, 36, 2631-2640.	0.8	12
2812	Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. BMC Cancer, 2015, 15, 223.	1.1	16
2813	pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression. World Journal of Surgical Oncology, 2015, 13, 66.	0.8	42

#	Article	IF	Citations
2814	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. Journal of Translational Medicine, 2015, 13, 84.	1.8	211
2815	Pharmacoeconomic effect of compliance with pharmacistâ€™s intervention based on cancer chemotherapy regimens: a cohort study. Journal of Pharmaceutical Health Care and Sciences, 2015, 1, 10.	0.4	3
2816	Cell Cycle Checkpoint and DNA Damage Response Defects as Anticancer Targets: From Molecular Mechanisms to Therapeutic Opportunities. , 2015, , 29-49.		6
2817	Avarol Induces Apoptosis in Pancreatic Ductal Adenocarcinoma Cells by Activating PERKâ€“eIF2Î±â€“CHOP Signaling. Marine Drugs, 2015, 13, 2376-2389.	2.2	22
2818	Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 13-27.	3.3	60
2819	Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Cancer Chemotherapy and Pharmacology, 2015, 75, 457-464.	1.1	16
2820	The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. Surgery, 2015, 157, 881-887.	1.0	91
2821	Assessing the benefitâ€“risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer. British Journal of Cancer, 2015, 112, 971-976.	2.9	26
2822	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. Acta OncolÃ³gica, 2015, 54, 993-1000.	0.8	7
2823	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2015, 33, 278-284.	0.8	102
2824	Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Critical Reviews in Oncology/Hematology, 2015, 95, 318-336.	2.0	18
2827	Proapoptotic and Antiapoptotic Proteins of the Bcl-2 Family Regulate Sensitivity of Pancreatic Cancer Cells Toward Gemcitabine and T-Cellâ€“mediated Cytotoxicity. Journal of Immunotherapy, 2015, 38, 116-126.	1.2	24
2828	Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model. Pancreas, 2015, 44, 144-151.	0.5	25
2829	Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology, 2015, 15, 145-150.	0.5	75
2830	Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. Anti-Cancer Drugs, 2015, 26, 90-100.	0.7	29
2831	Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer. Cancer Research, 2015, 75, 2292-2304.	0.4	67
2832	Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma. Cancer, 2015, 121, 673-680.	2.0	41
2833	The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: Combined meta-analysis of efficacy and safety profile. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 254-260.	0.7	7

#	Article	IF	Citations
2834	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 1475-1481.	0.8	152
2835	Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133+ pancreatic cancer cells. Human Cell, 2015, 28, 167-174.	1.2	36
2836	Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure. Expert Review of Anticancer Therapy, 2015, 15, 1183-1198.	1.1	11
2837	Opportunities to improve clinical trial design in urothelial bladder cancer. Clinical Research and Regulatory Affairs, 2015, 32, 61-69.	2.1	0
2838	A bioengineered murine model using CD24 + CD44 + pancreatic cancer stem cells for chemotherapy study. Biomedical Materials (Bristol), 2015, 10, 015004.	1.7	2
2839	Modulation of ROS production in photodynamic therapy using a pH controlled photoinduced electron transfer (PET) based sensitiser. Chemical Communications, 2015, 51, 16832-16835.	2.2	22
2840	Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 477-496.	0.8	27
2841	Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer. Japanese Journal of Clinical Oncology, 2015, 45, hyv141.	0.6	9
2842	AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-ÎºB mediated uPAR activation. Molecular Cancer, 2015, 14, 146.	7.9	6
2843	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 4284-4292.	0.8	431
2844	Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes and Diseases, 2015, 2, 299-306.	1.5	106
2845	Gemcitabine-releasing mesenchymal stromal cells inhibit inÂvitro proliferation of human pancreatic carcinoma cells. Cytotherapy, 2015, 17, 1687-1695.	0.3	43
2846	Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery, 2015, 158, 881-889.	1.0	9
2847	Phase I study of combination of pasireotide LARÂ+Âgemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 481-487.	1.1	11
2848	A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2015, 76, 785-792.	1.1	13
2849	Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. Stem Cells, 2015, 33, 2893-2902.	1.4	31
2850	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepatic Oncology, 2015, 2, 39-50.	4.2	10
2851	Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v56-v68.	0.6	1,015

#	Article	IF	Citations
2852	A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. DMM Disease Models and Mechanisms, 2015, 8, 1201-1211.	1.2	14
2853	GEMMs as preclinical models for testing pancreatic cancer therapies. DMM Disease Models and Mechanisms, 2015, 8, 1185-1200.	1.2	92
2854	Functional significance of macrophages in pancreatic cancer biology. Tumor Biology, 2015, 36, 9119-9126.	0.8	15
2855	Efficient â€œgreenâ€•encapsulation of a highly hydrophilic anticancer drug in metalâ€“organic framework nanoparticles. Journal of Drug Targeting, 2015, 23, 759-767.	2.1	66
2856	Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 692-698.	1.4	4
2857	Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Investigational New Drugs, 2015, 33, 1197-1205.	1.2	9
2858	Combinatorial treatment of CD95L and gemcitabine in pancreatic cancer cells induces apoptotic and RIP1-mediated necroptotic cell death network. Experimental Cell Research, 2015, 339, 1-9.	1.2	18
2859	The Triple-Code Model for Pancreatic Cancer. Surgical Clinics of North America, 2015, 95, 935-952.	0.5	20
2860	InÂsitu allicin generation using targeted alliinase delivery for inhibition of MIA PaCa-2 cells via epigenetic changes, oxidative stress and cyclin-dependent kinase inhibitor (CDKI) expression. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 1388-1409.	2.2	37
2861	Natural plant flavonoid apigenin directly disrupts Hsp90/Cdc37 complex and inhibits pancreatic cancer cell growth and migration. Journal of Functional Foods, 2015, 18, 10-21.	1.6	28
2862	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. , 2015, 155, 80-104.		82
2863	The inhibitory effects of xanthohumol, a prenylated chalcone derived from hops, on cell growth and tumorigenesis in human pancreatic cancer. Biomedicine and Pharmacotherapy, 2015, 73, 40-47.	2.5	39
2864	Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. European Journal of Surgical Oncology, 2015, 41, 1508-1514.	0.5	100
2865	Inhibitory effect of (â˜)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infectious Agents and Cancer, 2015, 10, 22.	1.2	45
2866	Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway. Acta Pharmacologica Sinica, 2015, 36, 614-626.	2.8	22
2867	Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3Î²-Snail pathway. Cell Death and Disease, 2015, 6, e1795-e1795.	2.7	66
2868	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resistance Updates, 2015, 23, 20-54.	6.5	57
2869	Personalized medicine in pancreatic cancer: the revolution has begun. Personalized Medicine, 2015, 12, 515-523.	0.8	1

#	Article	IF	Citations
2870	90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. European Journal of Cancer, 2015, 51, 1857-1864.	1.3	26
2871	Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. Expert Review of Gastroenterology and Hepatology, 2015, 9, 585-601.	1.4	3
2872	Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer. British Journal of Surgery, 2015, 102, 182-193.	0.1	143
2873	Targeted Oncolytic Herpes Simplex Virus Type 1 Eradicates Experimental Pancreatic Tumors. Human Gene Therapy, 2015, 26, 104-113.	1.4	25
2874	A c(RGDfE) conjugated multi-functional nanomedicine delivery system for targeted pancreatic cancer therapy. Journal of Materials Chemistry B, 2015, 3, 1049-1058.	2.9	22
2875	Multiple Layerâ€byâ€Layer Lipidâ€Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models. Advanced Functional Materials, 2015, 25, 788-798.	7.8	96
2876	Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis. Experimental and Molecular Pathology, 2015, 98, 41-46.	0.9	26
2877	A Preclinical Evaluation of SKLB261, a Multikinase Inhibitor of EGFR/Src/VEGFR2, as a Therapeutic Agent against Pancreatic Cancer. Molecular Cancer Therapeutics, 2015, 14, 407-418.	1.9	27
2878	Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Letters, 2015, 356, 656-668.	3.2	32
2879	The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth. Cancer Letters, 2015, 356, 392-403.	3.2	4
2880	Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies. International Journal of Pharmaceutics, 2015, 482, 38-46.	2.6	26
2883	Selective efficacy of zoledronic acid on metastasis in a patientâ€derived orthotopic xenograph (PDOX) nudeâ€mouse model of human pancreatic cancer. Journal of Surgical Oncology, 2015, 111, 311-315.	0.8	69
2884	An imaging-based platform for high-content, quantitative evaluation of therapeutic response in 3D tumour models. Scientific Reports, 2014, 4, 3751.	1.6	117
2885	Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy. Materials Science and Engineering C, 2015, 47, 40-47.	3.8	58
2886	Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 89-100.	1.9	107
2887	MUC1 Promoterâ€“Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	1.5	18
2888	Review: The Role of Hyperthermia in Treating Pancreatic Tumors. Indian Journal of Surgical Oncology, 2015, 6, 75-81.	0.3	11
2889	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World Journal of Gastroenterology, 2016, 22, 10124.	1.4	27

#	Article	IF	Citations
2890	Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: utility and experience from the clinic. Gastrointestinal Cancer: Targets and Therapy, 2016, , 13.	5.5	2
2891	Gli2 protein expression level is a feasible marker of ligand-dependent hedgehog activation in pancreatic neoplasms. Polish Journal of Pathology, 2016, 2, 136-144.	0.1	4
2892	Tremelimumab: research and clinical development. OncoTargets and Therapy, 2016, 9, 1767.	1.0	51
2893	FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study. Journal of Cancer, 2016, 7, 1861-1866.	1.2	35
2894	Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Central-European Journal of Immunology, 2016, 4, 404-418.	0.4	3
2895	Synthesis of a deuterated probe for the confocal Raman microscopy imaging of squalenoyl nanomedicines. Beilstein Journal of Organic Chemistry, 2016, 12, 1127-1135.	1.3	8
2896	Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World Journal of Clinical Oncology, 2016, 7, 27.	0.9	71
2897	Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. International Journal of Nanomedicine, 2016, 11, 1225.	3.3	32
2898	Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Design, Development and Therapy, 2016, 10, 1961.	2.0	39
2899	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. Journal of Cancer, 2016, 7, 1497-1514.	1.2	71
2900	Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?. Wspolczesna Onkologia, 2016, 2, 102-108.	0.7	6
2901	Therapeutic Effects of Microbubbles Added to Combined High-Intensity Focused Ultrasound and Chemotherapy in a Pancreatic Cancer Xenograft Model. Korean Journal of Radiology, 2016, 17, 779.	1.5	23
2902	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. Current Oncology, 2016, 23, 605-614.	0.9	6
2903	The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget, 2016, 7, 48265-48279.	0.8	10
2904	Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 2441.	1.4	71
2905	Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Yonsei Medical Journal, 2016, 57, 1124.	0.9	23
2906	The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer. Oncotarget, 2016, 7, 14291-14299.	0.8	13
2907	MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer. Oncotarget, 2016, 7, 4760-4769.	0.8	56

#	Article	IF	Citations
2908	Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?. Journal of Gastrointestinal Oncology, 2016, 7, 727-737.	0.6	2
2909	Endoscopic ultrasound in pancreatic cancer: innovative applications beyond the basics. Journal of Gastrointestinal Oncology, 2016, 7, 1019-1029.	0.6	11
2910	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. Journal of Gastrointestinal Oncology, 2016, 7, 738-749.	0.6	14
2911	Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Przeglad Gastroenterologiczny, 2016, 3, 155-162.	0.3	9
2912	The Role of miRNAs in the Regulation of Pancreatic Cancer Stem Cells. Stem Cells International, 2016, 2016, 1-7.	1.2	23
2913	Interleukin-8 in gastrointestinal inflammation and malignancy: induction and clinical consequences. International Journal of Interferon, Cytokine and Mediator Research, 2016, , 13.	1.1	18
2914	Systemic Chemotherapy in Advanced Pancreatic Cancer. Gut and Liver, 2016, 10, 340-7.	1.4	57
2915	Pancreatic Cancer from Molecular Pathways to Treatment Opinion. Journal of Cancer, 2016, 7, 1328-1339.	1.2	30
2916	Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. Journal of Cancer, 2016, 7, 283-288.	1.2	52
2917	Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview. Current Chemical Biology, 2016, 10, 98-108.	0.2	6
2918	Role of the tumor microenvironment in pancreatic adenocarcinoma. Frontiers in Bioscience - Landmark, 2016, 21, 31-41.	3.0	6
2919	The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer. International Journal of Molecular Sciences, 2016, 17, 137.	1.8	16
2920	Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy. International Journal of Molecular Sciences, 2016, 17, 718.	1.8	20
2921	Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. BMC Cancer, 2016, 16, 305.	1.1	36
2922	Curcumin AntiCancer Studies in Pancreatic Cancer. Nutrients, 2016, 8, 433.	1.7	100
2924	The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. International Journal of Biological Sciences, 2016, 12, 273-282.	2.6	89
2925	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. World Journal of Gastroenterology, 2016, 22, 7175.	1.4	25
2926	Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 786.	0.8	12

#	Article	IF	Citations
2927	P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. Oncotarget, 2016, 7, 51301-51310.	0.8	52
2928	Molecular-targeted Therapies in Gastrointestinal Cancer. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1051-1060.	0.0	0
2929	Preliminary data of the antipancreatic tumor efficacy and toxicity of long-circulating and pH-sensitive liposomes containing cisplatin. Nuclear Medicine Communications, 2016, 37, 727-734.	0.5	11
2930	Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Pancreas, 2016, 45, 593-600.	0.5	18
2931	Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma. Pancreas, 2016, 45, 117-122.	0.5	24
2932	Survival analysis of veteran patients with pancreatic cancer. Journal of Digestive Diseases, 2016, 17, 399-407.	0.7	6
2933	Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 614-618.	0.6	14
2934	Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. American Journal of Physiology - Renal Physiology, 2016, 310, G1124-G1137.	1.6	46
2935	Firstâ€line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. International Journal of Cancer, 2016, 139, 938-945.	2.3	38
2936	Control of Apoptosis in Treatment and Biology of Pancreatic Cancer. Journal of Cellular Biochemistry, 2016, 117, 279-288.	1.2	37
2937	Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy. Pancreas, 2016, 45, 761-771.	0.5	28
2938	Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma. British Journal of Surgery, 2016, 103, 1200-1208.	0.1	21
2939	Advances in Molecular Pathology and Treatment of Periampullary Cancers. Pancreas, 2016, 45, 32-39.	0.5	18
2940	S-1 plus nab -paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Journal of Surgical Oncology, 2016, 113, 413-419.	0.8	14
2941	Role of long non-coding RNA in tumor drug resistance. Tumor Biology, 2016, 37, 11623-11631.	0.8	74
2942	Novel microspheres based on triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae) for the improvement of gemcitabine release. Journal of Pharmacy and Pharmacology, 2016, 68, 275-281.	1.2	6
2943	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. European Journal of Surgical Oncology, 2016, 42, 1533-1539.	0.5	104
2944	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 2004-2012.	1.4	5

#	Article	IF	Citations
2945	Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3â€“MYC Interactions as a Target in Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 6153-6163.	3.2	56
2946	Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer. Pancreas, 2016, 45, 211-217.	0.5	69
2947	Early decrement of serum carbohydrate antigen 19â€9 predicts favorable outcome in advanced pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 506-512.	1.4	15
2948	Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Digestion, 2016, 94, 222-229.	1.2	16
2949	Bibliometric analysis of the top-cited gastroenterology and hepatology articles. BMJ Open, 2016, 6, e009889.	0.8	42
2950	Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy?. Journal of Oncology Practice, 2016, 12, 797-805.	2.5	10
2951	Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care. Oncologist, 2016, 21, 771-777.	1.9	35
2952	SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Clinical and Translational Oncology, 2016, 18, 1172-1178.	1.2	27
2953	Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia, 2016, 18, 765-774.	2.3	16
2954	Relevance of randomised controlled trials in oncology. Lancet Oncology, The, 2016, 17, e560-e567.	5.1	74
2955	Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC Cancer, 2016, 16, 443.	1.1	23
2956	Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer, 2016, 16, 850.	1.1	22
2957	Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. Journal of Oncology Practice, 2016, 12, 17-23.	2.5	15
2958	Combined treatment with cotylenin A and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells. Oncology Reports, 2016, 36, 968-976.	1.2	73
2959	MGDG extracted from spinach enhances the cytotoxicity of radiation in pancreatic cancer cells. Radiation Oncology, 2016, 11, 153.	1.2	25
2960	NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer, 2016, 16, 709.	1.1	48
2961	Interventional Radiology for Pancreatic Cancer. , 2016, , 1-43.		0
2962	Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma. Medicina ClÃnica (English Edition), 2016, 147, 465.e1-465.e8.	0.1	1

#	Article	IF	Citations
2963	Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors. Oncology, 2016, 91, 251-260.	0.9	34
2964	Phase I trial of <scp>GBS</scp>â€01 for advanced pancreatic cancer refractory to gemcitabine. Cancer Science, 2016, 107, 1818-1824.	1.7	46
2965	Antitumor effects of herbal mixture extract in the pancreatic adenocarcinoma cell line PANC1. Oncology Reports, 2016, 36, 2875-2883.	1.2	12
2966	Chemotherapy for Advanced Pancreatic Cancer. , 2016, , 1-48.		0
2968	Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial. BMJ Open, 2016, 6, e013220.	0.8	11
2969	Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Review of Anticancer Therapy, 2016, 16, 485-492.	1.1	19
2970	Palliative chemotherapy: oxymoron or misunderstanding?. BMC Palliative Care, 2016, 15, 33.	0.8	31
2971	CSF-1Râ€“Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. Journal of Immunology, 2016, 197, 179-187.	0.4	48
2972	Nucleoside analogs: ready to enter the era of precision medicine?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 865-877.	1.5	9
2973	A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer. Pancreatology, 2016, 16, 640-645.	0.5	35
2974	Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics, 2016, 17, 549-560.	0.9	4
2975	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Medical Oncology, 2016, 33, 48.	1.2	20
2976	Nanotherapeutics promises for colorectal cancer and pancreatic ductal adenocarcinoma. , 2016, , 147-201.		3
2977	Synthesis and in vitro growth inhibitory activity of novel silyl- and trityl-modified nucleosides. Bioorganic and Medicinal Chemistry, 2016, 24, 2716-2724.	1.4	14
2978	Hedgehog Signaling in Pancreatic Fibrosis and Cancer. Medicine (United States), 2016, 95, e2996.	0.4	35
2979	The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. Oncogenesis, 2016, 5, e182-e182.	2.1	24
2980	Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Medical Oncology, 2016, 33, 37.	1.2	1
2981	Safety of palliative chemotherapy in advanced pancreatic cancer. Expert Opinion on Drug Safety, 2016, 15, 947-954.	1.0	8

#	Article	IF	Citations
2982	Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application. Cellular Oncology (Dordrecht), 2016, 39, 295-318.	2.1	76
2983	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	5.1	719
2984	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844.	3.8	801
2985	Transcriptome Analysis of Piperlongumine-Treated Human Pancreatic Cancer Cells Reveals Involvement of Oxidative Stress and Endoplasmic Reticulum Stress Pathways. Journal of Medicinal Food, 2016, 19, 578-585.	0.8	21
2986	Prospective analysis of association between statins and pancreatic cancer risk in the Womenâ€™s Health Initiative. Cancer Causes and Control, 2016, 27, 415-423.	0.8	16
2987	Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX. Oncology, 2016, 90, 261-266.	0.9	21
2988	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemotherapy and Pharmacology, 2016, 78, 1-12.	1.1	152
2989	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treatment Reviews, 2016, 50, 35-47.	3.4	128
2990	Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. British Journal of Cancer, 2016, 115, 789-796.	2.9	56
2991	TGF-Î²-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis, 2016, 37, 1041-1051.	1.3	67
2992	Interfering with the Dimerization of the ErbB Receptors by Transmembrane Domain-Derived Peptides Inhibits Tumorigenic Growth in Vitro and in Vivo. Biochemistry, 2016, 55, 5520-5530.	1.2	7
2993	Discovery of a novel chimeric ubenimexâ€“gemcitabine with potent oral antitumor activity. Bioorganic and Medicinal Chemistry, 2016, 24, 5787-5795.	1.4	14
2994	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. British Journal of Cancer, 2016, 115, 188-194.	2.9	76
2996	Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancerâ€“stromal interactions in a mouse xenograft model. Cancer Science, 2016, 107, 1443-1452.	1.7	21
2997	Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. Tumor Biology, 2016, 37, 15283-15291.	0.8	38
2998	Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies â€“ experience of a community based hospital. Zeitschrift Fur Gastroenterologie, 2016, 54, 1138-1142.	0.2	6
2999	Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer. Molecular Pharmaceutics, 2016, 13, 3665-3675.	2.3	37
3000	FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. British Journal of Cancer, 2016, 115, 649-654.	2.9	40

#	Article	IF	Citations
3001	Update on the Management of Pancreatic Cancer in Older Adults. Current Oncology Reports, 2016, 18, 60.	1.8	8
3002	Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer. Cancer Genetics, 2016, 209, 582-591.	0.2	4
3003	Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. British Journal of Cancer, 2016, 115, 442-453.	2.9	39
3004	MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt. Cellular Physiology and Biochemistry, 2016, 38, 2366-2374.	1.1	32
3005	Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Medicine, 2016, 5, 88-99.	1.3	45
3006	TM4SF1 Regulates Pancreatic Cancer Migration and Invasion In Vitro and In Vivo. Cellular Physiology and Biochemistry, 2016, 39, 740-750.	1.1	42
3007	Targeting pancreatic cancer using a combination of gemcitabine with the omegaâ€3 polyunsaturated fatty acid emulsion, Lipidemâ„¢. Molecular Nutrition and Food Research, 2016, 60, 1437-1447.	1.5	21
3008	Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factorâ€Î¹<scp>B</scp> activation. Journal of Pineal Research, 2016, 60, 27-38.	3.4	53
3009	Pancreatic Cancer. Gastroenterology Clinics of North America, 2016, 45, 429-445.	1.0	73
3010	New treatment strategy with nuclear factor-ÎºB inhibitor for pancreatic cancer. Journal of Surgical Research, 2016, 206, 1-8.	0.8	13
3011	Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer, 2016, 65, 11-20.	1.3	19
3012	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). British Journal of Cancer, 2016, 115, 281-289.	2.9	61
3013	GFRÎ±2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Cancer Letters, 2016, 380, 434-441.	3.2	51
3014	InÂvitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better. Biochimie, 2016, 130, 4-13.	1.3	6
3015	Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nature Reviews Clinical Oncology, 2016, 13, 750-765.	12.5	181
3016	Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An <i>in Vitro</i> Study. Biological and Pharmaceutical Bulletin, 2016, 39, 1238-1246.	0.6	25
3017	Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Pancreatology, 2016, 16, 1085-1091.	0.5	21
3018	Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology, 2016, 16, 1106-1112.	0.5	13

#	Article	IF	Citations
3019	Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. Molecular Medicine Reports, 2016, 14, 2921-2928.	1.1	17
3020	Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer, 2016, 122, 3765-3775.	2.0	18
3021	Pancreatic cancer chemoradiotherapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 617-628.	1.0	11
3022	PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. Journal of Clinical Oncology, 2016, 34, 3914-3920.	0.8	210
3023	Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion, 2016, 94, 44-49.	1.2	28
3024	Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2016, 23, 4352-4360.	0.7	122
3025	A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2016, 34, 733-739.	1.2	31
3026	Ablation Strategies for Locally Advanced Pancreatic Cancer. Digestive Surgery, 2016, 33, 351-359.	0.6	36
3027	Combination of Two Targeted Medications (Bevacizumab Plus Cetuximab) Improve the Therapeutic Response of Pancreatic Carcinoma. Medicine (United States), 2016, 95, e3259.	0.4	14
3028	A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release, 2016, 243, 172-181.	4.8	332
3029	Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer. Surgical Clinics of North America, 2016, 96, 1287-1300.	0.5	14
3030	Management of Metastatic Pancreatic Adenocarcinoma. Surgical Clinics of North America, 2016, 96, 1391-1414.	0.5	10
3031	Gemcitabine and Antisense-microRNA Co-encapsulated PLGAâ€“PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. ACS Applied Materials & Interfaces, 2016, 8, 33412-33422.	4.0	74
3032	Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer. BMC Cancer, 2016, 16, 579.	1.1	29
3033	Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer, 2016, 16, 817.	1.1	28
3034	Quantitative assessment of pancreatic cancer precursor lesions in IHC-stained tissue with a tissue image analysis platform. Laboratory Investigation, 2016, 96, 1327-1336.	1.7	9
3035	Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer. Progress in Molecular Biology and Translational Science, 2016, 144, 277-320.	0.9	9
3036	Pancreatic cancer. Nature Reviews Disease Primers, 2016, 2, 16022.	18.1	1,301

#	Article	IF	Citations
3037	Radiotherapy for Pancreatic Cancer. , 2016, , 215-232.		0
3038	Systemic Therapy in Pancreatic Cancer. , 2016, , 247-273.		1
3039	Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer. Molecular and Clinical Oncology, 2016, 5, 283-288.	0.4	7
3040	Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomarkers in Cancer, 2016, 8s1, BIC.S34414.	3.6	44
3041	Cost-Effectiveness Analysis of Treatments for Metastatic Pancreatic Cancer Based on Prodige and MPACT Trials. Tumori, 2016, 102, 294-300.	0.6	14
3042	Current Status of Immunotherapy Treatments for Pancreatic Cancer. Journal of Clinical Gastroenterology, 2016, 50, 836-848.	1.1	11
3043	Masitinib plus gemcitabine for personalized treatment of PDAC patients with overexpression of ACOX1. Expert Review of Precision Medicine and Drug Development, 2016, 1, 479-485.	0.4	0
3044	Evolution of novel therapeutic options for pancreatic cancer. Current Opinion in Gastroenterology, 2016, 32, 401-407.	1.0	14
3045	A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer, 2016, 122, 2158-2167.	2.0	277
3046	Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Oncology Reports, 2016, 35, 3216-3226.	1.2	13
3047	Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer. Clinical Therapeutics, 2016, 38, 1174-1183.	1.1	10
3048	The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Review of Anticancer Therapy, 2016, 16, 697-703.	1.1	106
3049	Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. European Radiology, 2016, 26, 1835-1842.	2.3	37
3050	Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials. JAMA Oncology, 2016, 2, 1209.	3.4	55
3051	Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2784-2796.	0.8	267
3052	Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study. BMC Palliative Care, 2016, 15, 25.	0.8	7
3053	Gemcitabine induces cell senescence in human pancreatic cancer cell lines. Biochemical and Biophysical Research Communications, 2016, 477, 515-519.	1.0	28
3054	Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells. Oncology Letters, 2016, 11, 3527-3533.	0.8	24

#	Article	IF	Citations
3055	Development of Pancreatic Cancer: Targets for Early Detection and Treatment. Digestive Diseases, 2016, 34, 525-531.	0.8	4
3056	A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control. Chemical Communications, 2016, 52, 9434-9437.	2.2	54
3057	Implantation of radioactive 125I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36, 205-210.	1.0	6
3058	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. Clinical and Translational Oncology, 2016, 18, 653-659.	1.2	8
3059	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2016, 29, 832-845.	7.7	645
3060	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2654-2668.	0.8	292
3061	Induction Chemotherapy. , 2016, , .		3
3062	Evofosfamide, a new horizon in the treatment of pancreatic cancer. Anti-Cancer Drugs, 2016, 27, 723-725.	0.7	17
3063	DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer, 2016, 16, 21.	1.1	16
3064	Basal metabolic state governs AIF-dependent growth support in pancreatic cancer cells. BMC Cancer, 2016, 16, 286.	1.1	11
3065	The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World Journal of Surgical Oncology, 2016, 14, 60.	0.8	18
3066	Clinical application of computed tomography-guided 125I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases. European Journal of Medical Research, 2016, 21, 18.	0.9	7
3067	Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells. Biomacromolecules, 2016, 17, 2507-2513.	2.6	110
3068	Rethinking end-points for bone-targeted therapy inÂadvanced cancer. European Journal of Cancer, 2016, 63, 105-109.	1.3	6
3069	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. Pancreas, 2016, 45, 286-292.	0.5	12
3070	Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 1101-1111.	1.1	25
3071	Pancreatic cancer: yesterday, today and tomorrow. Future Oncology, 2016, 12, 1929-1946.	1.1	286
3072	Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncology Letters, 2016, 12, 727-730.	0.8	8

#	Article	IF	Citations
3073	Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 1-7.	0.6	24
3074	Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas, 2016, 45, 425-433.	0.5	14
3075	Pancreatic Adenocarcinoma in the FinistÃ¨re Area, France, Between 2002 and 2011 (1002 Cases). Pancreas, 2016, 45, 953-960.	0.5	7
3076	Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?. Surgery Today, 2016, 46, 139-148.	0.7	13
3077	Neurological Complications of Systemic Cancer and Antineoplastic Therapy. , 0, , .		3
3078	Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer. Pancreatology, 2016, 16, 249-258.	0.5	17
3079	Ability of simple organotin polyethers to inhibit pancreatic cancer. Journal of Macromolecular Science - Pure and Applied Chemistry, 2016, 53, 63-71.	1.2	5
3080	Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer. Clinical Colorectal Cancer, 2016, 15, 264-276.	1.0	8
3081	Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. Immunotherapy, 2016, 8, 117-125.	1.0	22
3082	Pancreatic cancer. Lancet, The, 2016, 388, 73-85.	6.3	1,826
3083	Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 2848-2854.	3.2	272
3084	Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience. Medical Oncology, 2016, 33, 4.	1.2	1
3085	Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 35-41.	1.1	14
3086	Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International Journal of Oncology, 2016, 48, 908-918.	1.4	25
3087	Meta-analyses of treatment standards for pancreatic cancer. Molecular and Clinical Oncology, 2016, 4, 315-325.	0.4	31
3088	The value of surrogate endpoints for predicting real-world survival across five cancer types. Current Medical Research and Opinion, 2016, 32, 731-739.	0.9	6
3090	Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Cancer Chemotherapy and Pharmacology, 2016, 77, 181-193.	1.1	24
3091	EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. Biomacromolecules, 2016, 17, 301-313.	2.6	41

#	Article	IF	Citations
3092	Pancreatic cancer: Update on immunotherapies and algenpantucel-L. Human Vaccines and Immunotherapeutics, 2016, 12, 563-575.	1.4	30
3093	Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 340-345.	0.6	20
3094	Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 498-504.	0.4	106
3095	Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World Journal of Surgical Oncology, 2016, 14, 59.	0.8	31
3096	Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. Molecular Pharmaceutics, 2016, 13, 1822-1832.	2.3	21
3097	The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. International Journal of Biochemistry and Cell Biology, 2016, 75, 131-139.	1.2	15
3098	Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. Cancer Research, 2016, 76, 1792-1803.	0.4	114
3099	Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 595-603.	1.1	131
3100	MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. Acta Biochimica Et Biophysica Sinica, 2016, 48, 202-208.	0.9	29
3101	Relevance of Sp Binding Site Polymorphism inWWOXfor Treatment Outcome in Pancreatic Cancer. Journal of the National Cancer Institute, 2016, 108, djv387.	3.0	33
3102	Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunology Research, 2016, 4, 225-233.	1.6	21
3103	Pancreatic adenocarcinoma. Current Problems in Surgery, 2016, 53, 107-154.	0.6	6
3104	Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. Future Oncology, 2016, 12, 901-908.	1.1	14
3105	IFNÎ³ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Cancer Discovery, 2016, 6, 400-413.	7.7	193
3106	Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.. European Journal of Cancer, 2016, 54, 96-103.	1.3	26
3107	Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Nutrition and Cancer, 2016, 68, 234-240.	0.9	12
3108	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 2016, 22, 278-287.	15.2	184
3109	The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncology, 2016, 12, 669-685.	1.1	32

#	Article	IF	Citations
3110	MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Letters, 2016, 373, 130-137.	3.2	62
3111	Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. ACS Nano, 2016, 10, 2702-2715.	7.3	215
3112	Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Letters, 2016, 381, 201-210.	3.2	46
3113	Choline Kinase Alpha (CHKÎ±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 323-333.	1.9	25
3114	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	2.0	35
3115	Current standards and new innovative approaches for treatment of pancreatic cancer. European Journal of Cancer, 2016, 57, 10-22.	1.3	138
3116	Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clinical and Translational Oncology, 2016, 18, 988-995.	1.2	16
3117	Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. Critical Reviews in Oncology/Hematology, 2016, 99, 286-298.	2.0	44
3118	Palliative Management of Unresectable Pancreas Cancer. Surgical Oncology Clinics of North America, 2016, 25, 327-337.	0.6	12
3119	Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?. OncoImmunology, 2016, 5, e1112942.	2.1	19
3120	Immunotherapy of Cancer. , 2016, , .		3
3121	Personalized Peptide Vaccine. , 2016, , 143-158.		0
3122	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Molecular Cancer Therapeutics, 2016, 15, 680-688.	1.9	49
3123	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. Oncology Letters, 2016, 11, 1101-1104.	0.8	8
3124	A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cancer Chemotherapy and Pharmacology, 2016, 77, 693-701.	1.1	10
3125	Optimizing initial chemotherapy for metastatic pancreatic cancer. Future Oncology, 2016, 12, 1125-1133.	1.1	5
3126	The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis, 2016, 19, 229-244.	3.7	30
3127	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters, 2016, 381, 259-268.	3.2	30

#	Article	IF	Citations
3128	Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy. Human Gene Therapy, 2016, 27, 184-192.	1.4	7
3129	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2016, 99, 158-169.	2.0	10
3130	Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Targeted Oncology, 2016, 11, 371-381.	1.7	23
3131	Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 477-484.	1.1	13
3132	Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. International Journal of Clinical Oncology, 2016, 21, 531-538.	1.0	3
3133	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. European Journal of Cancer, 2016, 54, 75-83.	1.3	145
3134	Emerging Systemic and Targeted Therapies. , 2016, , 159-168.		1
3135	Role of Radiation Therapy. , 2016, , 107-124.		0
3136	Ovarian Cancer in Elderly Patients. , 2016, , .		1
3138	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet, The, 2016, 387, 545-557.	6.3	878
3139	Prognostic and predictive markers in pancreatic adenocarcinoma. Digestive and Liver Disease, 2016, 48, 223-230.	0.4	105
3140	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology, 2016, 16, 14-27.	0.5	81
3142	The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Tumor Biology, 2016, 37, 3957-3967.	0.8	54
3143	Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. Immunopharmacology and Immunotoxicology, 2016, 38, 50-60.	1.1	8
3144	Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. International Journal of Clinical Oncology, 2016, 21, 118-125.	1.0	28
3145	The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene, 2016, 35, 833-845.	2.6	112
3146	Intravenous Ï‰-3 Fatty Acids Plus Gemcitabine. Journal of Parenteral and Enteral Nutrition, 2017, 41, 398-403.	1.3	18
3147	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 552-554.	0.6	19

#	Article	IF	Citations
3148	Bevacizumab and cetuximab with conventional chemotherapy reduced pancreatic tumor weight in mouse pancreatic cancer xenografts. Clinical and Experimental Medicine, 2017, 17, 141-150.	1.9	11
3149	Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 42-46.	0.6	5
3150	Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 507-511.	0.6	61
3151	Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 517-522.	0.6	4
3152	Antibody Drug and Radionuclide Conjugates for GI Cancers. , 2017, , 79-99.		1
3153	Potent effects of dioscin against pancreatic cancer via miRâ€149â€3Pâ€mediated inhibition of the Akt1 signalling pathway. British Journal of Pharmacology, 2017, 174, 553-568.	2.7	65
3154	Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer Treatment Reviews, 2017, 54, 24-33.	3.4	76
3155	Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. British Journal of Cancer, 2017, 116, 424-431.	2.9	11
3156	Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System. Value in Health, 2017, 20, 586-592.	0.1	16
3157	Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: <scp>VENUS</scp>â€<scp>PC</scp> study. Cancer Science, 2017, 108, 73-80.	1.7	54
3158	Epigenetics of epithelialâ€toâ€mesenchymal transition in pancreatic carcinoma. International Journal of Cancer, 2017, 141, 24-32.	2.3	29
3159	A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review. American Journal of Gastroenterology, 2017, 112, 537-554.	0.2	123
3160	Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. British Journal of Cancer, 2017, 116, 464-471.	2.9	21
3161	Metastatic Pancreatic Cancer. , 2017, , 117-135.		0
3162	Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma. Laboratory Investigation, 2017, 97, 302-317.	1.7	30
3163	Chemotherapy Use at the End of Life in Uganda. Journal of Global Oncology, 2017, 3, 711-719.	0.5	6
3164	Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease, 2017, 49, 692-696.	0.4	23
3165	Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e26-e28.	0.7	9

#	Article	IF	Citations
3166	Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1053-1059.	1.2	24
3167	Emerging protein kinase inhibitors for treating pancreatic cancer. Expert Opinion on Emerging Drugs, 2017, 22, 77-86.	1.0	11
3168	Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 159-170.	1.4	26
3169	Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. Scandinavian Journal of Gastroenterology, 2017, 52, 595-600.	0.6	12
3170	Gemcitabineâ€“erlotinib versus gemcitabineâ€“erlotinibâ€“capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group. European Journal of Cancer, 2017, 75, 73-82.	1.3	15
3171	Tackling pancreatic cancer with metronomic chemotherapy. Cancer Letters, 2017, 394, 88-95.	3.2	8
3172	Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy. Cancer Chemotherapy and Pharmacology, 2017, 79, 595-602.	1.1	12
3173	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 337-346.	3.7	28
3174	Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 69-92.	3.3	65
3175	Multivalent Small-Molecule Pan-RAS Inhibitors. Cell, 2017, 168, 878-889.e29.	13.5	213
3176	Dietary approach to attenuate human pancreatic cancer growth and migration with innoxiousness. Journal of Functional Foods, 2017, 30, 303-312.	1.6	15
3177	Targeted therapy of pancreatic cancer: biomarkers are needed. Lancet Oncology, The, 2017, 18, 421-422.	5.1	11
3178	Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1597-1605.	1.1	67
3179	Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer. Medical Oncology, 2017, 34, 38.	1.2	54
3180	Comparative Study of Percutaneous Transhepatic Biliary Stent Placement with or without Iodine-125 Seeds for Treating Patients with Malignant Biliary Obstruction. Journal of Vascular and Interventional Radiology, 2017, 28, 583-593.	0.2	30
3181	Emerging antibodies for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2017, 22, 39-51.	1.0	9
3182	MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Scientific Reports, 2017, 7, 42339.	1.6	196
3183	The one-carbon metabolism pathway highlights therapeutic targets for gastrointestinal cancer (Review). International Journal of Oncology, 2017, 50, 1057-1063.	1.4	41

#	Article	IF	Citations
3184	Noninvasive characterization of pancreatic tumor mouse models using magnetic resonance imaging. Cancer Medicine, 2017, 6, 1082-1090.	1.3	17
3185	Evaluation of Suppressive Effects of Tranilast on the Invasion/Metastasis Mechanism in a Murine Pancreatic Cancer Cell Line. Pancreas, 2017, 46, 567-574.	0.5	2
3186	Multiscale simulations reveal IRMOF-74-III as a potent drug carrier for gemcitabine delivery. Journal of Materials Chemistry B, 2017, 5, 3277-3282.	2.9	49
3187	Melittin inhibits tumor growth and decreases resistance toÂgemcitabine by downregulating cholesterol pathway geneÂCLUÂinÂpancreatic ductal adenocarcinoma. Cancer Letters, 2017, 399, 1-9.	3.2	34
3188	Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer. Pancreas, 2017, 46, 335-340.	0.5	75
3189	Therapeutic effects of Argyrin F in pancreatic adenocarcinoma. Cancer Letters, 2017, 399, 20-28.	3.2	8
3190	Hippo pathway mediates resistance to cytotoxic drugs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3729-E3738.	3.3	57
3191	Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine. Nano Research, 2017, 10, 3049-3067.	5.8	47
3192	Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. Critical Reviews in Oncology/Hematology, 2017, 115, 1-12.	2.0	26
3193	Stromal <scp>SPOCK</scp>1 supports invasive pancreatic cancer growth. Molecular Oncology, 2017, 11, 1050-1064.	2.1	27
3194	Paclitaxel: What has been done and the challenges remain ahead. International Journal of Pharmaceutics, 2017, 526, 474-495.	2.6	286
3195	Chemoresistance in pancreatic cancer: Emerging concepts. Oncology Letters, 2017, 13, 2507-2513.	0.8	53
3196	What treatment in 2017 for inoperable pancreatic cancers?. Annals of Oncology, 2017, 28, 1473-1483.	0.6	30
3197	Pancreatology. , 2017, , .		0
3199	High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. Pancreatology, 2017, 17, 629-634.	0.5	16
3200	Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. British Journal of Cancer, 2017, 116, 1544-1550.	2.9	18
3201	Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma. World Journal of Surgery, 2017, 41, 2619-2624.	0.8	16
3202	MicroRNA-21 as a prognostic biomarker in patients with pancreatic cancer â€“ A systematic review and meta-analysis. American Journal of Surgery, 2017, 214, 515-524.	0.9	32

#	Article	IF	Citations
3203	CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. European Radiology, 2017, 27, 3104-3116.	2.3	123
3204	Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?. Annals of Surgical Oncology, 2017, 24, 1406-1413.	0.7	45
3205	Myeloid-derived suppressor cells and their role in pancreatic cancer. Cancer Gene Therapy, 2017, 24, 100-105.	2.2	71
3206	Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?. Future Oncology, 2017, 13, 951-953.	1.1	3
3207	Platelet Ã— CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Pancreas, 2017, 46, 35-41.	0.5	24
3208	The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2105-2111.	1.2	29
3209	The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surgical Oncology Clinics of North America, 2017, 26, 431-453.	0.6	34
3210	A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (United States), 2017, 96, e5702.	0.4	17
3211	Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach. Scientific Reports, 2017, 7, 3437.	1.6	16
3212	Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Scientific Reports, 2017, 7, 2993.	1.6	40
3213	PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Scientific Reports, 2017, 7, 1917.	1.6	31
3214	The FOXO3/PGC-1Î² signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. Journal of Biological Chemistry, 2017, 292, 10813-10823.	1.6	34
3215	Longâ€term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study. Journal of Hepato-Biliary-Pancreatic Sciences, 2017, 24, 426-433.	1.4	37
3216	Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer. Pancreas, 2017, 46, 143-150.	0.5	10
3217	Current and future therapies for advanced pancreatic cancer. Journal of Surgical Oncology, 2017, 116, 25-34.	0.8	123
3218	Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment. Oncology Letters, 2017, 13, 4959-4964.	0.8	15
3219	Has survival improved following resection for pancreatic adenocarcinoma?. American Journal of Surgery, 2017, 214, 341-346.	0.9	34
3220	The microbiome and hepatobiliary-pancreatic cancers. Cancer Letters, 2017, 402, 9-15.	3.2	105

#	Article	IF	Citations
3221	Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma. Biomaterials, 2017, 139, 30-38.	5.7	81
3222	Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology, 2017, 47, 832-839.	0.6	9
3223	Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease. Pancreas, 2017, 46, 813-819.	0.5	33
3224	Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncology Letters, 2017, 13, 4917-4924.	0.8	25
3225	Accelerating progress in the fight against pancreatic cancer Proceedings of the 2017 Leo and Anne Albert Symposium for Pancreatic Cancer Research. Journal of Surgical Oncology, 2017, 116, 5-6.	0.8	0
3226	Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2Â´, 2Â´-Difluorodeoxycytidine (DHA-dFdC). Pharmaceutical Research, 2017, 34, 1224-1232.	1.7	3
3228	Pancreatic Cancer: â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€• Clinical Cancer Research, 2017, 23, 1629-1637.	3.2	38
3229	Pancreatic cancer: moving forward, step by step. The Lancet Gastroenterology and Hepatology, 2017, 2, 315-316.	3.7	1
3230	Gene expression profiling of patientâ€derived pancreatic cancer xenografts predicts sensitivity to the <scp>BET</scp> bromodomain inhibitor <scp>JQ</scp> 1: implications for individualized medicine efforts. EMBO Molecular Medicine, 2017, 9, 482-497.	3.3	66
3231	Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1670-1678.	3.2	114
3232	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs and Aging, 2017, 34, 331-357.	1.3	7
3233	Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo. BMC Cancer, 2017, 17, 216.	1.1	11
3234	Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Targeted Oncology, 2017, 12, 309-321.	1.7	37
3235	The role of stromal cancer-associated fibroblasts in pancreatic cancer. Journal of Hematology and Oncology, 2017, 10, 76.	6.9	281
3236	Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-linenab-paclitaxel plus gemcitabine or FOLFIRINOX. Expert Review of Clinical Pharmacology, 2017, 10, 559-565.	1.3	19
3237	Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Cancer Letters, 2017, 388, 139-148.	3.2	54
3238	Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. Journal of Medical Economics, 2017, 20, 345-352.	1.0	25
3239	Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth. Molecular Therapy - Nucleic Acids, 2017, 6, 80-88.	2.3	65

#	Article	IF	Citations
3240	Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 2017, 28, 354-361.	0.6	50
3241	Significant impact of divalent metal ions on the fidelity, sugar selectivity, and drug incorporation efficiency of human PrimPol. DNA Repair, 2017, 49, 51-59.	1.3	16
3242	Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. Pancreatology, 2017, 17, 146-149.	0.5	30
3244	Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Review of Anticancer Therapy, 2017, 17, 175-186.	1.1	96
3245	A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes. Gastroenterology, 2017, 152, 840-850.e3.	0.6	133
3246	Trichodermin induces c-Jun N-terminal kinase-dependent apoptosis caused by mitotic arrest and DNA damage in human p53-mutated pancreatic cancer cells and xenografts. Cancer Letters, 2017, 388, 249-261.	3.2	17
3247	EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointestinal Endoscopy, 2017, 86, 161-169.	0.5	58
3248	Chemotherapeutics. , 2017, , 295-313.		17
3249	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clinical and Translational Oncology, 2017, 19, 667-681.	1.2	27
3250	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology, 2017, 12, 97-109.	1.7	56
3251	Moving Beyond Conventional Clinical Trial End Points in Treatment-refractory Metastatic Colorectal Cancer: A Composite Quality-of-life and Symptom Control End Point. Clinical Therapeutics, 2017, 39, 2135-2145.	1.1	12
3252	Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. Journal of Controlled Release, 2017, 266, 355-364.	4.8	36
3253	Efficacy and Safety of Pancreas-Targeted Hydrodynamic Gene Delivery in Rats. Molecular Therapy - Nucleic Acids, 2017, 9, 80-88.	2.3	11
3254	Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia. Current Opinion in Supportive and Palliative Care, 2017, 11, 278-286.	0.5	23
3255	Phase I study of a chloroquineâ€“gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1005-1012.	1.1	61
3256	Patient-reported outcomes in cancer care â€” hearing the patient voice at greater volume. Nature Reviews Clinical Oncology, 2017, 14, 763-772.	12.5	181
3257	Effect of arenobufagin on human pancreatic carcinoma cells. Oncology Letters, 2017, 14, 4971-4976.	0.8	8
3258	Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry. Scientific Reports, 2017, 7, 12891.	1.6	5

#	Article	IF	Citations
3259	Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 136-140.	0.3	5
3260	Speeding towards individualized treatment for pancreatic cancer by taking an alternative road. Cancer Letters, 2017, 410, 63-67.	3.2	31
3261	Current Standards of Chemotherapy for Pancreatic Cancer. Clinical Therapeutics, 2017, 39, 2125-2134.	1.1	80
3262	Pancreatic Cancer: Current Status and Challenges. Current Pharmacology Reports, 2017, 3, 396-408.	1.5	15
3263	Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Cancer Treatment Reviews, 2017, 60, 32-43.	3.4	116
3264	Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therapeutic Advances in Gastroenterology, 2017, 10, 631-645.	1.4	39
3265	Second line treatment options for pancreatic cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1607-1617.	0.9	11
3266	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2017, 17, 951-964.	1.1	2
3267	Commentary: Pancreatic cancer: is the worst to come?. International Journal of Epidemiology, 2017, 46, 1774-1775.	0.9	14
3268	Trends in Neoadjuvant Approaches in Pancreatic Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1070-1077.	2.3	22
3269	How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?. Journal of Geriatric Oncology, 2017, 8, 407-412.	0.5	10
3270	Gemcitabine, Pyrrologemcitabine, and 2â€²â€²Fluoroâ€²â€²Deoxycytidines: Synthesis, Physical Properties, and Impact of Sugar Fluorination on Silver Ion Mediated Base Pairing. Chemistry - A European Journal, 2017, 23, 17740-17754.	1.7	16
3271	Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. Protein and Cell, 2017, 8, 926-931.	4.8	22
3272	Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. Acta Biomaterialia, 2017, 62, 257-272.	4.1	56
3274	Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Pancreatology, 2017, 17, 967-973.	0.5	40
3275	Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment. Molecular Cancer Therapeutics, 2017, 16, 2399-2409.	1.9	27
3276	Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study. International Journal of Oncology, 2017, 51, 607-614.	1.4	11
3277	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1028-1061.	2.3	762

#	Article	IF	Citations
3278	Preparation and Evaluation of 177Lu-Labeled Gemcitabine: An Effort Toward Developing Radiolabeled Chemotherapeutics for Targeted Therapy Applications. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 239-246.	0.7	3
3279	Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine (United States), 2017, 96, e6769.	0.4	20
3280	Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1â€“MAPK Interaction. Cancer Research, 2017, 77, 4328-4341.	0.4	70
3281	Pancreatic cancer screening: Still a delusion?. Pancreatology, 2017, 17, 754-765.	0.5	20
3282	Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. Cancer Letters, 2017, 406, 22-26.	3.2	47
3283	Production of a Mouse Monoclonal Antibody Against Mortalin by Whole Cell Immunization. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2017, 36, 169-175.	0.8	2
3284	Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2017, 39, 235-242.	1.0	4
3285	Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. Oncology Letters, 2017, 14, 903-908.	0.8	19
3286	The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Scientific Reports, 2017, 7, 5825.	1.6	56
3287	S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer. Medicine (United States), 2017, 96, e7611.	0.4	4
3288	The costs of care in haematological cancers: Health economic issues. Hematological Oncology, 2017, 35, 15-19.	0.8	3
3289	Gemcitabine Enhances Kras-MEKâ€“Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells. Pancreas, 2017, 46, 268-275.	0.5	6
3290	Survival of patients with advanced pancreatic cancer after iodine125 seeds implantation brachytherapy. Medicine (United States), 2017, 96, e5719.	0.4	16
3291	A case of mixed adenoneuroendocrine carcinoma of the pancreas. Medicine (United States), 2017, 96, e6225.	0.4	17
3292	Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine. Pancreas, 2017, 46, 203-208.	0.5	24
3293	New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. Expert Opinion on Emerging Drugs, 2017, 22, 223-233.	1.0	25
3294	Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer. Pancreas, 2017, 46, 1011-1017.	0.5	23
3295	Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993â€“2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1022-1027.	2.3	42

#	Article	IF	Citations
3296	Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer. Therapeutic Advances in Gastroenterology, 2017, 10, 563-572.	1.4	24
3297	Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. Oncology Letters, 2017, 14, 1505-1511.	0.8	7
3298	Cholesterol derivative-based liposomes for gemcitabine delivery: preparation,in vitro, andin vivocharacterization. Drug Development and Industrial Pharmacy, 2017, 43, 2016-2025.	0.9	10
3299	89Zr-anti-Î³H2AX-TAT but not 18F-FDG Allows Early Monitoring of Response to Chemotherapy in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 6498-6504.	3.2	20
3300	Clinical Management. Cancer Journal (Sudbury, Mass), 2017, 23, 343-349.	1.0	14
3301	Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Experimental and Molecular Medicine, 2017, 49, e406-e406.	3.2	108
3302	High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Scientific Reports, 2017, 7, 17188.	1.6	94
3303	Berries and other natural products in pancreatic cancer chemoprevention in human clinical trials. Journal of Berry Research, 2017, 7, 147-161.	0.7	45
3304	Clinical Management. Cancer Journal (Sudbury, Mass), 2017, 23, 355-361.	1.0	0
3305	Synergistic effects of the combination of 5-Azaâ€'CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer. Oncology Reports, 2018, 39, 264-270.	1.2	9
3306	Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices. Oncology Research and Treatment, 2017, 40, 784-788.	0.8	2
3307	The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Current Treatment Options in Oncology, 2017, 18, 73.	1.3	5
3308	Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer. Cancer Medicine, 2017, 6, 2840-2849.	1.3	41
3309	Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts. Cancer Science, 2017, 108, 2470-2477.	1.7	24
3310	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anti-Cancer Drugs, 2017, 28, 127-132.	0.7	4
3311	The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scandinavian Journal of Gastroenterology, 2017, 52, 1165-1171.	0.6	63
3313	Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Pancreas, 2017, 46, 994-1002.	0.5	21
3314	SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. Medical Oncology, 2017, 34, 136.	1.2	7

#	Article	IF	Citations
3315	Microfluidic technologies for anticancer drug studies. Drug Discovery Today, 2017, 22, 1654-1670.	3.2	63
3316	Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Annals of Oncology, 2017, 28, 2429-2435.	0.6	89
3317	Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. Medicine (United States), 2017, 96, e6544.	0.4	18
3318	Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer. Medicine (United States), 2017, 96, e7005.	0.4	38
3319	Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. BMC Cancer, 2017, 17, 374.	1.1	1
3320	Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 36.	3.5	24
3321	Does â€œOPTINABâ€•strategy (â€œstop-and-goâ€) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxelâ€“gemcitabine?. Cancer Chemotherapy and Pharmacology, 2017, 80, 371-375.	1.1	11
3322	Babaodan Capsule (å…«å®ä¸¹èƒ¶å›Š) combined with Qingyi Huaji Formula (æ¸…èƒ°åŒ–ç§˜æ–¹) in advanced pancreatic cancerâ€”a feas study. Chinese Journal of Integrative Medicine, 2017, 23, 937-942.	0.7	13
3323	Whatâ€™s new in treatment of pancreatic cancer: a patent review (2010â€“2017). Expert Opinion on Therapeutic Patents, 2017, 27, 1251-1266.	2.4	13
3324	Naringenin causes ASK1-induced apoptosis via reactive oxygen species in human pancreatic cancer cells. Food and Chemical Toxicology, 2017, 99, 1-8.	1.8	80
3325	Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. Journal of Cellular and Molecular Medicine, 2017, 21, 648-657.	1.6	447
3326	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Journal of Gastrointestinal Surgery, 2017, 21, 164-174.	0.9	124
3327	CRISPR/Cas9 Technique for Identification of Genes Regulating Oxaliplatin Resistance of Pancreatic Cancer Cell Line. BioNanoScience, 2017, 7, 97-100.	1.5	5
3328	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2017, 9, 75-82.	1.4	46
3329	Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. Pharmacoeconomics, 2017, 35, 83-95.	1.7	11
3330	Factors Affecting Adjuvant Therapy in Stage III Pancreatic Cancerâ€”Analysis of the National Cancer Database. Clinical Medicine Insights: Oncology, 2017, 11, 117955491772804.	0.6	7
3331	Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. Cancer Growth and Metastasis, 2017, 10, 117906441770928.	3.5	24
3332	Endoscopic ultrasound celiac plexus block and neurolysis. Techniques in Gastrointestinal Endoscopy, 2017, 19, 196-201.	0.3	0

#	Article	IF	Citations
3333	The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis. Oncology Letters, 2017, 15, 1441-1448.	0.8	7
3335	Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer â€œin a Koreanâ€•population: A single-center cohort study. Seminars in Oncology, 2017, 44, 420-427.	0.8	16
3336	Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterology, 2017, 17, 143.	0.8	17
3337	Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient. Medicine (United States), 2017, 96, e8725.	0.4	7
3338	Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy. Gut and Liver, 2017, 11, 298-305.	1.4	10
3339	The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Frontiers in Physiology, 2017, 8, 381.	1.3	30
3340	Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells. Medical Science Monitor, 2017, 23, 1613-1620.	0.5	14
3341	The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2017, 18, 600.	1.8	29
3342	Chemotherapy and radiotherapy for pancreatic cancer. , 2017, , 1032-1041.e3.		0
3343	Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine. Molecules, 2017, 22, 1515.	1.7	4
3344	Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics, 2017, 9, 39.	2.0	36
3345	Selective cytotoxicity of vanadium complexes on human pancreatic ductal adenocarcinoma cell line by inducing necroptosis, apoptosis and mitotic catastrophe process. Oncotarget, 2017, 8, 60324-60341.	0.8	40
3346	Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment. Cancers, 2017, 9, 93.	1.7	22
3347	Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers, 2017, 9, 157.	1.7	316
3348	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 909.	1.8	21
3349	Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. International Journal of Molecular Sciences, 2017, 18, 1231.	1.8	31
3350	The Application of Heptamethine Cyanine Dye DZ-1 and Indocyanine Green for Imaging and Targeting in Xenograft Models of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2017, 18, 1332.	1.8	33
3351	Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. International Journal of Molecular Sciences, 2017, 18, 1338.	1.8	431

#	Article	IF	Citations
3352	Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. Frontiers in Oncology, 2017, 7, 149.	1.3	75
3353	Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. Oncology Reports, 2017, 37, 3377-3386.	1.2	22
3354	Curcumin Induces Autophagy, Apoptosis, and Cell Cycle Arrest in Human Pancreatic Cancer Cells. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-13.	0.5	63
3355	Adjuvant Chemoradiotherapy (Gemcitabine-based) in Pancreatic Adenocarcinoma: The Pisa University Experience. Tumori, 2017, 103, 577-582.	0.6	3
3356	A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer. Journal of Cancer, 2017, 8, 1872-1883.	1.2	42
3357	Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT–2 pancreatic cancer mouse model. Oncology Letters, 2018, 15, 3091-3099.	0.8	15
3358	Irreversible Electroporation of the Pancreas Using Parallel Plate Electrodes in a Porcine Model: A Feasibility Study. PLoS ONE, 2017, 12, e0169396.	1.1	4
3359	Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2017, 12, e0169736.	1.1	16
3360	Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World Journal of Surgical Oncology, 2017, 15, 183.	0.8	112
3361	â€œHEATPACâ€• a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. Radiation Oncology, 2017, 12, 183.	1.2	20
3362	In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2017, 36, 91.	3.5	19
3363	Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). Journal of Experimental and Clinical Cancer Research, 2017, 36, 107.	3.5	63
3364	Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma. Journal of Pancreatic Cancer, 2017, 3, 49-52.	1.6	3
3365	Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RAS^{G12D}. Biomedical Research, 2017, 38, 29-40.	0.3	7
3366	lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients. Oncotarget, 2017, 8, 95108-95115.	0.8	27
3367	The Improvement of Care in Patients with Pancreatic Cancer. , 2017, , .		0
3368	The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 206-213.	0.5	3
3369	OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling. Oncotarget, 2017, 8, 29233-29246.	0.8	7

#	Article	IF	Citations
3370	Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer. Oncotarget, 2017, 8, 63635-63645.	0.8	6
3371	Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway. Journal of Cancer, 2017, 8, 1530-1541.	1.2	9
3372	Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting. Cancer Management and Research, 2017, Volume 9, 141-148.	0.9	31
3373	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (NCT01259063). Bladder Cancer, 2017, 3, 113-119.	0.2	13
3374	Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients With Pancreatic Cancer. Journal of Oncology Practice, 2017, 13, 157-166.	2.5	21
3375	Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2017, 8, 566-571.	0.6	67
3376	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 2017, 8, 683-695.	0.6	12
3377	Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 945-952.	0.6	11
3378	MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1. Neoplasma, 2017, 64, 358-366.	0.7	20
3379	Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray. Oncotarget, 2017, 8, 33265-33275.	0.8	13
3380	Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study. Journal of Gastrointestinal Oncology, 2017, 8, 710-720.	0.6	20
3381	Dendritic cell-based cancer immunotherapy for pancreatic cancer. Arab Journal of Gastroenterology, 2018, 19, 1-6.	0.4	7
3382	Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine. Anti-Cancer Drugs, 2018, 29, 295-306.	0.7	3
3383	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. Current Problems in Cancer, 2018, 42, 8-11.	1.0	0
3384	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 435-446.	0.7	9
3385	Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas, 2018, 47, 631-636.	0.5	15
3387	FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 125-135.	1.3	4
3388	Synthesis and Characterization of Thermosensitive Molecularly Imprinted Poly[allylacetoacetate/Nâ€vinyl caprolactam] for Selective Extraction of Gemcitabine in Biological Samples. ChemistrySelect, 2018, 3, 2571-2577.	0.7	4

#	Article	IF	Citations
3389	A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer. Cancer Biology and Therapy, 2018, 19, 497-506.	1.5	6
3390	4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Oncology Letters, 2018, 15, 6297-6301.	0.8	12
3391	Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. Pharmacological Research, 2018, 132, 72-79.	3.1	104
3392	Management of hyperbilirubinaemia in pancreatic cancer patients. European Journal of Cancer, 2018, 94, 26-36.	1.3	7
3393	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investigational New Drugs, 2018, 36, 732-741.	1.2	87
3394	Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Development and Industrial Pharmacy, 2018, 44, 1434-1442.	0.9	14
3395	Chemotherapy in patients with unresected pancreatic cancer in Australia: A populationâ€based study of uptake and survival. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 326-336.	0.7	15
3396	Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience. Clinical Colorectal Cancer, 2018, 17, e451-e456.	1.0	12
3397	Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2018, 25, 261-268.	1.4	31
3398	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Oncologist, 2018, 23, 704-711.	1.9	15
3400	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 573-578.	1.1	9
3401	Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review. International Cancer Conference Journal, 2018, 7, 20-25.	0.2	1
3402	Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncology Reports, 2018, 39, 1081-1089.	1.2	20
3403	The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Current Problems in Cancer, 2018, 42, 26-39.	1.0	20
3404	A phase I trial of the Î³-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 793-801.	2.9	90
3405	The potential of radiolabeled chemotherapeutics in tumor diagnosis: Preliminary investigations with ‹sup›68‹/sup›Gaâ€gemcitabine. Drug Development Research, 2018, 79, 111-118.	1.4	1
3406	A look at the progress of treating pancreatic cancer over the past 20 years. Expert Review of Anticancer Therapy, 2018, 18, 295-304.	1.1	23
3409	NF-ÎºB in pancreatic cancer: Its key role in chemoresistance. Cancer Letters, 2018, 421, 127-134.	3.2	71

#	Article	IF	Citations
3410	Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study. Cancer Immunology Research, 2018, 6, 320-331.	1.6	48
3411	The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care. Gynecologic Oncology, 2018, 148, 12-18.	0.6	22
3412	Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers. Molecular Therapy - Nucleic Acids, 2018, 10, 227-236.	2.3	51
3413	Microwave ablation of pancreatic tumors. Minimally Invasive Therapy and Allied Technologies, 2018, 27, 33-40.	0.6	30
3414	Medical oncology and pancreatic cancer: what the radiologist needs to know. Abdominal Radiology, 2018, 43, 383-392.	1.0	2
3415	A novel experimental model for human mixed acinarâ€“ductal pancreatic cancer. Carcinogenesis, 2018, 39, 180-190.	1.3	3
3416	Drug development and clinical trial design in pancreatico-biliary malignancies. Current Problems in Cancer, 2018, 42, 73-94.	1.0	5
3417	Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Japanese Journal of Clinical Oncology, 2018, 48, 535-541.	0.6	10
3418	Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations. BMC Cancer, 2018, 18, 309.	1.1	36
3419	Targeting FBPase is an emerging novel approach for cancer therapy. Cancer Cell International, 2018, 18, 36.	1.8	32
3420	Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53â€˜mutated pancreatic cancer MiaPaCaâ€˜2 spheres. Oncology Reports, 2018, 39, 2749-2758.	1.2	1
3421	Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. European Journal of Radiology, 2018, 104, 49-57.	1.2	22
3422	Chemotherapy and radiotherapy for advanced pancreatic cancer. The Cochrane Library, 2018, 2018, CD011044.	1.5	80
3423	Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. The Cochrane Library, 2018, 2018, CD011746.	1.5	51
3424	Pain in pancreatic ductal adenocarcinoma: A multidisciplinary, International guideline for optimized management. Pancreatology, 2018, 18, 446-457.	0.5	46
3425	Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 333-348.	8.2	762
3426	Interventional Radiology for Pancreatic Cancer. , 2018, , 815-856.		0
3427	Chemotherapy for Advanced Pancreatic Cancer. , 2018, , 875-921.		0

#	Article	IF	Citations
3428	Adjuvant Chemotherapy in Pancreatic Cancer. , 2018, , 1039-1071.		0
3429	Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer. , 2018, , 1203-1217.		0
3430	<scp>dCK</scp> negatively regulates the <scp>NRF</scp>2/<scp>ARE</scp> axis and <scp>ROS</scp> production in pancreatic cancer. Cell Proliferation, 2018, 51, e12456.	2.4	22
3431	Targeted agents for patients with advanced/metastatic pancreatic cancer. Medicine (United States), 2018, 97, e0115.	0.4	1
3432	A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer. Cancer Letters, 2018, 426, 25-36.	3.2	6
3433	Sensitive analysis and pharmacokinetic study of a novel gemcitabine carbamate prodrug and its active metabolite gemcitabine in rats using LC-ESI-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 249-257.	1.2	5
3434	Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel using thermo-responsive polymeric micelles for pancreatic cancer. Journal of Materials Chemistry B, 2018, 6, 2230-2239.	2.9	29
3435	Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the â€˜Arbeitsgemeinschaft Internistische Onkologieâ€™. European Journal of Cancer, 2018, 94, 95-103.	1.3	32
3436	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
3437	Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer. Phytomedicine, 2018, 44, 56-64.	2.3	10
3438	Nano-chemotherapy using cationic liposome that strategically targets the cell membrane potential of pancreatic cancer cells with negative charge. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1161-1165.	1.0	11
3439	Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 236-241.	0.6	15
3440	A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naÃ¯ve Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 230-235.	0.6	8
3441	Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut, 2018, 67, 497-507.	6.1	151
3442	Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Metaâ€Analysis. Journal of Cellular Biochemistry, 2018, 119, 511-523.	1.2	31
3443	Management of unresectable, locally advanced pancreatic adenocarcinoma. Clinical and Translational Oncology, 2018, 20, 113-118.	1.2	3
3444	Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer. International Journal of Hyperthermia, 2018, 34, 284-291.	1.1	35
3445	Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network metaâ€analysis. Journal of Cellular Biochemistry, 2018, 119, 5082-5103.	1.2	7

#	Article	IF	Citations
3446	Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?. Chinese Journal of Integrative Medicine, 2018, 24, 178-184.	0.7	9
3447	Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Letters, 2018, 413, 82-93.	3.2	23
3448	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 2018, 67, 2142-2155.	6.1	100
3449	Formulation and Pharmacokinetics of HSA-core and PLGA-shell Nanoparticles for Delivering Gemcitabine. AAPS PharmSciTech, 2018, 19, 812-819.	1.5	6
3450	Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network metaâ€analysis. Journal of Cellular Physiology, 2018, 233, 3352-3374.	2.0	14
3451	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. International Journal of Hyperthermia, 2018, 34, 969-979.	1.1	41
3452	Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Advances in Biological Regulation, 2018, 68, 77-87.	1.4	132
3453	Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 81, 355-364.	1.1	33
3454	Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine. Cancer Chemotherapy and Pharmacology, 2018, 81, 277-289.	1.1	27
3455	Xanthohumol inhibits angiogenesis by suppressing nuclear factorâ€ÎºB activation in pancreatic cancer. Cancer Science, 2018, 109, 132-140.	1.7	89
3456	Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literatureâ€based metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 163-169.	0.7	15
3457	Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. Journal of Gastrointestinal Cancer, 2018, 49, 1-8.	0.6	11
3458	Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 288-294.	0.9	6
3459	Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study. Clinical Oncology, 2018, 30, e16-e21.	0.6	15
3460	Co-treatment with a C1B5 peptide of protein kinase CÎ³ and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation. Biochemical and Biophysical Research Communications, 2018, 495, 962-968.	1.0	5
3461	Locally advanced pancreatic cancer: An emerging entity. Current Problems in Cancer, 2018, 42, 12-25.	1.0	13
3462	Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Investigational New Drugs, 2018, 36, 96-102.	1.2	150
3463	Recent advances in the management of pancreatic adenocarcinoma. Expert Review of Anticancer Therapy, 2018, 18, 51-62.	1.1	17

#	Article	IF	Citations
3464	A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 772-776.	0.6	13
3465	Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 867-873.	0.6	2
3466	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. JCO Precision Oncology, 2018, 2, 1-9.	1.5	30
3467	Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. Journal of Gastrointestinal Oncology, 2018, 9, 17-23.	0.6	58
3468	Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Annals of Pancreatic Cancer, 2018, 1, 20-20.	1.2	5
3469	The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 135-139.	0.6	11
3470	Immunotherapy in pancreatic adenocarcinomaâ€"overcoming barriers to response. Journal of Gastrointestinal Oncology, 2018, 9, 143-159.	0.6	42
3471	Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects. Journal of Gastrointestinal Oncology, 2018, 9, 377-389.	0.6	2
3472	Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo. International Journal of Oncology, 2018, 52, 851-860.	1.4	1
3473	LITAF is a potential tumor suppressor in pancreatic cancer. Oncotarget, 2018, 9, 3131-3142.	0.8	8
3474	Monoclonal Antibody Production Against Vimentin by Whole Cell Immunization in a Mouse Model. Iranian Journal of Biotechnology, 2018, 16, 97-104.	0.3	1
3475	Gemcitabine plus S-1 for metastatic pancreatic cancer. Medicine (United States), 2018, 97, e12836.	0.4	1
3476	Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Gastroenterology Research and Practice, 2018, 2018, 1-15.	0.7	28
3477	Chemotherapy in combination with stereotactic body radiation therapy (SBRT) for oligometastatic pancreatic cancer. BMJ Case Reports, 2018, 2018, bcr-2018-225846.	0.2	2
3478	Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 421-430.	0.8	25
3480	Correlation Between the Acquisition of Resistance to Gemcitabine Therapy and the Expression of HuR in Pancreatic Ductal Adenocarcinoma: A Case Report. International Surgery, 2018, 103, 116-120.	0.0	0
3481	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. International Journal of Molecular Sciences, 2018, 19, 3505.	1.8	69
3482	The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Diseases (Basel, Switzerland), 2018, 6, 103.	1.0	7

#	Article	IF	Citations
3483	From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. International Journal of Molecular Sciences, 2018, 19, 3584.	1.8	10
3484	Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics, 2018, 8, 5986-5994.	4.6	91
3485	A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. BMC Cancer, 2018, 18, 986.	1.1	8
3486	Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer. Anticancer Research, 2018, 38, 6537-6542.	0.5	4
3487	CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells. Anticancer Research, 2018, 38, 6107-6111.	0.5	4
3488	Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget, 2018, 9, 19396-19405.	0.8	37
3489	Metaâ€'analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatmentâ€'associated toxicities. Molecular Medicine Reports, 2019, 19, 477-489.	1.1	5
3490	Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Scientific Reports, 2018, 8, 17914.	1.6	65
3492	A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model. OncoTargets and Therapy, 2018, Volume 11, 8655-8672.	1.0	12
3493	The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 953-960.	1.1	1
3494	Hot water extract of Agaricus blazei Murrill specifically inhibits growth and induces apoptosis in human pancreatic cancer cells. BMC Complementary and Alternative Medicine, 2018, 18, 319.	3.7	15
3495	Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death. Oncology Reports, 2018, 39, 1984-1990.	1.2	10
3496	The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Switzerland), 2018, 3, 85.	0.6	4
3497	Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance. Frontiers in Cell and Developmental Biology, 2018, 6, 131.	1.8	91
3498	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2018, , 177-221.	0.0	0
3499	The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nationâ€wide cancer registryâ€based study from Taiwan. Cancer Medicine, 2018, 7, 5775-5788.	1.3	27
3500	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. Journal of Surgical Oncology, 2018, 118, 1021-1026.	0.8	20
3502	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta OncolÃ³gica, 2018, 57, 1655-1662.	0.8	70

#	Article	IF	Citations
3503	Advanced pancreatic cancer: The standard of care and new opportunities. Oncology Reviews, 2018, 12, 370.	0.8	10
3504	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
3505	Role of angiogenesis in pancreatic cancer biology and therapy. Biomedicine and Pharmacotherapy, 2018, 108, 1135-1140.	2.5	46
3506	Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma. Oncology Research and Treatment, 2018, 41, 619-625.	0.8	11
3507	Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma. Oncology Research and Treatment, 2018, 41, 590-594.	0.8	9
3508	Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies. Expert Review of Anticancer Therapy, 2018, 18, 1205-1217.	1.1	14
3509	Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. BMC Cancer, 2018, 18, 1034.	1.1	7
3510	Conversion surgery with gemcitabine plus nabâ€‘paclitaxel for locally advanced unresectable pancreatic cancer: A case report. Molecular and Clinical Oncology, 2018, 9, 389-393.	0.4	1
3511	Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 6633-6646.	1.0	1
3512	Drug Discovery from Natural Products for Pancreatic Cancer. , 0, , .		1
3513	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. British Journal of Cancer, 2018, 119, 1208-1214.	2.9	195
3514	Currently available first-line drug therapies for treating pancreatic cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1927-1940.	0.9	5
3515	Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis. Cancers, 2018, 10, 403.	1.7	13
3516	The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2018, 19, 3219.	1.8	60
3517	A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer, 2018, 18, 596.	1.1	110
3518	Inhibition of PI3K/AKT Signaling Pathway Radiosensitizes Pancreatic Cancer Cells with ARID1A Deficiency in Vitro. Journal of Cancer, 2018, 9, 890-900.	1.2	29
3519	Pancreatic ductal adenocarcinoma cell secreted extracellular vesicles containing ceramide-1-phosphate promote pancreatic cancer stem cell motility. Biochemical Pharmacology, 2018, 156, 458-466.	2.0	22
3520	Circulating microRNA-99 family as liquid biopsy marker in pancreatic adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2377-2390.	1.2	22

#	Article	IF	Citations
3521	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	104
3522	The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2018, 50, 562-574.	1.3	16
3523	Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score). Radiotherapy and Oncology, 2018, 129, 313-318.	0.3	15
3524	Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?. OncoTargets and Therapy, 2018, Volume 11, 4591-4608.	1.0	6
3525	Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy, 2018, Volume 12, 475-480.	2.0	19
3526	Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC. Carcinogenesis, 2018, 39, 1548-1559.	1.3	19
3527	FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Annals of Surgical Oncology, 2018, 25, 1896-1903.	0.7	88
3528	Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-Î°B signal pathways. Chemico-Biological Interactions, 2018, 290, 44-51.	1.7	14
3529	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology, 2018, 20, 897-906.	0.6	41
3530	Molecular Diagnostics in the Neoplasms of the Pancreas, Liver, Gallbladder, and Extrahepatic Biliary Tract. Clinics in Laboratory Medicine, 2018, 38, 367-384.	0.7	4
3531	A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Medical Oncology, 2018, 35, 100.	1.2	13
3532	E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments. Scientific Reports, 2018, 8, 8330.	1.6	21
3533	Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 245-250.	1.1	31
3534	Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. Acta OncolÃ³gica, 2018, 57, 1185-1191.	0.8	15
3535	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. International Journal of Cancer, 2018, 143, 2053-2064.	2.3	76
3536	Prognostic value of glypicanâ€1 for patients with advanced pancreatic cancer following regional intraâ€arterial chemotherapy. Oncology Letters, 2018, 16, 1253-1258.	0.8	25
3537	An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Case Reports in Oncological Medicine, 2018, 2018, 1-5.	0.2	4
3538	LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. Journal of Pharmacological Sciences, 2018, 137, 116-121.	1.1	37

#	Article	IF	Citations
3539	Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-10.	1.9	76
3540	Towards an Optimal Treatment Algorithm for Metastatic Pancreatic Ductal Adenocarcinoma (PDA). Current Oncology, 2018, 25, 90-94.	0.9	11
3541	Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Annals of Gastroenterological Surgery, 2018, 2, 274-281.	1.2	119
3542	TMSOTf assisted synthesis of 2â€™-deoxy-2â€™-[18F]fluoro-Î²-D-arabinofuranosylcytosine ([18F]FAC). PLoS ONE, 2018, 13, e0196784.	1.1	3
3543	Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs - Real World Outcomes, 2018, 5, 149-159.	0.7	33
3544	Stereocomplex Prodrugs of Oligo(lactic acid)_n-Gemcitabine in Poly(ethylene) Tj ETQq1 1 0.784314 rgBT /Overloc Stability and Enhanced Antitumor Efficacy. ACS Nano, 2018, 12, 7406-7414.	7.3	32
3545	Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. Cell Cycle, 2018, 17, 2019-2026.	1.3	18
3546	A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-10.	0.8	11
3547	Floxuridine Homomeric Oligonucleotides â€œHitchhikeâ€•with Albumin Inâ€…Situ for Cancer Chemotherapy. Angewandte Chemie, 2018, 130, 9132-9135.	1.6	10
3548	Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology, 2018, 18, 647-654.	0.5	35
3549	Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence. Advanced Healthcare Materials, 2018, 7, e1800593.	3.9	35
3550	Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. International Journal of Oncology, 2018, 52, 1011-1022.	1.4	111
3551	A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma. Anticancer Research, 2018, 38, 4805-4812.	0.5	3
3552	Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer, 2018, 18, 762.	1.1	77
3553	Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Surgical Oncology, 2018, 27, 619-624.	0.8	2
3554	Erlotinib. Recent Results in Cancer Research, 2018, 211, 1-17.	1.8	17
3555	Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumors. Pathology Research and Practice, 2018, 214, 1370-1375.	1.0	5
3556	Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells. Frontiers in Pharmacology, 2018, 9, 84.	1.6	15

#	Article	IF	Citations
3557	Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer. Molecular Therapy - Nucleic Acids, 2018, 12, 543-553.	2.3	68
3558	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-20.	0.8	13
3559	Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. Journal of Hematology and Oncology, 2018, 11, 71.	6.9	30
3560	Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study. Radiotherapy and Oncology, 2018, 129, 326-332.	0.3	19
3561	Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC Cancer, 2018, 18, 555.	1.1	16
3562	Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. Cancer Management and Research, 2018, Volume 10, 1907-1918.	0.9	6
3563	Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. Frontiers in Immunology, 2018, 9, 1044.	2.2	107
3564	Stereotactic Body Radiation Therapy in the Management of Upper GI Malignancies. Biomedicines, 2018, 6, 7.	1.4	4
3565	Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers, 2018, 10, 14.	1.7	26
3566	Targeted Therapies for Pancreatic Cancer. Cancers, 2018, 10, 36.	1.7	69
3567	A Phase II Study of Pelareorep (REOLYSINÂ®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers, 2018, 10, 160.	1.7	93
3568	Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy. Anticancer Research, 2018, 38, 4353-4360.	0.5	6
3569	Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics, 2018, 36, 1333-1343.	1.7	12
3571	Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience. Medical Oncology, 2018, 35, 115.	1.2	9
3572	Advances in oncolytic adenovirus therapy for pancreatic cancer. Cancer Letters, 2018, 434, 56-69.	3.2	33
3573	Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 20-27.	1.3	6
3574	The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Molecular Cancer, 2018, 17, 95.	7.9	67
3575	Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers, 2018, 10, 174.	1.7	12

#	Article	IF	Citations
3576	Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemiaâ€"A retrospective analysis. European Journal of Cancer, 2018, 100, 85-93.	1.3	7
3577	Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Oncogene, 2018, 37, 6041-6053.	2.6	38
3579	microRNA based prognostic biomarkers in pancreatic Cancer. Biomarker Research, 2018, 6, 18.	2.8	38
3580	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/â^' nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). BMC Cancer, 2018, 18, 747.	1.1	24
3581	Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Theranostics, 2018, 8, 3366-3379.	4.6	19
3582	Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer, 2018, 18, 72.	1.1	26
3583	SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas, 2018, 47, 637-642.	0.5	3
3584	Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC). Apoptosis: an International Journal on Programmed Cell Death, 2018, 23, 343-355.	2.2	38
3586	The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. Current Cancer Drug Targets, 2018, 18, 430-441.	0.8	1
3588	Evidence-based Management of Cancer Pain. Seminars in Oncology Nursing, 2018, 34, 215-226.	0.7	10
3589	UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy. Theranostics, 2018, 8, 1923-1939.	4.6	129
3590	New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. International Journal of Molecular Sciences, 2018, 19, 2468.	1.8	27
3591	Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers, 2018, 10, 77.	1.7	30
3592	USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Cancer Letters, 2018, 436, 129-138.	3.2	45
3593	Differentiation Therapy Targeting the Î²-Catenin/CBP Interaction in Pancreatic Cancer. Cancers, 2018, 10, 95.	1.7	39
3594	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. Journal of Cancer, 2018, 9, 1978-1988.	1.2	27
3595	Irreversible Electroporation in pancreatic ductal adenocarcinoma: IsÂthere a role in conjunction with conventional treatment?. European Journal of Surgical Oncology, 2018, 44, 1486-1493.	0.5	11
3596	Pancreatic cancer stem cells: A state or an entity?. Seminars in Cancer Biology, 2018, 53, 223-231.	4.3	71

#	Article	IF	Citations
3597	Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells inÃ¯Â¿Â½vitro. Oncology Letters, 2018, 15, 8761-8769.	0.8	6
3598	An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. Journal of Geriatric Oncology, 2018, 9, 373-381.	0.5	9
3599	Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future. Internal Medicine Journal, 2018, 48, 637-644.	0.5	3
3600	Anemarrhena asphodeloides Bunge and its constituent timosaponinâ€<scp>AIII</scp> induce cell cycle arrest and apoptosis in pancreatic cancer cells. FEBS Open Bio, 2018, 8, 1155-1166.	1.0	25
3601	The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma and Preclinical Models to Study It. , 2018, , 735-748.		0
3602	Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. Anticancer Research, 2018, 38, 3527-3533.	0.5	20
3603	Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. Targeted Oncology, 2018, 13, 461-468.	1.7	24
3604	The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 8666.	1.6	55
3605	Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Cancer Letters, 2018, 432, 251-259.	3.2	59
3606	Floxuridine Homomeric Oligonucleotides â€œHitchhikeâ€•with Albumin Inâ€…Situ for Cancer Chemotherapy. Angewandte Chemie - International Edition, 2018, 57, 8994-8997.	7.2	58
3607	Intracellular pathway of halloysite nanotubes: potential application for antitumor drug delivery. Journal of Materials Science, 2019, 54, 693-704.	1.7	27
3608	Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. International Journal of Cancer, 2019, 144, 981-990.	2.3	40
3609	Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial. Investigational New Drugs, 2019, 37, 127-138.	1.2	0
3610	Management and supportive treatment of frail patients with metastatic pancreatic cancer. Journal of Geriatric Oncology, 2019, 10, 398-404.	0.5	9
3612	Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy. Cancer Medicine, 2019, 8, 5554-5563.	1.3	3
3613	New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1173.	1.0	27
3614	PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. Oncogene, 2019, 38, 6662-6677.	2.6	55
3616	Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelialâ€“Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine. Nutrients, 2019, 11, 1856.	1.7	53

#	Article	IF	Citations
3617	Acute Pancreatitis, Chronic Pancreatitis and Pancreatic Neoplasms. , 2019, , 103-117.		0
3618	Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2019, 37, 2643-2650.	0.8	126
3619	Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?. Cancers, 2019, 11, 1095.	1.7	20
3620	FFâ€10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model. Cancer Science, 2019, 110, 2933-2940.	1.7	4
3621	Ablative, Endovascular, and Biliary Interventions for Patients with Pancreatic Cancer. Seminars in Interventional Radiology, 2019, 36, 203-212.	0.3	3
3622	Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability. Cancers, 2019, 11, 966.	1.7	12
3623	Impact on healthâ€related quality of life deteriorationâ€free survival of a firstâ€line therapy combining nabâ€paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. Cancer Medicine, 2019, 8, 5079-5088.	1.3	11
3624	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers, 2019, 11, 981.	1.7	29
3625	Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling . OncoTargets and Therapy, 2019, Volume 12, 5751-5765.	1.0	29
3627	Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 541-552.	1.5	14
3628	The Hippo Signaling Pathway in Pancreatic Cancer. Anticancer Research, 2019, 39, 3317-3321.	0.5	69
3629	State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?. Anticancer Research, 2019, 39, 3405-3412.	0.5	21
3630	Molecular radionuclide imaging of pancreatic neoplasms. The Lancet Gastroenterology and Hepatology, 2019, 4, 559-570.	3.7	15
3631	Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology. Mayo Clinic Proceedings, 2019, 94, 2291-2301.	1.4	61
3632	Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Critical Reviews in Oncology/Hematology, 2019, 143, 139-147.	2.0	100
3633	An update on treatment options for pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987556.	1.4	144
3634	Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender. , 2019, , 13-23.		0
3635	Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Gastroenterology Research and Practice, 2019, 2019, 1-17.	0.7	8

#	Article	IF	Citations
3636	First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. Journal of Gastrointestinal Oncology, 2019, 10, 910-917.	0.6	15
3637	Novel discoveries targeting gemcitabineâ€based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. Cancer Medicine, 2019, 8, 6403-6413.	1.3	17
3638	Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Journal of Translational Medicine, 2019, 17, 30.	1.8	58
3639	Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). International Journal of Radiation Oncology Biology Physics, 2019, 105, 606-617.	0.4	21
3640	Evolving Treatment Paradigms for Pancreatic Cancer. Visceral Medicine, 2019, 35, 362-372.	0.5	6
3641	Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma. European Journal of Radiology, 2019, 121, 108734.	1.2	9
3642	Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Pharmaceutics, 2019, 11, 574.	2.0	58
3643	New therapeutic targets in pancreatic cancer. Cancer Treatment Reviews, 2019, 81, 101926.	3.4	74
3644	Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects. Scientific Reports, 2019, 9, 15471.	1.6	7
3645	Conversion Surgery for Advanced Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1945.	1.0	20
3646	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. Current Oncology, 2019, 26, 665-681.	0.9	2
3647	Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells. Molecules, 2019, 24, 3829.	1.7	4
3649	Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. In Vivo, 2019, 33, 271-276.	0.6	26
3650	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinomaâ€"A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology, 2019, 10, 1832.	2.2	73
3651	Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Biomaterials, 2019, 222, 119421.	5.7	55
3652	The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1369.	1.0	7
3653	Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. International Journal of Molecular Sciences, 2019, 20, 4307.	1.8	30
3654	Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. PLoS ONE, 2019, 14, e0222155.	1.1	24

#	Article	IF	Citations
3655	Outcomes in patientsâ€‰â‰¥â€‰80Âyears with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. Medical Oncology, 2019, 36, 85.	1.2	6
3656	Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registryâ€"based study from the Japan Pancreas Society. Surgery, 2019, 166, 997-1003.	1.0	40
3657	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987112.	1.4	27
3658	Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescence to apoptosis. EBioMedicine, 2019, 47, 114-127.	2.7	21
3659	Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors. ACS Nano, 2019, 13, 11008-11021.	7.3	209
3660	Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort. Cancers, 2019, 11, 1326.	1.7	21
3661	Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987465.	1.4	8
3662	The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status. Journal of Oncological Science, 2019, 5, 85-89.	0.1	0
3663	Chemoresistance in Pancreatic Cancer. International Journal of Molecular Sciences, 2019, 20, 4504.	1.8	338
3664	Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact. Journal of Clinical Medicine, 2019, 8, 1402.	1.0	14
3665	A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 T Pancreatic Cancer. Journal of Pancreatic Cancer, 2019, 5, 35-42.	1.6	10
3666	Perioperative Clinical Trials for Pancreatic Cancer in the National Clinical Trials Network. Annals of Surgical Oncology, 2019, 26, 4173-4174.	0.7	0
3667	Effect of Adenomatous Polyposis Coli Loss on Tumorigenic Potential in Pancreatic Ductal Adenocarcinoma. Cells, 2019, 8, 1084.	1.8	7
3668	Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. International Journal of Molecular Sciences, 2019, 20, 4543.	1.8	68
3669	Plasma IFN-Î³-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Pancreatology, 2019, 19, 340-345.	0.5	33
3670	Capecitabine for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 399-409.	0.9	26
3671	Therapeutic efficacy of a novel Î²III/Î²IV-tubulin inhibitor (VERU-111) in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 29.	3.5	25
3672	mTOR Inhibitors in Advanced Biliary Tract Cancers. International Journal of Molecular Sciences, 2019, 20, 500.	1.8	23

#	Article	IF	Citations
3673	S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 615-622.	1.4	13
3674	A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Molecular Therapy - Oncolytics, 2019, 12, 56-67.	2.0	36
3675	USP34 Regulated Human Pancreatic Cancer Cell Survival <i>via</i> AKT and PKC Pathways. Biological and Pharmaceutical Bulletin, 2019, 42, 573-579.	0.6	8
3676	A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). Oncologist, 2019, 24, 589-e160.	1.9	27
3677	Internal enhancement of DNA damage by a novel bispecific antibodyâ€drug conjugateâ€like therapeutics via blockage of mTOR and PDâ€L1 signal pathways in pancreatic cancer. Cancer Medicine, 2019, 8, 643-655.	1.3	8
3678	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. Cell Reports, 2019, 26, 1518-1532.e9.	2.9	70
3679	Cytosolic 5â€²-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. EBioMedicine, 2019, 40, 394-405.	2.7	24
3680	FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. Pancreatology, 2019, 19, 325-330.	0.5	3
3681	Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC. Cellular and Molecular Biology Letters, 2019, 24, 30.	2.7	4
3682	Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience . OncoTargets and Therapy, 2019, Volume 12, 3077-3085.	1.0	14
3683	Nucleoside Analogues as Antibacterial Agents. Frontiers in Microbiology, 2019, 10, 952.	1.5	107
3684	Mechanisms of gemcitabine oral absorption as determined by in situ intestinal perfusions in mice. Biochemical Pharmacology, 2019, 168, 57-64.	2.0	4
3685	Role of surgical resection in the era of <scp>FOLFIRINOX</scp> for advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 416-425.	1.4	33
3686	Diosgenin exhibits tumor suppressive function via down-regulation of EZH2 in pancreatic cancer cells. Cell Cycle, 2019, 18, 1745-1758.	1.3	22
3687	Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells. BMC Cancer, 2019, 19, 596.	1.1	83
3688	Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 2019, 28, 583-592.	1.9	17
3689	H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. Viruses, 2019, 11, 562.	1.5	40
3690	Safety of radiofrequency ablation in patients with locally advanced, unresectable pancreatic cancer: A phase II study. European Journal of Surgical Oncology, 2019, 45, 2166-2172.	0.5	17

#	Article	IF	Citations
3691	The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75Âyears with unresectable pancreatic cancer compared with younger patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 647-654.	1.1	18
3692	New Perspective in Pancreatic Cancer. , 2019, , 151-161.		0
3693	Pharmacogenetics of treatments for pancreatic cancer. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 437-447.	1.5	20
3694	Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT. Cancer Letters, 2019, 459, 15-29.	3.2	13
3695	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. Cancer Letters, 2019, 459, 41-49.	3.2	35
3696	Alcoholic/Non-Alcoholic Digestive Diseases. , 2019, , .		0
3697	Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Cells, 2019, 8, 563.	1.8	5
3698	Arginine Starvation and Docetaxel Induce c-Mycâ€“Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Clinical Cancer Research, 2019, 25, 5122-5134.	3.2	47
3699	Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031. Scientific Reports, 2019, 9, 7643.	1.6	12
3700	Management of ductal pancreatic cancer. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 135-138.	0.3	2
3701	HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. EBioMedicine, 2019, 44, 403-418.	2.7	20
3702	Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer, 2019, 19, 468.	1.1	31
3703	The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Cancer Communications, 2019, 39, 26.	3.7	26
3704	Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?. Journal of Controlled Release, 2019, 305, 89-100.	4.8	45
3705	Association of time interval between cancer diagnosis and initiation of palliative chemotherapy with overall survival in patients with unresectable pancreatic cancer. Cancer Medicine, 2019, 8, 3471-3478.	1.3	11
3706	First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience. Journal of Oncological Science, 2019, 5, 1-5.	0.1	3
3707	A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Journal of Pancreatic Cancer, 2019, 5, 12-21.	1.6	2
3708	Targeted delivery systems for treatment of pancreatic cancer. , 2019, , 411-436.		1

#	Article	IF	Citations
3709	Effect of Sâ€1 on survival outcomes in 838 patients with advanced pancreatic cancer: A 7â€year multicenter observational cohort study in Taiwan. Cancer Medicine, 2019, 8, 2085-2094.	1.3	9
3710	Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiotherapy and Oncology, 2019, 136, 37-43.	0.3	34
3711	Landmark Trials in Oncology. , 2019, , .		0
3712	Sequential Targeting TGFâ€Î²2 Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. Small, 2019, 15, e1900631.	5.2	61
3713	ABCC3 is a novel target for the treatment of pancreatic cancer. Advances in Biological Regulation, 2019, 73, 100634.	1.4	18
3714	Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. Journal of Personalized Medicine, 2019, 9, 20.	1.1	14
3715	Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental and Clinical Cancer Research, 2019, 38, 162.	3.5	116
3716	Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. European Surgery - Acta Chirurgica Austriaca, 2019, 51, 153-164.	0.3	5
3717	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS ONE, 2019, 14, e0215409.	1.1	7
3718	Silver-Nanoparticle-Mediated Therapies in the Treatment of Pancreatic Cancer. ACS Applied Nano Materials, 2019, 2, 1758-1772.	2.4	16
3719	A phase I study of gemcitabineâ€‰+â€‰dasatinib (gd) or gemcitabineâ€‰+â€‰dasatinibâ€‰+â€‰cetuximab (GDC) in refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2019, 83, 1025-1035.	1.1	6
3720	Porcine Models of Pancreatic Cancer. Frontiers in Oncology, 2019, 9, 144.	1.3	30
3721	Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells. Cancer Biology and Therapy, 2019, 20, 855-865.	1.5	19
3722	MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells. International Journal of Oncology, 2019, 54, 991-1000.	1.4	14
3723	Molecular Markers for Treatment Response and Toxicity of Gemcitabine. , 2019, , 175-195.		2
3724	Preclinical pharmacodynamic evaluation of a new Src/<scp>FOSL</scp>1 inhibitor, <scp>LY</scp>â€1816, in pancreatic ductal adenocarcinoma. Cancer Science, 2019, 110, 1408-1419.	1.7	11
3725	Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Translational Oncology, 2019, 12, 683-692.	1.7	13
3726	Pancreatic Cancer and Possible Therapeutic Options. , 2019, , 57-85.		0

#	Article	IF	Citations
3727	Chemotherapy response of pancreatic cancer by diffusion-weighted imaging (DWI) and intravoxel incoherent motion DWI (IVIM-DWI) in an orthotopic mouse model. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2019, 32, 501-509.	1.1	5
3728	Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives . OncoTargets and Therapy, 2019, Volume 12, 1455-1463.	1.0	18
3729	Chemotherapy for pancreatic cancer. Presse Medicale, 2019, 48, e159-e174.	0.8	171
3730	Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis. BMC Cancer, 2019, 19, 318.	1.1	17
3731	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell, 2019, 35, 573-587.e6.	7.7	75
3732	Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016 . Cancer Management and Research, 2019, Volume 11, 2119-2127.	0.9	9
3733	Super-enhancers: novel target for pancreatic ductal adenocarcinoma. Oncotarget, 2019, 10, 1554-1571.	0.8	21
3734	Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients. International Journal of Hyperthermia, 2019, 36, 393-401.	1.1	7
3735	The distinct role of CD73 in the progression of pancreatic cancer. Journal of Molecular Medicine, 2019, 97, 803-815.	1.7	51
3736	Therapeutic efficacy of antiâ€MMP9 antibody in combination with nabâ€paclitaxelâ€based chemotherapy in preâ€clinical models of pancreatic cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 3878-3887.	1.6	22
3737	Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surgery Today, 2019, 49, 894-906.	0.7	25
3738	Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Journal of Clinical Oncology, 2019, 37, 230-238.	0.8	66
3739	Collagen Signaling in Cancer. , 2019, , 89-108.		2
3740	Lifetime alcohol intake and pancreatic cancer incidence and survival: findings from the Melbourne Collaborative Cohort Study. Cancer Causes and Control, 2019, 30, 323-331.	0.8	7
3741	MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. Cell Death and Disease, 2019, 10, 153.	2.7	36
3742	Reflections on depletion of tumor stroma in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 267-272.	3.3	13
3743	The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. Pancreas, 2019, 48, 275-280.	0.5	13
3744	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Scientific Reports, 2019, 9, 1788.	1.6	57

#	Article	IF	Citations
3745	Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. Frontiers in Oncology, 2019, 9, 56.	1.3	36
3746	Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study . OncoTargets and Therapy, 2019, Volume 12, 1341-1350.	1.0	14
3747	Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas. European Journal of Radiology, 2019, 112, 22-27.	1.2	3
3748	Evolving trends in pancreatic cancer therapeutic development. Annals of Pancreatic Cancer, 2019, 2, 17-17.	1.2	1
3749	Asiatic Acid Induces Apoptosis and Autophagy and Reduces MiR-17 and MiR-21 Expression in Pancreatic Cancer Cell Lines. Natural Product Sciences, 2019, 25, 298.	0.2	0
3750	Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of ILâ€8 production in pancreatic cancer. Oncology Reports, 2019, 41, 3508-3516.	1.2	10
3751	Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 243-246.	0.6	4
3752	SYNTHESIS AND OPTIMIZATION OF GEMCITABINE-LOADED MIL-101NH2 (Fe) NANOCARRIERS: RESPONSE SURFACE METHODOLOGY APPROACH. Asian Journal of Pharmaceutical and Clinical Research, 0, , 223-229.	0.3	0
3753	Pancreatic cancer resistance to chemotherapy. , 2019, , 171-194.		1
3754	Genetic manipulations with chemotherapy in pancreatic cancer. , 2019, , 141-152.		0
3755	Epidermal growth factor receptor role in pancreatic cancer. , 2019, , 295-324.		3
3756	Development of microRNA-based therapy for pancreatic cancer. Journal of Pancreatology, 2019, 2, 147-151.	0.3	16
3757	Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND). Future Oncology, 2019, 15, 4009-4017.	1.1	8
3758	Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma. Annals of Pancreatic Cancer, 2019, 2, 21-21.	1.2	7
3759	A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer. Scientific Reports, 2019, 9, 15929.	1.6	4
3760	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. Expert Review of Clinical Pharmacology, 2019, 12, 1081-1090.	1.3	22
3761	DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy. PLoS ONE, 2019, 14, e0225095.	1.1	2
3762	Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel. Pancreas, 2019, 48, 920-926.	0.5	30

#	Article	IF	Citations
3763	Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling . Cancer Management and Research, 2019, Volume 11, 10609-10621.	0.9	8
3764	Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance. Cancers, 2019, 11, 1998.	1.7	17
3765	Effect of Chemotherapeutic Agents on the Expression of Retinoid Receptors and Markers of Cancer Stem Cells and Epithelial-Mesenchymal Transition. Biochemistry (Moscow), 2019, 84, 1424-1432.	0.7	2
3766	Palliative chemotherapy in pancreatic cancerâ€"treatment sequences. Translational Gastroenterology and Hepatology, 2019, 4, 56-56.	1.5	21
3767	Clinical Benefit in the Treatment of Patients with Early Breast Cancer. Breast, 2019, 48, S115-S118.	0.9	1
3768	Adjuvant and neoadjuvant therapy for pancreatic cancer. Journal of Pancreatology, 2019, 2, 100-106.	0.3	26
3769	Xenografts Derived From Patients' Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer Patients. Pancreas, 2019, 48, 1294-1302.	0.5	4
3770	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. Pancreas, 2019, 48, 1274-1284.	0.5	2
3772	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. Gut, 2019, 68, 159-171.	6.1	246
3773	Systemic Chemotherapy as First-line Treatment for Metastatic Pancreatic Adenocarcinoma: A Bayesian Analysis. Internal Medicine, 2019, , .	0.3	0
3774	Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?. Journal of Gastrointestinal Cancer, 2019, 50, 860-866.	0.6	2
3775	Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC). Expert Opinion on Investigational Drugs, 2019, 28, 161-177.	1.9	62
3776	Systemic treatment of pancreatic cancer revisited. Seminars in Oncology, 2019, 46, 28-38.	0.8	81
3777	Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opinion on Pharmacotherapy, 2019, 20, 535-546.	0.9	22
3778	Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer. Journal of Controlled Release, 2019, 294, 237-246.	4.8	38
3779	Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-Ð°B pathway. Biomedicine and Pharmacotherapy, 2019, 109, 563-572.	2.5	31
3780	Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Cancer Letters, 2019, 442, 82-90.	3.2	40
3781	Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 2019, 68, 742-758.	6.1	68

#	Article	IF	Citations
3782	Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art. Journal of Controlled Release, 2019, 293, 21-35.	4.8	42
3783	Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. Journal of Cancer Research and Clinical Oncology, 2019, 145, 445-455.	1.2	6
3784	TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). European Journal of Cancer, 2019, 106, 78-88.	1.3	21
3785	Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis. European Journal of Cancer, 2019, 106, 99-105.	1.3	30
3786	Combined administration of naringenin and hesperetin with optimal ratio maximizes the anti-cancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway. Phytomedicine, 2019, 58, 152762.	2.3	57
3787	Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. BMC Cancer, 2019, 19, 28.	1.1	44
3788	Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer, 2019, 19, 40.	1.1	53
3789	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology, 2019, 19, 97-104.	0.5	34
3790	Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study. Pancreatology, 2019, 19, 114-121.	0.5	84
3791	Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition. Pharmacological Research, 2019, 139, 50-61.	3.1	11
3792	Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Pancreatology, 2019, 19, 88-96.	0.5	9
3793	How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Annals of Surgical Oncology, 2019, 26, 109-117.	0.7	64
3794	Small molecule tyrosine kinase inhibitors and pancreatic cancerâ€"Trials and troubles. Seminars in Cancer Biology, 2019, 56, 149-167.	4.3	23
3795	Combination therapy for the treatment of pancreatic cancer through hyaluronic acidâ€decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study. Journal of Cellular Physiology, 2019, 234, 4959-4969.	2.0	52
3796	HIF1Î±-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers. Journal of Drug Targeting, 2019, 27, 797-805.	2.1	18
3797	Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Investigational New Drugs, 2019, 37, 473-481.	1.2	9
3798	Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. Journal of Geriatric Oncology, 2019, 10, 420-426.	0.5	4
3799	A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. Journal of Gastrointestinal Cancer, 2019, 50, 62-68.	0.6	51

#	Article	IF	Citations
3800	Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Investigational New Drugs, 2019, 37, 76-86.	1.2	1
3801	Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer. Investigational New Drugs, 2020, 38, 350-359.	1.2	5
3802	Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. Journal of the Formosan Medical Association, 2020, 119, 97-105.	0.8	3
3803	A Comparative Analysis of Survival and Funding Discrepancies in Cancers With High Mortality. Annals of Surgery, 2020, 271, 296-302.	2.1	6
3804	Clutter Reduction and Target Tracking in Through-the-Wall Radar. IEEE Transactions on Geoscience and Remote Sensing, 2020, 58, 486-499.	2.7	15
3805	Cetuximab in Pancreatic Cancer Therapy: A Systematic Review and Meta-Analysis. Oncology, 2020, 98, 53-60.	0.9	24
3806	Outcomes of enteral metallic stent in patients with pancreatic carcinoma and gastric outlet obstruction: A single center experience. Journal of the Formosan Medical Association, 2020, 119, 238-246.	0.8	7
3807	Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 603-611.	0.5	4
3808	The Potential to Source a Patientâ€™s Imaginative Powers in Treating Cancer: Illustrated in Three Cases. Complementary Medicine Research, 2020, 27, 55-60.	0.5	0
3809	Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device. Journal of Controlled Release, 2020, 317, 23-33.	4.8	38
3810	The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2020, 51, 868-876.	0.6	9
3811	Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma. ACS Applied Materials & Interfaces, 2020, 12, 3327-3340.	4.0	43
3812	External validation of the BesanÃ§on nomogram in Asian patients with advanced pancreatic cancer receiving second-line chemotherapy: A multi-institute experience in Taiwan. Pancreatology, 2020, 20, 116-124.	0.5	1
3813	Efficacy of Sâ€1 in secondâ€line chemotherapy after nabâ€paclitaxel plus gemcitabine for patients with advanced pancreatic cancer. Cancer Reports, 2020, 3, e1215.	0.6	11
3814	White paper on pancreatic ductal adenocarcinoma from society of abdominal radiologyâ€™s disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdominal Radiology, 2020, 45, 716-728.	1.0	40
3815	Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1. Journal of Cancer, 2020, 11, 479-487.	1.2	12
3816	High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics, 2020, 10, 1136-1150.	4.6	24
3817	Carcinoma of the Pancreas. , 2020, , 1342-1360.e7.		1

#	Article	IF	Citations
3818	A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology, 2020, 20, 254-264.	0.5	44
3819	Biodistribution and Pharmacokinetic Study of Gemcitabine Hydrochloride Loaded Biocompatible Iron-Based Metal Organic Framework. Journal of Inorganic and Organometallic Polymers and Materials, 2020, 30, 2827-2841.	1.9	21
3820	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology, 2020, 20, 101-109.	0.5	17
3821	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. British Journal of Cancer, 2020, 122, 333-339.	2.9	141
3822	Microbiota in pancreatic health and disease: the next frontier in microbiome research. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 53-64.	8.2	175
3823	Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology, 2020, 158, 1433-1449.e27.	0.6	23
3824	Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines. Bioorganic Chemistry, 2020, 94, 103472.	2.0	30
3825	Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery, 2020, 155, e195047.	2.2	37
3826	Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines. Investigational New Drugs, 2020, 38, 1207-1217.	1.2	4
3827	Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice. Cancers, 2020, 12, 63.	1.7	36
3828	Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 365-372.	2.0	18
3829	A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC). Hpb, 2020, 22, 649-659.	0.1	15
3830	Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer, 2020, 20, 950.	1.1	10
3831	Bioactive compounds, antioxidant capacity and antitumoral activity of ethanolic extracts from fruits and seeds of Eugenia involucrata DC. Food Research International, 2020, 137, 109615.	2.9	19
3832	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094797.	1.4	7
3833	FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Pancreatology, 2020, 20, 1519-1525.	0.5	6
3834	Saikosaponin D Inhibits Proliferation and Promotes Apoptosis Through Activation of MKK4â€“JNK Signaling Pathway in Pancreatic Cancer Cells . OncoTargets and Therapy, 2020, Volume 13, 9465-9479.	1.0	15
3835	Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism. Gut, 2021, 70, 1713-1723.	6.1	27

#	Article	IF	Citations
3836	Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer. Scientific Reports, 2020, 10, 17817.	1.6	10
3837	Precision Therapy of Pancreatic Cancer: From Bench to Bedside. Visceral Medicine, 2020, 36, 373-380.	0.5	3
3838	Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro. Life Sciences, 2020, 263, 118523.	2.0	31
3839	Circadian Genes as Therapeutic Targets in Pancreatic Cancer. Frontiers in Endocrinology, 2020, 11, 638.	1.5	16
3840	A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5092-5101.	3.2	28
3841	Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Frontiers in Oncology, 2020, 10, 1018.	1.3	6
3842	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Ca-A Cancer Journal for Clinicians, 2020, 70, 375-403.	157.7	237
3843	Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 3402.	1.7	23
3844	Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines, 2020, 8, 496.	1.4	10
3845	Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Scientific Reports, 2020, 10, 20662.	1.6	3
3846	Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097084.	1.4	3
3847	Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097491.	1.4	9
3848	New insights into benefits of combination treatment with yttrium-90 and gemcitabine in patients with intrahepatic cholangiocarcinoma. Journal of Gastrointestinal Oncology, 2020, 11, 833-835.	0.6	0
3849	Sodium cantharidinate, a novel anti-pancreatic cancer agent that activates functional p53. Science China Life Sciences, 2020, 64, 1295-1310.	2.3	12
3852	A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells. Scientific Reports, 2020, 10, 12192.	1.6	18
3853	Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093794.	1.4	12
3854	Protein arginine methylation promotes therapeutic resistance in human pancreatic cancer. Cytokine and Growth Factor Reviews, 2020, 55, 58-69.	3.2	4
3855	Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiotherapy and Oncology, 2020, 152, 63-69.	0.3	19

#	Article	IF	Citations
3856	Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta Biomaterialia, 2020, 106, 289-300.	4.1	29
3858	Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Cancers, 2020, 12, 1955.	1.7	26
3859	Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma. AAPS PharmSciTech, 2020, 21, 231.	1.5	6
3860	Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?. Cytokine and Growth Factor Reviews, 2020, 56, 141-148.	3.2	8
3861	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombinationâ€“deficient Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5462-5476.	3.2	20
3862	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Pancreatology, 2020, 20, 1682-1688.	0.5	13
3863	Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent. Pancreas, 2020, 49, 1264-1275.	0.5	5
3864	Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules, 2020, 10, 1474.	1.8	19
3865	Elaborating piperazinyl-furopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3KÎ±) inhibitors to combat pancreatic cancer. RSC Advances, 2020, 10, 32103-32112.	1.7	6
3866	Predictive implications of decreased <scp>CA19</scp>â€9 at 8â€‰weeks during nabâ€paclitaxel plus gemcitabine for the induction of secondâ€line chemotherapy for patients with advanced pancreatic cancer. Cancer Reports, 2020, 3, e1289.	0.6	9
3867	Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Genes, 2020, 11, 1098.	1.0	9
3868	A novel siRNAâ€“gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer. NAR Cancer, 2020, 2, zcaa016.	1.6	5
3869	Advances in Gold Nanoparticle-Based Combined Cancer Therapy. Nanomaterials, 2020, 10, 1671.	1.9	60
3870	Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Cellular Oncology (Dordrecht), 2020, 43, 1161-1174.	2.1	40
3871	Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patientâ€derived xenograft tumors. Molecular Carcinogenesis, 2020, 59, 1227-1240.	1.3	6
3872	Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. Internal Medicine Journal, 2020, , .	0.5	2
3873	Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress . OncoTargets and Therapy, 2020, Volume 13, 12705-12720.	1.0	16
3874	Synergistic Anticancer Effect of Gemcitabine Combined With Impressic Acid or Acankoreanogein in Panc-1 Cells by Inhibiting NF-Î°B and Stat 3 Activation. Natural Product Communications, 2020, 15, 1934578X2097423.	0.2	2

#	Article	IF	Citations
3875	The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma. Biomedicines, 2020, 8, 565.	1.4	15
3876	The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Annals of Pancreatic Cancer, 2020, 3, 3-3.	1.2	2
3877	Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma . Cancer Management and Research, 2020, Volume 12, 12657-12666.	0.9	4
3878	Differential Gemcitabine Sensitivity in Primary Human Pancreatic Cancer Cells and Paired Stellate Cells Is Driven by Heterogenous Drug Uptake and Processing. Cancers, 2020, 12, 3628.	1.7	16
3879	The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells. In Vivo, 2020, 34, 3195-3203.	0.6	9
3880	The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers. Cancers, 2020, 12, 3250.	1.7	22
3881	FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure. Pancreas, 2020, 49, 574-578.	0.5	11
3882	Duration of therapy for locally advanced pancreatic cancer: Does it matter?. Cancer Medicine, 2020, 9, 4572-4580.	1.3	10
3883	Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Molecular Cancer Therapeutics, 2020, 19, 1623-1635.	1.9	9
3884	SMAD4 and the TGFÎ² Pathway in Patients with Pancreatic Ductal Adenocarcinoma. International Journal of Molecular Sciences, 2020, 21, 3534.	1.8	58
3885	The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Scientific Reports, 2020, 10, 7420.	1.6	19
3886	Surgical resection of metastatic pancreatic cancer: is it worth it?â€”a 15-year experience at a single Chinese center. Journal of Gastrointestinal Oncology, 2020, 11, 319-328.	0.6	11
3887	Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance. Investigational New Drugs, 2020, 38, 1707-1716.	1.2	13
3888	Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. European Journal of Cancer Care, 2020, 29, e13268.	0.7	4
3889	Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers, 2020, 12, 1327.	1.7	40
3890	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092342.	1.4	14
3891	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical Oncology, 2020, 37, 61.	1.2	9
3892	Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. Molecular and Cellular Biochemistry, 2020, 472, 187-198.	1.4	10

#	Article	IF	Citations
3893	MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer. Disease Markers, 2020, 2020, 1-13.	0.6	22
3894	Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. Targeted Oncology, 2020, 15, 407-410.	1.7	17
3895	Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment. Journal of Cancer, 2020, 11, 4316-4323.	1.2	4
3896	Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, , e333-e343.	1.8	1
3897	PAWI-2: A novel inhibitor for eradication of cancer. Medicinal Chemistry Research, 2020, 29, 1147-1159.	1.1	1
3898	Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. Journal of Controlled Release, 2020, 324, 545-559.	4.8	19
3899	Biomimetic Gemcitabineâ€“Lipid Prodrug Nanoparticles for Pancreatic Cancer. ChemPlusChem, 2020, 85, 1283-1291.	1.3	12
3900	Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. BMC Cancer, 2020, 20, 541.	1.1	9
3901	DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Cancer Biology and Therapy, 2020, 21, 749-757.	1.5	2
3902	Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo . Cancer Management and Research, 2020, Volume 12, 4645-4665.	0.9	19
3903	Noninvasive Preclinical Evaluation of Targeted Nanoparticles for the Delivery of Curcumin in Treating Pancreatic Cancer. ACS Applied Bio Materials, 2020, 3, 4643-4654.	2.3	25
3904	Recapitulating Pancreatic Tumor Microenvironment through Synergistic Use of Patient Organoids and Organâ€onâ€aâ€Chip Vasculature. Advanced Functional Materials, 2020, 30, 2000545.	7.8	62
3905	PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin Î²3-KRAS-dependent pancreatic cancer stem cells. Scientific Reports, 2020, 10, 9162.	1.6	10
3906	A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-ÎºB activation. Cancer Chemotherapy and Pharmacology, 2020, 85, 699-709.	1.1	9
3907	Neoadjuvant Treatment in Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 245.	1.3	145
3908	hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Letters, 2020, 479, 112-122.	3.2	33
3909	Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer. Cancer Immunology Research, 2020, 8, 609-617.	1.6	12
3910	Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JCO Oncology Practice, 2020, 16, e678-e687.	1.4	31

#	Article	IF	Citations
3911	Controlled drug release from polyelectrolyteâ€“drug conjugate nanoparticles. Journal of Materials Chemistry B, 2020, 8, 2887-2894.	2.9	13
3912	Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Cancers, 2020, 12, 618.	1.7	16
3913	Downregulation of miR-486-5p Enhances the Anti-Tumor Effect of 5-Fluorouracil on Pancreatic Cancer Cells . OncoTargets and Therapy, 2020, Volume 13, 1649-1659.	1.0	10
3914	Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Molecular Cancer, 2020, 19, 50.	7.9	192
3915	Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation. International Journal of Molecular Sciences, 2020, 21, 1605.	1.8	11
3916	Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. Journal of Clinical Medicine, 2020, 9, 648.	1.0	24
3917	Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periampullary and pancreatic adenocarcinoma. International Journal of Cancer, 2020, 146, 3461-3473.	2.3	39
3918	Developing effective combination therapy for pancreatic cancer: An overview. Pharmacological Research, 2020, 155, 104740.	3.1	46
3919	Cytotoxicity of juglone and thymoquinone against pancreatic cancer cells. Chemico-Biological Interactions, 2020, 327, 109142.	1.7	29
3920	(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. Bioorganic Chemistry, 2020, 101, 104022.	2.0	2
3921	Research Progress on Slit/Robo Pathway in Pancreatic Cancer: Emerging and Promising. Journal of Oncology, 2020, 2020, 1-7.	0.6	11
3922	Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR) Tj ETQq1 1 0.784314 rgBT /	2.1	34
3923	Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). Cancers, 2020, 12, 1681.	1.7	20
3924	Selective Induction of Cellular Toxicity and Anti-tumor Efficacy by N-Methylpiperazinyl Diarylidenylpiperidone and its Pro-nitroxide Conjugate through ROS-mediated Mitochondrial Dysfunction and G2/M Cell-cycle Arrest in Human Pancreatic Cancer. Cell Biochemistry and Biophysics, 2020, 78, 191-202.	0.9	4
3925	Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature. Anticancer Research, 2020, 40, 3995-4000.	0.5	9
3926	Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Annals of Palliative Medicine, 2020, 9, 1631-1642.	0.5	10
3927	MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2. Technology in Cancer Research and Treatment, 2020, 19, 153303382092814.	0.8	4
3928	Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data. BMC Public Health, 2020, 20, 1002.	1.2	1

#	Article	IF	Citations
3929	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de CancÃ©rologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). European Journal of Cancer, 2020, 136, 25-34.	1.3	6
3930	Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 6.	1.3	14
3931	Impact of ethanolic extract of Equisetum arvense (EA1) on pancreatic carcinoma AsPC-1 cells. Saudi Journal of Biological Sciences, 2020, 27, 1260-1264.	1.8	8
3932	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. Expert Opinion on Drug Safety, 2020, 19, 187-204.	1.0	5
3933	Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib â€“ results from a non-interventional multi-center study. BMC Cancer, 2020, 20, 155.	1.1	3
3934	Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro . International Journal of Nanomedicine, 2020, Volume 15, 991-1003.	3.3	18
3935	A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Pancreas, 2020, 49, 187-192.	0.5	22
3936	Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems. Scientific Reports, 2020, 10, 337.	1.6	46
3937	Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta OncolÃ³gica, 2020, 59, 705-712.	0.8	9
3938	Pharmacometabolomics Identifies 3-Hydroxyadipic Acid, d-Galactose, Lysophosphatidylcholine (P-16:0), and Tetradecenoyl-l-Carnitine as Potential Predictive Indicators of Gemcitabine Efficacy in Pancreatic Cancer Patients. Frontiers in Oncology, 2020, 9, 1524.	1.3	11
3939	Inhibition of TGF-Î² signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. Scientific Reports, 2020, 10, 2935.	1.6	18
3940	An empirical investigation of timeâ€varying costâ€effectiveness across the product life cycle. Health Economics (United Kingdom), 2020, 29, 580-590.	0.8	3
3941	A [60]fullerene nanoconjugate with gemcitabine: synthesis, biophysical properties and biological evaluation for treating pancreatic cancer. Cancer Nanotechnology, 2020, 11, .	1.9	14
3942	Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Japanese Journal of Clinical Oncology, 2020, 50, 483-489.	0.6	44
3943	Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. European Journal of Cancer, 2020, 129, 50-59.	1.3	17
3944	Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma. Frontiers in Oncology, 2020, 9, 1443.	1.3	16
3945	Photodynamic Therapy for ras-Driven Cancers: Targeting G-Quadruplex RNA Structures with Bifunctional Alkyl-Modified Porphyrins. Journal of Medicinal Chemistry, 2020, 63, 1245-1260.	2.9	34
3946	Small molecule inhibitors in pancreatic cancer. RSC Medicinal Chemistry, 2020, 11, 164-183.	1.7	21

#	Article	IF	Citations
3947	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. Journal of Clinical Oncology, 2020, 38, 1378-1388.	0.8	265
3948	Anticancer activities of fatty acids and their heterocyclic derivatives. European Journal of Pharmacology, 2020, 871, 172937.	1.7	85
3949	Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. Journal of Geriatric Oncology, 2020, 11, 640-646.	0.5	5
3950	GSK-3: An important kinase in colon and pancreatic cancers. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118626.	1.9	16
3951	Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin Î±3 in human pancreatic cancer. Scientific Reports, 2020, 10, 537.	1.6	4
3952	PTBP3 promotes malignancy and hypoxiaâ€induced chemoresistance in pancreatic cancer cells by ATG12 upâ€regulation. Journal of Cellular and Molecular Medicine, 2020, 24, 2917-2930.	1.6	32
3953	Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression. Cancers, 2020, 12, 277.	1.7	3
3954	The dual roles of calycosin in growth inhibition and metastatic progression during pancreatic cancer development: A â€œTGF-Î² paradoxâ€• Phytomedicine, 2020, 68, 153177.	2.3	21
3955	Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy. Journal of Materials Chemistry B, 2020, 8, 2410-2417.	2.9	6
3956	Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, 2020, 12, 1047.	1.7	95
3957	Immunotherapy for pancreatic cancer: A 2020 update. Cancer Treatment Reviews, 2020, 86, 102016.	3.4	276
3958	Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice. Frontiers in Pharmacology, 2020, 11, 457.	1.6	19
3959	Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?. Biology, 2020, 9, 80.	1.3	45
3960	Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1625-1645.	1.2	14
3961	Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Molecular Therapy - Oncolytics, 2020, 17, 107-117.	2.0	25
3962	Role of Conversion Surgery for Unresectable Pancreatic Cancer After Longâ€Term Chemotherapy. World Journal of Surgery, 2020, 44, 2752-2760.	0.8	9
3963	Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clinical and Translational Oncology, 2020, 22, 1963-1975.	1.2	26
3964	Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews, 2020, 100, 1707-1751.	13.1	156

#	Article	IF	Citations
3966	A novel 20-gene prognostic score in pancreatic adenocarcinoma. PLoS ONE, 2020, 15, e0231835.	1.1	9
3967	A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 3641-3648.	3.2	41
3968	Recent advances and prospects in gemcitabine drug delivery systems. International Journal of Pharmaceutics, 2021, 592, 120043.	2.6	52
3969	Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer. Annals of Pharmacotherapy, 2021, 55, 738-744.	0.9	1
3970	Organoid model: A new hope for pancreatic cancer treatment?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188466.	3.3	35
3971	Phase <scp>II</scp> study evaluating the association of gemcitabine, trastuzumab and erlotinib as firstâ€line treatment in patients with metastatic pancreatic adenocarcinoma (<scp>GATE</scp> 1). International Journal of Cancer, 2021, 148, 682-691.	2.3	23
3972	Factors associated with the initiation of chemotherapy within 90 days of death in metastatic colorectal cancer patients: a population-based study. Supportive Care in Cancer, 2021, 29, 1535-1542.	1.0	2
3973	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease, 2021, 53, 117-121.	0.4	1
3974	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Trends in Cancer, 2021, 7, 15-28.	3.8	61
3975	Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 554-565.	3.2	8
3976	Quality of life and outcome of patients with metastatic pancreatic cancer receiving firstâ€line chemotherapy with nabâ€paclitaxel and gemcitabine: Realâ€life results from the prospective <scp>QOLIXANE</scp> trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. International Journal of Cancer, 2021, 148, 1478-1488.	2.3	13
3977	A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Annals of Oncology, 2021, 32, 250-260.	0.6	45
3978	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1529-1536.	1.2	4
3979	Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer. Translational Oncology, 2021, 14, 100965.	1.7	11
3980	A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Radiotherapy and Oncology, 2021, 155, 232-236.	0.3	30
3981	Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells. Bioorganic and Medicinal Chemistry Letters, 2021, 33, 127725.	1.0	7
3982	DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1â€mediated antioxidant effects. Journal of Cellular and Molecular Medicine, 2021, 25, 2163-2175.	1.6	33
3983	Efficacy and feasibility of re-irradiation using carbon ions for pancreatic cancer that recurs after carbon-ion radiotherapy. Clinical and Translational Radiation Oncology, 2021, 26, 24-29.	0.9	7

#	Article	IF	Citations
3984	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Pancreatology, 2021, 21, 192-199.	0.5	8
3985	Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101541.	0.7	8
3986	An evaluation of olaparib for the treatment of pancreatic cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 521-526.	0.9	4
3987	Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Annals of Gastroenterological Surgery, 2021, 5, 7-23.	1.2	23
3988	Pancreatic cancer drug-sensitivity predicted by synergy of p53-Activator Wnt Inhibitor-2 (PAWI-2) and protein biomarker expression. Investigational New Drugs, 2021, 39, 131-141.	1.2	2
3989	Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy. Journal of Cancer Research and Clinical Oncology, 2021, 147, 579-591.	1.2	17
3990	Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Annals of Surgery, 2021, 273, 341-349.	2.1	268
3991	Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110185.	1.4	9
3992	Pharmacological ascorbate and use in pancreatic cancer. , 2021, , 515-521.		0
3993	Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and metaâ€analysis. Journal of Pathology: Clinical Research, 2021, 7, 99-112.	1.3	14
3994	A novel P38Î± MAPK activator Bruceine A exhibits potent anti-pancreatic cancer activity. Computational and Structural Biotechnology Journal, 2021, 19, 3437-3450.	1.9	12
3995	Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance. Cells, 2021, 10, 260.	1.8	4
3996	The efficacy of a new high-intensity focused ultrasound therapy for metastatic pancreatic cancer. International Journal of Hyperthermia, 2021, 38, 288-295.	1.1	10
3997	Treatment Strategies for Frail and Elderly Patients with Pancreatic Cancer. , 2021, , 207-215.		0
3998	Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cancer-associated/Normal Fibroblasts. Cancer Genomics and Proteomics, 2021, 18, 221-243.	1.0	8
3999	The Elderly Patient with Pancreatic Cancer: Trends and Medical Oncology. , 2021, , 595-611.		0
4000	Radiation Therapy in the Management of a Pancreatic Cancer. Clinical Gastroenterology, 2021, , 127-143.	0.0	0
4001	Water Soluble Iron-Based Coordination Trimers as Synergistic Adjuvants for Pancreatic Cancer. Antioxidants, 2021, 10, 66.	2.2	7

#	Article	IF	Citations
4002	Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results. Radiation Oncology, 2021, 16, 3.	1.2	13
4003	Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. Turkish Journal of Medical Sciences, 2021, 51, 1727-1732.	0.4	3
4004	Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. , 2021, , 51-60.		0
4005	Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets. Central-European Journal of Immunology, 2021, 46, 258-263.	0.4	2
4006	Deuterium Depletion Inhibits Cell Proliferation, RNA and Nuclear Membrane Turnover to Enhance Survival in Pancreatic Cancer. Cancer Control, 2021, 28, 107327482199965.	0.7	6
4007	Internal medicine treatment of pancreatic lesions. , 2021, , 141-180.		0
4008	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. Advances in Experimental Medicine and Biology, 2021, 1301, 7-24.	0.8	1
4009	CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma. ACS Nano, 2021, 15, 1186-1198.	7.3	32
4010	Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110030.	1.4	9
4011	Treatment Approach for Pancreatic Cancer with Peritoneal Dissemination. , 2021, , 195-205.		0
4012	Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report. Future Science OA, 2021, 7, FSO659.	0.9	5
4013	Retroperitoneal Necrosis as a Rare Complication After Celiac Plexus Block. Cureus, 2021, 13, e13169.	0.2	0
4014	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Seminars in Oncology, 2021, 48, 34-46.	0.8	7
4015	Adjuvant therapy for patients with resectable pancreatic ductal adenocarcinoma. Suizo, 2021, 36, 12-19.	0.1	0
4016	Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer. Cancers, 2021, 13, 601.	1.7	14
4017	The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Cells, 2021, 10, 497.	1.8	28
4018	LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma. Carcinogenesis, 2021, 42, 546-556.	1.3	39
4019	Irreversible electroporation of locally advanced pancreatic cancer. Seminars in Oncology, 2021, 48, 84-94.	0.8	10

#	Article	IF	Citations
4020	TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma. Journal of Cellular Physiology, 2021, 236, 6868-6883.	2.0	17
4021	PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1Î±/VMP1 Axis in Pancreatic Cancer. Pancreas, 2021, 50, 227-234.	0.5	26
4022	Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/Î²-catenin pathway. Life Sciences, 2021, 287, 119205.	2.0	23
4023	Improved pentamethine cyanine nanosensors for optoacoustic imaging of pancreatic cancer. Scientific Reports, 2021, 11, 4366.	1.6	9
4024	Radiotherapy for locally advanced pancreatic ductal adenocarcinoma. Seminars in Oncology, 2021, 48, 106-110.	0.8	9
4026	Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharmacologica Sinica, 2021, 42, 1725-1741.	2.8	53
4027	Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut. Neoplasia, 2021, 23, 246-256.	2.3	20
4028	Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische OnkologieÂwith an integrated analysis of the â€˜burden of therapyâ€™ method. European Journal of Cancer, 2021, 146, 95-106.	1.3	21
4029	Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 2889-2901.	0.9	16
4030	Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma. European Journal of Medicinal Chemistry, 2021, 213, 113135.	2.6	9
4031	Introducing longitudinal cumulative dose to describe chemotherapy patterns over time: Case study of a colon cancer trial. International Journal of Cancer, 2021, 149, 394-402.	2.3	6
4032	Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology. Journal of Experimental and Clinical Cancer Research, 2021, 40, 102.	3.5	64
4033	pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer. ACS Applied Materials & Interfaces, 2021, 13, 12824-12835.	4.0	23
4034	A novel laparoscopic near-infrared fluorescence spectrum system for photodynamic diagnosis of peritoneal dissemination in pancreatic cancer. Photodiagnosis and Photodynamic Therapy, 2021, 33, 102157.	1.3	6
4035	Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Journal of Gastrointestinal Surgery, 2021, 25, 2871-2880.	0.9	5
4036	Girdin Knockdown Increases Gemcitabine Chemosensitivity to Pancreatic Cancer by Modulating Autophagy. Frontiers in Oncology, 2021, 11, 618764.	1.3	4
4037	TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment. Molecular Therapy, 2021, 29, 920-936.	3.7	31
4038	The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas. Clinical and Translational Radiation Oncology, 2021, 27, 109-113.	0.9	7

#	Article	IF	Citations
4039	Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-Î²1/SMAD2/3 pathway and ABCC1 transactivation. Cell Death and Disease, 2021, 12, 334.	2.7	45
4040	Solasodine, Isolated from Solanum sisymbriifolium Fruits, Has a Potent Anti-Tumor Activity Against Pancreatic Cancer. Drug Design, Development and Therapy, 2021, Volume 15, 1509-1519.	2.0	9
4041	Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2021, 123, 1432-1440.	0.8	20
4042	Tissue-Engineering the Fibrous Pancreatic Tumour Stroma Capsule in 3D Tumouroids to Demonstrate Paclitaxel Response. International Journal of Molecular Sciences, 2021, 22, 4289.	1.8	7
4043	Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Advanced Therapeutics, 2021, 4, 2000262.	1.6	9
4044	Suppression of Wnt/Î²-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer. Biochemical and Biophysical Research Communications, 2021, 549, 40-46.	1.0	18
4046	Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41. Journal of Gastrointestinal Oncology, 2021, 12, S80-S90.	0.6	5
4047	Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience. Journal of Gastrointestinal Oncology, 2021, 12, 464-473.	0.6	16
4048	History of preoperative therapy for pancreatic cancer and the MD Anderson experience. Journal of Surgical Oncology, 2021, 123, 1414-1422.	0.8	3
4049	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Biomedicines, 2021, 9, 389.	1.4	21
4050	Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. Journal of Gastrointestinal Oncology, 2021, 12, 455-463.	0.6	2
4051	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers, 2021, 13, 1781.	1.7	17
4052	Sister Mary Joseph Nodules: A Case Report about a Rare Location of Skin Metastasis. Case Reports in Oncology, 2021, 14, 664-670.	0.3	5
4053	Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine. Scientific Reports, 2021, 11, 9404.	1.6	17
4054	Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. Trials, 2021, 22, 313.	0.7	11
4055	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open, 2021, 6, 100049.	2.0	21
4056	Nobiletin Inhibits Cell Growth, Migration and Invasion, and Enhances the Anti-Cancer Effect of Gemcitabine on Pancreatic Cancer Cells. Natural Product Communications, 2021, 16, 1934578X2110040.	0.2	0
4058	A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment Tools. Reviews on Recent Clinical Trials, 2021, 16, 180-192.	0.4	5

#	Article	IF	Citations
4059	Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Annals of Oncology, 2021, 32, 600-608.	0.6	69
4060	Opportunities and challenges of fatty acid conjugated therapeutics. Chemistry and Physics of Lipids, 2021, 236, 105053.	1.5	14
4061	Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. Pancreas, 2021, 50, 685-695.	0.5	4
4062	Treatment landscape of metastatic pancreatic cancer. Cancer Treatment Reviews, 2021, 96, 102180.	3.4	82
4063	Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer. Biomolecules, 2021, 11, 780.	1.8	1
4064	Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer, 2021, 21, 537.	1.1	27
4065	Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 676291.	1.6	7
4066	A redox probe screens MTHFD1 as a determinant of gemcitabine chemoresistance in cholangiocarcinoma. Cell Death Discovery, 2021, 7, 89.	2.0	5
4067	A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. Medicine (United States), 2021, 100, e26052.	0.4	5
4068	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. Translational Oncology, 2021, 14, 101056.	1.7	17
4070	NHS-IL12, a Tumor-Targeting Immunocytokine. ImmunoTargets and Therapy, 2021, Volume 10, 155-169.	2.7	23
4071	LINC00460 promotes pancreatic cancer progression by sponging miRâ€491â€5p. Journal of Gene Medicine, 2021, 23, e3333.	1.4	9
4072	A polymeric micellar drug delivery system developed through a design of Experiment approach improves pancreatic tumor accumulation of calcipotriol and paclitaxel. International Journal of Pharmaceutics, 2021, 601, 120523.	2.6	6
4073	A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models. Pharmaceutical Research, 2021, 38, 1093-1106.	1.7	9
4074	Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment. BMJ Case Reports, 2021, 14, e238395.	0.2	3
4075	Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine		

#	Article	IF	Citations
4078	MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Molecular Therapy - Oncolytics, 2021, 21, 340-355.	2.0	13
4079	Î±1,6-Fucosyltransferase contributes to cell migration and proliferation as well as to cancer stemness features in pancreatic carcinoma. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129870.	1.1	15
4080	A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, 672.	1.1	0
4081	<scp>PMEPA1</scp> interference activates <scp>PTEN</scp>/<scp>PI3K</scp>/<scp>AKT</scp>, thereby inhibiting the proliferation, invasion and migration of pancreatic cancer cells and enhancing the sensitivity to gemcitabine and cisplatin. Drug Development Research, 2022, 83, 64-74.	1.4	10
4083	Performance status as prognostic factor in phase III trials of firstâ€line chemotherapy of unresectable or metastatic pancreatic cancer: A trialâ€level metaâ€analysis. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 232-239.	0.7	4
4084	Efficacy of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer: A real life experience and outcome from a tertiary referral centre.. Journal of Cancer & Allied Specialties, 2021, 7, .	0.1	1
4085	Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Cellular and Molecular Life Sciences, 2021, 78, 5505-5526.	2.4	20
4086	Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. Oncologist, 2021, 26, 825-e1674.	1.9	11
4087	Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial. Pancreatology, 2021, 21, 796-804.	0.5	2
4088	Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1416-1422.	0.6	11
4089	Determining Chemotherapy Agents in Saliva through Spectrometry and Chromatography Methods Correlated with Periodontal Status in Oncology Patients. Applied Sciences (Switzerland), 2021, 11, 5984.	1.3	2
4090	Current controversies and advances in the management of pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 472-494.	0.8	9
4091	Current Status of Treatment for Pancreatic Cancer in Japan and Prospects for the Future. Nihon Ika Daigaku Igakkai Zasshi, 2021, 17, 98-107.	0.0	0
4092	The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. World Journal of Surgical Oncology, 2021, 19, 182.	0.8	16
4093	A Tumorâ€Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer. Small, 2021, 17, e2101208.	5.2	22
4094	Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery. International Journal of Pharmaceutics, 2021, 602, 120659.	2.6	10
4095	Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer. Cancers, 2021, 13, 2940.	1.7	8
4096	Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals, 2021, 14, 589.	1.7	32

#	Article	IF	Citations
4097	Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). Journal of Geriatric Oncology, 2022, 13, 82-87.	0.5	13
4098	Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 699610.	2.0	4
4099	Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Diagnostics, 2021, 11, 1195.	1.3	9
4100	Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Abdominal Radiology, 2021, 46, 4800-4816.	1.0	9
4102	Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clinical Cancer Research, 2021, 27, 6622-6637.	3.2	7
4103	[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Research, 2021, 11, 70.	1.1	11
4104	Emerging Treatment Strategies in Pancreatic Cancer. Pancreas, 2021, 50, 773-787.	0.5	3
4105	Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 700315.	1.3	10
4106	Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities. Pharmaceuticals, 2021, 14, 740.	1.7	9
4107	The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers, 2021, 13, 3470.	1.7	15
4108	Fluorinated thiazolidinol drives autophagic cell death in pancreatic cancer cells via AMPK activation and perturbation of critical sentinels of oncogenic signaling. Chemico-Biological Interactions, 2021, 343, 109433.	1.7	4
4109	Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer. Anticancer Research, 2021, 41, 3643-3648.	0.5	2
4110	Palliative Chemotherapy and the Surgical Oncologist. Surgical Oncology Clinics of North America, 2021, 30, 545-561.	0.6	0
4111	Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. BMC Cancer, 2021, 21, 853.	1.1	4
4112	Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. European Journal of Cancer, 2021, 151, 3-13.	1.3	29
4113	Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. Asian Journal of Pharmaceutical Sciences, 2022, 17, 35-52.	4.3	17
4114	The novel ER stress inducer Sec C triggers apoptosis by sulfating ER cysteine residues and degrading YAP via ER stress in pancreatic cancer cells. Acta Pharmaceutica Sinica B, 2022, 12, 210-227.	5.7	10
4115	Evaluating the stability of opioid efficacy over 12 months in patients with chronic noncancer pain who initially demonstrate benefit from extended release oxycodone or hydrocodone. Pain, 2021, Publish Ahead of Print, .	2.0	2

#	Article	IF	Citations
4116	The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduction and Targeted Therapy, 2021, 6, 249.	7.1	131
4117	Drug-Eluting Stents: Their Preventative/Prophylactic Role Against Gemcitabine Induced Acute Coronary Syndrome. Cureus, 2021, 13, e16384.	0.2	0
4118	Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1531-1542.	2.3	21
4119	Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer. JNCI Cancer Spectrum, 2021, 5, pkab074.	1.4	2
4121	Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology, 2021, 21, 903-911.	0.5	15
4122	Tissue factor and its procoagulant activity on cancerâ€associated thromboembolism in pancreatic cancer. Cancer Science, 2021, 112, 4679-4691.	1.7	20
4123	Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients. Chemotherapy, 2021, 66, 107-112.	0.8	8
4124	Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 519-525.	0.6	0
4125	Gemcitabine-loaded microbubble system for ultrasound imaging and therapy. Acta Biomaterialia, 2021, 130, 385-394.	4.1	21
4126	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC Cancer, 2021, 21, 936.	1.1	12
4127	Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers, 2021, 13, 4173.	1.7	11
4128	è†µç™Œã«å¯¾ã™ã‚‹è¡“å‰æ²»ç™‚. Suizo, 2021, 36, 251-256.	0.1	1
4129	Modelling optimal control of African trypanosomiasis disease with cost-effective strategies. Journal of Biological Systems, 0, , .	0.5	0
4130	UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. United European Gastroenterology Journal, 2021, 9, 860-871.	1.6	28
4131	Uncovered versus covered metallic stents for the management of unresectable malignant distal biliary obstruction: a randomized multicenter trial. Scandinavian Journal of Gastroenterology, 2021, 56, 1229-1235.	0.6	9
4132	Antibody therapy in pancreatic cancer: mAb-ye weâ€™re onto something?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188557.	3.3	6
4133	Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors?. Surgery, 2021, 170, 1807-1814.	1.0	7
4134	Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101709.	0.7	1

#	Article	IF	Citations
4135	The structure elucidation of novel arabinogalactan LRP1-S2 against pancreatic cancer cells growth in vitro and in vivo. Carbohydrate Polymers, 2021, 267, 118172.	5.1	15
4136	The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy. Acta Histochemica, 2021, 123, 151769.	0.9	13
4137	Postoperative and long-term survival in relation to life-expectancy after pancreatic surgery in elderly patients (cohort study). Annals of Medicine and Surgery, 2021, 69, 102724.	0.5	0
4138	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. Anti-Cancer Drugs, 2021, 32, 779-785.	0.7	2
4139	SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1045-1053.	2.3	1
4140	Prediction and identification of synergistic compound combinations against pancreatic cancer cells. IScience, 2021, 24, 103080.	1.9	2
4141	The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers, 2021, 13, 4442.	1.7	37
4142	Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World Journal of Clinical Oncology, 2021, 12, 787-799.	0.9	12
4143	Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma. Frontiers in Oncology, 2021, 11, 688889.	1.3	7
4144	Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. Journal of Hepato-Biliary-Pancreatic Sciences, 2022, 29, 741-757.	1.4	4
4145	Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. Pancreatology, 2021, 21, 1064-1070.	0.5	3
4146	Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway. Frontiers in Oncology, 2021, 11, 754146.	1.3	10
4147	Clinical translation of immunomodulatory therapeutics. Advanced Drug Delivery Reviews, 2021, 176, 113896.	6.6	8
4148	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treatment Reviews, 2021, 99, 102208.	3.4	4
4149	Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	3
4151	Inhibitor Library Screening Identifies Ispinesib as a New Potential Chemotherapeutic Agent for Pancreatic Cancers. Cancer Science, 2021, 112, 4641-4654.	1.7	4
4152	Gadofullerene nanoparticles extend survival rate and down-regulate thrombin expression in orthotopic pancreatic cancer. Science China Materials, 2022, 65, 508-517.	3.5	2
4153	Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long term follow-up: implication in the progression of cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1033-1047.	2.0	9

#	Article	IF	Citations
4154	Integrative Network Pharmacology of Moringa oleifera Combined with Gemcitabine against Pancreatic Cancer. Processes, 2021, 9, 1742.	1.3	0
4155	Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surgical Oncology Clinics of North America, 2021, 30, 673-691.	0.6	1
4156	Treatment Paradigms for Older Adults with Pancreatic Cancer: a Nuanced Approach. Current Treatment Options in Oncology, 2021, 22, 104.	1.3	3
4157	Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). European Journal of Cancer, 2021, 157, 21-30.	1.3	18
4158	Decreasing hyaluronic acid combined with drug-loaded nanoprobes improve the delivery and efficacy of chemotherapeutic drugs for pancreatic cancer. Cancer Letters, 2021, 523, 1-9.	3.2	10
4159	Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial. Yonsei Medical Journal, 2021, 62, 671.	0.9	4
4160	Biomarkers in Pancreatic Cancer. , 2021, , 467-487.		1
4162	Chelidonine Induces Apoptosis via GADD45a-p53 Regulation in Human Pancreatic Cancer Cells. Integrative Cancer Therapies, 2021, 20, 153473542110061.	0.8	6
4165	CÃ¡ncer de pÃ¡ncreas. Medicine, 2021, 13, 1345-1352.	0.0	0
4166	Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 1400-1406.	0.7	10
4167	FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Cancer Chemotherapy and Pharmacology, 2021, 87, 397-404.	1.1	5
4168	Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer. Nutrition and Cancer, 2021, , 1-10.	0.9	3
4169	A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. Journal of Cancer, 2021, 12, 912-917.	1.2	5
4170	Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost?. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	0
4171	Surgery for locally advanced pancreatic ductal adenocarcinomaâ€"is it only about the vessels?. Journal of Gastrointestinal Oncology, 2021, 12, 2503-2511.	0.6	4
4172	Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Medicine (United States), 2021, 100, e24068.	0.4	13
4173	A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International Journal of Clinical Oncology, 2021, 26, 941-950.	1.0	15
4174	Non-pegylated Liposomal Doxorubicin as Palliative Chemotherapy in pre-Treated Advanced Pancreatic Cancer: A Retrospective Analysis of Twenty-Eight Patients. Technology in Cancer Research and Treatment, 2021, 20, 153303382110421.	0.8	4

#	Article	IF	Citations
4175	Preoperative (Neoadjuvant) Therapy for Resectable Adenocarcinoma of the Pancreas. , 2002, , 243-254.		2
4176	Conformal Radiation Therapy in Pancreatic Cancer. , 2002, , 295-300.		1
4177	Pankreaserkrankungen. , 2005, , 762-776.		1
4178	From Inception to Invasion: Modeling Pathways to Pancreatic Cancer. , 2008, , 159-179.		3
4179	Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer. , 2008, , 511-533.		3
4180	Targeting the Tumor Microenvironment (Stroma) for Treatment of Metastasis. , 2008, , 259-270.		1
4181	Diagnostic and Therapeutic Response Markers. , 2010, , 675-701.		7
4182	Interventional Radiology for Pancreatic Cancer. , 2010, , 859-894.		1
4183	Chemotherapy for Advanced Pancreatic Cancer. , 2010, , 913-949.		1
4184	Adjuvant Chemotherapy in Pancreatic Cancer. , 2010, , 1051-1077.		2
4185	Chemotherapy of Pancreatic Cancer. , 1998, , 265-280.		2
4186	Clinical Activity of Gemcitabine as a Single Agent and in Combination. , 2006, , 253-288.		3
4187	Nucleoside Radiosensitizers. , 2006, , 289-329.		2
4189	Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-25.	0.1	1
4190	CyberKnife Radiosurgery for Pancreatic Cancer. , 2007, , 227-239.		2
4191	Pancreatic Cancer: Step by Step Forward. , 2008, 177, 1-2.		2
4192	Primary Advanced Unresectable Pancreatic Cancer. , 2008, 177, 79-93.		35
4193	Antiangiogenic Strategies in Pancreatic Cancer. , 2008, 177, 123-129.		2

#	Article	IF	Citations
4194	Targeted Therapy of the Epidermal Growth Factor Receptor in the Treatment of Pancreatic Cancer. Recent Results in Cancer Research, 2008, 177, 131-136.	1.8	6
4195	First-Line Chemotherapy in Advanced Pancreatic Cancer. , 2008, 177, 57-60.		7
4196	Second-Line Chemotherapy in Advanced Pancreatic Cancer. , 2008, 177, 61-64.		3
4197	Erlotinib. Recent Results in Cancer Research, 2010, 184, 21-31.	1.8	3
4198	Mouse Models of Pancreatic Cancer. , 2013, , 57-91.		1
4200	Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. Journal of Gastroenterology, 2020, 55, 369-382.	2.3	48
4201	Carcinoma of the Pancreas. , 2008, , 1595-1611.		5
4202	Tumors of the Pancreas. , 2010, , 1017-1034.e4.		7
4203	Chemotherapy and radiotherapy for pancreatic and periampullary cancer. , 2012, , 972-978.e2.		1
4204	Sustained release of lipophilic gemcitabine from an injectable polymeric hydrogel for synergistically enhancing tumor chemoradiotherapy. Chemical Engineering Journal, 2020, 396, 125320.	6.6	49
4206	Title is missing!. Annals of Oncology, 2000, 11, 165-172.	0.6	3
4208	Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene, 2017, 36, 5639-5647.	2.6	19
4209	Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. , 0, .		1
4210	Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Bioscience Reports, 2020, 40, .	1.1	24
4211	Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clinical Science, 2020, 134, 2091-2115.	1.8	59
4212	Combining gemcitabine with radiation in pancreatic cancer: Understanding important variables influencing the therapeutic index. Seminars in Oncology, 2001, 28, 25-33.	0.8	41
4213	The role of chemoradiation therapy in locally advanced pancreatic cancer. Hpb, 2005, 7, 109-13.	0.1	3
4214	Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma. Journal of Pancreatic Cancer, 2017, 3, 49-52.	1.6	1

#	Article	IF	Citations
4215	Marimastat in Patients With Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 247-252.	0.6	101
4216	Combined Chemoradiotherapy for Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 309-314.	0.6	14
4217	A Phase II Trial of 5-Fluorouracil, Leucovorin, and Interferon Alpha 2A (IFN-Î± 2a) in Metastatic Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 37-39.	0.6	11
4218	Modulation of Fluorouracil by Methotrexate, Leucovorin, and Cisplatin (M-FLP) in the Treatment of Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 314-318.	0.6	4
4219	Cisplatin, Cytarabine, Caffeine, and Continuously Infused 5-Fluorouracil (PACE) in the Treatment of Advanced Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 420-424.	0.6	20
4220	Novel chemotherapeutic agents for gastrointestinal cancers. Current Opinion in Oncology, 1999, 11, 299.	1.1	5
4221	Current Status of and Future Prospects for the Medical Management of Adenocarcinoma of the Exocrine Pancreas. Journal of Clinical Gastroenterology, 2000, 30, 357-363.	1.1	8
4222	COMPARISON OF NEORAL DOSE MONITORING WITH CYCLOSPORINE TROUGH LEVELS VERSUS 2-HR POSTDOSE LEVELS IN STABLE LIVER TRANSPLANT PATIENTS1,2. Transplantation, 1998, 66, 1621-1627.	0.5	139
4223	CLINICAL BENEFIT OF NEORAL DOSE MONITORING WITH CYCLOSPORINE 2-HR POST-DOSE LEVELS COMPARED WITH TROUGH LEVELS IN STABLE HEART TRANSPLANT PATIENTS1. Transplantation, 1999, 68, 1839-1842.	0.5	142
4224	Gemcitabine versus Gemcitabine???Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group. Journal of Thoracic Oncology, 2007, , 135-140.	0.5	16
4225	Pancreatic cancer cells retain the epithelial-related phenotype and modify mitotic spindle microtubules after the administration of ukrain in vitro. Anti-Cancer Drugs, 2012, 23, 935-946.	0.7	12
4226	A Phase 2 Trial of Glufosfamide in Combination With Gemcitabine in Chemotherapy-Naive Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 111-116.	0.6	17
4227	Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 121-124.	0.6	40
4228	Duloxetine improves cancer-associated pain in a mouse model of pancreatic cancer through stimulation of noradrenaline pathway and its antitumor effects. Pain, 2020, 161, 2909-2919.	2.0	14
4229	Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expression Predicts Poor Prognosis. Pancreas, 2017, 46, 1296-1304.	0.5	15
4230	Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head. Pancreas, 2020, 49, 621-628.	0.5	13
4232	Ductal Pancreatic Cancer in Humans and Mice. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 65-72.	2.0	75
4233	A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. BMJ Case Reports, 2014, 2014, bcr2013202040-bcr2013202040.	0.2	2

#	Article	IF	Citations
4234	Effect of flutamide on survival in patients with pancreatic cancer. BMJ: British Medical Journal, 1999, 318, 326-326.	2.4	1
4235	Segmentation of Venous Vessel in MRI using Transferred Convolutional Neural Network. , 2019, , .		1
4236	Progress in the chemotherapy of pancreatic carcinoma. World Chinese Journal of Digestology, 2009, 17, 1422.	0.0	4
4237	Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Clinical Cancer Research, 2019, 25, 6452-6462.	3.2	43
4238	Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer. Journal of Cancer Treatment and Research, 2015, 3, 42.	0.2	2
4239	Polysaccharide-Based Nanoparticles for Cancer Therapy. Journal of Nanopharmaceutics and Drug Delivery, 2013, 1, 335-354.	0.3	4
4240	Postoperative Gemcitabine Alone and Concurrent with Radiation Therapy in Locally Advanced Pancreatic Carcinoma. Tumori, 2010, 96, 560-567.	0.6	2
4241	Molecular-Targeted Agents in Pancreatic Cancer. Cancer Control, 2004, 11, 32-38.	0.7	7
4242	Radioembolization with Yttrium-90 Microspheres for Pancreatic Cancer Liver Metastases: Results from a Pilot Study. Tumori, 2010, 96, 955-958.	0.6	21
4243	A pH-Induced Reversible Assembly System with Resveratrol-Controllable Loading and Release for Enhanced Tumor-Targeting Chemotherapy. Nanoscale Research Letters, 2019, 14, 305.	3.1	11
4244	Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer, 2020, 20, 449.	1.1	39
4245	Computed tomography-guided 125I seed interstitial implantation for head and neck cancer patients with unmanageable cervical lymph node metastases. World Journal of Surgical Oncology, 2015, 13, .	0.8	2
4246	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Journal of Clinical Oncology, 2006, 24, 4115-4115.	0.8	3
4247	The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis. Medical Science Monitor, 2020, 26, e921515.	0.5	3
4248	First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. World Journal of Clinical Cases, 2020, 8, 4022-4033.	0.3	6
4249	Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer. World Journal of Clinical Cases, 2020, 8, 5564-5575.	0.3	7
4250	Hedgehog Promotes Neovascularization in Pancreatic Cancers by Regulating Ang-1 and IGF-1 Expression in Bone-Marrow Derived Pro-Angiogenic Cells. PLoS ONE, 2010, 5, e8824.	1.1	71
4251	Murine Pancreatic Adenocarcinoma Dampens SHIP-1 Expression and Alters MDSC Homeostasis and Function. PLoS ONE, 2011, 6, e27729.	1.1	41

#	Article	IF	Citations
4252	EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer. PLoS ONE, 2012, 7, e31067.	1.1	93
4253	Evaluation of a Gene-Directed Enzyme-Product Therapy (GDEPT) in Human Pancreatic Tumor Cells and Their Use as In Vivo Models for Pancreatic Cancer. PLoS ONE, 2012, 7, e40611.	1.1	12
4254	Regional Intra-Arterial vs. Systemic Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2012, 7, e40847.	1.1	39
4255	Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. PLoS ONE, 2012, 7, e52095.	1.1	41
4256	Gemcitabine Eliminates Double Minute Chromosomes from Human Ovarian Cancer Cells. PLoS ONE, 2013, 8, e71988.	1.1	40
4257	Increased Risk of High-Grade Hemorrhage in Cancer Patients Treated with Gemcitabine: A Meta-Analysis of 20 Randomized Controlled Trials. PLoS ONE, 2013, 8, e74872.	1.1	2
4258	Targeting and Cytotoxicity of SapC-DOPS Nanovesicles in Pancreatic Cancer. PLoS ONE, 2013, 8, e75507.	1.1	39
4259	Digitoflavone Inhibits Î°BÎ± Kinase and Enhances Apoptosis Induced by TNFÎ± through Downregulation of Expression of Nuclear Factor Î°B-Regulated Gene Products in Human Pancreatic Cancer Cells. PLoS ONE, 2013, 8, e77126.	1.1	17
4260	Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis. PLoS ONE, 2014, 9, e87103.	1.1	16
4261	CXCR4-A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis. PLoS ONE, 2015, 10, e0130192.	1.1	32
4262	Salivary MicroRNA in Pancreatic Cancer Patients. PLoS ONE, 2015, 10, e0130996.	1.1	95
4263	FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. PLoS ONE, 2015, 10, e0135907.	1.1	16
4264	Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines. PLoS ONE, 2016, 11, e0160658.	1.1	40
4265	Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63. PLoS ONE, 2017, 12, e0179884.	1.1	5
4266	Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS ONE, 2017, 12, e0180628.	1.1	4
4267	Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan. PLoS ONE, 2020, 15, e0244487.	1.1	3
4268	Current Controversies in the Stage-Specific Multidisciplinary Management of Pancreatic Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e157-e164.	1.8	5
4269	Geriatric Oncology and Clinical Trials. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e127-e131.	1.8	10

#	Article	IF	Citations
4270	Mucinous Cystic Neoplasms of Pancreas. Gastroenterology Research, 2014, 7, 44-50.	0.4	22
4271	1-Pamitoyl-2-Linoleoyl-3-Acetyl-rac-Glycerol May Reduce Incidence of Gemcitabine-Induced Neutropenia: A Pilot Case-Controlled Study. World Journal of Oncology, 2015, 6, 410-415.	0.6	3
4272	Electrochemotherapy in pancreatic adenocarcinoma treatment: pre-clinical and clinical studies. Radiology and Oncology, 2016, 50, 14-20.	0.6	19
4273	Preoperative In-Hospital Rehabilitation Improves Physical Function in Patients with Pancreatic Cancer Scheduled for Surgery. Tohoku Journal of Experimental Medicine, 2020, 251, 279-285.	0.5	10
4274	Pancreatic Cancer: Local Success and Distant Failure. Oncologist, 1998, 3, 178-188.	1.9	17
4275	The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. Pancreas (Fairfax, Va), 2019, 3, 9-14.	1.4	18
4276	Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax, Va), 2019, 3, e1-e4.	1.4	69
4277	Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. IssledovaniÃ¢ I Praktika V Medicine, 2020, 7, 118-134.	0.1	3
4278	Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.. Acta Biochimica Polonica, 2019, 52, 601-607.	0.3	12
4279	Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1. Aging, 2019, 11, 8860-8878.	1.4	40
4280	Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence. Oncoscience, 2015, 2, 572-575.	0.9	21
4281	The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget, 2016, 7, 61136-61151.	0.8	46
4282	The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget, 2016, 7, 75081-75093.	0.8	11
4283	Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. Oncotarget, 2016, 7, 71937-71950.	0.8	11
4284	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, 7, 82953-82960.	0.8	22
4285	Bisdemethoxycurcumin exerts pro-apoptotic effects in human pancreatic adenocarcinoma cells through mitochondrial dysfunction and a GRP78-dependent pathway. Oncotarget, 2016, 7, 83641-83656.	0.8	19
4286	A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer. Oncotarget, 2017, 8, 29925-29934.	0.8	10
4287	Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling. Oncotarget, 2017, 8, 58417-58429.	0.8	12

#	Article	IF	Citations
4288	MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). Oncotarget, 2017, 8, 47490-47496.	0.8	37
4289	Downregulation of X-linked inhibitor of apoptosis protein by â€˜7-Benzylidenenaltrexone maleateâ€™ sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. Oncotarget, 2017, 8, 61057-61071.	0.8	5
4290	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget, 2017, 8, 44295-44311.	0.8	29
4291	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget, 2010, 1, 515-529.	0.8	12
4292	SWI/SNF aberrations sensitize pancreatic cancer cells to DNA crosslinking agents. Oncotarget, 2018, 9, 9608-9617.	0.8	10
4293	B7-H3 combats apoptosis induced by chemotherapy by delivering signals to pancreatic cancer cells. Oncotarget, 2017, 8, 74856-74868.	0.8	16
4294	STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines. Oncotarget, 2017, 8, 78556-78572.	0.8	8
4295	Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget, 2017, 8, 92401-92410.	0.8	20
4296	Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget, 2017, 8, 113662-113672.	0.8	5
4297	MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy. Oncotarget, 2017, 8, 107500-107512.	0.8	55
4298	Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Oncotarget, 2017, 8, 112636-112646.	0.8	20
4299	A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget, 2017, 8, 111346-111355.	0.8	39
4300	Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget, 2018, 9, 5274-5286.	0.8	24
4301	Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to Î³-irradiation. Oncotarget, 2014, 5, 10251-10270.	0.8	34
4302	Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. Oncotarget, 2018, 9, 19994-20007.	0.8	10
4303	Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growthin vitroandin vivo. Oncotarget, 2018, 9, 28434-28444.	0.8	27
4304	Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. Oncotarget, 2018, 9, 25617-25629.	0.8	10
4305	The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma. Oncotarget, 2018, 9, 28069-28082.	0.8	6

#	Article	IF	Citations
4306	Anchorage-dependent multicellular aggregate formation induces a quiescent stem-like intractable phenotype in pancreatic cancer cells. Oncotarget, 2018, 9, 29845-29856.	0.8	3
4307	Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget, 2018, 9, 31861-31876.	0.8	4
4308	A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Oncotarget, 2015, 6, 746-754.	0.8	21
4309	Cyr61/CCN1 targets for chemosensitization in pancreatic cancer. Oncotarget, 2019, 10, 3579-3580.	0.8	8
4310	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. Oncotarget, 2020, 11, 3489-3501.	0.8	30
4311	Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget, 2015, 6, 4553-4561.	0.8	85
4312	Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the â€œTHERAPYâ€phase 1-2 trial. Oncotarget, 2015, 6, 12796-12808.	0.8	56
4313	Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cellsin vitroandin vivo. Oncotarget, 2015, 6, 5517-5535.	0.8	48
4314	Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Oncotarget, 2015, 6, 39140-39150.	0.8	21
4315	MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget, 2015, 6, 14440-14455.	0.8	59
4316	Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget, 2015, 6, 27312-27331.	0.8	47
4317	Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget, 2015, 6, 33290-33305.	0.8	29
4318	Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and Î²-catenin signaling. Oncotarget, 2015, 6, 35931-35948.	0.8	37
4319	Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Oncotarget, 2016, 7, 3217-3232.	0.8	59
4320	Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment. Oncotarget, 2016, 7, 13182-13196.	0.8	55
4321	Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. Oncotarget, 2016, 7, 17103-17110.	0.8	25
4322	FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget, 2016, 7, 31586-31601.	0.8	88
4323	Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Oncotarget, 2016, 7, 46988-47001.	0.8	10

#	Article	IF	Citations
4324	Pancreatic cancer: treatment approaches and trends. Journal of Cancer Metastasis and Treatment, 2018, 4, 30.	0.5	23
4325	Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. , 2020, 3, 572-585.		4
4326	Drug metabolism and pancreatic cancer. Annals of Gastroenterology, 2016, 30, 54-61.	0.4	5
4327	The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Cancer Biology and Medicine, 2019, 16, 688-699.	1.4	65
4328	Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Annals of Translational Medicine, 2016, 4, 165-165.	0.7	19
4329	Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy. Annals of Translational Medicine, 2018, 6, 405-405.	0.7	2
4330	Role of erlotinib in the management of pancreatic cancer. Therapeutics and Clinical Risk Management, 2006, 2, 435-445.	0.9	23
4331	Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer. Current Medicinal Chemistry, 2018, 25, 2585-2594.	1.2	64
4332	Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Current Medicinal Chemistry, 2020, 26, 7196-7211.	1.2	9
4333	A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy. Current Drug Metabolism, 2020, 20, 958-966.	0.7	9
4334	Treatment of Pancreatic Cancer with Pharmacological Ascorbate. Current Pharmaceutical Biotechnology, 2015, 16, 759-770.	0.9	41
4335	Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?. Current Cancer Drug Targets, 2013, 13, 460-471.	0.8	19
4336	Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study. Current Cancer Drug Targets, 2020, 20, 887-895.	0.8	8
4337	Pharmacogenomics of Cytochrome P450 Enzymes in Tumours. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2004, 2, 243-254.	0.3	3
4338	Pancreatic Cancer: Promises and Failures of Target Therapies. Reviews on Recent Clinical Trials, 2016, 11, 33-38.	0.4	6
4339	Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine. In Vivo, 2017, 31, 731-735.	0.6	6
4340	Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer. In Vivo, 2018, 32, 637-642.	0.6	5
4341	Chemotherapy in the elderly: are their needs being met?. Therapy: Open Access in Clinical Medicine, 2009, 6, 893-902.	0.2	2

#	Article	IF	Citations
4342	Targeting Notch signaling in pancreatic cancer patients - rationale for new therapy. Advances in Medical Sciences, 2009, 54, 136-42.	0.9	25
4344	Gemcitabine combined with S-1 chemotherapy is effective for pancreatic and gastric double cancers. Suizo, 2006, 21, 365-372.	0.1	3
4345	A digest of the Pancreatic Cancer Registry Report 2007. Suizo, 2008, 23, 105-123.	0.1	47
4346	A phase I study of gemcitabine and S-1 concurrent radiotherapy in patients with locally advanced pancreatic cancer. Suizo, 2010, 25, 109-116.	0.1	2
4347	A case of pancreatic cancer combined with metastases to skin and muscle: a case report. Suizo, 2012, 27, 54-61.	0.1	2
4348	A case of intraductal tubulopapillary neoplasm of the pancreas with portal vein tumor thrombus. Suizo, 2014, 29, 729-735.	0.1	5
4349	Clinical Appraisal of Hyperthermic Treatment Combined with Low Dose of Gemcitabine Hydrochlo Ride for the Unresectable Pancreas Cancer. Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 2004, 20, 161-170.	0.4	4
4350	Clinical Results of Systemic Chemotherapy Combined with Regional Hyperthermia. Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 2007, 23, 49-61.	0.4	8
4351	Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma. Korean Journal of Radiology, 2020, 21, 316.	1.5	18
4352	Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Cancers, 2020, 12, 3866.	1.7	17
4353	Molecular Targeted Intervention for Pancreatic Cancer. Cancers, 2015, 7, 1499-1542.	1.7	30
4354	Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines. Cells, 2020, 9, 1251.	1.8	12
4355	Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World Journal of Gastroenterology, 2008, 14, 3681.	1.4	29
4356	Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. World Journal of Gastroenterology, 2008, 14, 5311.	1.4	8
4357	A patient with unresectable advanced pancreatic cancer achieving long-term survival with Gemcitabine chemotherapy. World Journal of Gastroenterology, 2008, 14, 6876.	1.4	5
4358	Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy. World Journal of Gastroenterology, 2008, 14, 7183.	1.4	19
4359	Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor Î³ involves angiogenesis inhibition. World Journal of Gastroenterology, 2009, 15, 441.	1.4	44
4360	Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World Journal of Gastroenterology, 2004, 11, 447.	1.4	25

#	Article	IF	Citations
4361	Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World Journal of Gastroenterology, 2005, 11, 1091.	1.4	33
4362	Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World Journal of Gastroenterology, 2006, 12, 1597.	1.4	40
4363	Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy. World Journal of Gastroenterology, 2006, 12, 7299.	1.4	13
4364	Importance of performance status for treatment outcome in advanced pancreatic cancer. World Journal of Gastroenterology, 2007, 13, 224.	1.4	69
4365	Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World Journal of Gastroenterology, 2007, 13, 2945.	1.4	37
4366	Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer?. World Journal of Gastroenterology, 2007, 13, 4306.	1.4	10
4367	Exploiting novel molecular targets in gastrointestinal cancers. World Journal of Gastroenterology, 2007, 13, 5845.	1.4	16
4368	Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report. World Journal of Gastroenterology, 2010, 16, 3853.	1.4	5
4369	Neoadjuvant treatment for resectable pancreatic cancer: Time for phase III testing?. World Journal of Gastroenterology, 2010, 16, 4883.	1.4	16
4370	Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 1357.	1.4	17
4371	Pancreatic cancer: Translational research aspects and clinical implications. World Journal of Gastroenterology, 2012, 18, 1417.	1.4	23
4372	Adjuvant and neoadjuvant treatment in pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 1565.	1.4	46
4373	Role of taxanes in pancreatic cancer. World Journal of Gastroenterology, 2012, 18, 4457.	1.4	7
4374	FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World Journal of Gastroenterology, 2012, 18, 4533.	1.4	41
4375	Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?. World Journal of Gastroenterology, 2012, 18, 4944.	1.4	66
4376	Developments in metastatic pancreatic cancer: Is gemcitabine still the standard?. World Journal of Gastroenterology, 2012, 18, 736.	1.4	61
4377	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World Journal of Gastroenterology, 2013, 19, 4511.	1.4	13
4378	Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials?. World Journal of Gastroenterology, 2013, 19, 1173.	1.4	48

#	Article	IF	Citations
4379	Pancreatic biomarkers: Could they be the answer?. World Journal of Gastroenterology, 2014, 20, 7819.	1.4	8
4380	Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 2014, 20, 7849.	1.4	22
4381	hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review. World Journal of Gastroenterology, 2014, 20, 8482.	1.4	67
4382	Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 8545.	1.4	15
4383	Pancreatic cancer: advances in treatment. World Journal of Gastroenterology, 2014, 20, 9354-60.	1.4	144
4384	Therapeutic applications of curcumin for patients with pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 9384-91.	1.4	84
4385	Role of non-coding RNAs in pancreatic cancer: the bane of the microworld. World Journal of Gastroenterology, 2014, 20, 9405-17.	1.4	18
4386	Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 9570-9577.	1.4	48
4387	Pancreatic cancer-improved care achievable. World Journal of Gastroenterology, 2014, 20, 10405.	1.4	16
4388	Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. World Journal of Gastroenterology, 2014, 20, 10769.	1.4	20
4389	MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 11199.	1.4	40
4390	Adjuvant therapy in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 14733.	1.4	36
4391	S-1 in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 15110.	1.4	41
4392	Icotinib plus gemcitabine for metastatic pancreatic cancer: A case report. World Journal of Gastroenterology, 2015, 21, 3441-3446.	1.4	3
4393	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. World Journal of Gastroenterology, 2015, 21, 4788.	1.4	56
4394	New targeted therapies in pancreatic cancer. World Journal of Gastroenterology, 2015, 21, 6127.	1.4	43
4395	Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World Journal of Gastroenterology, 2015, 21, 8271.	1.4	36
4396	Perspectives in the treatment of pancreatic adenocarcinoma. World Journal of Gastroenterology, 2015, 21, 9297.	1.4	124

#	Article	IF	Citations
4397	Advanced pancreatic cancer - how to choose an adequate treatment option. World Journal of Gastroenterology, 2015, 21, 10709.	1.4	3
4398	Cancer immunotherapy for pancreatic cancer utilizing Î±-gal epitope/natural anti-Gal antibody reaction. World Journal of Gastroenterology, 2015, 21, 11396.	1.4	13
4399	HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World Journal of Gastroenterology, 2015, 21, 13004.	1.4	34
4400	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 748.	1.4	16
4401	Management of pancreatic cancer in the elderly. World Journal of Gastroenterology, 2016, 22, 764.	1.4	113
4402	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 6987.	1.4	68
4403	Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 7046.	1.4	24
4404	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 7275.	1.4	26
4405	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World Journal of Gastroenterology, 2016, 22, 7440.	1.4	15
4406	Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World Journal of Gastroenterology, 2016, 22, 10502.	1.4	3
4407	Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World Journal of Gastroenterology, 2016, 22, 2678.	1.4	177
4408	Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World Journal of Gastroenterology, 2017, 23, 5875.	1.4	70
4409	Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review. World Journal of Gastroenterology, 2017, 23, 7478-7488.	1.4	23
4410	ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?. World Journal of Gastroenterology, 2018, 24, 3222-3238.	1.4	77
4411	p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World Journal of Gastroenterology, 2018, 24, 3709-3723.	1.4	33
4412	Adjuvant therapy in pancreatic cancer. World Journal of Gastroenterology, 2001, 7, 482.	1.4	18
4413	Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: Results of feasibility study. World Journal of Gastroenterology, 2003, 9, 2561.	1.4	28
4414	Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma. Radiation Oncology Journal, 2018, 36, 210-217.	0.7	1

#	Article	IF	Citations
4415	Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells. International Journal of Oncology, 2020, 56, 783-793.	1.4	19
4416	Targeting TM4SF5 with antiâ€'TM4SF5 monoclonal antibody suppresses the growth and motility of human pancreatic cancer cells. Oncology Letters, 2020, 19, 641-650.	0.8	3
4417	Akt inhibitor MKâ€'2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine. Oncology Letters, 2020, 19, 1999-2004.	0.8	12
4418	Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/Pâ€'glycoprotein and MRPs expression. Oncology Letters, 2020, 20, 1-1.	0.8	13
4419	Pancreatic cancer cell apoptosis is induced by a proteoglycan extracted from GanodermaÂlucidum. Oncology Letters, 2020, 21, 34.	0.8	9
4420	Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer. Korean Journal of Internal Medicine, 2002, 17, 259-262.	0.7	19
4421	Forskolin sensitizes pancreatic cancer cells to gemcitabine via Stat3 and Erk1/2 inhibition. AIMS Molecular Science, 2017, 4, 224-240.	0.3	8
4422	Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. Journal of Gastrointestinal Oncology, 2012, 3, 326-34.	0.6	44
4423	A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. Journal of Gastrointestinal Oncology, 2013, 4, 123-30.	0.6	16
4424	Current and future systemic treatment options in metastatic pancreatic cancer. Journal of Gastrointestinal Oncology, 2014, 5, 280-95.	0.6	33
4425	Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial. Journal of Gastrointestinal Oncology, 2014, 5, 433-9.	0.6	10
4426	Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. Journal of Gastrointestinal Oncology, 2015, 6, 115-25.	0.6	22
4427	Adjuvant radiation therapy for pancreatic cancer: a review of the old and the new. Journal of Gastrointestinal Oncology, 2015, 6, 436-44.	0.6	20
4428	Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. Journal of Gastrointestinal Oncology, 2015, 6, 511-5.	0.6	22
4429	Chemotherapy for advanced cancers. Annals of Palliative Medicine, 2014, 3, 203-28.	0.5	11
4430	Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613. Annals of Translational Medicine, 2014, 2, 91.	0.7	17
4432	Molecular Characteristics of Pancreatic Ductal Adenocarcinoma. Pathology Research International, 2011, 2011, 1-16.	1.4	43
4433	Pancreatic cancer in an Asian population. Endoscopic Ultrasound, 2015, 4, 56.	0.6	14

#	Article	IF	Citations
4434	Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol. Endoscopic Ultrasound, 2019, 8, 235.	0.6	13
4435	The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective. Endoscopic Ultrasound, 2017, 6, 66.	0.6	3
4436	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Indian Journal of Medical Research, 2018, 148, 284.	0.4	5
4437	Phase II Trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma. Cancer Research and Treatment, 2002, 34, 111-116.	1.3	2
4438	Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis. Cancer Research and Treatment, 2008, 40, 22.	1.3	11
4439	A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Research and Treatment, 2012, 44, 127-132.	1.3	9
4440	Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Research and Treatment, 2015, 47, 266-273.	1.3	9
4441	Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Research and Treatment, 2016, 48, 1264-1273.	1.3	40
4442	Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Cancer Research and Treatment, 2020, 52, 254-262.	1.3	14
4443	Anticancer Effect of Phellinus linteus; Potential Clinical Application in Treating Pancreatic Ductal Adenocarcinoma. Journal of Carcinogenesis & Mutagenesis, 2013, 01, .	0.3	2
4444	Repositioning of Non-Steroidal Anti Inflammatory Drug (NSAIDs) for Cancer Treatment: Promises and Challenges. Journal of Nanomedicine & Nanotechnology, 2016, 7, .	1.1	15
4445	Gemcitabine Degradation in Whole Blood from Humans, Dogs, Cats, and Horses. Journal of Veterinary Science & Technology, 2012, 03, .	0.3	1
4446	Tanshinone IIA Could Inhibit Pancreatic Cancer BxPC-3 Cells through Increasing PERK, ATF6, Caspase-12 and CHOP Expression to Induce Apoptosis. Journal of Biomedical Science and Engineering, 2015, 08, 149-159.	0.2	4
4447	A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with <i>nab</i>-Paclitaxel at a Single Institution. Journal of Cancer Therapy, 2014, 05, 605-610.	0.1	2
4448	Irreversible electroporation and the pancreas: What we know and where we are going?. World Journal of Gastrointestinal Surgery, 2015, 7, 138.	0.8	9
4449	FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 182-194.	0.8	40
4450	FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. World Journal of Gastrointestinal Oncology, 2020, 12, 332-346.	0.8	7
4451	Molecular predictors of gemcitabine response in pancreatic cancer. World Journal of Gastrointestinal Oncology, 2011, 3, 153.	0.8	64

#	Article	IF	Citations
4452	Genomic alterations in pancreatic cancer and their relevance to therapy. World Journal of Gastrointestinal Oncology, 2015, 7, 250.	0.8	24
4453	Is metastatic pancreatic cancer an untargetable malignancy?. World Journal of Gastrointestinal Oncology, 2016, 8, 297.	0.8	8
4454	Molecular therapeutics in pancreas cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 366.	0.8	18
4455	Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World Journal of Gastrointestinal Oncology, 2016, 8, 555.	0.8	32
4456	Road map for pain management in pancreatic cancer: A review. World Journal of Gastrointestinal Oncology, 2016, 8, 599.	0.8	44
4457	Pancreatic cancer: New hopes after first line treatment. World Journal of Gastrointestinal Oncology, 2016, 8, 682.	0.8	20
4458	Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World Journal of Gastrointestinal Oncology, 2017, 9, 235.	0.8	19
4459	Evolving treatment landscape for early and advanced pancreatic cancer. World Journal of Gastrointestinal Oncology, 2017, 9, 281.	0.8	26
4460	Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer. Turkish Journal of Gastroenterology, 2011, 22, 60-64.	0.4	1
4462	Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines. Swiss Medical Weekly, 2011, 141, w13208.	0.8	34
4463	Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response. Gut and Liver, 2013, 7, 611-615.	1.4	14
4464	Expression of Heat Shock Protein 70 Modulates the Chemoresponsiveness of Pancreatic Cancer. Gut and Liver, 2013, 7, 739-746.	1.4	17
4465	Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Gut and Liver, 2020, 14, 135-143.	1.4	6
4466	Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Gut and Liver, 2020, 14, 387-394.	1.4	31
4467	Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer. International Journal of Biological Markers, 2003, 18, 295-300.	0.7	9
4468	Targeting metastatic upper gastrointestinal adenocarcinomas. World Journal of Clinical Oncology, 2011, 2, 135.	0.9	4
4469	Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers. World Journal of Clinical Oncology, 2011, 2, 158.	0.9	22
4470	An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report. World Journal of Clinical Oncology, 2011, 2, 299.	0.9	6

#	Article	IF	Citations
4471	Impact of tumour associated macrophages in pancreatic cancer. BMB Reports, 2013, 46, 131-138.	1.1	82
4472	Stability of Generic Versions of Gemcitabine Hydrochloride Preparation for Injection. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 550-555.	0.0	3
4473	Distinct Risk Factor Profiles of Gemcitabine Plus Nab-paclitaxel-induced Neutropenia in Patients with Pancreatic Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2018, 44, 107-116.	0.0	1
4474	Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chinese Journal of Cancer, 2014, 33, 267-276.	4.9	17
4475	Current Systemic Treatment Options for Metastatic and Unresectable Pancreatic Cancer. , 0, , .		1
4476	Pathological Complete Response after S-1 Therapy for an Unresectable Pancreatic Head Cancer with Liver Metastasis. Japanese Journal of Gastroenterological Surgery, 2017, 50, 461-468.	0.0	1
4477	Clinicopathological Features of Delayed Isolated Lung Metastases after Radical Pancreatectomy for Pancreatic Cancer. Japanese Journal of Gastroenterological Surgery, 2010, 43, 1270-1275.	0.0	8
4478	Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 598.	2.3	63
4479	Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 202-210.	2.3	281
4480	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 439-457.	2.3	564
4481	First-line treatment for advanced pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 129-32.	1.5	7
4482	Thromboembolism and anticoagulation in pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 135-7.	1.5	6
4483	Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. JOP: Journal of the Pancreas, 2013, 14, 395-400.	1.5	4
4484	Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?. JOP: Journal of the Pancreas, 2013, 14, 354-8.	1.5	11
4485	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. JOP: Journal of the Pancreas, 2013, 14, 515-20.	1.5	3
4487	Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP: Journal of the Pancreas, 2012, 13, 497-501.	1.5	69
4488	Long Term Survivors with Metastatic Pancreatic Cancer Treated with Gemcitabine Alone or Plus Cisplatin: a Retrospective Analysis of an Anatolian Society of Medical Oncology Multicenter Study. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1841-1844.	0.5	9
4489	Gemcitabine-based Concurrent Chemoradiotherapy Versus Chemotherapy Alone in Patients with Locally Advanced Pancreatic Cancer. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2129-2132.	0.5	6

#	Article	IF	Citations
4490	Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6573-6578.	0.5	10
4491	MiR-21 Upregulation Induced by Promoter Zone Histone Acetylation is Associated with Chemoresistance to Gemcitabine and Enhanced Malignancy of Pancreatic Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7529-7536.	0.5	36
4492	Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7119-7123.	0.5	15
4493	Pancreatic Carcinoma, Thrombosis and Mean Platelet Volume: Single Center Experience from the Southeast Region of Turkey. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9143-9146.	0.5	17
4494	An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5681-5686.	0.5	8
4495	Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6001-6006.	0.5	6
4496	Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biology and Medicine, 2015, 12, 284-91.	1.4	5
4497	Cancer of Exocrine Pancreas. UNIPA Springer Series, 2021, , 645-674.	0.1	0
4498	Pre-clinical Models of Metastasis in Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 748631.	1.8	14
4499	Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. World Journal of Gastroenterology, 2021, 27, 6572-6589.	1.4	14
4500	Systemic Therapy for Metastatic Pancreatic Cancer. Current Treatment Options in Oncology, 2021, 22, 106.	1.3	33
4501	Possible Role of Cytochrome P450 1B1 in the Mechanism of Gemcitabine Resistance in Pancreatic Cancer. Biomedicines, 2021, 9, 1396.	1.4	9
4502	Heterogeneity in Pancreatic Cancer Fibroblastsâ€"TGFÎ² as a Master Regulator?. Cancers, 2021, 13, 4984.	1.7	9
4503	Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World Journal of Gastroenterology, 2021, 27, 6527-6550.	1.4	23
4504	TPH1 and 5-HT7 Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 5305.	1.7	7
4505	Pankreastumoren. , 2000, , 735-754.		0
4508	Upper Gastrointestinal Cancer. , 2001, , 130-149.		0
4509	Gemcitabine plus epirubicin in advanced pancreatic cancer: A phase II multicenter trial. Oncology Reports, 2001, 8, 1111-5.	1.2	5

#	Article	IF	Citations
4510	Novel Therapeutic Targets for Drug Development. , 2002, , 397-405.		0
4512	Pankreaskarzinom. , 2002, , 595-606.		0
4514	Pharmaceutical Care on Pancreatic Cancer Chemotherapy-Appropriate Usage of G-CSF (granulocyte) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	2
4515	Erkrankungen von Leber, Gallenwegen und Pankreas. , 2003, , 863-954.		0
4516	Pankreaserkrankungen. , 2003, , 722-736.		0
4517	Gastrointestinal Cancers. Medical Radiology, 2003, , 49-80.	0.0	0
4518	Pankreaskarzinom. , 2003, , 85-98.		0
4520	Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the Gastrointestinal Tract. , 2003, , 461-487.		0
4521	Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study. Cancer Research and Treatment, 2003, 35, 213-217.	1.3	0
4522	Identifying Agents to Test in Phase III Trials. , 2004, , 539-578.		0
4523	Hyperthermie. , 2004, , 563-577.		0
4524	Targeting VEGF in Pancreatic Cancer. , 2004, , 107-116.		0
4525	Novel Alternatives to Chemotherapy in Advanced Disease: Gastrin Antibodies. , 2004, , 93-98.		0
4526	Novel Alternatives to Chemotherapy in Advanced Disease: Gene Transfer. , 2004, , 99-120.		0
4527	Gender and Gastrointestinal Malignancies: Incidence and Response to Treatment. , 2004, , 664-670.		0
4528	Measurement of Symptoms and Quality of Life in Pancreatic Disease. , 2004, , 441-450.		0
4529	Curatively Resected Locally Advanced Pancreatic-Head Cancer by Down-Staging with 5-FU-Based Chemoradiotherapy and Gemcitabine: A Case Report. Japanese Journal of Gastroenterological Surgery, 2004, 37, 434-439.	0.0	0
4530	Ablative Therapies for Gastrointestinal Malignancies: The Gastrointestinal Oncologistâ€™s Viewpoint. , 2005, , 466-471.		0

#	Article	IF	Citations
4531	Trends in the Treatment of Colorectal Cancer. Oncology & Hematology Review, 2005, 00, 1.	0.2	0
4532	A case of severe interstitial pneumonitis after gemcitabine treatment combined with whole liver radiotherapy for prevention of recurrence of pancreatic carcinoma. Suizo, 2005, 20, 55-60.	0.1	0
4533	Assessment and strategy of treatment for inoperable pancreatic cancer. Suizo, 2005, 20, 349-356.	0.1	5
4534	Long-term surviver with multiple lung metastases after pancreatectomy treated by continuous administration of gemcitabine hydrochloride. Suizo, 2005, 20, 547-553.	0.1	2
4535	5-Fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.. Suizo, 2005, 20, 416-417.	0.1	0
4536	Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreas cancer. Journal of Clinical Oncology, 2005, 23, 4234-4234.	0.8	0
4537	Profiles and Legacies. , 2005, , 289-334.		0
4538	A CASE OF SMALL PANCREATIC CANCER WITH INTRADUCTAL SPREADING AND REGIONAL LYMPH NODE METASTASIS. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2006, 67, 1390-1394.	0.0	0
4539	Gastrointestinale Tumoren. , 2006, , 500-539.		0
4540	Chemotherapy for Cancer Pain Management. , 2006, , 459-464.		0
4541	Pankreaskarzinom. , 2006, , 3969-3998.		0
4543	Influence of telling patients chemotherapeutic endpoints on quality of terminal care. Palliative Care Research, 2006, 1, 121-128.	0.0	0
4544	A study of resected small pancreatic cancer. Suizo, 2006, 21, 323-328.	0.1	2
4545	Pathological evaluation of advanced pancreatic cancer after gemcitabine treatment. Suizo, 2006, 21, 346-352.	0.1	0
4546	Horizons for Cancer Chemotherapy (and Nonchemotherapy). , 2006, , 445-457.		0
4548	Quality of Life and Hepatobiliary Tumors. , 2007, , 404-417.		0
4549	Liver Abscesses and An Intrahepatic Pseudoaneurysm caused by Arterial Infusion Therapy for Unresectable Pancreatic Cancer. Japanese Journal of Gastroenterological Surgery, 2007, 40, 91-96.	0.0	0
4550	Combined chemotherapy with S-1 and gemcitabine induced duodenal penetration of pancreatic head cancer: Report of a case. Suizo, 2007, 22, 576-581.	0.1	5

#	Article	IF	Citations
4551	Retrospective analysis of chemoradiotherapy for locally advanced pancreatic cancer. Suizo, 2007, 22, 43-47.	0.1	1
4552	Improvement of Cancer Cachexia with Chemothermotherapy in a Patient with Advanced Pancreatic Cancer. Thermal Medicine, 2007, 23, 159-170.	0.0	0
4553	Recent advances in chemotherapy for pancreatic carcinoma. Suizo, 2007, 22, 10-13.	0.1	0
4554	Malignome des Gastrointestinaltrakts. , 2007, , 573-690.		0
4555	Multimodal Therapy for Select Gastrointestinal Malignancies. , 2007, , 315-327.		0
4556	Present status of adjuvant chemotherapy for pancreatic cancer. Suizo, 2007, 22, 26-29.	0.1	3
4557	Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer. Suizo, 2007, 22, 592-594.	0.1	0
4558	Outcomes of gemcitabine treatment for invasive ductal pancreatic cancer. Suizo, 2007, 22, 30-35.	0.1	0
4559	Radiation Therapy in the Management of Cancer Pain. , 2007, , 328-336.		0
4560	Efforts to improve the anti-tumor effect of gemcitabine in human pancreatic cancer. Suizo, 2007, 22, 21-25.	0.1	0
4561	Molecular Basis of Radiation Therapy. , 2008, , 593-604.		2
4562	Improved Patients Outcomes by Chemotherapy mainly with Gemcitabine for Resected and Unresected Pancreatic Cancer. Japanese Journal of Gastroenterological Surgery, 2008, 41, 717-722.	0.0	1
4564	Incorporation of Genomics and Proteomics in Drug and Biomarker Development. , 2008, , 713-721.		0
4565	Adjuvant Chemoradiation for Pancreatic Cancer: Past, Present and Future. , 2008, , 535-547.		0
4566	A LONG-TERM SURVIVOR OF RECURRENT BILE DUCT CANCER TREATED WITH BYPASS SURGERY AND GEMCITABINE, TS-1 ADMINISTRATION. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		
4567	A case of long survival in advanced pancreatic cancer with multiple liver metastases successfully treated by combined chemotherapy of S-1 and gemcitabine. Suizo, 2008, 23, 510-518.	0.1	0
4568	An Overview of Clinical Trials of Targeted Therapies in Pancreatic Cancer. , 2008, , 565-575.		0
4569	Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine. Annals of Cancer Research and Therapy, 2008, 16, 21-22.	0.1	0

#	Article	IF	Citations
4570	Novel Targets for the Treatment of Pancreatic Cancer I: Insulin-like Growth Factor Receptor. , 2008, , 665-676.		0
4571	A case report: Curatively resected locally advanced pancreatic head cancer by improvement of extrapancreatic nerve plexus invasion with gemcitabine-based chemoradiotherapy. Suizo, 2008, 23, 525-532.	0.1	0
4572	IVã€€æ¶ˆåŒ–å™¨ç™Œã®å†…ç§‘çš„æ²»ç™‚æ³•ã»ç™‚,. Okayama Igakkai Zasshi, 2008, 119, 301-309.	0.0	0
4573	State of the Art in Radiation Therapy for Pancreas Cancer. , 2008, , 481-496.		0
4574	The Evolution of Chemoradiation Strategies for Locally Advanced Pancreatic Cancer. , 2008, , 497-510.		0
4575	Identification of the drug resistance related protein and possible application for the pancreatic cancer chemotherapy.. Seibutsu Butsuri Kagaku, 2008, 52, 31-34.	0.1	0
4576	Local Recurrence after Surgical Resection of Pancreatic Cancer Effectively Treated with Combined Chemoradiotherapy; A Case Report with 5-Year Survival. Japanese Journal of Gastroenterological Surgery, 2008, 41, 1610-1614.	0.0	0
4578	Cancer of the Exocrine Pancreas: Surgery and Multimodal Treatment. , 2009, , 89-100.		0
4579	Gemcitabine Changes the Gene Expression in Human Pancreatic Cancer Cells: Search for New Therapeutic Molecular Targets. , 2009, , 33-38.		0
4580	JPN (Japan Pancreas Society) guidelines for the management of pancreatic cancer. Okayama Igakkai Zasshi, 2009, 121, 195-198.	0.0	0
4581	Chemotherapy and Radiotherapy in Pancreatic Cancer. , 2009, , 481-500.		0
4582	A Case Report of the Primary Double Cancers of Duodenum and Pancreas. Japanese Journal of Gastroenterological Surgery, 2009, 42, 1562-1567.	0.0	1
4583	Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine. Suizo, 2009, 24, 208-209.	0.1	0
4584	The usefulness of perfusion-weighted magnetic resonance imaging in advanced pancreatic cancer. Suizo, 2009, 24, 747-748.	0.1	0
4586	A CASE OF COLONIC PERFORATION DURING CHEMOTHERAPY WITH GEMCITABIN HYDROCHLORIDE FOR PANCREATIC CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2009, 70, 3136-3140.	0.0	2
4587	Disseminated Carcinoma of Unknown Primary Site: Detection with F-Fluorodeoxyglucose-Positron Emission Tomography. , 2010, , 59-71.		0
4588	The European Study Group for Pancreatic Cancer (ESPAC) Trials. , 2010, , 109-121.		0
4589	Chemotherapie beim Pankreaskarzinom. , 2010, , 380-385.		0

#	Article	IF	Citations
4590	Cancer of the Pancreas. , 2010, , 801-819.		0
4591	A case of drug-induced hemolytic uremic syndrome during adjuvant chemotherapy with gemcitabine hydrochloride after resection of pancreatic cancer. Suizo, 2010, 25, 125-131.	0.1	1
4592	A case of remnant pancreatic cancer resected 4 years after pancreaticoduodenectomy for cancer of the papilla of Vater. Suizo, 2010, 25, 542-547.	0.1	1
4593	Clinical Decision Making in Pancreatic Cancer. , 2010, , 623-649.		2
4594	Antiangiogenic cancer therapy using peptide vaccine for patients with advanced pancreatic cancer. Suizo, 2010, 25, 53-58.	0.1	0
4595	A New Preclinical Paradigm for Pancreas Cancer. , 2010, , 73-93.		2
4597	Malignant Tumors. , 2010, , 1519-1566.		0
4598	MicroRNA Profiling and Its Application in Drug Discovery in Pancreatic Cancer. , 2010, , 171-180.		0
4599	Novel Drugs for Intraperitoneal Therapy for Ovarian Cancer. , 2010, , 95-108.		0
4601	Unresectable Pancreatic Cancer. , 2011, , 205-224.		0
4602	Leber-, Gallenwegs- und Pankreaserkrankungen. , 2011, , 445-528.		0
4603	ChimiothÃ©rapie et radiothÃ©rapie des cancers pancrÃ©atiques. , 2011, , 415-424.		0
4604	Cancer Stem Cells in Pancreatic Cancer. , 2011, , 79-97.		0
4605	Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. , 2011, , 347-355.		0
4606	Stereotactic Body Radiation Therapy for Tumors of the Pancreas. , 2011, , 279-285.		0
4607	Pancreas Cancer. , 2011, , 2763-2765.		0
4608	Anti-tumor effect of the insulin-like growth factor-1 receptor (IGF-1R) on human pancreatic cancer cells in both in vitro and in vivo studies. Suizo, 2011, 26, 575-582.	0.1	0
4610	Principles of Medical Oncology and Chemotherapy. , 2012, , 3-13.		0

#	Article	IF	Citations
4611	Quality of life and hepatopancreatobiliary tumors. , 2012, , 418-435.e2.		1
4613	A case of pancreatic cancer with liver metastasis surviving 50 months after surgery. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2012, 73, 1238-1242.	0.0	1
4614	A Case of Pancreatic Cancer After Heart Transplantation. International Heart Journal, 2012, 53, 205-207.	0.5	4
4615	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
4616	Malignome des Gastrointestinaltrakts. , 2012, , 557-665.		0
4617	Could Gemcitabine Change the Suffering of Pancreatic Cancer Patients?:- Varidation of this Decade and Expectation of Next Decade. Pancreatic Disorders & Therapy, 2012, 02, .	0.3	0
4619	Phase I Clinical Trial of Peptide Vaccination with KIF20A and VEGFR1 Epitope Peptides in Patients with Advanced Pancreatic Cancer. Pancreatic Disorders & Therapy, 2012, 02, .	0.3	4
4620	Cost-utility analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer. Suizo, 2012, 27, 185-193.	0.1	0
4621	The quandary of autoimmune pancreatitis and pancreatic ductal adenocarcinoma: A case report and review of IgG4 immunostaining in a cohort of patients receiving neoadjuvant chemotherapy. International Journal of Hepatobiliary and Pancreatic Diseases, 2012, 2, 38.	0.2	0
4622	Current Perspectives and Future Trends of Systemic Therapy in Advanced Pancreatic Carcinoma. , 0, , .		0
4623	Immunotherapy of the Pancreatic Cancer. , 0, , .		0
4624	Immunotherapy for Pancreatic Cancer. , 0, , .		0
4625	Multi-Disciplinary Management of Metastatic Pancreatic Cancer. , 0, , .		0
4627	Pancreatic Cancer (Exocrine). , 2013, , 119-131.		0
4628	Le cancer du pancrÃ©as. Bulletin De L'Academie Nationale De Medecine, 2012, 196, 1819-1828.	0.0	2
4629	Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe. , 2013, , 129-143.		0
4631	Total Stomach-Preserving Duodenojejunostomy for Unresectable Cancer of the Head of the Pancreas. Yamaguchi Medical Journal, 2013, 62, 211-215.	0.1	0
4632	Cisplatin plus Gemcitabine in patients with inoperable or metastatic pancreatic cancer. IOSR Journal of Dental and Medical Sciences, 2013, 11, 65-71.	0.0	0

#	Article	IF	Citations
4633	Gemcitabine cures metastatic hepatic carcinoma and bone metastasis. World Journal of Hematology, 2013, 2, 115.	0.1	0
4634	Recent Developments and Current Issues in the Treatment of Pancreatic Cancer. Journal of Cancer Therapy, 2013, 04, 13-27.	0.1	1
4635	Gemcitabine Induced Bone-marrow Suppression in Pancreatic or Biliary Tract Cancer Patients with Moderate Renal Dysfunction. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	1
4636	Systemische und regionale Chemotherapie beim fortgeschrittenen und metastasierten Pankreaskarzinom. , 2013, , 217-224.		0
4637	Cancerâ€”Integrated Naturopathic Support. , 2013, , 440-461.		0
4638	Impact of ABO Blood Types on Survival after Pancreatectomy for Pancreatic Cancer. Journal of Cancer Therapy, 2013, 04, 7-12.	0.1	1
4639	Stage II Trial of Capecitabine Joined Together with Thalidomide in Second-Line Medicine of Progressed Pancreatic Growth. Pancreatic Disorders & Therapy, 2013, 03, .	0.3	0
4640	Development of multidisciplinary therapy including surgical resection and chemotherapy for pancreatic cancer through clinical trials. Suizo, 2013, 28, 12-20.	0.1	0
4641	A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin in cancer patients.. Journal of Clinical Oncology, 2013, 31, 290-290.	0.8	0
4643	Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 192-192.	0.8	1
4644	Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Research, 2013, 2, 105.	0.8	1
4645	Clinical study report. , 2013, , 289-291.		4
4646	Clinical Trial Designs for Approval of New Anticancer Agents. Cancer Drug Discovery and Development, 2014, , 785-802.	0.2	0
4647	Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancerâ€”A Potential Strategy for Improved Survival. Journal of Cancer Therapy, 2014, 05, 1072-1091.	0.1	2
4648	ç‰¹é›†ã•ã¸ãŸã£ã¦. Suizo, 2014, 29, 871-872.	0.1	0
4649	Medical Oncology. , 2014, , 71-82.		0
4651	A Systematic Review of Neoadjuvant Therapy Compared to the â€œResection Firstâ€•Approach for Patients with Borderline Resectable Pancreatic Adenocarcinoma. Journal of Cancer Therapy, 2014, 05, 91-100.	0.1	1
4652	Incidence Rather than Magnitude: A Lower Bound on the Share of Responders. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
4653	Progress and perspectives of post-operative adjuvant chemotherapy for adenocarcinoma of the pancreas. Suizo, 2014, 29, 878-884.	0.1	0
4654	The current status of FOLFIRINOX for unresectable pancreatic cancer. Suizo, 2014, 29, 885-891.	0.1	0
4655	Pyrimidine Antimetabolitesâ˜†. , 2014, , .		0
4656	RAS Genes and Cancer. , 2014, , 157-171.		0
4657	A case of pathological complete response after chemotherapy by S-1 and gemcitabine for a pancreatic cancer with para-aortic lymph node metastasis. Suizo, 2014, 29, 898-904.	0.1	5
4659	Carcinoma of the Pancreas. , 2014, , 1397-1415.e7.		3
4660	Gene Expression Profiling of Pancreatic Cancer Reveals a Significant Deregulation of the TGF-Î² Pathway and the Discovery of Genes for Prognosis. Global Journal of Human Genetics & Gene Therapy, 2014, 1, 67-76.	0.0	0
4661	Pankreaskarzinom. , 1998, , 621-638.		0
4662	Biological Approaches to the Therapy of Pancreatic Cancer. , 1999, , 222-229.		0
4663	Advances in the Management of Pancreatic Cancer. , 1999, , 294-304.		0
4664	Hepatobiliary Cancer, Pancreatic Cancer, and Neuroendocrine Cancers of the GI Tract. , 1999, , 721-762.		0
4665	Pancreatic and Periampullary Tumors. , 1999, , 239-258.		0
4666	Nab-Paclitaxel in Patients with Advanced Pancreatic Cancer: Case Series. Journal of Case Reports, 2014, 4, 295-299.	0.1	0
4667	Quality of Life Measures. , 2015, , 95-110.		0
4668	Liver Metastases from Pancreatic Adenocarcinoma. , 2015, , 95-109.		0
4669	Thromboprophylaxis in Pancreatic Cancer: Why isnÂ't Prime Time Here Compared to Multiple Myeloma?. Pancreatic Disorders & Therapy, 2015, 05, .	0.3	0
4670	Pankreaskarzinom. , 2015, , 1-11.		0
4671	Pancreatic Cancer and Sphingolipids. , 2015, , 211-233.		0

#	Article	IF	Citations
4672	Increasing Bioavailability of Cytotoxic Agents through Prolonged Therapy and Addition of Polymechanistic Antiangiogenic Agents Enhances Antitumor Response in Pancreatic Cancer. Biochemistry & Pharmacology: Open Access, 2015, 04, .	0.2	0
4673	Gemcitabine Plus Erlotinib Combination Therapy in Four Patients with Unresectable Advanced Recurrent Pancreatic Cancer:. Journal of the Nihon University Medical Association, 2015, 74, 106-108.	0.0	0
4674	A Case of Successful Management of Liver Metastasis from a Pancreatic Carcinoma by Combined Hepatectomy and Chemotherapy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 657	0.0	0
4675	Stereotactic body radiotherapy (SBRT) reirradiation for recurrent pancreas cancer.. Journal of Clinical Oncology, 2015, 33, 451-451.	0.8	0
4676	Advances in Gastrointestinal Surgery. GI Surgery Annual, 2015, , 179-237.	0.0	0
4677	Pancreatic CancerPancreatic Cancer. , 2015, , 315-336.		0
4678	Pankreastumoren. , 2015, , 557-567.		0
4679	Pancreatic Head Cancer with Paraaortic Lymph Node Metastases Successfully Resected after Gemcitabine+S-1 Chemotherapy. Japanese Journal of Gastroenterological Surgery, 2015, 48, 698-705.	0.0	0
4680	Cell-Specific Aptamers for Targeted Therapy. , 2015, , 301-337.		0
4682	Real-World Evaluation of Hematologic Toxicity Associated with nab-Paclitaxel Plus Gemcitabine for Advanced Pancreatic Cancer. American Journal of Cancer Research and Clinical Oncology, 0, , .	0.0	0
4683	Erlotinib for advanced pancreatic cancer. The Cochrane Library, 0, , .	1.5	0
4684	BP-C2 improves Functional status, Quality of Life and Corrects Biochemical Imbalances as Adjuvant Therapy to FOLFIRINOX Treatment: A Case of Advanced Inoperable Pancreatic Cancer. Journal of Clinical Case Reports, 2015, 05, .	0.0	1
4685	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
4686	Malignome des Gastrointestinaltrakts. , 2015, , 579-693.		0
4687	Clinical Observation of High Intensity Focused Ultrasound (HIFU) Ablation Combined with Qingyihuaji Formula for Salvage Treatment for Advanced Pancreatic Cancer Patients Failed to Systemic Chemotherapy. Asian Case Reports in Oncology, 2015, 04, 1-7.	0.0	0
4688	A case of long term survival of pancreatic cancer with paraaortic nodal metastasis. Suizo, 2015, 30, 137-143.	0.1	0
4689	Efficacy and Safety of Fixed-Dose-Rate Infusions of Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer. Journal of Analytical Oncology, 2015, 4, 44-51.	0.1	0
4690	Anti-mutagenic Activity of Salvia merjamie Extract Against Gemcitabine. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1501-1506.	0.5	1

#	Article	IF	Citations
4693	Current Treatment Options for Metastatic Pancreatic Adenocarcinoma.. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2015, 25, 263-274.	0.1	1
4694	Genetic factors affecting patient responses to pancreatic cancer treatment. Annals of Gastroenterology, 2016, 29, 466-476.	0.4	5
4695	Adjuvant Chemotherapy in Pancreatic Cancer. , 2016, , 1-34.		0
4696	Hyperthermia Combined with Chemotherapy: Pancreatic Cancer. , 2016, , 275-285.		0
4697	Systemic and Regional Chemotherapy for Advanced and Metastasized Pancreatic Cancer. , 2016, , 243-251.		0
4698	How to Design Clinical Trials?. , 2016, , 79-93.		1
4699	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2016, , 1-27.		0
4700	Cranial Bone Metastasis from Pancreatic Cancer Associated with Dysphagia. Japanese Journal of Gastroenterological Surgery, 2016, 49, 1023-1028.	0.0	1
4701	Unresectable Pancreatic Adenocarcinoma: Eight Years Later. World Journal of Oncology, 2016, 7, 17-20.	0.6	0
4702	Qualitative Progress of Pharmaceutical Care for Cancer Chemotherapy Based on Discovery, Assessment and Prophylactic Method of Adverse Drug Reaction Overlooked by Healthcare Professional. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2016, 42, 137-144.	0.0	1
4703	Pankreaskarzinom beim alten und geriatrischen Patienten. , 2016, , 1-9.		0
4704	Therapy-Associated Myeloid Dysplasia in a Long-Surviving Patient with Pancreatic Cancer. Cureus, 2016, 8, e687.	0.2	1
4705	A Case of Pneumatosis Cystoides Intestinalis after Erlotinib-containing Chemotherapy for Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2016, 21, 156-162.	0.0	0
4706	Pankreas. , 2017, , 199-226.		0
4707	The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice?. Endoscopic Ultrasound, 2017, 6, 87.	0.6	1
4708	Palliative Care and Pancreatic Disease. , 2017, , 127-149.		0
4709	Chemotherapy in the Management of Pancreatic Cancer. , 2017, , 387-419.		0
4710	Chemotherapy for Advanced Pancreatic Cancer. , 2017, , 1-48.		0

#	Article	IF	Citations
4711	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
4713	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 1-27.		0
4714	Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer. , 2017, , 1-15.		0
4715	è†µè‡“æ²»ç™‚ã®å‰é•å”€æ‰‹è¡“å¾ç‹¬ã•ã‚‰é›†å¦çš„æ²»ç™‚ã®æ™‚ä»£ã¸. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College	0.0	0
4717	Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer. , 2017, , 749-775.		0
4719	A CLINICOPATHOLOGICAL STUDY AND MANAGEMENT OF CARCINOMA PANCREAS. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 2225-2230.	0.1	0
4720	THE PERIOPERATIVE FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS UNDERGOING BILIARY SURGERIES. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 2236-2243.	0.1	0
4721	Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed. , 2018, , 205-217.		0
4722	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	0.8	0
4723	Can Nigella Sativa and Pure Honey Improved Chemoradiotherapy Effects in Advanced Pancreatic Cancer. Journal of Nutritional Health & Food Engineering, 2017, 7, .	0.5	0
4724	Long Lasting Response in Metastatic Pancreatic Exocrine Cancer: Abnormality or Diagnostic Miss? A Case Report with Brief Literature Review. Pancreatic Disorders & Therapy, 2018, 08, .	0.3	0
4725	Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260.		0
4726	Superiority and Non-inferiority Phase III Oncology Trials. , 2018, , 203-216.		0
4727	Pankreaskarzinom beim alten und geriatrischen Patienten. , 2018, , 333-341.		0
4728	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. , 2018, , 191-224.		0
4729	4ï¼Žåˆ‡é™ä¸èƒ½è†µç™Œã«å¯¾ã™ã‚‹æ²»ç™‚æˆ¦ç•¥ã®ç¾çŠ¶ã¨èª²é¡Œ. Suizo, 2018, 33, 37-47.	0.1	0
4732	Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer. In Vivo, 2018, 32, 653-657.	0.6	8
4733	Gemcitabineï¼‹<i>nab</i>-Paclitaxelä½µç”¨ç™‚æ³•å¾ŒãÂ«åˆ‡é™å•èƒ½ã¨ã•ã‚ã£ãŸå±€æ‰€é€²è¡Œåˆ‡é™ä¸èƒ½è†µç™Œã		

#	Article	IF	Citations
4735	Treatment of Advanced Pancreatic Carcinoma. , 2019, , 255-268.		0
4736	Treatment Sequencing for Locally Advanced Pancreatic Cancer. , 2019, , 105-112.		0
4737	A Case of Pancreatic Head Cancer with a Hepatic Metastasis that Showed Complete Response to Administration of Gemcitabine + Nab-Paclitaxel Therapy. Nihon Gekakei Rengo Gakkaishi (Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	g0	0
4739	Landmark Trials in Selected Gastrointestinal Cancers. , 2019, , 123-168.		0
4740	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2019, , 1-28.		0
4741	Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. Oncology & Hematology Review, 2019, 15, 27.	0.2	2
4742	Resectable and Borderline Resectable Pancreatic Cancer. , 2019, , 235-254.		0
4744	Pankreas duktal adenokarsinomunda NF-Kappa B ekspresyonu. Cukurova Medical Journal, 2019, 44, 1-1.	0.1	0
4745	Potential mechanism of ferroptosis in pancreatic cancer (Review). Oncology Letters, 2020, 19, 579-587.	0.8	24
4746	Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis. JCO Precision Oncology, 2019, 3, 1-22.	1.5	8
4747	Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study. Meditsinskiy Sovet, 2019, , 74-82.	0.1	0
4748	Hepatocyte Growth Factor and Macrophage-stimulating Protein â€œHingeâ€•Analogs to Treat Pancreatic Cancer. Current Cancer Drug Targets, 2019, 19, 782-795.	0.8	1
4749	Chemotherapy for patients with unresesctable pancreatic cancer is recommended in the Clinical Practice Guidelines for Pancreatic Cancer 2019. Suizo, 2020, 35, 69-74.	0.1	0
4751	A prognostic nomogram for pancreatic ductal adenocarcinoma patientsâ€™ all-cause survival in a Surveillance, Epidemiology, and End Results analysis. Translational Cancer Research, 2020, 9, 3586-3599.	0.4	1
4752	Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity in vitro and in vivo through targeting the NF-Î²B signaling pathway in pancreatic cancer. Aging, 2020, 12, 11116-11138.	1.4	11
4753	Assessment of the treatment effects of chemoradiotherapy in patients with pancreatic cancer. Suizo, 2020, 35, 280-292.	0.1	1
4754	Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. Journal of Palliative Medicine, 2022, 25, 720-727.	0.6	22
4755	CD95L Inhibition Impacts Gemcitabine-Mediated Effects and Non-Apoptotic Signaling of TNF-Î± and TRAIL in Pancreatic Tumor Cells. Cancers, 2021, 13, 5458.	1.7	0

#	Article	IF	Citations
4757	Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis. Genes, 2021, 12, 1701.	1.0	24
4758	Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1579-1591.	0.7	29
4759	Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases. Frontiers in Oncology, 2021, 11, 729490.	1.3	2
4760	MicroRNAâ€'7 modulates cellular senescence to relieve gemcitabine resistance by targeting PARP1/NFâ€'ÎºB signaling in pancreatic cancer cells. Oncology Letters, 2020, 21, 139.	0.8	10
4762	Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Current Oncology, 2021, 28, 209-219.	0.9	2
4763	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2021, , 1-22.		0
4764	In Frail Elderly Patients, Low-Dose Gemcitabine over 6-Hour Infusion Is Equally Effective and Less Toxic Than the Standard Gemcitabine Protocol for Advanced Pancreatic Adenocarcinoma: A Randomized Phase II Trial. Journal of Cancer Therapy, 2020, 11, 124-141.	0.1	2
4766	Prolonged Infusion of Low Dose Gemcitabine in Advanced Pancreatic Carcinoma. Journal of Cancer Therapy, 2020, 11, 401-409.	0.1	1
4767	Drug-eluting Biliary Stent. The Korean Journal of Pancreas and Biliary Tract, 2020, 25, 11-17.	0.0	0
4768	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2020, , 731-757.		1
4769	Pancreatic cancer: Ukrainian and world tendencies. Practical Oncology, 2020, 3, 42-45.	0.1	1
4770	Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 1089-1107.	1.9	1
4771	Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). International Journal of Oncology, 2021, 59, .	1.4	5
4772	Bioinspired adhesive microneedle patch with gemcitabine encapsulation for pancreatic cancer treatment. Chemical Engineering Journal, 2022, 431, 133362.	6.6	29
4773	Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 743908.	1.8	29
4774	OXCT1 Enhances Gemcitabine Resistance Through NF-ÎºB Pathway in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 698302.	1.3	4
4775	How open is the therapeutic horizon for pancreatic cancer patients?. Hepatobiliary and Pancreatic Diseases International, 2022, 21, 1-3.	0.6	3
4776	Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review). International Journal of Oncology, 2020, 57, 631-664.	1.4	28

#	Article	IF	Citations
4777	Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer. The Korean Journal of Pancreas and Biliary Tract, 2020, 25, 72-82.	0.0	1
4778	Intraoperative Radiation for Pancreatic Cancer. , 2002, , 287-293.		0
4779	Radiation Sensitizers, Fractionation Schedules, and Future Clinical Trials. , 2002, , 301-310.		0
4782	Ethics of Clinical Oncology Research. , 2006, , 127-142.		0
4783	Medical management of pancreatic cancer. , 0, , 102-113.		0
4785	Pankreasneoplasien. , 2005, , 415-422.		0
4789	Unresectable Locally Advanced Pancreatic Cancer: Concurrent Chemotherapy. , 2008, , 227-236.		0
4790	Spinal Metastases From Gastrointestinal Malignancies. , 2006, , 131-139.		0
4794	Oncological Management of Pancreatic Cancer in Advanced Stages. , 2008, , 549-557.		0
4795	Management of Locally Advanced and Recurrent Pancreas Cancer. , 2008, , 689-694.		0
4796	Survival After Medical and Surgical Treatment of Pancreatic Adenocarcinoma. , 2008, , 695-704.		0
4797	Pankreaskarzinom. , 0, , 713-733.		0
4798	Neoplasien des Pankreas und der Gallenwege. , 2007, , 976-984.		0
4799	Adjuvant Therapy in Patients with Pancreatic Cancer. , 2008, 177, 49-56.		0
4800	Neoadjuvant and Adjuvant Strategies for Chemoradiation. , 2008, 177, 65-77.		0
4802	Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdominal Imaging, 2006, 31, 568.	2.0	0
4803	Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. Journal of Oncology, 2020, 2020, 1-10.	0.6	0
4804	Design, Synthesis, and Biological Evaluation of 4-amino Substituted 2Hchromen- 2-one Derivatives as an NEDD8 Activating Enzyme Inhibitor in Pancreatic Cancer Cells. Medicinal Chemistry, 2020, 16, 969-983.	0.7	0

#	Article	IF	Citations
4806	Emerging therapies in pancreas cancer. Journal of Gastrointestinal Oncology, 2011, 2, 93-103.	0.6	11
4807	Effect of flutamide on survival in patients with pancreatic cancer. Study needs to be repeated on a much larger scale. BMJ: British Medical Journal, 1999, 318, 326-7; author reply 328.	2.4	0
4808	Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. Cmaj, 1998, 158, 1727-34.	0.9	15
4809	Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic Cancer. The Journal of Applied Research, 2004, 4, 635-646.	2.0	4
4810	Optimal adjuvant therapy for resected pancreatic cancer: chemotherapy or chemoradiotherapy?. Gastrointestinal Cancer Research: GCR, 2007, 1, 182-7.	0.8	2
4811	Thromboembolism in gastrointestinal cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, 267-72.	0.8	6
4812	Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale Journal of Biology and Medicine, 2009, 82, 1-6.	0.2	46
4813	The role of radiation therapy in pancreas cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, 20-8.	0.8	25
4814	Targeted therapies for pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S16-9.	0.8	15
4815	Particle radiation therapy for gastrointestinal malignancies. Gastrointestinal Cancer Research: GCR, 2007, 1, S50-9.	0.8	1
4816	Pancreatic adenocarcinoma: new strategies for success. Gastrointestinal Cancer Research: GCR, 2009, 3, S11-5.	0.8	14
4817	Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics: Targets and Therapy, 2009, 3, 419-28.	3.0	29
4818	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics: Targets and Therapy, 2009, 3, 429-41.	3.0	3
4819	Interaction between Gemcitabine and Warfarin Causing Gastrointestinal Bleeding in a Patient with Pancreatic Cancer. The Journal of Applied Research, 2005, 5, 434-437.	2.0	2
4820	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S43-7.	0.8	2
4821	Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P and T, 2009, 34, 554-64.	1.0	17
4822	The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointestinal Cancer Research: GCR, 2009, 3, 197-203.	0.8	3
4825	Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evidence, 2007, 2, 111-9.	4.7	1

#	Article	IF	Citations
4827	Diagnosing and managing pancreatic cancer. Practitioner, 2011, 255, 21-5, 2-3.	0.3	5
4828	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget, 2010, 1, 515-29.	0.8	9
4829	Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Gastrointestinal Cancer Research: GCR, 2011, 4, 128-34.	0.8	9
4830	A 71-year-old man with a large cystic pancreatic mass. Gastrointestinal Cancer Research: GCR, 2012, 5, 29-31.	0.8	0
4831	Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP: Journal of the Pancreas, 2011, 12, 377-83.	1.5	3
4832	A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 77-83.	0.8	12
4833	A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2012, 5, 155-60.	0.8	3
4835	2013 american society of clinical oncology. P and T, 2013, 38, 420-4.	1.0	0
4838	New possibilities and potential benefits for local control in locally recurrent pancreatic cancer. Journal of Gastrointestinal Oncology, 2013, 4, 340-2.	0.6	2
4839	Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Research, 2011, 31, 1093-103.	0.5	35
4840	Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Molecular Imaging, 2011, 10, 153-67.	0.7	18
4841	Arterial resection for pancreatic cancer: a modern surgeon should change its behavior according to the new therapeutic options. Giornale Di Chirurgia, 2014, 35, 5-14.	0.5	4
4842	Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial. International Journal of Clinical and Experimental Medicine, 2015, 8, 21159-65.	1.3	4
4843	Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. American Journal of Cancer Research, 2016, 6, 84-90.	1.4	8
4845	Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN. American Journal of Translational Research (discontinued), 2017, 9, 1886-1895.	0.0	22
4846	Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kobe Journal of Medical Sciences, 2017, 63, E9-E16.	0.2	0
4847	A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged â‰¥75 years: a study protocol for an open-label randomised feasibility study. BMJ Open Gastroenterology, 2018, 5, e000187.	1.1	2
4850	Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. JOP: Journal of the Pancreas, 2018, 19, 75-85.	1.5	16

#	Article	IF	Citations
4851	Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer. American Journal of Cancer Research, 2018, 8, 1812-1822.	1.4	12
4852	Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. American Journal of Cancer Research, 2019, 9, 390-405.	1.4	7
4853	The up-regulation of Axl is associated with a poor prognosis and promotes proliferation in pancreatic ductal adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2019, 12, 1626-1633.	0.5	2
4854	Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells. American Journal of Translational Research (discontinued), 2020, 12, 3702-3714.	0.0	0
4855	New Developments in the Treatment of Pancreatic Cancer: Highlights from the 44th ASCO Annual Virtual Meeting, May 29-31, 2020. JOP: Journal of the Pancreas, 2020, 21, 108-111.	1.5	1
4856	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. American Journal of Cancer Research, 2020, 10, 3047-3060.	1.4	3
4857	Simultaneous microRNA-612 restoration and 5-FU treatment inhibit the growth and migration of human PANC-1 pancreatic cancer cells. EXCLI Journal, 2021, 20, 160-173.	0.5	1
4858	Metastatic pancreatic adenocarcinoma treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin as a II line chemotherapy. OnCOReview, 2021, 11, 44-47.	0.1	1
4859	MiR-199 Reverses the Resistance to Gemcitabine in Pancreatic Cancer by Suppressing Stemness through Regulating the Epithelialâ€“Mesenchymal Transition. ACS Omega, 2021, 6, 31435-31446.	1.6	3
4860	Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma. Cancers, 2021, 13, 5717.	1.7	9
4861	Comment on â€œImplications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma by Crippa et al.â€• Annals of Surgery, 2022, 276, e136-e137.	2.1	1
4862	The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. JAMA Network Open, 2021, 4, e2133388.	2.8	3
4863	Anticancer Effect of Heparinâ€“Taurocholate Conjugate on Orthotopically Induced Exocrine and Endocrine Pancreatic Cancer. Cancers, 2021, 13, 5775.	1.7	2
4864	Clinical Studies on Ultrafractionated Chemoradiation: A Systematic Review. Frontiers in Oncology, 2021, 11, 748200.	1.3	5
4865	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	5.8	10
4867	Peptide dendrimers as potentiators of conventional chemotherapy in the treatment of pancreatic cancer in a mouse model. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 121-132.	2.0	12
4868	IMB5036 inhibits human pancreatic cancer growth primarily through activating necroptosis. Basic and Clinical Pharmacology and Toxicology, 2022, 130, 375-384.	1.2	8
4869	Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer. Medicine (United States), 2021, 100, e27870.	0.4	4

#	Article	IF	Citations
4870	Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 4912-4922.	1.3	6
4872	Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report. Journal of Oncology Pharmacy Practice, 2022, , 107815522110735.	0.5	1
4873	Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine. Biomedicines, 2022, 10, 149.	1.4	5
4874	A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine. Translational Oncology, 2022, 16, 101329.	1.7	12
4875	Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer. Translational Oncology, 2022, 16, 101315.	1.7	8
4879	Targeted therapies in the treatment of pancreatic carcinoma. , 2003, 5, 434-442.		0
4881	Super-enhancers modulate interleukin-6 expression and function in cancers. Translational Cancer Research, 2020, 9, 5555-5565.	0.4	1
4882	High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. International Journal of Oncology, 2020, 58, 57-69.	1.4	3
4883	Cardamonin Promotes the Apoptosis and Chemotherapy Sensitivity to Gemcitabine of Pancreatic Cancer Through Modulating the FOXO3a-FOXM1 Axis. Dose-Response, 2021, 19, 155932582110421.	0.7	8
4884	A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain. Anticancer Research, 2022, 42, 343-348.	0.5	0
4885	Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells â€“ An Analysis for Patients With Incurable Pancreatic Cancer. Anticancer Research, 2022, 42, 1181-1187.	0.5	1
4886	Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer - Results from a prospective phase IV clinical trial. Journal of Geriatric Oncology, 2022, 13, 662-666.	0.5	3
4887	FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study). Cancer Diagnosis & Prognosis, 2022, 2, 101-106.	0.3	1
4888	FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Journal of Chemotherapy, 2022, 34, 465-471.	0.7	5
4890	Towards an integrative understanding of cancer mechanobiology: calcium, YAP, and microRNA under biophysical forces. Soft Matter, 2022, 18, 1112-1148.	1.2	11
4891	Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas. Journal of Gastrointestinal Surgery, 2022, 26, 869-886.	0.9	5
4892	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. British Journal of Cancer, 2022, 126, 1394-1400.	2.9	5
4893	Arterial Administration of DNA Crosslinking Agents with Restraint of Homologous Recombination Repair by Intravenous Low-Dose Gemcitabine Is Effective for Locally Advanced Pancreatic Cancer. Cancers, 2022, 14, 220.	1.7	1

#	Article	IF	Citations
4894	Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan. JAMA Network Open, 2022, 5, e2145515.	2.8	6
4895	Macrophage C/EBPÎ´ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner. Biomedicines, 2022, 10, 219.	1.4	4
4896	S-Adenosylmethionine enhances the inhibitory effect of gemcitabine against pancreatic cancer cells via suppression of the EGFR/AKT pathways. Molecular and Cellular Toxicology, 0, , 1.	0.8	1
4897	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology, 2022, 169, 103571.	2.0	17
4898	Employing Novel Porcine Models of Subcutaneous Pancreatic Cancer to Evaluate Oncological Therapies. Methods in Molecular Biology, 2022, 2394, 883-895.	0.4	5
4899	Synthesis and in silico evaluation of novel uridyl sulfamoylbenzoate derivatives as potential anticancer agents targeting M1 subunit of human ribonucleotide reductase (hRRM1). Medicinal Chemistry Research, 2022, 31, 1109-1119.	1.1	1
4900	Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Visceral Medicine, 2022, 38, 20-29.	0.5	7
4901	Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer. Cancers, 2022, 14, 638.	1.7	16
4902	Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Frontiers in Oncology, 2022, 12, 822039.	1.3	4
4903	Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Surgery, 2022, 171, 1464-1470.	1.0	15
4904	Oxygen-carrying microfluidic microcapsules for enhancing chemo-sonodynamic therapy on patient-derived tumor organoid models. Chemical Engineering Journal, 2022, 435, 134871.	6.6	29
4905	Ferroptosis in cancer and cancer immunotherapy. Cancer Communications, 2022, 42, 88-116.	3.7	179
4906	Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 819.	1.7	17
4907	Matrix stiffening and acquired resistance to chemotherapy: concepts and clinical significance. British Journal of Cancer, 2022, 126, 1253-1263.	2.9	7
4908	Establishment of a mouse model of pancreatic cancer using human pancreatic cancer cell line S2-013-derived organoid. Human Cell, 2022, 35, 735-744.	1.2	4
4909	Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. JOP: Journal of the Pancreas, 2014, 15, 19-24.	1.5	8
4910	Quality of life in patients with pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 317-8.	1.5	11
4911	Multimodality treatment by FOLFOX plus HIFU in a case of advanced pancreatic carcinoma. A case report. JOP: Journal of the Pancreas, 2015, 16, 66-9.	1.5	10

#	Article	IF	Citations
4912	Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review. Journal of Gastrointestinal Oncology, 2021, 13, 0-0.	0.6	0
4915	Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database. Cancers, 2022, 14, 1105.	1.7	2
4916	SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Cancers, 2022, 14, 916.	1.7	6
4917	Targeting the Endocannabinoidome in Pancreatic Cancer. Biomolecules, 2022, 12, 320.	1.8	6
4918	The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. Biomedicines, 2022, 10, 517.	1.4	7
4919	Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Cancers, 2022, 14, 985.	1.7	25
4920	Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review. International Journal of Molecular Sciences, 2022, 23, 2093.	1.8	2
4922	Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)â€"basis and current status. Ecancermedicalscience, 0, 16, .	0.6	0
4923	Multidisciplinary treatment of pancreatic cancer: a case report. Gland Surgery, 2022, 11, 628-636.	0.5	0
4924	Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort. Annals of Translational Medicine, 2022, 10, 294-294.	0.7	5
4925	Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers, 2022, 14, 1354.	1.7	6
4926	Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancerÂvia inhibiting the Nrf2 pathway. Journal of Experimental and Clinical Cancer Research, 2022, 41, 90.	3.5	4
4927	GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. Molecular Cancer Therapeutics, 2022, 21, 960-973.	1.9	4
4928	Upregulation of PODXL and ITGB1 in pancreatic cancer tissues preoperatively obtained by EUS-FNAB correlates with unfavorable prognosis of postoperative pancreatic cancer patients. PLoS ONE, 2022, 17, e0265172.	1.1	2
4929	Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer. Investigational New Drugs, 2022, 40, 546-555.	1.2	5
4930	Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. Oncologist, 2022, , .	1.9	2
4931	Interstitial Lung Disease Associated with <i>Agaricus blazei</i> Murill in a Patient with Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine-Based Therapy. Case Reports in Gastroenterology, 2022, 16, 229-234.	0.3	1
4932	Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. Journal of Pathology, 2022, 257, 607-619.	2.1	13

#	Article	IF	Citations
4933	Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Cancer Letters, 2022, 537, 215591.	3.2	7
4934	Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Clinical and Translational Radiation Oncology, 2022, 34, 15-22.	0.9	6
4935	Effects of Tumor Microenvironment Acidification on Progression of Pancreatic Ductal Adenocarcinoma: A Review. Asia-Pacific Journal of Oncology, 2021, , 17-26.	0.2	0
4936	Complete remission and long-term response to gemcitabine + nab-paclitaxel in patient with metastatic pancreatic adenocarcinoma. Onkologie (Czech Republic), 2021, 15, 252-254.	0.0	0
4937	MicroRNAs in Pancreatic Cancer and Chemoresistance. Pancreas, 2021, 50, 1334-1342.	0.5	1
4938	Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers, 2022, 14, 68.	1.7	2
4939	Regional and age differences in specialised palliative care for patients with pancreatic cancer. BMC Palliative Care, 2021, 20, 192.	0.8	6
4940	Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 6164.	1.7	8
4941	HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers, 2021, 13, 6163.	1.7	8
4942	Glycometabolic rearrangementsâ€“aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential. Expert Opinion on Therapeutic Targets, 2021, 25, 1077-1093.	1.5	7
4943	Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma. South Asian Journal of Cancer, 0, , .	0.2	0
4944	Hippo Pathway in Regulating Drug Resistance of Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 13431.	1.8	15
4945	After me, the deluge. Biomedical Journal, 2021, 44, 645-650.	1.4	0
4946	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	10
4948	Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment. Cancers, 2021, 13, 6391.	1.7	18
4949	Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. Biomedicines, 2021, 9, 1814.	1.4	1
4950	Novel Compound C150 Inhibits Pancreatic Cancer Cell Epithelial-to-Mesenchymal Transition and Tumor Growth in Mice. Frontiers in Oncology, 2021, 11, 773350.	1.3	1
4951	The evolution of clinical outcomes in metastatic pancreatic adenocarcinoma: a 10-year experience at a tertiary referral center. Expert Review of Gastroenterology and Hepatology, 2022, , 1-8.	1.4	1

#	Article	IF	Citations
4963	A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer patients aged â‰¥75 years: a study protocol for an open-label randomised feasibility study. BMJ Open Gastroenterology, 2018, 5, e000187.	1.1	3
4964	Coeliac plexus radiosurgery for pain management in patients with advanced cancer : study protocol for a phase II clinical trial. BMJ Open, 2022, 12, e050169.	0.8	1
4966	Emerging drugs in pancreatic cancer. Expert Opinion on Emerging Drugs, 2004, 9, 73-89.	1.0	0
4970	Current status and future direction of chemotherapy for pancreatic cancer. Chinese Clinical Oncology, 2013, 2, 6.	0.4	3
4971	Molecular docking investigation of calotropone as a potential natural therapeutic agent against pancreatic cancer.. Journal of Advanced Pharmaceutical Technology and Research, 2022, 13, 44-49.	0.4	7
4972	Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series. JOP: Journal of the Pancreas, 2014, 15, 38-41.	1.5	2
4973	Preclinical research in treatment of pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 384-7.	1.5	2
4974	First line therapy for metastatic pancreatic cancer. JOP: Journal of the Pancreas, 2013, 14, 340-3.	1.5	4
4975	Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP: Journal of the Pancreas, 2013, 14, 337-9.	1.5	6
4976	Role of neoadjuvant therapy in management of pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 354-7.	1.5	0
4977	High-dose corticosteroid therapy for erlotinib-induced interstitial lung disease in Japanese patient with advanced pancreatic cancer. JOP: Journal of the Pancreas, 2014, 15, 611-4.	1.5	1
4978	Endoscopic findings of upper gastrointestinal lesions in patients with pancreatic cancer. JOP: Journal of the Pancreas, 2012, 13, 420-6.	1.5	2
4979	Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?. JOP: Journal of the Pancreas, 2012, 13, 358-60.	1.5	2
4980	Research in pancreatic cancer: an update after ASCO 2012. JOP: Journal of the Pancreas, 2012, 13, 330-1.	1.5	1
4981	Highlights on the first line treatment of metastatic pancreatic cancer. JOP: Journal of the Pancreas, 2012, 13, 361-7.	1.5	3
4983	c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer. Frontiers in Pharmacology, 2022, 13, 851512.	1.6	4
4984	Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma. Advances in Oncology, 2022, 2, 35-45.	0.1	0
4985	PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Neoplasia, 2022, 30, 100793.	2.3	6

#	Article	IF	Citations
4987	FOLFIRINOX in Advanced Pancreatic Cancer, NEMROCK Experience. Cancer and Oncology Research, 2014, 2, 35-41.	0.2	0
4988	The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. Scientific Reports, 2022, 12, 8244.	1.6	8
4989	Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Biochemical and Biophysical Research Communications, 2022, 615, 9-16.	1.0	3
4990	Molecular Mechanism of Curcumin and Its Analogs as Multifunctional Compounds against Pancreatic Cancer. Nutrition and Cancer, 2022, 74, 3096-3108.	0.9	3
4991	The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling. Journal of the National Cancer Institute, 2022, 114, 1279-1286.	3.0	8
4992	Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer. Pancreas, 2022, 51, 278-281.	0.5	5
4994	Overcoming immunotherapeutic resistance in PDAC: SIRPÎ±-CD47 blockade. Pharmacological Research, 2022, 181, 106264.	3.1	4
4997	ELECTROCHEMOTHERAPY IN THE TREATMENT OF UNRESECTABLE PANCREATIC CANCER. Modern Medical Technologies, 2022, , 40-45.	0.1	0
4998	Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. Frontiers in Immunology, 2022, 13, .	2.2	7
4999	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. Cancers, 2022, 14, 2486.	1.7	29
5000	The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 0, 12, .	1.3	3
5001	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers, 2022, 14, 2588.	1.7	7
5002	Is Artesunate the Best Partner of Gemcitabine in Pancreatic Cancer?. European Journal of Education and Pedagogy, 2022, 3, 1-12.	0.2	1
5003	Endoscopic ultrasound-guided injectable therapy for pancreatic cancer: A systematic review. World Journal of Gastroenterology, 2022, 28, 2383-2395.	1.4	7
5004	Human amniotic fluid mesenchymal stem cells attenuate pancreatic cancer cell proliferation and tumor growth in an orthotopic xenograft mouse model. Stem Cell Research and Therapy, 2022, 13, .	2.4	8
5009	Trends in the surgical treatment for pancreatic cancer in the last 30 years. BioScience Trends, 2022, 16, 198-206.	1.1	4
5010	Immunotherapy for patients with pancreatic adenocarcinoma. Onkologie (Czech Republic), 2022, 16, 127-129.	0.0	0
5011	Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective. Cancers, 2022, 14, 3113.	1.7	3

#	Article	IF	Citations
5013	Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present. Biomolecules, 2022, 12, 815.	1.8	15
5014	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2022, 176, 103749.	2.0	37
5015	Clinical Trials in Hepatopancreatobiliary Surgery: Assessing Trial Characteristics, Early Discontinuation, Result Reporting, and Publication. Journal of Gastrointestinal Surgery, 2022, 26, 1628-1636.	0.9	0
5016	E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2. , 2022, 39, .		7
5017	Endoscopic ultrasound as a reliable tool for assessment of pancreatic adenocarcinoma treatment: Example of in situ gene therapy. Endoscopy International Open, 2022, 10, E910-E916.	0.9	0
5018	Patient-Reported Outcomes in Lung Cancer. Medical Radiology, 2022, , .	0.0	0
5019	A ferrocene-containing nucleoside analogue targets DNA replication in pancreatic cancer cells. Metallomics, 2022, 14, .	1.0	1
5021	Management of elderly patients with unresectable pancreatic cancer. Japanese Journal of Clinical Oncology, 0, , .	0.6	1
5022	Limitation and challenges in using pancreatic cancerâ€derived organoids as a preclinical tool. Cancer Communications, 0, , .	3.7	0
5024	Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. Cancers, 2022, 14, 3250.	1.7	4
5025	Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Cancer Research, 2022, 82, 3375-3393.	0.4	2
5026	Antibody-Based Approaches to Target Pancreatic Tumours. Antibodies, 2022, 11, 47.	1.2	7
5027	Multimodal Therapies against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches toward Ultimate Nanomedicine Treatments. Advanced Therapeutics, 2022, 5, .	1.6	8
5028	Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma. Molecular Oncology, 2022, 16, 3034-3051.	2.1	8
5029	GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer. PeerJ, 0, 10, e12728.	0.9	5
5030	Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Molecular Cancer Therapeutics, 2004, 3, 641-646.	1.9	82
5031	The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Molecular Cancer Therapeutics, 2004, 3, 451-457.	1.9	66
5032	Cystic Pancreatic Lesions. , 2023, , 177-196.		0

#	Article	IF	Citations
5034	Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma. Annals of the Academy of Medicine, Singapore, 2015, 44, 388-396.	0.2	4
5035	Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness. International Journal of Nanomedicine, 0, Volume 17, 3239-3249.	3.3	7
5036	Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia by targeting the AP4/galectin-1 pathway. Biomaterials Science, 2022, 10, 5989-6002.	2.6	8
5037	Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer. Medicine (United States), 2022, 101, e29532.	0.4	3
5039	Eriodictyol Attenuates Cholangiocarcinoma Malignancy by Regulating HMOX1 Expression: An In Vitro Study. Anticancer Research, 2022, 42, 3789-3798.	0.5	1
5040	Myofibroblastic CAF Density, Not Activated Stroma Index, Indicates Prognosis after Neoadjuvant Therapy of Pancreatic Carcinoma. Cancers, 2022, 14, 3881.	1.7	5
5042	Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Journal of the National Cancer Center, 2022, 2, 205-215.	3.0	5
5043	Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon. , 2022, 39, .		2
5044	Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Frontiers in Pharmacology, 0, 13, .	1.6	4
5045	Prokineticin 2 in cancer-related inflammation. Cancer Letters, 2022, 546, 215838.	3.2	10
5046	Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models. Cancer Letters, 2022, 545, 115478.	3.2	8
5047	The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. Cancer Letters, 2022, 548, 215868.	3.2	9
5048	Emerging roles of hnRNP A2B1 in cancer and inflammation. International Journal of Biological Macromolecules, 2022, 221, 1077-1092.	3.6	7
5049	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2022, , 535-556.		0
5050	Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma. Pancreas, 2022, 51, 684-693.	0.5	3
5052	Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Medicina (Lithuania), 2022, 58, 1298.	0.8	0
5053	Identification of Novel Ribonucleotide Reductase Inhibitors for Therapeutic Application in Bile Tract Cancer: An Advanced Pharmacoinformatics Study. Biomolecules, 2022, 12, 1279.	1.8	1
5054	From Molecular Mechanisms to Therapeutics: Understanding MicroRNA-21 in Cancer. Cells, 2022, 11, 2791.	1.8	24

#	Article	IF	Citations
5056	Cytotoxic Chemotherapy in Advanced Pancreatic Cancer. Hematology/Oncology Clinics of North America, 2022, 36, 1011-1018.	0.9	2
5057	Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Scientific Reports, 2022, 12, .	1.6	6
5058	The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence. Medicine (United States), 2022, 101, e30566.	0.4	0
5059	Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
5060	Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Cancer Communications, 0, , .	3.7	1
5061	Realâ€world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as firstâ€line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma. Asia-Pacific Journal of Clinical Oncology, 2023, 19, .	0.7	1
5062	Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals, 2022, 15, 1199.	1.7	9
5064	A case of pathological complete response with liposomal irinotecanâ€‰+â€‰5-FU/LV for unresectable locally advanced pancreatic cancer. Surgical Case Reports, 2022, 8, .	0.2	0
5065	Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability. Drug Resistance Updates, 2022, 65, 100866.	6.5	21
5066	Prioritizing the Patient Experience: Early Integration of Supportive/Palliative Care in Pancreatic Cancer Management. , 2022, , 343-350.		0
5067	Molecular Profiling and Precision Medicine for Pancreatic Cancer. , 2022, , 255-267.		0
5068	Management of Locally Advanced/Metastatic Disease: Medical Oncology. , 2022, , 97-106.		0
5069	Patient Reported Outcomes and Quality of Life. , 2022, , 351-373.		0
5070	Systemic immune changes accompany combination treatment with immunotoxin <scp>LMB</scp>â€100 and nabâ€paclitaxel. Cancer Medicine, 2023, 12, 4236-4249.	1.3	2
5071	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
5072	Decision-Making Regarding Perioperative Therapy in Individuals with Localized Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America, 2022, 36, 961-978.	0.9	2
5073	ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer. Aging, 2022, 14, 7941-7958.	1.4	2
5074	Exosome-mediated cell-cell communication within pancreatic cancer tumor microenvironment: a narrative review. Journal of Pancreatology, 0, Publish Ahead of Print, .	0.3	0

#	Article	IF	Citations
5075	Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer. Journal of Clinical Medicine, 2022, 11, 5895.	1.0	0
5076	Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. Cancer Medicine, 0, , .	1.3	2
5078	Marine-Inspired Drugs and Biomaterials in the Perspective of Pancreatic Cancer Therapies. Marine Drugs, 2022, 20, 689.	2.2	5
5079	Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Expert Opinion on Emerging Drugs, 2022, 27, 345-368.	1.0	4
5080	The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188826.	3.3	5
5081	The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Study. Internal Medicine, 2023, , .	0.3	2
5082	Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. Oncologist, 0, , .	1.9	2
5085	Tumor and stroma COL8A1 secretion induces autocrine and paracrine progression signaling in pancreatic ductal adenocarcinoma. Matrix Biology, 2022, 114, 84-107.	1.5	5
5086	Back to basic: Trials and tribulations of alkalizing agents in cancer. Frontiers in Oncology, 0, 12, .	1.3	9
5087	Development of doped ZnO-based biomimicking and tumor-targeted nanotheranostics to improve pancreatic cancer treatment. Cancer Nanotechnology, 2022, 13, .	1.9	6
5088	Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?. ESMO Open, 2022, 7, 100638.	2.0	11
5093	Providing Hope in Terminal Cancer: When is it Appropriate and When is it Not?. Annals of the Academy of Medicine, Singapore, 2011, 40, 50-55.	0.2	19
5094	A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study. Cancer Control, 2022, 29, 107327482211412.	0.7	1
5095	Pancreatic cancers. Advances in Magnetic Resonance Technology and Applications, 2023, , 315-340.	0.0	0
5096	Tumor-targeted molybdenum disulfide@barium titanate coreâ€“shell nanomedicine for dual photothermal and chemotherapy of triple-negative breast cancer cells. Journal of Materials Chemistry B, 2023, 11, 1044-1056.	2.9	8
5097	Screening for Pancreatic Cancer: Current Status and Future Directions. European Medical Journal (Chelmsford, England), 0, , 59-67.	3.0	1
5098	Epithelial to Mesenchymal Transition as Mechanism of Progression of Pancreatic Cancer: From Mice to Men. Cancers, 2022, 14, 5797.	1.7	6
5099	Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunology, Immunotherapy, 2023, 72, 1285-1300.	2.0	8

#	Article	IF	Citations
5100	The Involvement of Long Non-Coding RNAs in Glutamine-Metabolic Reprogramming and Therapeutic Resistance in Cancer. International Journal of Molecular Sciences, 2022, 23, 14808.	1.8	4
5101	Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Health Economics Review, 2022, 12, .	0.8	1
5102	A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Gastroenterology, 2023, 164, 476-480.e4.	0.6	2
5103	Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier. Materials Today, 2023, 62, 33-50.	8.3	9
5104	Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. The Cochrane Library, 2022, 2022, .	1.5	0
5105	Barriers and opportunities for gemcitabine in pancreatic cancer therapy. American Journal of Physiology - Cell Physiology, 2023, 324, C540-C552.	2.1	16
5106	Current treatment landscape of pancreatic cancer patients in a network of office-based oncologists in Germany. Future Oncology, 0, , .	1.1	0
5108	A small Rho GTPase RAB25 with a potential role in chemotherapy resistance in pancreatic cancer. Cancer Biomarkers, 2022, , 1-13.	0.8	0
5109	Hydroxychavicol as a potential anticancer agent (Review). Oncology Letters, 2022, 25, .	0.8	2
5110	Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. Heliyon, 2022, 8, e12064.	1.4	5
5111	Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Annals of Epidemiology, 2023, 78, 28-34.	0.9	2
5112	Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers, 2022, 14, 6223.	1.7	6
5114	Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. Journal of Clinical Medicine, 2023, 12, 465.	1.0	2
5115	Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Cancers, 2023, 15, 416.	1.7	6
5116	Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Biomedicines, 2023, 11, 119.	1.4	2
5118	The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 2022, 51, e107-e109.	0.5	1
5119	Stroma-targeting strategies in pancreatic cancer: a double-edged sword. Journal of Physiology and Biochemistry, 2023, 79, 213-222.	1.3	7
5120	Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Medicine (United States), 2022, 101, e32150.	0.4	1

#	Article	IF	Citations
5122	Time to Onset of Gemcitabine-induced Thrombotic Microangiopathy in a Japanese Population: A Case Series and Large-scale Pharmacovigilance Analysis. Cancer Diagnosis & Prognosis, 2022, 3, 115-123.	0.3	0
5123	A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. Frontiers in Endocrinology, 0, 14, .	1.5	0
5124	Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic cancer by deformable image registration. Frontiers in Oncology, 0, 12, .	1.3	0
5125	The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study. World Journal of Surgical Oncology, 2023, 21, .	0.8	0
5126	Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model. PLoS Computational Biology, 2023, 19, e1010104.	1.5	2
5127	Unveiling the gemcitabine drug complexation with cucurbit[n]urils (nâ€‰=â€‰6â€“8): a computational analysis. Structural Chemistry, 2023, 34, 1869-1882.	1.0	0
5128	Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. Targeted Oncology, 2023, 18, 51-76.	1.7	2
5129	Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair. Antioxidants and Redox Signaling, 2023, 39, 432-444.	2.5	1
5130	Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resistance Updates, 2023, 68, 100960.	6.5	36
5131	Pancreatic Cancer Treatment by Using Theragnostic Nanoparticles. , 2022, , 149-168.		0
5132	Pancreatic Cancer: Nanoparticle Targeted Therapy Via Epidermal Growth Factor Receptor. , 2022, , 111-128.		0
5133	Pancreatic intra-arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma: A pilot study. Journal of Cancer Research and Therapeutics, 2022, 18, 1945.	0.3	1
5134	Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey. ESMO Open, 2023, 8, 100777.	2.0	2
5135	Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPinâ€“Toxin Fusion in a Pancreatic Cancer Xenograft Model. International Journal of Molecular Sciences, 2023, 24, 2838.	1.8	2
5136	Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Acta Pharmaceutica Sinica B, 2023, 13, 1554-1567.	5.7	7
5137	Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomizedâ€“controlled open-label Phase II study. Gastroenterology Report, 2022, 11, .	0.6	0
5138	Use of timeâ€‘density curves of dynamic contrastâ€‘enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma. Oncology Reports, 2023, 49, .	1.2	0
5139	microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer. Cancers, 2023, 15, 1230.	1.7	5

#	Article	IF	Citations
5141	Integrated clinical analysis and data mining assessed the impact of NOX4 on the immune microenvironment and prognosis of pancreatic cancer. Frontiers in Oncology, 0, 13, .	1.3	0
5142	Challenges in Diagnosis and Treatment of Pancreatic Exocrine Insufficiency among Patients with Pancreatic Ductal Adenocarcinoma. Cancers, 2023, 15, 1331.	1.7	6
5143	Gemcitabine-induced peripheral vascular disease and prolonged response in a patient with metastatic pancreatic adenocarcinoma: A case report. World Journal of Clinical Cases, 0, 11, 1372-1378.	0.3	1
5144	Fluoropyrimidine combination therapy versus fluoropyrimidine monotherapy for gemcitabine-refractory advanced pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2023, 18, e0282360.	1.1	0
5145	Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma. Journal of Clinical Medicine, 2023, 12, 2211.	1.0	0
5146	Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects. Frontiers in Oncology, 0, 13, .	1.3	0
5147	Neoadjuvant therapy for pancreatic cancer. Nature Reviews Clinical Oncology, 2023, 20, 318-337.	12.5	61
5148	Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival. Function, 2023, 4, .	1.1	6
5149	Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. Advances in Cancer Research, 2023, , .	1.9	0
5150	The Gut Microbiome and Pancreatic Cancer Development and Treatment. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Overl	1.0	3
5151	STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Cell Death and Disease, 2023, 14, .	2.7	5
5152	Anticancer Activity of Novel Difluorinated Curcumin Analog and Its Inclusion Complex with 2-Hydroxypropyl-Î²-Cyclodextrin against Pancreatic Cancer. International Journal of Molecular Sciences, 2023, 24, 6336.	1.8	3
5153	Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic Cancer Using Nanotechnology. Current Cancer Drug Targets, 2023, 23, .	0.8	1
5154	Tripleâ€Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemoâ€Immunotherapy in Preclinical Cancer Models. Advanced Science, 2023, 10, .	5.6	7
5155	FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Annals of Surgical Oncology, 2023, 30, 4417-4428.	0.7	10
5156	Chronic effects of pulsed high intensity focused ultrasound aided delivery of gemcitabine in a mouse model of pancreatic cancer. Ultrasonics, 2023, 132, 106993.	2.1	2
5157	Development of a magnetic solid phase extraction method for gemcitabine from rat plasma by using magnetic graphene oxide calix[6]arene composite and its application to pharmacokinetics. Separation Science and Technology, 0, , 1-11.	1.3	0
5158	Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. Digestive Diseases and Sciences, 0, , .	1.1	0

#	Article	IF	Citations
5159	The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients. Pancreas, 2022, 51, 1153-1159.	0.5	1
5160	Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions. Advances in Cancer Research, 2023, , .	1.9	0
5202	Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis. Updates in Surgery, 0, , .	0.9	0
5234	Recent advances in nanocarriers for pancreatic cancer therapy. , 2024, , 169-211.		0
5240	Clinical practice guidelines for interventional treatment of pancreatic cancer. , 2024, , 345-373.		0
5247	Management of malignant hypercalcemia in cancer patientsâ€”aÂshort review. Memo - Magazine of European Medical Oncology, 2023, 16, 263-267.	0.3	1
5249	Supportive Care Challenges and Management in Pancreatic Cancer. , 2023, , 159-168.		0
5250	Therapy for Metastatic Pancreatic Cancer. , 2023, , 57-65.		0